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Abstract 
Primary cilia are microtubule-based “antennae-like” organelles extending from 
the apical surface of most mammalian cells. They integrate mechanical or 
chemical signals essential for cell homeostasis and differentiation through 
several cooperating compartments. Mutations in genes that encode ciliary 
proteins or proteins essential for correct ciliary function are the cause of a major 
group of inherited and variable developmental disorders known as ciliopathies. 
Functional interactions between ciliary compartments, the molecular basis of 
variable clinical phenotypes, and the mechanisms of cilia formation are all still 
poorly understood. 
The presence or absence of cilia can be easily imaged and quantitated. This 
lends itself to high-throughput, high-content imaging in reverse genetic screens 
of cellular phenotypes. siRNA reverse genetic screens were performed to 
assess increased cilia incidence and identified that ROCK2 is a key negative 
regulator of ciliogenesis. Analysis showed ROCK2 acts through a mechanism 
involving actin remodelling and acto-myosin contraction. Pharmacological 
inhibition of ROCK2 may therefore comprise a novel therapeutic approach for 
treatment of a broad group of ciliopathy disease classes. Further screening of a 
data-set for supernumerary primary cilia, added to the evidence that cytokinesis 
is not a prerequisite for ciliogenesis. Disruption of the centralspindilin complex 
caused mitotic failure and maturation of supernumerary centrosomes, leading to 
the formation of the supernumerary cilia, a known cellular phenotype of severe 
ciliopathies. Finally, a combinatorial screening approach to generate double 
genetic perturbations of ciliary genes identified reciprocal synthetic genetic 
interactions between anterograde intraflagellar transport (the IFT B complex) 
and the transition zone. 
Reverse genetics screening techniques have identified novel regulators and 
pathways of ciliogenesis, and a potential therapeutic target for ciliopathies. 
Furthermore, combinatorial screening has highlighted a novel and complex 
interaction in ciliary biology, that may provide potential new insights into ciliary 
organisation and disease pathomechanisms. 
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Chapter 1  
Introduction 
1.1 The primary cilium 
The hair-like organelles, that protrude from the surface of most types of 
eukaryotic cells, were first noted by Anthony van Leeuwenhoek in 1675 as “little 
legs” on the protozoa he was observing, thus making cilia the oldest known 
cellular organelle. These “little legs” were later called cilia, after the Latin for 
eyelash, by Otto Muller in 1786. However, the distinction between motile, 
flagella-like cilia observed by Leeuwenhoek and non-motile cilia was first 
described in the 19th century (1). As a consequence, early research on cilia 
focused on motile cilia and their similarities to the eukaryotic flagellum, leaving 
the primary cilium mostly ignored and perceived as a vestigial cellular structure. 
In retrospect, this seems to be a strange view because early researchers knew 
that primary cilia were highly conserved organelle across major animal phyla, 
albeit with some variations in function and structure. It is only in the last 20 
years that the importance of these fascinating organelles has been fully 
appreciated, following the many recent seminal discoveries of their involvement 
in many essential signalling and developmental pathways in humans. Primary 
cilia are now part of the scientific mainstream in modern biomedical research 
(1).  
1.1.1 Primary vs motile cilia 
There are two main types of cilia: motile cilia and primary cilia (Figure 1.1). 
Motile cilia include sperm flagella and the numerous cilia of airway epithelial 
multi-ciliated cells. The latter mediate the muco-ciliary escalator that moves 
mucus up and out of the respiratory tract. In contrast, primary cilia are static and 
known to have a more specialised sensory role. Primary cilia are present on 
nearly all cells within the human body except hepatocytes (2) and leukocytes. 
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A) Primary Cilium   B) Motile Cilium 
 
Figure 1.1 Primary vs motile Cilia 
A) The primary cilium is an hair-like structure that protrudes from the apical 
membrane of many eukaryotic animal cells. It has a 9+0 microtubule 
doublet arrangement in the axoneme that protrudes from the basal body. 
B) A motile cilium also protrudes from the membrane of cells. but differs in 
its internal microtubule structure. The majority of motile cilia have a pair of 
central microtubules making a 9+2 arrangement (exceptions include nodal 
cilia). Dynein arms and radial spokes allow the microtubules to slide 
against each other to generate movement. An example ciliary beat pattern 
of tracheal cilia is represented in the bottom right corner, consisting of a 
whipping-like motion. 
1.1.1.1 Motile cilia 
Motile cilia are an essential organelle conserved in many animals and are 
ubiquitous in vertebrates, large animals such as mammals, and humans (3). To 
facilitate their beat patterns the majority of motile cilia have a different structural 
arrangement of microtubules, comprising a 9+2 arrangement (4), and different 
motor proteins in the ciliary axoneme. Spermatozoa have a single motile cilium 
required for movement, although most cells in mammalian adults with motile 
cilia form arrays of these motile cilia. These cells are terminally differentiated 
because of the vast number of centrioles (from 30 up to 300 (5)) required to 
produce the ciliary arrays. Motile cilia when in arrays, synchronise their beat 
patterns within cells and tissues to produce directional fluid flow (6). This fluid 
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flow is essential in tissues such as the lungs, nasal passage and fallopian tubes 
for correct tissue function (6).  
1.1.1.2 Primary cilia 
Primary cilia are static and have a major sensory role in cells (7), with a different 
ultrastructure to motile cilia, including a 9+0 microtubule doublet arrangement in 
the axoneme (Figure 1.1) (4). They also protrude from the apical membrane of 
cells, but in some cases are held within a deep membrane invagination known 
as the ciliary pocket (8). They are able to sense chemical and mechanical 
stimuli and transduce signals into the cell.  
1.1.2 Specialised cilia 
There are several specialised cilia that have essential roles for correct organ 
function. Renal cilia and kinocilia, displayed on hair cells of the inner ear, 
mediate mechanosensation (9, 10) . Renal cilia are displayed as solitary 
organelles on renal epithelial cells in order to detect fluid flow (9), whereas 
kinocilia cooperate with actin-rich stereocilia in order detect mechanosensation 
of soundwaves and also fluid flow in the utricular macula for balance (10). Other 
specialised cilia include olfactory cilia that are essential for chemosensation in 
the nasal mucus (11), the photoreceptor connecting cilium essential for 
phototransduction (12, 13), and nodal cilia in embryogenesis (14). 
1.1.2.1 Photoreceptor connecting cilium 
The outer segments of retinal photoreceptors mediate phototransduction (12). 
These highly-specialised neurons have a highly modified primary cilium termed 
the connecting cilium, which attaches the inner and outer segments of the 
photoreceptor (12). The base of the cilium is in the inner segment and the cilium 
then joins to the outer segment where the ciliary axoneme extends (15). This 
cilium is required for the phototransduction cascade and transport of rhodopsin 
and other essential proteins and lipids from the cell body to the outer segment 
(Reviewed in Khanna, 2015 (15)). 
Since the photoreceptor and connecting cilium is vastly complex, this is the 
likely reason that the retina is highly susceptible to the effect of mutations in 
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ciliary genes and, as a result, inherited retinal dystrophy is a common 
phenotype across the spectrum of ciliopathies. 
1.1.2.2 Nodal cilia 
Single motile cilia are present in the developing embryo and are essential for 
the initiation and maintenance of asymmetric flow in the embryonic node. This 
asymmetric flow is required for distribution of morphogens at the embryonic 
node and subsequent correct left/right patterning in the developing embryo (14, 
16). These mono-motile cilia generate leftward flow in the vertebrate embryonic 
node (in mammals) and Kupffer’s vesicle (in fish) in order to establish gradients 
of developmental proteins and to produce patterning across the embryo (14, 
16). These mono-motile cilia are found around the pit of the node, however 
there is a second type of nodal sensory cilia which have an important role in 
breaking embryo symmetry (17).. These primary cilia are non-motile and are 
found on the crown cells which surround the edges of the indentation in the 
node (17). With such essential roles in embryogenesis, it is not surprising that 
mutations in ciliary genes cause complex, multi-organ developmental defects 
that include laterality defects. 
1.2 Primary cilia structure 
1.2.1 Ultra-structure 
Most of ciliary ultra-structure was determined from early transmission electron 
microscopy (TEM) studies in the 60s and 70s (18-22). The cilium is made up of 
distinct compartments that each contribute to overall structure and function. The 
ciliary membrane is an extension of the apical plasma membrane, but has a 
unique composition of proteins and lipids (23). The cilium is therefore a cellular 
organelle that is not completely membrane bound. It originates from a mature 
mother centriole in the cytoplasm (24, 25), and forms an  axonemal structure 
that protrudes from the cell (Figure 1.2).  
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Figure 1.2 Ultra-structure of the primary cilium 
The primary cilium is formed from the mother centriole (termed basal body 
when docked to the membrane),, that attaches to the cell membrane with 
support from distal appendages. Microtubules extend from the basal body 
and form a 9+0 microtubule doublet arrangement at the transition zone 
and becomes singlet microtubules at the ciliary tip. The transition zone 
tethers the ciliary membrane to the microtubules using distinctive Y-
shaped linkers. The ciliary membrane is a continuation of the cell 
membrane but is highly specialised, containing a different complement of 
phospholipids and signalling receptors. 
1.2.1.1 Ciliary pocket 
The part of the membrane that surrounds the lower portion of the cilium and 
connects directly to the cell membrane is called the ciliary pocket (also known 
as the ciliary pit in older literature). It is primarily seen as a full membrane 
invagination in non-polarized cell types, such as hTERT-immortalized Retinal 
Pigment Epithelial cell line (RPE-1). In polarized cells, however, it also present 
at low incidence, for example in ~10% of mouse inner medullary collecting duct 
(IMCD3) cells (8). This region of the cilium mediates the interactions of the 
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ciliary membrane with the basal body via the distal appendages (23, 24), and 
the ciliary pocket therefore reflects the positioning of the basal body (8). 
The ciliary pocket is relatively poorly defined. However, it is known to be very 
dynamic, due constant endocytosis which recycles ciliary receptors and for 
fusion of ciliary vesicles delivering membrane proteins (8, 26). The ciliary pocket 
is also surrounded by actin bundles which help to deliver ciliary-targeted 
vesicles and maintain the shape and depth of the pocket (27). As this is the 
fusion site for the delivery of new membrane proteins, the ciliary pocket also 
works to regulate transport into and out of the cilium in association with the 
transition zone. 
1.2.1.2 Basal body and appendages 
The basal body is the name given to the matured mother centriole when it has 
docked and formed a cilium. The mother centriole has a stable 9+0 microtubule 
triplet arrangement and is approximately 500 x 250 nm (28, 29). These 
microtubule triplets extend to become the ciliary axoneme.  
When docked at the cell membrane the basal body is supported by the distal 
and/or sub-distal appendages anchoring it to the ciliary pocket in vertebrate 
cells (30). In cells with submerged cilia, such as non-polarised cells including 
RPE-1 cells, the basal body and cilium is submerged within the ciliary pocket 
(31). The basal body in these cells, as with most vertebrate cells, is associated 
with the Golgi apparatus (32). This positioning of the cilium is maintained by 
centrosome cohesion and the presence of sub-distal appendages. The sub-
distal appendages are not essential for cilia assembly, unlike the distal 
appendages, and therefore the role of sub-distal appendages varies between 
cell types. However, they are generally thought to give further ciliary stability 
and contribute to centriole linkage (33). 
RPE-1 cells with mutations in both centrosome cohesion linkers (CEP128-/-) and 
sub-distal appendages (C-NAP-/-), cilia are able to surface as they are no longer 
restrained to the Golgi apparatus or associated with a deep ciliary pocket (33). 
Surfaced cilia have exacerbated signalling responses (Figure 1.3) in their ability 
to detect flow or to accumulate signalling receptors such as Smoothened (33). 
Therefore, the overall positioning of the cilium is regulated by both the sub-distal 
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appendages and centriole cohesion complex, as single mutants of one or the 
other structure cause the cilium to remain submerged (33). Therefore, 
regulation of these structures may be responsible for the surfacing of cilia in 
polarised cell types. This, in turn, informs the choice of cell model for ciliary 
research into signalling and mechanosensation, as well as the light microscopy 
method used to visualize ciliary processes. 
 
Figure 1.3 Positioning of the basal body contributes to ciliary function 
A) Sub-distal appendages and centriole cohesion are required for cilia to 
be submerged and close to the Golgi apparatus. These cilia usually occur 
in non-polarised cells and have reduced signalling capabilities. B) The 
positioning of the basal body with a small ciliary pocket is held by distal 
appendages. Without centrosome cohesion the cilium can surface. These 
cilia have full signalling capacity, seen by increased localisation of 
signalling receptors and also increased mechanosensation. Image 
adapted from (30) Figure 1, and used with copyright permissions.  
1.2.1.3 The transition zone 
Just above the basal body is the transition zone (TZ), a highly complex structure 
that acts as the ciliary gate, regulating the movement of proteins into and out of 
the cilium. The TZ starts 10nm above the distal appendages (34) of the basal 
body and extends into the base of the axoneme. It is approximately 300-350nm 
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the TZ that the microtubule arrangement changes from the 9 triplet microtubules 
to the signature 9+0 microtubule doublet arrangement (35). TEM has also 
revealed clear Y-shaped linkers in the TZ that appear to tether the membrane 
the microtubule doublets (36). 
1.2.1.4 The axoneme 
The central structure of the cilium is a microtubule arrangement that extends 
from the basal body in the 9+0 formation previously mentioned, with the plus 
end of the microtubules at the tip of the cilium. The axoneme of primary cilia can 
vary from 1-9µm in length, dependant on cell type (37), and is surrounded by 
the ciliary membrane. As there is no translational machinery within the cilium, 
proteins that are made in the cytoplasm or cell body must be trafficked into and 
along the axoneme to build, maintain and disassemble the cilium throughout the 
cell cycle. The microtubules act as tracks to allow trafficking of transport trains 
to and from the ciliary tip (38) . 
1.2.2 Molecular structure 
There are over 1000 known ciliary proteins (39, 40) that contribute to the 
cilium’s diverse functions, and recent publications have identified several 
hundred further candidate proteins (40, 41). The cilium must therefore have a 
highly organized molecular structure, where the localisation of and translocation 
of these proteins are tightly regulated. Despite a well-characterized ultra-
structure, defined by electron microscopy studies, the molecular organisation of 
proteins within the cilium is still relatively undefined. This is due to the limitations 
of traditional protein-protein interaction studies and the restricted resolution of 
confocal microscopy techniques. Recent advances in super-resolution 
microscopy, and proximity labelling methods such as the “APEX” method (42) 
and use of localization reagents such as nanobodies or tagged non-antibody 
binding proteins (“Affimers”) (43), should soon lead to a more defined molecular 
organisation of the cilium (44). 
1.2.2.1 Ciliary membrane 
There are an abundance of different signalling receptors that make up the 
specific composition of the ciliary membrane, reflecting the cilium’s role in a 
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wide range of signalling pathways (23). The ciliary membrane has several sub-
compartments, each with an individual composition of proteins, associated with 
the ciliary pocket, axoneme and ciliary tip (23). Furthermore, lipid composition 
differs not only compared to the cell membrane but even throughout the sub-
regions of the ciliary membrane (23).  
Despite high levels of endocytic activity, specific signalling receptors are not 
found to localise to the ciliary pocket, although they may be present transiently. 
The current opinion is that the pocket is primarily a site of vesicle docking that 
transports new membrane proteins during maintenance of the cilium (8). This 
model therefore predicts that soluble NSF attachment receptor (SNARE) 
proteins and vesicle regulators such as Rabin8 and exocyst localise to the 
ciliary pocket (45-47). 
The main length of the axoneme is the location for the majority of signalling 
receptors that are responsible for the many functions of the primary cilium. 
Once trafficked, the distribution of proteins along the ciliary membrane and 
anchoring of ciliary membrane proteins is partially regulated by the small 
GTPase ARL13B. ARL13B interacts with actin (48) and tubulin (49) to ensure 
the correct distribution of membrane proteins along the axoneme, and possibly 
mediates the interactions between membrane proteins and the axoneme during 
signal transduction (49). Separate to this, ARL13B has roles in recruitment of 
proteins to the ciliary membrane (49) through endocytic trafficking of ciliary 
cargo (48). 
The ciliary tip is known to have a different composition of proteins, including 
clathrins and actin, because the ciliary tip can also be a source of extracellular 
vesicles (ECV) (50). The most well-investigated of these ECVs are from the 
retina outer segment, which allow recycling of opsins through endocytosis of 
ECVs by the retinal pigment epithelial cells (51). In other cell types, ECVs are 
poorly characterised, but purified ECVs have been shown to contain ciliary 
proteins and transmembrane signalling molecules (52, 53). Therefore, ECVs 
may be used as a type of ciliary paracrine signalling between cells, or as a way 
for the cilium to rapidly regulate the levels of signalling proteins during signalling 
responses (50). 
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1.2.2.2 The axoneme and intraflagellar transport 
The axonemal microtubules are post-translationally modified as they extend. 
The main stem of the axoneme is made up of alpha/beta tubulin heterodimers in 
which the alpha tubulin is acetylated (54). The plus end of the tubules are at the 
ciliary tip and are unmodified until incorporated into the main axoneme. 
Axonemal extension and transport of cargo along these tubules is controlled by 
intraflagellar transport (IFT) proteins. IFT proteins are split into two types, IFT-A 
and IFT-B, which form macromolecular complexes to continuously traffic cargo 
throughout the cilium (55). 
Although peripheral and core IFT proteins are highly conserved between 
different organisms the IFT-A and IFT-B complexes have different compositions 
of proteins. First characterised in 2009 in mice (56), the mammalian IFT-B 
complex is made up of 10 core IFTB proteins and a further 6 peripheral proteins 
(57). The core and peripheral proteins form a large complex through 
interactions of IFT52 and IFT88 from the core complex, with IFT38 and IFT57 
from the peripheral complex (57). Across IFT proteins, most domains are not 
required for complex formation and stability, and as most do not have enzymatic 
activity (58). An exception to this would be IFT140 in the stabilisation and 
formation of the IFTA complex  However the complexes have a range of 
domains available for protein-protein interactions with an assortment of cargos 
(55, 59). The difference between these domains and the few stability domains 
are reviewed in Bhogaraju et al., 2013 (58).  
IFT-B has been shown to gather in two distinct pools around the transition zone, 
at the sub-distal appendages and distal to the transition zone, presumably for 
collection of cargo (60). The exact interactions between IFT and cargos is not 
well-defined and is thus an area of on-going research. It is currently known that 
ciliary cargo is trafficked by motor proteins that travel along the ciliary 
microtubules. IFT-B works in complex with kinesin motors to facilitate 
anterograde transport to the ciliary tip (61). To select the cargo, IFT works in 
conjunction with the BBSome, an eight-membered protein complex that 
regulates the stability of IFT trains (multiple cargo associated with IFT and 
motor proteins) (62, 63). The BBSome complex also has a non-specific binding 
motif which allows it to select and carry a variety of ciliary cargos with IFT (64), 
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of which much work provides evidence for a BBSome role in exit of cargo 
selectively. For entry and trafficking, Tulp3 has also been shown to act as an 
adaptor for g-protein coupled receptors in the ciliary membrane to be carried by 
and IFT-A (65). Highlighting a surprising role for IFT-A in transport of protein 
into the cilium rather than solely in retrograde transport. 
Once at the tip, cargo is collected by IFT-A which work with dynein motor 
proteins for retrograde transport (66). IFT-A is a complex of at least six proteins 
(67) and transport of cargo also occurs in association with the BBSome. If not 
shuttled back down the axoneme, cargo accumulates and forms a bulbous 
ciliary tip, as seen in mutants of IFT-A proteins (68). IFT-A is not only important 
in transport within the cilium, but has been implicated in proper ciliogenesis 
(69).  
There is evidence that shows IFT-A proteins are involved in the recruitment of 
proteins during ciliogenesis not just ciliary retrograde transport. In RPE-1 and 
HEK293 mutants of the IFT-A protein IFT121, membrane proteins ARL13B, 
INPP5E and SSTR3 were not observed in the cilium (70). SMO localisation was 
also defective in the presence of Sonic Agonist (SAG) in MEF with null 
mutations (71). This is further supported by evidence in C. elegans where IFT-A 
has also been implicated in the recruitment of transition zone proteins during 
ciliogenesis (72). 
1.2.2.3 Transition zone 
The transition zone (TZ) is a highly protein dense region of the cilium that 
makes up the ciliary gate, separating the cilium from the cell cytoplasm. The TZ 
is separated into different functional modules: the NPHP module, the core and 
peripheral MKS modules, the JBTS module and the Inversin compartment (73) 
(Figure 1.4), although these do not directly correspond to the structural 
arrangement in the cilium. The TZ is known to be made up of at least 87 
proteins (associated with the Gene Ontology term (74, 75) “transition zone” 
found using AmiGo database 
(http://amigo.geneontology.org/amigo/search/bioentity) (76)), and a further 600 
proteins are currently being screened as potential TZ proteins (personal 
communication, Dr Katarzyna Szymanska, University of Leeds). Many of these 
may only localise transiently, but it is clear that the molecular organisation must 
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be precise and tightly regulated. Although these functional modules have been 
defined, our understanding of the molecular organisation of the transition zone 
is limited to a few recent super-resolution microscopy studies (44, 60, 77).  
2D stimulated emission depletion (STED) microscopy was used in RPE-1 cells 
to describe the lateral localisations of RPGRIP1L, CEP290, MKS1, TMEM67 
and TCTN2 in relation to centrin, a centrosomal protein, and CEP164, distal 
appendage protein (60). CEP290 was the only protein tested that did not have 
distinct peak localisations on either side of the axoneme and instead localised 
throughout the whole axoneme of the cilium, proximal to the other proteins 
imaged (60). RPGRIP1L has a similar localisation throughout the axoneme but 
more consistently showed intensity peaks on the edges of microtubules. 
TMEM67 and TCTN2 had a larger radial diameter and were also seen in some 
images to extend into the ciliary axoneme. MKS1 was located between these 
two groups of proteins (Figure 1.4B) (60).  
Independently it has been shown from an cross section view that the MKS and 
NPHP modules form concentric rings, each with individual 9-fold symmetry of 
punctate staining, presumably due to microtubule association (34).  
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Figure 1.4 Molecular organisation of the transition zone 
A) The primary cilium transition zone is made up of several functional 
complexes, or modules. The MKS modules, (core and peripheral) are 
made up of transmembrane (TMEM) proteins. The NPHP module  is in the 
ciliary lumen and binds to the microtubule doublets. It is primarily made up 
of NPHP1, NPHP4 and RPGRIP1L, and then further includes the Inversing 
module made up of NEK8 and NPHP3, and the JBTS module made up 
from NPHP5 and CEP290. Adapted from (35) Figure 3C with copyright 
permissions. B) Confirmed localisation of a selection of transition zone 
proteins in relation to centrosomal proteins in RPE-1 cells from STED 
microscopy. RPGRIP1L is associated with the microtubules in the ciliary 
lumen, MKS1 is central in the ciliary lumen whereas both TMEM67 and 
TCTN2 are associated with the ciliary membrane, TMEM67 is spatially 
positioned more internally on the membrane than TCTN2. Adapted from 











Aerial View of Predicted Complex Arrangement Lateral View of Confirmed Arrangement in RPE-1
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1.2.2.3.1 Hierarchy of organisation 
The hierarchy of proteins in the TZ ensures correct molecular organisation and 
recruitment of other transition zone proteins, which is key for function. 
RPGRIP1L is at the top of this hierarchy (summarised in Figure 1.5) (78). 
RPGRIP1L self-assembles and then is able to recruit and assemble the proper 
composition of the TZ cells in a cell-dependant manner (79). However NPHP1, 
also high in the hierarchy, appears to have a minor role in aiding the recruitment 
of RPGRIP1L (78). SIM microscopy of Nphp1−/−  mouse embryonic fibroblasts 
had 15% less RPGRIP1L localised to the transition zone compared to controls 
(34). However, the determination of proteins in functional modules and their 
hierarchy of organisation in the TZ was mostly defined through genetic 
interaction studies in C.elegans (80, 81).  
The TZ and its interaction with the ciliary membrane and pocket make up the 
ciliary gate (80). The main proteins in the TZ that contribute to ciliary gate 
function are RPGRIP1L and CEP290 (82), although the correct amount of 
CEP290 in the TZ is regulated by RPGRIP1L (82) . The other ciliary luminal-
localised proteins, such as inversin and the NPHPs are located within the ciliary 
membrane and outside of the microtubules and are not essential for ciliary gate 
function (78). This, in turn, suggests that the hierarchy of proteins in the TZ 
does not reflect the importance of their function. NPHP4, which is high in the 
ciliary hierarchy (Figure 1.5), is not essential for ciliary gate function (82).  
This also highlights some functional redundancy within the TZ and ciliary gate. 
As a functional TZ can still be formed and maintained even with complete 
knock-outs of proteins, during the evolution of mammalian cilia it is possible that 
proteins have evolved to compensate in the absence of another or where 
genetically duplicated. 
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Figure 1.5 Hierarchy of organisation in the transition zone 
RPGRIP1L is the primary organising protein of the transition zone and 
localises independent of other TZ proteins. RPGRIP1L recruits NPHP4, 
B9D2, B9D1 and TMEM67, which in turn ensure the organisation of the 
MKS complexes. However proteins at the bottom of this hierarchy  
(TMEM216, MKS1 and TMEM67) are associated with severe ciliopathies 
such as Meckel syndrome and Joubert syndrome. Proteins with  saturated 
colour represent greater association with severe phenotypes. The inversin 
complex spans from the basal body to the above the transition zone and 
into the ciliary axoneme. It physically interacts (black arrows) with all other 
modules, and has been suggested to act as a bridge for interactions 
between modules (78). Image presented is from (78), Figure 2 and used 
with copyright permissions. 
1.3 Primary ciliogenesis 
Primary ciliogenesis is tightly linked to the cell cycle, since the basal body 
functions as both the mitotic spindle and is derived from the mother centriole 
(28). Cilia were originally thought to form in cells during both G1 or post-
mitotically at G0 in quiescent cells. However, recent work in mouse cell models 
presented evidence that ciliogenesis can occur throughout the cell cycle and 
was not restricted to G1 as previously thought (83). Subsequently, it was 
hypothesised that the capacity of daughter cells to ciliate is inherited, and that 
cells are pre-primed for ciliogenesis based on the inheritance of the mother 
centriole (83, 84). 
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The full molecular mechanism of ciliogenesis is yet to be fully defined, however 
two pathways have been described. The first is an extracellular pathway where 
the centriole matures and migrates straight to the plasma membrane, where it 
docks though distal appendages and extends its axoneme through IFT (Figure 
1.6) (25). The second pathway is an intracellular pathway, by which a ciliary 
vesicle initially forms at the mature centrosome, ciliary proteins are recruited, 
and a nascent cilium forms within the cell, prior to docking at the plasma 
membrane and before fully extending (Figure 1.6) (25). 
 
Figure 1.6 Two pathways of primary ciliogenesis 
There are two suggested pathways for ciliogenesis: A) Extracellular 
ciliogenesis occurs after the mature mother centriole is localised to the 
apical plasma membrane. CP110 is removed from the centrosome which 
allows the recruitment of membrane proteins and IFT for axoneme 
extension. A transition zone forms and after full axoneme extension the 
primary cilium is formed. B) The intracellular pathway describes the first 
stage of ciliogenesis as comprising the recruitment of pre-cilliary vesicles 
to the distal appendages. Once fused these form a ciliary vesicle, which is 
associated with the loss of CP110. Recruitment of membrane proteins and 
IFT allows the formation of a nascent cilium into the ciliary vesicle. Once a 
transition zone forms the cilium docks and fuses with the plasma 
membrane. Adapted from (25) Figure 4 with Copyright permissions. 
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1.3.1 Centriole to centrosome conversion 
A pre-requisite to ciliogenesis is the conversion of the inherited centrioles into a 
full mature centrosome (25). The centrosome is made up two linked centrioles 
surrounded by a dynamic matrix of proteins that control the centrosome’s 
functions (25). The proximal end of the centriole recruits peri-centriolar matrix 
(PCM), made up of hundreds of proteins that form an amorphous mass around 
the centrioles, however it has been shown using 3D-structured illumination that 
there are distinct rings of proteins, such as pericentrin and CEP215 amongst 
the PCM (85). Following the PCM, centriole satellites are recruited. These 
satellites include proteins such as PCM1, alongside proteins found elsewhere in 
the cilium such as CEP290 and BBS4 (86). The PCM and satellites interact to 
allow the satellites to shuttle proteins the PCM for and the recruitment of other 
ciliary proteins from the cytosol (87). 
Once the PCM is accumulated, the distal end of the mother centriole also forms 
distal appendages (DAPs) that attach to the main microtubule structure (24). 
Furthermore, in some cell types the centriole also recruits sub-distal 
appendages as discussed in Section 1.2.1.2. As it is only the mother centriole 
that recruits DAPs, DAP proteins such as CEP164 (88), are often used as a 
mother centriole markers to allow researchers to distinguish the two centrioles. 
siRNA knock-downs of DAPs such as CEP164 show that these are essential for 
the docking of the centriole (24).  
1.3.2 Pre-ciliary vesicles 
The first stage of intracellular ciliogenesis is the formation of a pre-ciliary 
vesicle. It has been demonstrated in human RPE-1 cells that RAB11-associated 
vesicles recruit Rabin8 to the centrosome, which in turn is able to recruit and 
locally activate RAB8 (89). These vesicles are first trafficked using dynein along 
microtubules to the PCM (90). At the PCM, the vesicles use myosin-Va to travel 
along the branched actin network associated with the centrosome to the DAPs 
(90). Here, the RAB11-associated vesicles then become associated with each 
of the DAPs. These distal vesicles are remodelled by EPS15-homology-domain-
containing proteins to increase the proximity to the vesicles (46). The vesicles 
are then able to fuse together to form a pre-ciliary vesicle, a process mediated 
by SNAP29 (46).  
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After the pre-ciliary vesicle has formed, the membrane extends and ciliary-
specific proteins are recruited. As the axoneme extends through active IFT, 
transition zone proteins are also recruited for the formation of a transition zone 
and a full nascent cilium (Figure 1.6). 
1.3.3 Basal body docking 
Although it has been shown that during initial ciliogenesis, vesicle transport 
required for ciliogenesis is dependent on myosin-Va as described in 1.3.2, the 
transport mechanism of the centrosome to the apical membrane or the transport 
of a whole nascent cilium is not understood. Once at the membrane, docking 
only occurs after TTBK2 is targeted to the mother centriole through cell cycle 
cues (24). This is required to signal the removal of the CP110 distal protein, 
which acts as a cap to the distal region of the centriole. This distal cap is 
stabilised by Kif24 to prevent inappropriate ciliary assembly, which also acts to 
destabilise microtubules as a further preventative mechanism against ciliary 
formation (91). This removal of CP110 and TTBK2 is essential for basal body 
docking at the plasma membrane (24). 
Through an unknown mechanism, the distal appendages then bind to the 
plasma membrane to support and dock the mother centriole. Once docked, the 
centriolar microtubules are able to extend to begin the formation of the ciliary 
axoneme. 
1.3.4 Actin remodelling in ciliogenesis 
Actin remodelling factors have recently been shown to negatively regulate 
ciliogenesis (92-94). The timing of these actin dynamics and their exact role in 
ciliogenesis still requires further research, as it is poorly understood and 
currently only modelled with global actin changes, which do not reflect the likely 
local and nuanced changes during normal ciliogenesis. In general, actin 
depolymerisation, through either siRNA knock-down of actin regulators or 
chemical inhibition of actin polymerisation with cytochalasin D, promotes 
ciliogenesis in all cell culture conditions (confluency and presence/absence of 
serum). 
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As discussed in section 1.3.2, actin is also required around the centrosome for 
delivery of ciliary vesicles and cargo. Furthermore, acto-myosin contraction, in 
co-ordination with microtubule remodelling, has been implicated in the 
movement of the basal body to the apical membrane during ciliogenesis (95). 
Although these structural changes to the actin cytoskeleton promote 
ciliogenesis, actin remodelling has also been shown to transcriptionally control 
the negative regulators of ciliary disassembly Aurora A and Plk1 through YAP-
mediated Hippo signalling (92). 
A whole genome siRNA screen that was published in 2010 sought to identify 
modulators of ciliogenesis and cilia length (96). The two main regulators that 
were further investigated were gelsolin (GSN), a positive regulator, and actin-
related protein 3 (ACTR3), a negative regulator. Both are involved in the 
regulation of actin filament stabilisation: GSN severs actin filaments and ACTR3 
inhibits branching. Knock-downs of these genes, in parallel with cytochalasin D 
treatment (a chemical inhibitor which depolymerises F-actin by binding actin 
monomers), suggested an important role of branched F-actin in modulating 
ciliogenesis, with dynamic or destabilised actin promoting ciliogenesis and 
increased cilia length. Cytochalasin D has also independently been shown to 
rescue ciliogenesis under siRNA knock-down conditions of CEP290, NPHP5 
and IFT88 (70, 97). These observations provide additional evidence to support 
the essential role of actin cytoskeleton regulation in modulating ciliogenesis. 
Additionally, a follow-on paper by researchers who were involved in the 2010 
genome screen further investigated actin regulators. This included LIMK2 and 
TESK1, separate actin regulators (98). When either of these proteins were 
knocked-down by siRNA there was a significant increase in cilia incidence (98). 
The authors linked this to increased vesicle trafficking, which in-turn signalled 
changes in Yes-associated protein/tafazzin (YAP/TAZ) localisation and Hippo 
signalling (98). 
It was proposed by Kim et al. 2010, that destabilised F-actin allows for 
increased vesicle trafficking, whereas stabilised F-actin would create a physical 
barrier to ciliary vesicle trafficking around the base of the cilium or centrosome 
during ciliogenesis (92). However, both the screen and downstream work did 
not take into account the over-expression of Smo (their ciliary marker) (96, 98). 
When Smo is overexpressed it artificially activates the Shh pathway, and Smo 
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overexpression causes excessive GLI activation which is linked to cancer 
progression and cell cycle dysregulation (99), thus potentially interfering with 
the ciliary phenotypes assessed. 
As actin cytoskeleton remodelling had been implicated in the regulation of 
ciliogenesis initiation, separate studies assessed the possible role of non-
muscle myosins in the remodelling of actin during ciliogenesis (100). A study by 
Rao et al. found that the myosin heavy chains Myh10 and Myh9 acted 
antagonistically to modulate ciliogenesis (101). Myh10-dependent actin 
dynamics were shown to regulate the correct localisation of pre-ciliary complex 
proteins  PCM1 and CEP290, and promote ciliogenesis. Interestingly, loss of 
cilia following Myh10 knock-down could be rescued by treatment with 
blebbistatin (100), a chemical inhibitor of acto-myosin contraction.  
An interacting partner of CEP290 at the centrosome, CP110, has also been 
linked to F-actin destabilisation through microRNA regulation (102). F-actin 
destabilisation was described as stimulating the accumulation of 
pericentrosomal pre-ciliary compartment proteins to the mother centriole, an 
important prerequisite stage of ciliogenesis (102). 
Although there is increasing evidence for the role of actin destabilisation in 
promoting ciliogenesis, in multi-ciliated cells these is support for the opposite 
(103). F-actin stabilisation and an enriched actin web supports the docking of 
basal bodies in mouse tracheal epithelial cells, promoting ciliogenesis (103). 
This was induced by Forkhead box protein J1 (FOXJ1), which promoted RhoA 
activity during ciliogenesis (103), and thus is likely to regulate the activation of 
ROCK-mediated actin remodelling. However, as discussed by Kim et. al. 2010 
(98), this process may be downstream of initial dynamic actin remodelling which 
allows centriole migration.  
1.3.5 Maintenance of cilia 
Due to the high volume of traffic into and out of the cilium during normal cell 
homeostasis, ciliary maintenance and stability is essential for its function. The 
constant renewal of ciliary membrane proteins and transduction of signal 
requires functional IFT and delivery of cargo from the cytoplasm to the cilium. 
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1.3.5.1 Vesicle trafficking maintains ciliary signalling and membrane 
composition 
Currently the mechanism for the delivery of ciliary membrane proteins is not 
fully understood. It is thought that ciliary cargo is arranged into ciliary-specific 
vesicles at the trans Golgi network (TGN) (104). On these vesicles, proteins 
containing ciliary targeting sequences (CTS) (105) are recognised and mark the 
vesicles to be trafficked to the cilium (Figure 1.7). These CTS are highly 
variable between proteins, and a set consensus sequence has yet to be found, 
possibly reflecting the non-specific binding region in the BBSome that is able to 
recognise a wide range of cargos (64). The specificity of cargos could be 
regulated through the recognition of these sequences by small GTPases such 
as ARL13B and RABs, which in turn interact with the BBSome, however 
evidence has also been published refuting this hypothesis (64). There is further 
evidence suggesting that the BBSome interacts with Rabin8 to regulate RAB8- 
and RAB11-marked vesicles (106). RAB8 directly interacts with RAB11 (106), 
and this marks vesicles as ciliary-specific. These marked vesicles are thought to 
be trafficked along the actin cytoskeleton (92, 102, 107) rather than 
microtubules, and would therefore move by association with myosin motors 
(108). These vesicles then accumulate at the ciliary base where Rabin8, in co-
ordination with the exocyst complex, tethers the vesicles to the periciliary 
membrane or ciliary pocket and membrane proteins are deposited by fusion, 
mediated by SNARE proteins, allowing lateral diffusion of proteins into the 
cilium (45, 47, 109). Furthermore, CEP290 has also been shown to interact with 
RAB8 (86), possibly recruiting the vesicles to the base of the cilium. Another 
transition zone protein CC2D2A has also been shown to facilitate protein 
transport through RAB8-dependant processes in photoreceptors, highlighting 
that many ciliary components have multiple roles in ciliogenesis and ciliary 
maintenance. This vesicle trafficking mechanism is also important in initial 
ciliogenesis as discussed in (Section 1.3).  
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Figure 1.7 Vesicular transport to the cilium 
Vesicle transport to the cilium. RAB8- and RAB11- marked vesicles are 
formed at the trans Golgi network. These vesicles can then be trafficked 
along actin filaments to the ciliary pocket, where they tether to the 
membrane through interaction with Rabin8 and exocyst, before fusion and 
delivery of membrane protein cargo. Other proteins implicated in vesicle 
transport include the BBSome and IFTs. Figure adapted from (110) Figure 
1.3 and use licensed under CC BY-ND 2.0 with Copyright. 
 
Another hypothesis for ciliary transport emphasises a role for IFT-B in targeting 
ciliary cargo. IFT20 has been shown to be directly associated with the TGN and 
mediates transport of polycystin-2 in mammalian cilia (104). It was hypothesised 
that IFT20 interacts with PKD-2 and marks vesicles for ciliary transport, and this 
direct binding to an IFT-B protein allows it to remain attached and to be shuttled 
in ciliary membrane (111). IFT-A has also been implicated in ciliary vesicle 
trafficking; IFT121 mutant RPE-1 cells have reduced formation of RAB8 
vesicles and delivery of membrane proteins (70, 71), suggesting a role for IFT-A 
in transport outside of the cilium. 
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1.3.5.2 Actin stabilisation maintains ciliary structure and function 
The ultrastructure and function of the ciliary pocket is maintained by stable and 
dynamic actin filaments. This membrane invagination is maintained by stable 
and dynamic actin filaments, where more dynamic actin is found at the distal 
end of the ciliary pocket to facilitate vesicle trafficking of ciliary cargo (112). 
Alongside actin negatively regulating ciliogenesis and cilia length, it has also 
been implicated in ciliary stability (113). Human and mouse mutant models of  
KDM3A-/-, a multifunctional protein shown to have roles as a transcription factor 
for free actin, have reduced cellular actin levels and an associated increase in 
cilia. As there is reduced actin around the base of the cilium in KDM3A mutants, 
it was proposed that the loss of this physical gate would allow for an increase in 
IFT at the cilium, disrupting the balance of transport proteins (113). This 
dysregulation is further compounded by actin instability causing an increase in 
cilia length, further disrupting the balance and regulation of IFT (113).  
RhoA is the activator of ROCK, a key actin remodelling regulator (114, 115). 
RhoA has been shown to contribute to the molecular pathology of ciliopathies: 
increased RhoA levels were observed in dermal fibroblasts from ciliopathy 
patients with TMEM216 mutations (99). Independently, RhoA has also been 
shown to mislocalise in patients with JBTS syndrome (specifically caused by 
TMEM237 mutations), and patient fibroblasts had increased actin stress fibres 
(116). 
Cellular phenotypes observed in many ciliopathies are caused by defects of the 
actin cytoskeleton (99, 117, 118). A study into Bardet-Biedl syndrome found 
Bbs4- and Bbs6-deficient renal epithelial cells derived from mutant mice had 
very low cilia incidence, associated with increased focal adhesions and 
abnormal actin stress fibres (117). These aberrant changes in the actin 
cytoskeleton were ascribed to highly up-regulated RhoA expression (119). 
RhoA-GTP is a direct activator of ROCK2, and thus increased ROCK2 activity 
would lead to increased stress fibre formation and F-actin stabilisation. When 
these cells were treated with Y27632, a non-specific inhibitor of ROCK and 
ribosomal S6 kinase (RSK) families, cilia incidence was rescued. Thus, it was 
suggested that the actin cellular phenotype was the cause of the loss of cilia in 
the Bbs4 and Bbs6 mouse mutants (117). 
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1.3.5.3 IFT-A maintains the ciliary transition zone 
Furthermore, the delivery of proteins is also regulated at the ciliary gate. The 
transition zone must be stable in order to correctly allow the necessary proteins 
to diffuse into and out of the ciliary axoneme, maintaining the highly specialised 
composition of the ciliary membrane. IFTA-dynein, mediating retrograde IFT, 
has been implicated in the recruitment and building of a functional transition 
zone during ciliogenesis (113), as well as for maintenance of the transition zone 
in C. elegans (72). Dynein mutants were shown to have high concentrations of 
ectopic, mis-assembled transition zone proteins which were able to diffuse out 
of the transition zone and localise at the tip of a short bulbous cilium (72, 120), 
highlighting an important function for IFT-A in transition zone assembly and 
stability.  
 
Figure 1.8 IFT-A maintains transition zone integrity 
In wild-type cilia some transition zone proteins diffuse along the ciliary 
membrane and mis-localise at the base of the cilium. These are retrieved 
by IFT-A/dynein retrograde transport to maintain the transition zone. IFT-A 
mutants present with a short and bulbous cilium, with an accumulation of 
transition zone proteins at the tip of the cilium. These cannot be retrieved 
by IFT-A, and therefore compromise the transition zone’s integrity. Figure 
adapted from (72) and used with Copyright permissions. 
Wild-Type
IFT-A Mutant
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1.3.6 Disassembly of cilia 
As cilia are tightly linked to the cell cycle, complete disassembly must occur by 
the end of G2 to allow the centriole to be repurposed as a spindle pole in 
mitosis. Until recently it has been thought that ciliary resorption occurs by S-
phase prior to centriole duplication. However new evidence from mouse cells 
expressing a fluorescence ciliary marker and cell cycle biosensor shows that 
ciliary retention can occur until late G2 (83).  
Although the timing of ciliary resorption varies and can occur throughout the cell 
cycle, presumably the signalling pathways that activate it are constant. Studies 
into cilia resorption add serum to cell cultures to trigger the restart of the cell 
cycle, and have characterised resorption to occur in two waves, the first 
occurring before S phase and the second occurring in G2 (121). However, the 
full molecular mechanisms behind these waves of resorption are still poorly 
understood. 
It is known that signalling for ciliary resorption is regulated by Aurora A (AurA), a 
centrosomal kinase that signals for mitosis. Aurora A activation leads to the 
direct phosphorylation of histone deacetylase 6 (HDAC6) (122). This in turn 
deacetylates the ciliary axoneme, promoting ciliary disassembly. 
Inositol polyphosphate-5-phosphatase E (INPP5E) has also been linked to the 
regulation of ciliary disassembly. INPP5E dephosphorylates PI(3,4,5)P3 and 
PI(4,5)P2 in the ciliary membrane, and is thought to maintain the ratios of these 
phospholipids to confer ciliary stability (123). Loss of INPP5E is associated with 
more rapid ciliary disassembly, likely due to unbalanced levels of phospholipids 
and the ciliary response to cell cycle signals. 
Research over the last 5 years has further revealed that disassembly of cilia 
occurs after an initial de-capping step. This de-capping is controlled by 
intraciliary F-actin and PI(4,5)P2, to bud off the tip of the cilium (50). This 
budding has been hypothesised as a mechanism to quickly dispose of ciliary 
membrane proteins at the ciliary tip (53). This de-capping step then signals, 
through an unknown mechanism, to initiate full ciliary disassembly (50). The full 
resorption of the remaining cilium is also poorly defined. It is unknown if the 
cilium is resorbed from the base, or is disassembled from the tip down.  
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There is also recent evidence that mammalian cilia are lost in a whole-cilium 
shedding event (124). It was shown by Mirvis et al. that intracellular calcium 
levels controlled IMCD3 cells decision to de-ciliate. The deciliation occurred via 
resorption as discussed above or by whole cilium shedding, which could then 
be recovered from cell growth media (124). 
1.4 Primary cilia function 
Primary cilia have a variety of roles in many cellular signalling pathways, and 
also have many important functions throughout the stages of embryo 
development by establishing the flow of morphogens through nodal cilia (14, 
125), but also in many developmental signalling pathways (126). As previously 
mentioned they have an essential for phototransduction in photoreceptors and 
have diverse roles in mechanosensation of flow in vessels, ducts and tubules in 
several organ types. Alongside these dedicated roles, cilia are also involved in 
more general cell homeostasis(126). 
1.4.1 Signalling 
Primary cilia are often described as antennae-like (7), not only for their 
structural shape but because they mediate a diverse range of signalling 
pathways they are involved in, such as; Hedgehog (Hh) (127, 128), Wnt 
signalling (129), mammalian target of rapamycin (mTOR) (130), Hippo (131), G 
protein coupled receptor (GPCR) (132), extracellular signal-related kinase/c-jun 
N-terminal kinase (ERK/JNK) (133), and transforming growth factor beta (TGF) 
(134) signalling. 
Cilia have a known role in the mammalian target of rapamycin mTOR signalling, 
which regulates cell proliferation, autophagy and protein production (135). 
mTOR signalling is implicated in the aetiology of kidney cysts in mouse models 
(136). The presence and size of these kidney cysts can be reduced with 
rapamycin, which inhibits the mTOR signalling which is dysregulated by cilia 
loss (135, 137). 
The Hippo signalling pathway, a conserved pathway regulating cell proliferation, 
has also been linked to cilia (131). NPHP proteins and interactors negatively 
regulate Hippo signalling in relation to cell proliferation and ciliary disassembly 
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(131, 138, 139). Other signalling pathways that have been linked to ciliopathy 
pathology or cilia regulation include GPCR signalling (reviewed in (132)), 
receptor tyrosine kinase (RTK) signalling (Reviewed in Christensen et al., 2017 
(140)), and ERK/JNK signalling which has been linked to polycystic kidney 
disease pathology (133) and regulation of ciliary length (141). Furthermore, 
TGF signalling pathways are thought to be transduced through the ciliary 
pocket, and receptors have been shown to localise to the ciliary tip (134, 142). 
1.4.1.1 Hedgehog (Hh) signalling 
Hedgehog (Hh) signalling is a conserved pathway essential for embryo 
development and tissue regeneration. When dysreglated Sonic Hh signalling 
can also lead to inherited cancers such as Gorlin syndrome (143). 
There are three mammalian ligands: Indian hedgehog (Ihh), Desert hedgehog 
(Dhh), and Sonic Hedgehog (Shh). The best characterised of this family is 
Sonic Hedgehog (Shh) (144), which is essential in generation of the anterior-
posterior axis, axial skeleton, spinal cord and developing limb bud, as well as 
regulating neural tube cell fate (145). 
Patched (Ptch1), a 12 transmembrane domain glycoprotein is the signal 
transducer of Hh signalling, and is located in the ciliary membrane and ciliary 
pocket. Here, Ptch1 can inhibit the translocation of Smoothened (Smo) into the 
cilium. While Smoothened is excluded, full length Gli (GliFL) is transported into 
and out of the cilium normally. GliFL is sequestered by the key Shh regulator 
SuFu. Once sequestered, GliFL is phosphorylated and targeted for proteasomal 
cleavage in the cytoplasm, turning it into the Gli transcriptional repressor (GliR). 
GliR translocates to the nucleus and suppresses the expression of Shh target 
genes such as cyclins (146). 
When Shh is present, it binds to Ptch1. This initiates Ptch1 to move out of and 
be excluded from the ciliary membrane, allowing the translocation of Smo into 
the ciliary membrane. GliFL is then differentially phosphorylated and activated 
(termed GliA) by an unknown mechanism. GliA is transported out of the cilium 
where it then acts as a transcriptional activator, turning on genes and initiating a 
feedback loop by expressing Ptch1 and protein regulators of Gli degradation. It 
is also thought that cytosolic GliFL is activated to GliA by a separate poorly 
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described mechanism (146). This pathway is the most common one tested in 
assays of ciliary function.  
A) Absence of Hh    B) Presence of Hh 
 
Figure 1.9 Hedgehog signalling in cilia 
A) Schematic diagram shows the localisation of signalling components 
without the presence of Hedgehog (Hh). Ptch1 prevents translocation of 
Smo into the cilium. This leads to full length Gli (GliFL) being transported 
out of the cilium and cleaved into the repressor form (GliR). This represses 
gene expression of target genes. B) In the presence of Hh, this binds to 
Ptch1 and thus allows Smo translocation into the ciliary membrane. Smo 
presences leads to activation of Gli (GliA). This is transported out of the 
cilium and activates target genes once in the nucleus. Adapted from (146) 
Figure 1 with copyright permissions.  
 
1.4.1.2 Wnt Signalling 
Wnt signalling is a highly-conserved signalling pathway that regulates a plethora 
of cellular processes such as; motility, stem cell renewal, polarity and 
organogenesis (Reviewed in Logan and Nusse, 2004 (129)). Dysregulated Wnt 
signalling is associated with severe embryogenesis defects such as spina bifida 
(147) and in adults, can lead to several types of cancer (reviewed in Zhan et. al, 
2017 (148)). There are two main arms of the Wnt signalling pathway: the 
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canonical and non-canonical, both of which are initiated by the binding of a Wnt 
ligand to a Frizzled (Fzd) receptor. Canonical Wnt signalling leads to the 
activation of Wnt targeted gene expression, whereas the non-canonical Wnt 
pathway  either turns on Wnt targeted genes or leads to actin remodelling. 
1.4.1.2.2  Canonical Wnt signalling 
In canonical Wnt signalling, Wnt binds to a seven transmembrane Frizzled 
receptor, of which there are 10 in humans (149). Once Wnt is bound, Frizzled 
associates with its co-receptor LRP5/6, leading to the recruitment and 
phosphorylation of Dishevelled (Dvl) at the plasma membrane. This activation of 
Dishevelled recruits and disassembles the destruction complex through binding 
axin. The destruction complex, made up of axin, casein kinase 1 (CK1), 
adenomatous polyposis coli (APC) and glycogen synthase kinase 3 (GSK3) 
is responsible for β-catenin degradation in the absence of Wnt. Once the 
destruction complex is disassembled, this allows the accumulation of β-catenin 
levels in the cytoplasm, leading it to translocate into the nucleus (150). Once in 
the nucleus, β-catenin acts with co-transcriptional activators and transcription 
factor/lymphoid enhancer-binding factor (TCF/LEF) proteins, to turn on genes 
such as cyclin D 1 (151). 
In the absence of Wnt, CK1 and GSK3 of the destruction complex 
phosphorylate β-catenin. This phosphorylation targets β-catenin for degradation 
through the proteasome (150). 
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1.4.1.2.3  Non-canonical Wnt signalling 
There are two sub-arms of non-canonical Wnt signalling. The first is the 
Wnt/Ca2+ pathway in which the signal is transduced by calcium signalling which 
also leads to the transcription of Wnt activated genes and calcium-sensitive 
kinases (eg. protein kinase C). The second sub-arm is the Wnt/planar cell 
polarity (PCP) pathway, which controls cell migration and orientation. This 
pathway occurs through different co-receptors, which cause the activation of 
RhoA, leading to changes in actin regulation and the cytoskeleton (152).  
1.4.1.2.1  Wnt signalling through primary cilia 
It has been controversially suggested that loss of cilia, due to Ift88 mutations in 
mice, was associated with an increase in both cytoplasmic and nuclear β-
catenin levels (153), suggesting an over activation of canonical Wnt signalling. It 
has also been noted that suppression or silencing of BBS1, BBS4 or Kif3a 
causes stabilisation of β-catenin. However, loss of cilia in zebrafish, a lower 
eukaryote, has been shown to affect Hh signalling but not Wnt signalling (154). 
This suggest, although refuted (154, 155) that the association between Wnt 
signalling and cilia could be specific to mammals. 
Inversin has been shown to be essential in recruiting Dishevelled in response to 
Wnt binding of Frizzled receptors. Inversin is localised to the basal body of cilia 
and interacts with NPHP proteins in the transition zone. When mutated, these 
genes cause nephronophthisis, a ciliopathy that has developmental 
(microcystic) and degenerative kidney defects correlated to excessive Wnt 
signalling (156).  
Once recruited to the membrane by Inversin, both Inversin and NPHP4 can 
antagonise Dishevelled and reduce the downstream transduction of signal, 
allowing levels of the destruction complex to remain active and reduce the 
accumulation of β-catenin (Figure 1.10). However, this is still a disputed topic as 
zebrafish ciliopathy models such as IFT mutants still have normal regulation of 
Wnt signalling. This is further disputed in the IFT mouse models, with reports of 
normal responses to Wnt in the mouse embryonic fibroblasts (MEFs) (155). The 
complexity of this pathway makes dissecting the exact role of cilia in Wnt 
signalling difficult. It may be that compensatory mechanisms are at play, or fine 
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control of Wnt signalling through the cilium is dispensable. It may also be a 
time-dependant process and, only be important in the initial stages of 
development, rather than postnatal growth or tissue function (157, 158).  
 
Figure 1.10 Cilia in canonical Wnt singalling 
Schematic diagram showing canonical Wnt signalling with and without the 
presence of a cilium. Under normal conditions -catenin is degraded by 
the destruction complex in the cytoplasm. When Wnt binds to the Frizzled 
receptor (Fzd), along with its co-receptor LRLP5/6 it recruits Dishevelled 
(Dvl) to the membrane and activates it. This in turn causes the destruction 
complex to be recruited to the membrane, therefore allowing -catenin to 
accumulate and translocate into the nucleus to work with transcriptional 
activators to turn on Wnt activated genes. In the presence of the primary 
cilium, inversin (INV) and NPHP4 inhibit the activation of Dvl and therefore 
modulate the level of signal transduction, giving fine control in response to 
Wnt signalling. Adapted from (159) Figure 4, use licensed under the 
Creative Commons Attribution 4.0 International License. 
1.5 Ciliopathies and disease 
1.5.1 Non-motile ciliopathies 
Non-motile ciliopathies are a spectrum of usually autosomal recessive disorders 
that are caused by mutations that affect ciliary structure or function. Due to the 
presence of primary cilia on most cells in the body, the phenotypic spectrum 
and multi-system pathology of ciliopathies greatly varies. This spectrum ranges 
from isolated retinal degeneration to a collection of more severe phenotypes 
including perinatal death. Examples of non-motile ciliopathy phenotypes include 
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retinal degeneration, polycystic kidneys, polydactyly, obesity, neural tube 
defects, learning disabilities, skeletal dysplasia, hypoplasia of essential organs 
and laterality defects. 
Ciliopathies are an expanding class of disorders, as an increasing number of 
previously defined and new conditions become associated with the 
dysregulation of primary ciliary processes. Individually, ciliopathies are rare, but 
as a group of inherited disorders, ciliopathies are comparatively common 
compared to other inherited diseases.  
Management of ciliopathy patients focuses on systematic therapy. There are 
however, no clear guidelines for the management of these patients, likely due to 
the pleiotropy of phenotypes. The best studied are listed with their associated 
mutated genes and phenotypes in Table 1.1. 
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Table 1.1 Ciliopathy genes and phenotypes 
Mutations in genes highlighted in bold cause more than one ciliopathy, 
phenotypes highlighted in bold are common across several ciliopathies. Human 
Phenotype data source: Online Mendelian Inheritance in Man, OMIM®; 
Associated Genes data source: U.S. National Library of Medicine. This is not an 
extensive list of phenotypes. Other phenotypes may be present in individual 
families or are less common amongst patients. List generated from the most 
common ciliopathies, as recognised by the Ciliopathy Alliance (160). Autosomal 
Dominant form of the disease is denoted by (AD), Autosomal Recessive by 
(AR) and X-linked by (XL).  




ALMS1, RYR2 Short stature, Obesity, 






abnormalities, Renal failure, 
Skeletal abnormalities, 
Developmental delay, 
Diabetes, Hyperthyroidism,  
Bardet-Biedl 
Syndrome 
ARL6, BBS1, BBS2, BBS4, BBS5, 
BBS7, BBS9, BBS10, BBS12, 













CEP120, CSPP1, DYNC2H1, 
IFT80, IFT140, IFT172, TTC21B, 





AHI1, ARL13B, B9D1, B9D2, 
C2CD3, CC2D2A, CEP41, 
CEP104, CEP120, CEP290, 
CPLANE1, CSPP1, IFT172, 
INPP5E, KIF7, MKS1, NPHP1, 
OFD1, PDE6D, POC1B, 
RPGRIP1L, TCTN1, TCTN2, 
TCTN3, TMEM67, TMEM107, 
TMEM138, TMEM216, TMEM231, 
TMEM237, TTC21B, ZNF423 
Macrocephaly, Ptosis, 
Breathing dysregulation, 
Ataxia, Hypotonia, Molar 
Tooth Sign (on MRI), 





AIPL1, CEP290, CRB1, CRX, 
GUCY2D, IMPDH1, IQCB1, LCA5, 
LRAT, NMNAT1, PRPH2, RD3, 









B9D1, B9D2, CC2D2A, CEP290, 
MKS1, RPGRIP1L, TMEM67, 
TMEM216 
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abnormalities, 
Hypogenitalism, Polycystic 
kidneys, Perinatal Death  
Nephronophthisis ANKS6, CEP83, CEP164, GLIS2, 
INVS, NEK8, NPHP1, NPHP3, 
NPHP4, TMEM67, TTC21B, 
WDR19, ZNF423 
Nephronophthisis, Tubular 
atrophy, End stage renal 




AD: DNAJB11, GANAB, PKD1, 
PKD2 
AR: DZIP1L, FCYT, PKHD1 
Polycystic kidney, Renal 




AD: ABCA4, ARL3, BEST1, CA4, 
CRB1, FSCN2, GUCA1B, IMPDH1, 
KIF3B, KLHL7, NR2E3, NRL, 
PRPF3, PRPF4, PRPF6, PRPF8, 
PRPF31, PRPH2, RDH12 RHO, 
ROM1, RP9, RGR, SEMA4A, 
SNRNP200, TOPORS 
AR: ABCA4, AGBL5, AHR, 
ARHGEF18, ARL2BP, ARL6, 
BBS2, C2ORF71, C8ORF37, 
CDHR1, CERKL, CLCC1, CLRN1, 
CNGA1, CNGB1, CRB1, CWC27, 
DHDDS, DHX38, EYS, FAM161A, 
HGSNAT, HK1, IDH3B, IFT43, 
IFT140, IFT172, IMPG2, KIAA1549, 
KIZ, MAK, MERTK, NEK2, NR2E3, 
PDE6A, PDE6B, PDE6G, 
POMGT1, PRCD, PROM1, PRPH2 
RBP3, REEP6, RDH12, RGR, 
RHO, ROM1, RP1L1, RPE65, 
SAG, SEMA4A, SLC7A14, TTC8, 
TULP1, USH2A, ZNF408, ZNF513 
XL: OFD1, RP2, RPGR 
Retinitis pigmentosa, 




CEP290, IQCB1, NPHP1, NPHP4, 
SDCCAG8, WDR19 
Nephronophthisis, End 
stage renal disease, Retinal 
degeration, Polyuria, 
Anemia 
Usher Syndrome ADGRV1, AR, ARSG, CDH23, 
CEP250, CIB2, CLRN1, ESPN, 
GPR98, HARS1, MYO7A, 
PCDH15, PDZD7, SANS, USH1C, 
USH1E, USH1H, USH1K, USH2A, 
WHRN 
Hearing loss, Retinitis 
pigmentosa, Delayed motor 
development,  
 
1.5.1.1 Genetic heterogeneity and pleiotropy 
As can be seen in Table 1.1, different mutations in the same gene can cause 
different disorders and phenotypes. This phenomenon is known as pleiotropy, 
where a single gene/allele can produce two or more unrelated affects. In 
addition, mutations in over 30 different genes can cause the same disorder, as 
observed for Joubert Syndrome (JBTS). There is also a high-level of genetic 
heterogeneity, with extensive phenotypic overlap between ciliopathies 
(phenotypes highlighted in bold), but also extensive phenotypic variation within 
each disorder. It has even been documented that members of the same family 
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can present with phenotypic variation (161). For example in family members 
with the same mutation in TMEM216, one member was diagnosed with MKS 
whereas a sibling was diagnosed with JBTS (99). Another extreme example is 
CEP290: mutations in this gene can either cause isolated retinal degeneration 
(162)(such as in some cases of Leber Congenital Amaurosis), or result in the 
far more severe MKS (163) which often presents with anencephaly, skeletal 
abnormalities and cardiovascular defects. Phenotype variation can sometimes 
be explained by simple genotype-phenotype correlations (for example, the 
difference in effect between a severe frame-shift causing a null allele in 
comparison to a hypomorphic missense mutation). However, this simple 
explanation does not provide a satisfactory explanation of the full spectrum of 
phenotype variation across ciliopathies generally. This gap in our understanding 
and the extent of variation makes diagnosis and clinical management of 
ciliopathies a continuing clinical challenge. 
1.5.2.1.1  Expressivity and penetrance 
Expressivity describes a given genotype not being expressed homogenously 
across a population, such that there is a spectrum of a phenotype. A simple 
example of this is seen in the autosomal dominant disease Marfan syndrome, 
where there is variable expressivity of the FBN1 gene. Heterozygous individuals 
often present with elongated digits (arachnodactyly), but amongst this patient 
population digit length is highly variable. Some patients present with extremely 
long digits and associated loose joints, whereas others have fingers just at the 
higher end of the average range (164). These highly variable phenotypes are 
usually attributed to modifier alleles or environmental factors.  
Penetrance describes the presence or absence of a given pathogenic 
phenotype in a population that all carry the same genotype. In contrast to 
expressivity, the expression of phenotypic features does not vary. An example 
of this is Huntington’s disease, where alleles are defined by the number of CAG 
repeats. Alleles with <27 repeats are associated with a normal phenotype, 
whereas alleles with >40 repeats are fully penetrant, such that 100% of people 
with that allele present with the disease (165). There are also incompletely 
penetrant alleles: 36-38 CAG repeat alleles present with the disease in only 
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0.25% of people with that allele. These alleles have also been shown to be at a 
high frequency throughout the general population (166). 
Epistasis describes the interactions between genes. It is a well-defined 
mechanism that affects expressivity and penetrance of diseases. For normal 
cellular function genes must interact positively and negatively for regulation of 
expression, responses to signalling, and developmental pathways. As a 
consequence, epistasis is likely to be ubiquitous in complex disease 
phenotypes (167). Ciliopathies are likely to have a combination of both variable 
expressivity and penetrance (Figure 1.11).  
 
 
Figure 1.11 Penetrance vs expressivity 
The penetrance of a dominant allele determines if the phenotype expresses 
or not, represented as either blue or white in the schematic. Expressivity of 
a dominant allele determines the extent that a dominant phenotype is 
expressed, represented as a range of colours between blue and white. 
Ciliopathies are thought to have a combination of both variable penetrance 
and expressivity across the disease causing genes. 
1.5.2.1.2  Modifier alleles in ciliopathies 
Ciliopathies are mostly diagnosed as autosomal recessive Mendelian 
conditions, for which a biallelic genotype at a single locus is causative for the 
disease phenotype. However, several studies have suggested that the 
additional inheritance of modifier alleles can be an explanation for the 
phenotypic variability in ciliopathies (161, 168). Modifier alleles are variants of 
one gene which modify the molecular expression or function of a separate, 
causative disease locus (reviewed in Kousi and Katsanis, 2015 (169)). Modifier 
allele studies in mice have shown that they affect penetrance, expressivity and 
pleiotropy through epistasis (170), causing the spectrum of phenotypes. 
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Modifier alleles are not to be confused with protective alleles, which instead 
modify an individual’s susceptibility to a non-inherited disease. Modifier alleles 
have been described in autosomal dominant polycystic kidney disease 
(ADPKD). Mice trans-heterozygous for Pkd1 and Pkd2 have a far more severe 
phenotype than single heterozygote mice, suggesting a synergistic epistatic 
interaction between the two genes (171).  
Several retinal degeneration phenotypes have also been associated with 
modifier alleles. RPGR mutant mice were found to have a more severe retinal 
degeneration phenotype with a non-disease causing heterozygous mutation in 
CEP290 (172). The RPGRIP1L A229T allele has also been shown to be 
enriched in BBS and Senior-Løken syndrome (SLS) patients with retinal 
degeneration, compared to an unaffected ethnic-matched population. Khanna et 
al., 2010, described this allele as a modifier that determines retinal 
degeneration in ciliopathy patients (173). 
A group of proteins called molecular chaperones are also considered as more 
global disease modifiers. Chaperones, such as the stress induced heat shock 
proteins (HSP) 70 and HSP90, are essential for the correct assembly of 
proteins (reviewed in Li and Srivastava, 2004 (174)). They have been implicated 
in the expressivity of different mutations because of their role in protein folding, 
and therefore acting as global modifiers of different alleles through widespread 
epistasis (175). Different functional polymorphisms of chaperones therefore 
interact with all variations of alleles differently, which in turn can cause protein 
mis-folding (176). Furthermore, BBS6, 10 and 12 encode are described as 
chaperonin-like proteins, but their role is thought to be specifically for the correct 
assembly and stability of the BBSome. BBS6 evolved from a cytosolic 
chaperonin subunit and acquired a specialised PCM function, so that it can 
encapsulate substrates but is not involved in protein folding (177). Phenotypes 
caused by mutations in these genes have been described as a 
“chaperonopathies’, and it is recognised that these phenotypes are more severe 
than other BBS types, for example in individuals with BBS1 mutations (178). 
Thus, it seems reasonable to hypothesize that different alleles of these genes 
may differentially interact with the BBSome, leading to different expressivity of 
other BBS mutations. However, the molecular data to support this hypothesis is 
lacking at the present time. 
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Over the last decade there has been conflicting evidence for existence of 
modifier alleles in ciliopathies, and despite the isolated examples discussed 
above there are still not widespread systemic functional studies to support these 
hypotheses, there are also too few families with defined alleles that are 
discordant for disease phenotypes for a meaningful study. However, modifier 
alleles still provide a possible explanation of pleiotropy in ciliopathies, but 
human whole-exome or genome sequencing data from ciliopathy patients has 
not yet shown enrichment for secondary, potential modifier alleles in ciliopathy 
genes (179, 180). This does not exclude the possibility of modifier alleles 
located in non-ciliopathy genes or in non-coding regions.  
1.5.2.1.3 Triallelism in ciliopathies 
Triallelic inheritance is a phenomenon by which a phenotype only manifests if 
an individual carries three mutant alleles. This is a type of oligogenic 
inheritance, which refers to a trait that is determined by more than one gene 
locus. Note that this is different to polygenic inheritance which highly complex 
and involved multiple genes and environmental factors. 
Ciliopathies, in particular BBS (181, 182), are one of the few disorders with 
evidence of this digenic triallelic inheritance pattern (three mutant alleles 
inherited between two gene loci), with all three mutant alleles necessary for 
expression of the phenotype. This is therefore a different phenomenon to 
modifier alleles and expressivity discussed above, because biallelic alleles in 
the primary disease locus are not necessary and sufficient for expression of the 
disease phenotype. 
Beales et al., 2003 (183), analysed 259 individual BBS families to investigate 
oligogenic disease inheritance. They identified the BBS1 p.M30R allele, which 
is present in the general population, and that individuals biallelic for p.M30R are 
asymptomatic. In rare instances, the BBS phenotype did not manifest until at 
least one of these alleles in BBS1 is inherited with two mutations at another 
locus, such as BBS2 or BBS4. In another study, an affected family with a 
compound heterozygote mutation in BBS2, only manifested the BBS phenotype 
when inherited with a single p.M30R BBS1 allele (183). The possible genotypes 
and expression of triallelic inheritance is summarised in Table 1.2. 
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Table 1.2 Digenic triallelic Inheritance in BBS 
This table provides an example of triallelic inheritance, based on the 
results of Beales et al., 2003 (183), summarizing the possible genotypes in 
two loci and the possible combinations of inherited alleles. For the 
phenotype to manifest (+), three mutant alleles (b) must be inherited 
across both loci. Therefore only three of nine possible combinations of 
allele inheritance are causative for BBS, and biallelic inheritance for at 
least one gene locus must occur. Therefore, both parents must be carries 
of mutant alleles at one locus, and at least one parent carries a mutant 
allele at the second locus. 
Gene Locus 1 
(BBS 1 M30R) 






BB BB BBBB - 
BB Bb BBBb - 
BB bb BBbb - 
Bb BB BbBB - 
Bb Bb BbBb - 
Bb bb Bbbb + 
bb BB bbBB - 
bb Bb bbBb + 
bb bb bbbb + 
 
1.5.2 Primary cilia in cancer  
The role of the cilium in  essential signalling and developmental has already 
been discussed, but the strong link to cell cycle progression also implicates cilia 
in both sporadic and inherited forms of cancer. Cilia formation and disassembly 
are very tightly linked to the cell cycle, and one of the hallmarks of cancer is 
deregulation of the cell cycle causing over-proliferation cells, hence a logical link 
to cilia dysregulation in contributing to cancer cell phenotypes. The cilium has 
been described as the “tumour suppressor organelle”. A clear example of cilia 
loss correlating with increased cell proliferation has been noted in tumour cells 
and surrounding stromal cells in the early stages of breast cancer (184), 
although does not directly imply that the cilia loss was the cause of cell 
proliferation. 
As well as cell cycle disruption, changes to ciliary-regulated signalling such as 
Wnt and mTOR also have links to cancer progression (148, 185). Cilia loss has 
been specifically described as a mechanism for tumour survival through drug 
resistance, specifically in medulloblastoma (186). By removing the targeting 
signalling response, the drugs are no longer effective. However, in contradiction 
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to this, some tumours develop due to de-regulated ciliary signalling such as 
Smoothened-dependant tumours, and therefore require persistence of cilia to 
develop (186). This highlights a complicated association between cilia incidence 
and cancer development, with each disease association specific to the tumour 
type. Alongside these complications, cancer research is a very broad field of 
study and thus the ciliary role in cancer is still poorly understood and under-
studied. The current knowledge is further discussed in several excellent recent 
reviews (187-189). 
1.5.3 Primary Cilia in other disease 
There is strong recent evidence that suggests ciliary function has an important 
role in diabetes. Cilia are associated with regulating hormonal signals in the 
hypothalamus (190) and are present on α and δ-cells in the pancreas of mice 
and rats (191). Ciliary dysfunction in some mouse models (including Rpgrip1l+/-
(192), BBS2-/- and Bbs4-/- (193)), is reported to be associated with excessive 
eating, possibly through ciliary dysregulation in the hypothalamus, the brain 
centre for weight regulation. These mice have also been shown to have 
impaired insulin secretion, possibly regulated by pancreatic cilia (194), causing 
glucose tolerance to decrease. These symptoms are the pre-requisite for type 
two diabetes. Thus it has been proposed (195) that cilia have a metabolic role in 
the onset of diabetes through weight regulation and insulin secretion. 
Interestingly, diabetes and obesity are often present in ciliopathy patients and 
these phenotypes are part of the primary diagnostic criteria for BBS (196). It has 
been very recently shown that pancreatic islet B cells lacking cilia are unable to 
respond to glucose and thus regulate intracellular Ca2+ levels which in turn, 
regulates insulin secretion (197) providing the mechanistic link between cilia 
and diabetes pathology. 
Cilia have a clear role in development and definition of laterality, and therefore 
congenital heart defects are a frequent clinical feature of some ciliopathies 
(198). However, cilia have also been implicated in sporadic and complex forms 
of heart disease such as vascular aneurisms, atherosclerosis and heart disease 
(199). As previously described in 1.4, primary cilia are mechanosensors of flow 
in many organ systems (200), which appears to include blood vessels. Mouse 
models with conditional endothelial knock out of Ift88 have shown a direct 
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correlation between flow rate and presence of primary cilia (201). Areas of high 
shear stress such as the aorta in the mice displayed short or had absence of 
cilia on endothelial cells, whereas areas of lower flow rates allowed cilia 
elongation. This is turn was associated with the presence of atherosclerosis 
plaques (201).  
1.5.4 Models of Ciliopathies 
As the evidence for a ciliary role in a wider range of conditions expands, the 
need for more diverse disease models increases. This is further confounded 
when modelling disorders with a range of expressivity of disease phenotype. 
Several well-characterised eukaryotic models such as Chalmydomonas, 
Xenopus, zebrafish and mouse are used for different areas of ciliary research 
despite the range of models for ciliary biology, the differences in genetics and 
physiology can limit the relevance of each model for a human disease state.  
Bardet-Biedl Syndrome (BBS) is an example of a pleiotropic ciliopathy that has 
a phenotypic spectrum, as discussed in Section 1.5, which makes traditional 
animal modelling of this condition difficult. It is also often reported that full 
phenotypes are not fully reiterated in murine models (202). Furthermore, human 
dermal fibroblasts and derived induced pluripotent stem cells (iPSCs) have 
clonal variation even for the same individual, presumably due to epigenetic 
changes (203). As a consequence, despite well-studied murine models, many 
aspects of ciliopathy pathogenesis will remain unexplored until more 
physiological or relevant models of disease states can be generated. 
The high conservation of ciliary proteins and ease of study makes many of 
these model organisms ideal for investigating the basis of ciliary structure, 
function and formation. Therefore these models gives reliable if not precise 
insight into the molecular basis behind human disease mechanisms. 
1.5.4.1 Unicellular eukaryotic models 
Simple single-cell models such as Chlamydomonas and Tetrahymena have 
greatly contributed to our understanding of ciliary biology. For example, highly 
conserved IFT complexes were first identified in Chlamydomonas flagella (204), 
and the use of electron microscopy in this model provided essential insight into 
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ciliogenesis and protein trafficking within the cilium (205). Tetrahymena is also 
commonly used in structural and protein work as it has 1000 cilia per cell (206).  
1.5.4.2 Caenorhabditis Elegans 
Validation work and studies into other orthologues of ciliary genes have also 
been extensively researched in higher multicellular organisms such as in C. 
elegans which have neuronal sensory cilia (207). These nematode worms are a 
great model for studying developmental biology as every cell division and 
differentiation throughout the nematodes worm has been described and 
documented. They are also quick to grown and easily to genetically 
maniputlate. However, conservation between human and nematode worms is 
low with many essential proteins in mammalian cilia not having a orthologue in 
the worm to study. 
1.5.4.3 Zebrafish Models 
Zebrafish are a vertebrate model that has cilia on nearly all their cell types. 
Zebrafish are useful to study ciliary effects during development because the 
embryos are transparent and can be genetically manipulated by either 
morpholino oligonucleotide knock-down or transgenesis (208). However, the 
interpretation of zebrafish models of human ciliopathies must be carefully 
considered, because the zebrafish do not manifest a full renal cyst phenotype, 
despite having the characteristic curved tail seen in ciliopathy models (209). 
Furthermore, unlike human renal cilia which are immotile, zebrafish have motile 
renal cilia (16). 
The zebrafish genome has also caused issues for researchers when modelling 
disease. The genome is duplicated and there are many genes that do not have 
orthologues in other species, making it harder to specifically and accurate 
knock-down gene expression but to also accurately sequence and align the 
zebrafish genome. This lead to genetic studies in zebrafish being behind other 
model organisms. 
1.5.4.4 Mouse Models 
Out of all commonly used laboratory models, mice have the most similar 
genome to humans (upwards of 99% (210)). Despite this similarity, ciliopathy 
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gene knock-outs in murine models often show varied phenotypic severity and 
organ specificity differences compared to the human condition. For example, 
mutant mouse models of JBTS genes do not usually display the molar tooth 
sign, the diagnostic feature of JBTS patients (211). The Nphp1 knock-out 
mouse, modelling the most common gene mutated in nephronophthisis (212), 
does not present with kidney cysts as in the human disease but does display 
other ciliopathy-like features such as retinal dystrophy and male infertility (213). 
Thus, although the closest model organism to humans, further supporting work 
needs to be carried out in a human model system to confirm the relevance of 
findings. Despite these differences, mouse models are the most comprehensive 
mammalian model we have to work with commonly in a laboratory setting. They 
provide essential insight and act and pre-clinical models for potential 
therapeutics. 
1.5.4.5 Mouse and Human Cell Lines 
Immortalised mammalian cell lines can offer well-characterised in vitro models 
that can be used for validation of research findings that are observed in other 
eukaryotic models, but without the expense of maintaining a mouse model. 
Murine inner medullary collecting duct cells (mIMCD3) are easy to culture, can 
form polarized monolayers and display long cilia that can be useful for 
immunofluorescence microscopy and protein localization studies. As an 
alternative, the hTERT-immortalized Retinal Pigment Epithelial cell line (hTERT 
RPE-1) is a human immortalized diploid cell model with shorter primary cilia. As 
a human cell line these can be used to confirm findings from other eukaryotic 
models and are particularly useful for studying ciliopathies with a retinal 
phenotype. However, it is important to consider that RPE-1 cells are not 
functioning RPE and have adapted to grow in cell culture. Many other 
commonly used cell models no longer genetically resemble their donor as they 
can become ploidy over time or when immortalised.  
Non-immortalised patient-derived primary cells, usually dermal fibroblasts, can 
offer molecular insight into patient mutations and pathological mechanisms. 
However cellular phenotypes in fibroblasts can change under culture conditions 
and fibroblasts do not present an overt disease phenotype in ciliopathy patients. 
Therefore, more relevant models would use cell lines from affected tissue types. 
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Biopsies from patients can be an intrusive means of cell collection for research 
studies, but recent work has exploited urine-derived human epithelial cells as a 
more acceptable means of collecting patient tissue (214). However, these cells 
do not proliferate in culture and are derived from mixed renal cell populations. 
Genome editing technology such as the CRISPR/Cas9 system (discussed in 
1.6.5.1 and 1.6.7), offers the ability to make both cell models of specific ciliary 
gene knock-outs, or exactly model patient mutations, in many different cell-
types. The other advantage is that cell-lines are isogenic, which is a presumably 
a confounding factor in the use of patient-derived dermal fibroblasts. Therefore 
cell models make an affordable and simpler model for investigating ciliogenesis 
regulators and the molecular mechanisms, without the influence of potential of 
variable epistatic effects due to different genetic backgrounds. However, a 
single mother cell line should be used throughout experiments as it is common 
to note clone to clone variation between laboratories. 
1.5.4.6 iPSCs and organoids 
Different patient genetic backgrounds can affect the interpretation of results 
when investigating epistasis in primary cells, and the lack of this phenotypic 
diversity in animal models or immortalised cell lines is apparent across 
ciliopathy research. Using immortalised cell lines in this thesis allowed 
interpretation to be attributed to the administered genetic perturbations only, 
and therefore phenotypes could be ascribed to the specific genetic interactions 
due to introduced mutations rather than unknown epistatic effects. 
Another benefit to patient-derived iPSCs is that the retrieval of cells is not an 
invasive procedure compared to direct tissue biopsies. Alongside being a 
directly relevant human model, research with iPSCs and derived organoids 
does not require government licencing, unlike work with animal models. 
Organoids resemble a middle ground between animal models and cell lines, as 
they resemble tissues but still lack the complexity of a full animal models. Many 
clinical development compounds have the desired effect on cell lines, but the 
majority do not progress to clinical trials because they do not provide a 
therapeutic effect or have additional deleterious effects when tested in pre-
clinical model organisms. So, although not generally suitable for high-
throughput work, they are an ideal pre-clinical model for investigating the 
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molecular pathology of ciliopathies, and potentially model to test therapeutics 
(215).  
However, for future work in the field of ciliopathies, patient-derived primary cells 
would be invaluable for investigating patient-specific epistatic interactions. 
These phenotypes could be accurately modelled in patient-derived induced 
pluripotent stem cells (iPSCs), which can then be differentiated into appropriate 
disease-affected cells and organoids. However, patient derived cell lines would 
have high-variability. A more time consuming option would be to induce patient 
specific mutations into a control mother iPSC cell line using CRISPR/Cas9 
editing so that the genetic background is consistent through experiments.  
First developed for intestinal tissue (216), ciliopathy organoid models include 
optic cups to study LCA (217) and kidney organoids to model cysts in polycystic 
kidney disease (PKD) (218). These organoids could be a future research tool 
for helping to gain a more accurate understanding of complex ciliary biology. 
This is a highly specialised, expensive and committing technique in terms of 
both time and effort. These limitations made organoids unsuitable for use in this 
thesis and high-throughput screening.  
1.6 Genetic manipulation in biomedical research 
1.6.1 History of Genetics 
A rudimentary understanding of genetics and inheritance began as early as the 
Ancient Greek era, when Hippocrates described pangenesis as the process that 
determines the inheritance of specific traits (219). Following the advances of 
cell theory and the invention of the microscope in 1595, Charles Darwin 
elaborated the theory of pangenesis by suggesting that each organ gave off 
small “germules” that then accumulated in the mother after intercourse to form 
the foetus (220). 
In the mid-19th century the first use of experimental genetics was performed by 
Gregor Mendel. Mendel used cross-pollination of pea plants to describe strong 
individual hereditary factors, each of which were present in pairs. Each single 
factor, one from each parent, was responsible for a trait that was passed on to 
the next generation of pea plant (221). Mendel is now known as the “father of 
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genetics”, and his experimental work provided evidence that contradicted the 
previous ideas put forward by the pangenesis theory. This work is the basis of 
Mendelian inheritance and the foundation of modern genetics. 
Following Mendel, Boveri’s experiments described “chromatic elements”, which 
were later named chromosomes. He described the inheritance pattern of 
chromosomes, which exactly followed Mendel’s theory of inheritance (222). 
1.6.2 Forward Genetics 
A rise in experimental genetics and interest in hereditary factors came about 
after Boveri’s experiments in 1900, when Mendel’s work was rediscovered by 
Hugo De Vries, who then went on to develop mutation theory (223). Following 
De Vries, Thomas Hunt Morgan worked to prove Mendel and De Vries’ theories 
by using mutational screening in the Drosophila fly. Morgan’s group used either 
natural mutants or, in later studies, randomly mutated the fruit fly using 
chemicals or radiation, then observed resulting phenotypes. This is a technique 
now called forward genetics, in which the phenotype is identified first and then 
linked back to the causative gene that was mutated. These experiments also 
provided the first evidence that genes were associated with chromosomes, and 
that genes in close proximity on a chromosomes were inherited together (the 
phenomenon called genetic linkage). Following Morgan, George Beadle and 
Edward Tatum developed the “one gene one enzyme hypothesis” in 1941 (224), 
the concept that allowed genes to be characterized based on the enzyme they 
produced. All of these discoveries went on to win Nobel Prizes. 
1.6.3 Molecular genetics 
During the early 1950s Rosalind Franklin and Raymond Gosling were carrying 
out x-ray diffraction experiments on fibres of deoxynucleic acid (DNA). Their 
now famous Photo 51 was shared with Watson and Crick who went on to 
describe the molecular structure of DNA in 1953 (225). Once the structure of 
DNA was defined new technologies quickly developed, ushering in the era of 
molecular genetics. This was soon followed by the discovery of restriction 
enzymes 1968 and the development of Sanger sequencing in 1977. 
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Furthermore, gene delivery was developed which allowed exogenous genes to 
transferred into organisms and allowed scientists to make genetically modified 
bacteria that produced insulin in 1978. The Polymerase chain reaction (PCR) 
was developed by Kary Banks Mullis and Randall Saiki in 1983 which allowed 
easy amplification of target DNA (226), followed by early attempts at genome 
engineering and the manipulation of gene expression. The completion of the 
first draft of the Human Genome project in 2003 (227), ushered in the most 
recent advances in next generation sequencing technologies. This in turn led to 
new gene discoveries, rare disease alleles being identified and a diagnosis 
given to patient families and to the era of personalised medicine. 
1.6.4 Reverse Genetics 
A major gap in knowledge in the new genomic era is the capacity to infer 
correlations between genotypes and phenotypes. Earlier methods to delineate 
these genotype-phenotype correlations used forward genetics, which worked 
from the observed phenotype in order to identify the causative genotype in the 
mutated gene. With the completion of the Human Genome Project, the reverse 
of this workflow could now be implemented, which works by targeting or 
mutating known sequences in a specific gene of interest, then observing the 
resulting phenotype. This methodology was termed reverse genetics. 
1.6.4.1 RNA Interference and Genome Screening 
RNA interference (RNAi), the endogenous mechanism for post-translation 
silencing of mRNA, was discovered in the early 1990s (228) and the 
mechanism of function was elucidated in the early 2000s from research in 
plants (229). In 1998, double stranded small interfering RNA (siRNA) was found 
to be more efficient at producing gene knock-down in C.elegans (230) and thus 
was eventually adopted and optimised for use across many different model 
organisms and cell models. In 2003, a whole genome RNAi library was 
generated for C.elegans (231), allowing for the full genome-wide analysis of 
gene function in a high-throughput format using the so-called “reverse genetics” 
workflow. This was the first systematic use of this methodology, and it allowed 
for unbiased analysis of all genes in a single high-throughput experiment. This 
provides specific phenotype data in a much quicker time scale, which has 
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accelerated researcher capacity to infer genotype-phenotype correlations and 
define gene function.  
siRNAs also provide researchers with a transient/acute knock-down of gene 
expression. This differs from the chronic depletion seen in a knock-out model. 
When using siRNA this does not allow for genetic compensation to act in the 
model being tested, often presenting different results to a complete knock-out 
model. 
1.6.5 Modern molecular genetics 
1.6.5.1 Genome engineering 
Before the era of modern genetics, genome engineering (generating specific 
changes to a target genome) was a laborious process that required significant 
investment of time and effort. In 1985, zinc finger nucleases were discovered 
which are a fusion of a DNA nuclease (Fok1), which generates double strand 
breaks, with a DNA binding domain that can be specifically engineered by 
changing 4 key amino-acids in its alpha helix to recognise different DNA 
sequences (232). In 2011 similar technology in transcription activator-like 
effector nucleases (TALENs) was discovered. TALENS also require protein 
engineering in order to determine the specificity of DNA cleavage (233). The 
original methods of genome engineering was therefore complicated and time 
consuming.  
The clustered regularly spaced short palindromic repeats/Cas9 (CRISPR/Cas9) 
system was originally discovered in 1987, but molecular genetics had a 
breakthrough in 2012 when Jennifer Doudna and Emmanuelle Charpentier 
were able to describe its molecular mechanism (234). They also realised the 
potential to use CRIPSR/Cas9 in other organisms, outside of the prokaryotes it 
was discovered in, to specifically target genes of interest. The system could be 
used to induce insertions and/or deletions (indels) through non-homologous 
end-joining. This error prone repair allowed for quick, efficient and specific 
genome editing in almost any animal or cell model. Then, in 2013 Feng Zhang’s 
research group published a protocol describing how they adapted 
CRISPR/Cas9 for use as a programmable genome editing tool in eukaryotic 
cells (235), not long after TALENs were being adopted. CRISPR/Cas9 is 
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arguably one of the biggest impacts in molecular biology and genetics research 
in the last 10 years and has even been translated into early-stage clinical trials 
since 2018. 
1.6.6 Modern Reverse Genetics Tools 
1.6.6.1 Small interfering RNA (siRNA) and small hairpin RNA (shRNA) 
Experimentally designed small hairpin ribonucleic acid (shRNA) or small 
interfering RNAs (siRNAs) can be delivered to animals or cell models through 
injection, transfection or by generating a transgenic model. These small RNAs 
take advantage of the endogenous cellular mechanism of RNA interference for 
gene silencing and control of gene expression (Figure 1.12).  
 
Figure 1.12 RNAi and Experimental Knock-down 
A) siRNA or shRNA is delivered to the cell. B) dsRNA is recognised and 
cleaved by dicer. C) Argonaut binds to the guide stand of the cleaved 
RNA. D) Argonuat and the guide stand form a complex which is targeted to 
the complementary mRNA. E) Targeted mRNA is cleaved by RISC and 
degraded. This halts transcription and creates a protein knock-down. 
When shRNA is expressed experimentally, it is processed by a protein called 
Dicer to create 21 base-pair double stranded RNA (dsRNA) (236). This 21 
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cells directly as a short dsRNA oligonucleotide. Argonaute binds to a single 
guide strand of the dsRNA and signals the formation of the RNAi-induced 
silencing complex (RISC). The antisense guide strand of the RNA specifically 
targets complementary mRNA to be bound by RISC. The targeted messenger 
RNA (mRNA) is then cleaved by Argonaute and degraded (236). Recurrent 
targeting and degradation of the targeted mRNA suspends protein translation, 
leading to a functional knock-down of expression of the targeted gene. 
Depending on the stability and turnover of the protein expressed from that gene, 
a functional knock-down can occur within a few hours or a few days. 
Experimental siRNAs are small and modified and can induce RISC without 
inducing a full viral response, which, if activated, would non-specifically reduce 
total protein expression (237). By overcoming this innate response that was 
described when RNAi was discovered, this provides the experimental means to 
impose specific knock-down of only the targeted gene. This makes siRNA an 
ideal molecular tool to specifically manipulate gene expression. 
Viral transduction and in vitro reverse transcription of a virally-integrated shRNA 
gene can provide a constitutive knock-down of the targeted gene. This 
technique can also provide another level of control if the shRNA is expressed 
under an inducible promoter. Viral transduction can often deliver shRNA to 
difficult-to-transfect cell types (such as SH-SY5Y the human neuroblastoma cell 
line and patient primary cells), increasing the options for more relevant cell 
models. However, viral insertion mutagenesis of actively-transcribing regions of 
the genome, and the potential off-target effects of using only a single shRNA, 
have to be taken into consideration. Viral particle production, optimisation and 
final cell line validation are time-consuming and require more stringent 
Genetically Modified Organisms Class II working conditions, making it a less 
convenient method to set up. However, a key advantage is the ability to 
investigate longer-term processes and the effects of time-dependant knock-
down. 
1.6.6.2 High-throughput siRNA screening 
As the specificity and popularity of siRNA as a molecular tool increased, siRNA 
screening was developed (231). Whole genome libraries of siRNAs were 
produced commercially so that in a high-throughput format, every gene in the 
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genome of interest could be specifically knocked-down. It allowed a non-biased 
approach to be taken when identifying genes that contribute to the cellular 
phenotype of interest, which in turn increases the chances of novel discoveries. 
Screening requires a lot of optimisation because of the high experimental 
variation that can arise from the high-throughput setup of a cell-based assay, 
unless many processes are carried out robotically. Furthermore, under ideal 
experimental circumstances, siRNAs should be individually optimised for 
concentration and knock-down time for each gene to ensure functional knock-
down. However, this is impossible in a high-throughput setup, and so siRNAs 
are either induced for the same length of time (stable transfection) or 
transfected at the same concentration (transient transfection) across the whole 
panel of siRNAs being screened. Screening therefore requires several 
validation steps and downstream work to ensure that a specific knock-down of 
the target gene was achieved in the set time-frame and concentration. It should 
be considered as a “hypothesis generating” approach to identify further avenues 
of investigation. 
1.6.6.3 Advantages and disadvantages of experimental siRNA knock-
downs 
As RNA is relatively unstable, several nanomoles of dsRNA are required for a 
functional knock-down in experimental conditions, which can increase 
experimental costs and off-target effects. The use of transfected siRNA also 
only provides a transient knock-down, and therefore limits the experimental use 
of this technique to investigate shorter term effects. Short-term knock-down can 
also be an advantage, since it has been shown that full knock-outs in model 
organism such as mice and zebrafish induce compensatory mechanisms that 
can affect phenotypes and thus mask the function of the targeted gene (238). 
Knock-downs are a well-optimised methodology and due to their transient 
effects are a short-term experiment that can be easily scaled-up for high-
throughput approaches. This allows screening of several genes quickly to 
identify primary hits of interest for further investigation. Experimentally, rather 
than induce the full endogenous RNAi response, which can cause non-specific 
knock-down of all gene expression, direct transfection of siRNA is used. This 
double stranded 21nt RNA bypasses the normal immune response induced by 
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foreign RNA. Despite this, non-specific off-target effects remain one of the 
biggest drawbacks of siRNA knock-downs as a reverse genetics technique. 
Thus, for many whole genome screens unless each siRNA has previously been 
confirmed to be specific, either during optimisation or is purchased and 
validated commercially, some phenotypic changes may be due to off-target 
effects. This is a major potential source of skew in data that confound 
meaningful analysis. To reduce these effects, pools of several different siRNAs 
targeting the same mRNA were used throughout this project. Each siRNA in a 
pool is therefore at a lower concentration but the total RNA is at working 
concentrations. This dilutes off-target effects of each individual siRNA, whilst 
the total pool of siRNAs still provides a functional knock-down. Throughout this 
thesis siRNA pools were therefore used in experiments to increase the 
specificity and accuracy of the experiments. 
1.6.7 CRISPR/Cas9 
CRISPR/Cas9 is an endonuclease driven by a designed guide RNA (gRNA) 
which targets a gene-specific 20 nucleotide sequence, upstream of a 
protospacer adjacent motif (PAM) sequence (NGG for Streptococcus-derived 
Cas9) within the target gene (Figure 1.13). Once the gRNA is bound to the 
target sequence, Cas9 recognises the PAM sequence and cleaves the DNA to 
generate a double strand break 3 base-pairs upstream. DNA repair 
mechanisms, such as non-homologous end joining (NHEJ), are then recruited 
to repair the break, but the mechanism is error-prone because the nuclease 
remains attached to the DNA and interrupts repair machinery (239). The error in 
repair therefore generates random insertions/deletions (Indels) at the cleavage 
site, creating frame-shifts and functional knock-outs of the targeted gene. If the 
system is delivered with an engineered repair template, homologous 
recombination can insert (“knock-in”) exact patient mutations (240) (Figure 
1.13). 
The main drawbacks of this technology are delivery in certain cell models, 
potential off-target effects, and editing efficiency. Editing efficiency further 
decreases when using the homologous repair (HR) system, and improvements 
in efficiency are the subject of many recent studies and advances in the 
CRISPR/Cas9 field (241, 242). 
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Figure 1.13 CRISPR/Cas9 and DNA repair pathways 
A) Cas9 cleaves target DNA and is repaired by non-homologous end 
joining (NHEJ). This error-prone repair pathway causes random insertions 
or deletions at the Cas9 targeted site. This can then generate a frameshift 
in the target gene, leading to a knock-out of the gene, or expression of a 
non-functional protein. B) The same system can be used to insert exact 
patient mutations by using the homologous recombination repair pathway; 
an engineered DNA repair template is delivered to the cells alongside the 
CRISPR/Cas9 system to allow precise repair at the targeted region. 
Adapted from (235) Figure 2 with Copyright permissions. 
1.6.7.1 Advances and uses of CRISPR/Cas9 
With the exponential advances made in CRISPR/Cas9 technology, since the 
work in this thesis was completed, it could soon be performed on a similar 
timescale to siRNA experiments (as little as 72hours). Viral delivery systems 
can also be used for primary cells, or cell lines that are difficult to transfect. 
Alongside improvements in delivery methods, the reagents have also improved. 
One popular method is to form a ribonucleotide protein complex of purified 
Cas9 protein with guide RNA. The guide RNA can be in the form of a synthetic 
single guide (sgRNA), or separate CRISPR RNA (crRNA) associated with 
fluorescently tagged trans-activating CRISPR RNA (tracrRNA). This allows 
reagents to be directly targeted to the nucleus without the expression delay that 
A) B) 
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occurs with the use of older plasmid-based approaches and which also requires 
self-assembly of the protein and RNA after expression. Fluorescently tagged 
tracrRNA also allows for fluorescent-associated cell sorting (FACS) of 
transfected cells for single cell clone selection. 
Different species of endonucleases, such as Cpf1 (243) or Cas9 engineered 
with nuclear localisation signals (244), have also been developed to improve 
transport and localisation into the nucleus upon delivery. However, there are 
mixed reports on the relative benefit of improved nuclear localisation for 
increased editing efficiency (245). Cas9 has also been engineered to have 
variable PAM recognition sequences (including NG, GAT and GAA) to increase 
potential editing target sites (246). Therefore, there are more potential target 
regions that can be edited with a much higher efficiency and specificity than 
before. 
1.6.7.2 Homology-directed repair and precision editing 
Homology directed repair (HDR) is used to model patient mutations, repair 
mutations, make fusion proteins, or knock-in whole expression cassettes and 
remains the most versatile technique to generate specific edits. However, both 
knock-ins of small single base changes and larger 1kb regions are far less 
efficient than generating random indels or base editing. The need for an efficient 
delivery of a repair template, and to induce the specific HDR pathway reduces 
the overall number of desired edits. HDR is also not possible in many cell types 
that are terminally differentiated, non-dividing or do not express HDR 
machinery. This therefore has been the focus for many contemporary 
methodologies in improving CRISPR/Cas9 technology.  
Initially, Suzuki et al. developed a homology independent targeted integration 
(HITI) method to make edits in non-dividing cells. This takes advantage of the 
remaining non-homologous end joining (NHEJ) repair pathway that is present in 
these cell types (244). The system uses CRISPR/Cas9 to cut both the target 
region and the homology template. The cells are then able to use NHEJ and 
repair the DSB on the template DNA into the target region. However, in theory 
the repair template can be knocked into any location with a DSB or it could be 
knocked-in in either orientation, so clones must be rigorously screened. It is 
also possible that because NHEJ is error-prone, mutations may occur around 
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the insert sites, which may cause frame-shifts or deleterious mutations. 
However, this methodology improves specific knock-in efficiencies from <5% for 
HDR to >45% for HITI in dividing cells such as HEK293 cells (244). 
Later research utilised machine learning to optimise the design of single 
stranded donor templates by showing that the composition of the 3’ arm is key 
to inducing microhomology-mediated end joining repair rather than HDR and 
that the distance to the double stand break made a crucial contribution to repair 
efficiency (247). Over-expression of B-cell lymphoma-extra-large (BCL-XL) 
could improve HDR efficiency 10-fold in stem cells by increasing their survival 
post-transfection (248). Another approach transfected two donor templates 
containing selection cassettes, allowing modified clones to be isolated using 
dual antibiotic selection to increase the specificity and frequency of 
homozygous edits (249). However, this approach was still limited by 
transfection efficiency.  
These methodologies have the potential to be used for in vivo gene therapies 
(250) and have been used to treat autosomal dominant retinitis pigmentosa in 
pre-clinical rat models with a premature stop codon substituting the serine 
codon at 334 in the Rho gene (251). The retina is an ideal tissue for gene 
therapy as shown by the many research groups developing the therapies for 
retinal disease (reviewed in Cherenk et al., 2016 (252)). The retina has even 
been the subject of an on-going gene therapy clinical trial for a ciliopathy 
(Leber’s congenital amaurosis; ClinicalTrials.gov Identifier: NCT03872479).  
1.6.7.2.1  Base editing 
Base editing was originally developed for cytidine to thymine (C:G>T:A) base 
changes, but new subsequent fusion proteins later allowed adenine to guanine 
(A:T>G:C) changes (253). This new technology was designed as a quicker and 
easier way to generate specific base changes in order to introduce missense 
mutations and to overcome the issues of low efficiency in homology-directed 
repair approaches. C:G>T:A base pair editing was important to develop 
because C:G>T:A transitions are the most common cause of missense 
mutations, accounting for half of pathogenic single-nucleotide variants (SNVs) 
(253). C:G>T:A transitions arise from spontaneous deamination of cytosine, 
which can happen up to 500 times a day in each human cell (254). In turn the 
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A:T>G:C base editing system was developed to be able to repair these 
common mutations in human disease or model pathogenic SNVs that could not 
be modelled with the C:G>T:A base editor (253). 
However, the basic concept is the same for both base editors and is 
summarised in Figure 1.14. For C:G>T:A editing; nuclease-deficient Cas9 
(nCas9) is fused to a cytidine deaminase (such as APOBEC1), a uracil DNA 
glycosylase inhibitor (UGI), and in some cases a fluorescent tag such as GFP. 
This fusion protein is targeted to the region of interest in the genome by the 
guide sequence on the crRNA. Any cytidine within a 5-nucleotide editing 
window will act as a substrate for the deaminase and will be converted to uracil. 
This is then protected by the UGI which inhibits base excision repair of the 
uracil. The Cas9 creates a single strand nick in the DNA to encourage 
mismatch repair, permanently converting the C:G>T:A (255). 
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Figure 1.14 CRISPR/Cas9 base editing 
A) Nickase-Cas9 (nCas9) is fused to APOBEC1 (cytidine deaminase), UGI 
(uracil DNA glycosylase inhibitor), and GFP. The guide sequence of a 
crispr RNA (green) targets the nCas9 complex to the DNA region of 
interest. Any cytidine bases within the defined editing window of the 
APOBEC1 fusion protein will be deaminated to uracil. These uracils are 
protected from base excision repair by UGI. When repaired or copied, the 
uracil is read as a thymidine and the base pair is changed from C:G>T:A. 
B) nCas9 is fused to two TadA domains. As described in A), the guide 
specifically targets the nCas9 complex. Adenine is deaminated to inosine, 
which is recognised as a guanine during repair or replication, therefore 
changing the base pair from A:T>G:C 
For A:T>G:C editing, nCas9 is instead fused to adenine deaminase TadA. It is 
also targeted to the genome by the guide sequence but has a variable editing 
window. Adenines are converted to inosine, which are read as guanine by DNA 
polymerases, thus incorporating the base change during DNA repair or 
replication (253). 
Improvements in base editing have also been developed, and there are now 
several generations of base editors (256). For example, targeted APOBEC1 
mutations were used to change the size and positioning of the editing window in 
C:G>T:A base editing (257). This approach allows for alternative bases along 
the target region to be edited with a single guide sequence, expanding the list of 
possible base changes throughout the genome. 
1.6.7.1.2  CRISPR prime editing 
Efficiency of HDR and specific editing is such that desired mutations can be 
screened for in as few as 30 clones, however precision had yet to be optimised. 
Base editing can cause mutations across the editing window (255), this can 
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Furthermore, unwanted edits can occasionally occur from HDR and the 
technologies mentioned above. David Liu’s research group therefore recently 
developed a new technology that aims improve the precision of specific 
CRISPR/Cas9 mediated editing called CRISPR Prime editing (258) and is 
summarised in Figure 1.15 
CRISPR prime editing uses a nickase Cas9 to guide a synthetic prime editing 
RNA (pegRNA) to the target region in the genome. This pegRNA is both a guide 
RNA and a reverse transcriptase repair template in one single RNA. Once 
bound, Cas9 nicks the DNA to release the top strand which can then bind to the 
reverse transcriptase template of the pegRNA. The reverse transcriptase 
domain then transcribes in the desired edit by directly polymerising DNA to the 
nicked strand. This heteroduplex DNA is then targeted by a secondary gRNA 
and nickase Cas9. This nicks the bottom strand in proximity to the edited region 
to encourage the cell to incorporate the edited strand during repair or replication 
(258). 
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Figure 1.15 CRISPR/Cas9 prime editing 
Prime editing occurs by three main steps: A) Nickase D10A Cas9 (nCas9) 
is directed to the target genomic sequence by the guide region in the prime 
editing guide RNA (pegRNA; green). This region is homologous and binds 
to the target DNA. nCas9 makes a single-strand break in the DNA, 
releasing the top strand of the DNA complex. This region is complimentary 
to the binding region of the pegRNA. Next to the binding region is the 
desired edit (red), followed by a homologous region to the target sequence 
(blue). The reverse transcriptase fused to nCas9 extends the nicked DNA 
to match the pegRNA sequence. B) This region of new DNA binds using 
the new homology region (blue). The 5’ flap of the original DNA is then 
cleaved by endogenous exonucleases, allowing the DNA to repair with a 
mismatch where the designed precise edit has been inserted. C) A 
different guide RNA recruits nCas9 downstream of the edit on the opposite 
strand. nCas9 nicks the DNA to promote DNA repair and incorporation of 
the new designed edit. 
 
This technique extends the editing capacity across the genome because edits 
can occur up to 30bp from the PAM sequence and PAMs occur approximately 
every 8bp throughput the genome (258), whereas previous techniques left 
regions of the genome unreachable for targeted and specific editing (253). More 
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pathway, thus minimises unwanted edits and improved overall precision of 
editing.  
1.6.7.3 Whole genome CRISPR/Cas9 screens 
The availability of commercially designed and validated CRISPR gRNA 
sequences has led to the development of CRISPR/Cas9 whole genome 
screens. These screens require cells that are stably transfected to expresses 
Cas9. Unlike siRNA screens, which target the mRNA and transiently knock-
down gene expression, CRISPR/Cas9 screens generate random mutations at 
the genomic DNA level. Therefore, these screens require highly efficient guide 
sequences to ensure that a high proportion of the cell population have received 
deleterious mutations in order for accurate assessment of phenotypes. 
However, further technical developments in precise genome editing such as 
HDR or base editing would be needed for more researchers to adopt this 
demanding technique. Currently, the efficiency of high-throughput 
CRISPR/Cas9 screens is limited and as indel formation is random, there is 
likely to be inconsistencies in phenotypes across the cell populations being 
analysed, each of which would not be characterised and attributed to a known 
mutation. Once the technique becomes more reliable, efficient and specific, 
these screens could offer a new approach to reverse genetic screening and 
highlight the differences in phenotype between transient knock-down and 
genomic level knock-out. 
1.6.8 Using Reverse Genetics to Study Cilia and Ciliopathies 
1.6.8.1 siRNA screening to study cilia 
There are several data sets available that have utilised whole genome siRNA 
screening as an unbiased technique to investigate ciliary biology, including the 
mouse genome screen data set that was used throughout this thesis (259). The 
whole genome screening technique has led to several important findings and 
the identification of novel mechanisms in ciliary biology. In 2010, a “druggable” 
genomic screen was published that further implicated actin remodelling as a 
modulator of ciliary length (260). A genome-wide screen was published in 2013 
that focused on human centriole biogenesis and showed that TRIM37 prevents 
over duplication of centrioles (261). In 2015, a similar screen to that used in this 
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thesis, but in a human cell line, aimed to identity positive ciliopathy regulators 
and found a novel JBTS gene (262). In 2016 Kim et al. published a whole 
genome screen investigating links between ciliogenesis and the cell cycle 
identified and provided further evidence for the role of the ubiquitin proteasome 
system in ciliary disassembly (93). Furthermore, the role of the proteasome was 
highlighted in a recent siRNA screen that aimed to identify antagonistic 
interactions that influence Wnt signalling in a BBS4 Bardet Biedl syndrome cell 
model (263). 
With the advent of CRISPR/Cas9 approaches, there has also been a genome-
wide CRISPR/Cas9 screen into ciliary function and Hedgehog signalling (264). 
This screen identified new transition zone components FAM92A and TTC23, 
described the novel ciliopathy gene TXNDC15, and defined the role of FAM92A 
and TTC23, two previously uncharacterised genes in centriole stability. 
1.6.8.2 CRISPR/Cas9 to study cilia 
CRISPR/Cas9 genome editing offers a quick and easy-to-use technology that 
can generate stable human cell models for molecular studies of the cilium and 
ciliopathies. To combat the variation in phenotypes seen between different 
patient mutations, CRISPR/Cas9 with HR could be used to model patient-
specific mutations in a tissue type of interest, in order to generate a model that 
is directly relevant to patient phenotypes. Although these models will not have 
the same genetic background as patients, they offer a quicker and inexpensive 
model compared to using patient-derived iPSCs. A further advantage is that 
multiple disease causing mutations can be compared on the same genetic 
background by deriving a panel of mutant cell lines from the same mother cell 
line. Patient-derived iPSCs may be more directly relevant to a single patient for 
therapeutic stem cell replacements, but the different genetic background 
between patients can be an additional source of pleiotropy for ciliopathy 
phenotypes. Therefore, a panel of cell models will be a useful tool for high-
throughput screening, molecular screening, genetic interaction studies and 
structural studies of the cilium, complementing published and on-going work in 
human cell lines. 
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1.7 Preliminary Work leading to or included in this thesis 
1.7.1 Primary Whole Genome siRNA Screen 
A primary whole genome siRNA screen was carried out in Prof. Colin A. 
Johnson’s research group as part of a system biology project to identify new 
regulators of ciliogenesis (259). The screen aimed to identify potential ciliopathy 
genes and positive regulators of ciliogenesis. The full data set was published in 
2015 along with follow-up validation work from the group and collaborators. This 
data-set was adopted for reanalysis and use throughout Chapters 3 and 4 of 
this thesis. Screen protocols were also adopted and re-optimised for use 
throughout Chapters 3-5 of this thesis.  
1.7.2 Cell lines 
In 2015, my work in Prof. Colin A. Johnson’s group included developing and 
optimising the use of CRISPR/Cas9 technology in RPE-1 to develop cellular 
models of ciliopathies. A panel of genes were targeted, and both polyclonal and 
single cell clones were generated. These cells were adopted and validated for 
use throughout Chapter 5 of this thesis.  
Other cell lines included mIMCD3 cells expressing GFP-Life-Act,  which were 
kindly made and gifted by Dr. Chiara Galloni from Dr. Georgia Mavria’s 
Research Group, University of Leeds. Work from the Mavria Research group 
also included phenotyping the Rock2-/- mouse for angiogenesis defects, 
presented in Dr. Gary Grant’s thesis (265). Dr. Grant identified that mouse had 
ciliary defects and mis-organisation of cilia across vessel lumens. Work with 
these cells also showed that drugs that affect actin remodelling can increase 
cilia length or incidence, which supported work presented in Chapter 3 of this 
thesis. 
1.8 Aims & Objectives 
The overall aim of this project was to improve ciliopathy patient quality of life 
through greater understanding of their genetic disease and though identifying 
potential therapeutic pathways. Furthermore, to understand the molecular and 
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genetic mechanisms that regulate ciliogenesis, which would give insight into the 
spectrum of ciliopathy phenotypes seen across each disease. 
A secondary aim was to identify novel the regulators of ciliogenesis which is an 
area of poor characterisation considering its importance across the spectrum of 
inherited and non-inherited disease. Any identified regulators could then be 
further investigated, in order to elucidate some of the molecular mechanisms of 
regulation and contribute to the overall aim of the project. 
The hypotheses to be tested in this thesis were therefore: 
‘Ciliogenesis is specifically regulated and timed within the cell cycle. It therefore 
has negative regulatory pathways that have yet to be identified.’ 
 ‘The spectrum of phenotypes seen in ciliopathies is not due to the inheritance 
of many different SNPs throughout the genome and environmental factors, but 
can be explained through epistatic genetic interactions between ciliary genes’  
Therefore the 3 key experimental objectives of this research project were to: 
• Identify novel regulators of ciliogenesis using reverse genetics and 
screening techniques in relevant and well-characterised cell models. 
• Design and develop a combinatorial screen with CRISPR/Cas9 edited 
cell lines to identify potential genetic interactions that contribute to 
ciliogenesis in known ciliopathy genes. 
• Investigate the molecular mechanisms that underlie any identified 
regulators or interactions. 
The first part of this project used a previously published whole genome siRNA 
screen data-set to identify potential genes that, once perturbed, either increased 
cilia incidence across a cell population, or increased the number of cilia per 
individual cell in the population. 
The second part of this project developed a new screening methodology 
designed to identify synthetic genetic interactions that regulate ciliogenesis: 
specifically cilia incidence and cilia size. The aim was to further understand the 
hierarchy of proteins in the organisation of cilia during ciliogenesis, following on 
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from work in C.elegans (80), and mice (79). The overall purpose of this part of 
project was to substantiate the effect of potential modifier alleles of ciliary 
phenotypes, and to investigate genetic and biochemical interactions between 
different structural modules of the cilium. This in turn would generate a primary 
data-set that could be used to understand the potential mechanistic basis for 
the pleiotropy that is observed in ciliopathies. 
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Chapter 2  
Materials and Methods 
2.1 Materials 
All materials were supplied by Sigma-Aldrich unless otherwise stated. 
 Suppliers 
Table 2.1 List of suppliers 
List of suppliers for all reagents used throughout this thesis. Supplier name 
and headquarters address is given.  
Company Name Address 
Abcam plc. Discovery Drive Cambridge Biomedical Campus, Cambridge, CB2 
0AX, U.K. 
Addgene 490 Arsenal Way, Suite 100, Watertown, MA 02472, U.S.A 
American Type Culture 
Collection® (ATCC®) 
10801 University Boulevard, Manassas, VA 20110, U.S.A 
Applied BIosystems 120 Birchwood Blvd, Birchwood, Warrington WA3 7QH, U.K. 
Bethyl Laboratories 25043 FM 1097, Montgomery, TX 77356, U.S.A 
Bioline Edge Business Centre, Humber Rd, London NW2 6EW, U.K. 
BIO-RAD The Junction 3rd And 4th Floor, Station Road, Watford, WD17 1ET, 
U.K. 
Calbiochem 10394 Pacific Center Ct, San Diego, CA 92121, U.S.A 




Dellaertweg 9b, 2316 WZ, Leiden, The Netherlands 
ChromoTek Am Klopferspitz 19, 82152 Planegg, Germany 
Clent Life Science Suite 3, Faraday House, King William St, Amblecote, Stourbridge 
DY8 4HD, U.K. 
Clontech Laboratories The Danby Building, Edmund Halley Road, Oxford Science Park, 
Oxford, Oxon, OX4 4DQ, U.K. 
Corning Elwy House, Lakeside Business Village, St Davids Park Ewloe, 
Flintshire, CH5 3XD, U.K. 
Dako, Agilent 
Technologies 
5301 Stevens Creek Blvd., Santa Clara, CA 95051, U.S.A 
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Dharmacon, Horizon 
Discovery Group 
Cambridge Research Park, 8100 Beach Dr, Waterbeach, 
Cambridge CB25 9TL, U.K. 
Fisher Scientific UK Bishop Meadow Rd, Loughborough LE11 5RG, U.K. 




3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, U.K. 
Ibidi GmbH Lochhamer Schlag 11, 82166 Gräfelfing, Germany 
Invitrogen 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, U.K. 
Merck Millipore Suite 21, Building 6, Croxley Green Business Park, Watford, 
Hertfordshire, WD18 8YH, U.K. 




Binsfelder street 77, 52351 Dueren, Germany 
Perkin Elmer Chalfont Road Buckinghamshire, Seer Green, HP9 2FX, U.K. 
Proteintech Europe 4th Floor, 196 Deansgate, Manchester, M3 3WF, U.K. 
Qiagen Skelton House Lloyd Street North, Manchester, M15 6SH, U.K. 
Santa Cruz 
Biotechnology 
Bergheimer Str. 89-2, 69115 Heidelberg, Germany 
Scientific Laboratory 
Supplies 
Wilford Industrial Estate, Ruddington Lane, Wilford, Nottingham, 
NG11 7EP, U.K. 
Sigma-Aldrich The Old Brickyard, New Rd, Gillingham, Dorset, SP8 4XT, U.K. 
Thermo Scientific UK 3rd Floor 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, U.K. 
VWR Chemicals 
International 
Hunter Blvd, Magna Park, Lutterworth, LE17 4XN, U.K. 
Ximbio 2 Redman Place, London, E20 1JQ, U.K. 
Zymo Research 17062 Murphy Avenue, Irvine, California, 92614, U.S.A 
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• 1X Phosphate-buffered Saline (PBS) (Autoclaved and filter sterilised) 
• 1X Phosphate-buffered Saline 0.05 % [v/v] Tween20 (PBST) 
• 1X Tris-buffered Saline (TBS) 
• 1X Tris-buffered Saline 0.05 % [v/v] Tween20 (TBST) 
2.1.3.1 Lysis Buffer for Protein Extraction 
• 50 mM Trizma® hydrochloride pH8 
• 1 mM EDTA pH8 
• 150 mM NaCl 
• 0.01 % [v/v] Triton™ X-100 
• 1 % [v/v] Glycerol  
Stored at 4 °C. 100X Halt™ Protease Inhibitor Cocktail and 100X Halt™ 
Phosphatase Inhibitor Cocktail (Thermo Scientific™) were diluted to 1X in the 
buffer before use. 
2.1.3.2 Lysis Buffer for Genomic DNA Extraction 
• 10 mM Trizma® hydrochloride pH8 
• 100 mM EDTA pH8 
• 0.25 % [w/v] Sodium dodecyl sulphate 
Stored at 4 °C. Ribonuclease A from bovine pancreas was diluted to 40 ng/ml in 
the buffer before use. 
2.1.3.3 Gel Loading Buffer (6X) 
• 1X TAE 
• 0.15 % [w/v] Orange G 
• 60 % [v/v] Glycerol 
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2.1.3.4 Co-Immunoprecipitation Dilution Buffer 
• 10 mM Tris/Cl pH 7.5 
• 150 mM NaCl 
• 0.5 mM EDTA 
Stored at 4 °C. 100X Halt™ Protease Inhibitors (Thermo Scientific™) were 
diluted to 1X in the buffer before use. 
2.1.3.5 Co-Immunoprecipitation Wash Buffer 
• 10 mM Tris/Cl pH 7.5 
• 150 mM NaCl 
• 0.5 mM EDTA 
Stored at 4 °C. 100X Halt™ Protease Inhibitors (Thermo Scientific™) were 
diluted to 1X in the buffer before use 
2.1.3.6 Fluorescent Activated Cell Sorting (FACS) Buffer 
• 2 mM EDTA 
• 25 mM HEPES 
• 1 % [v/v] Heat inactivated Fetal Bovine Serum (FBS) 
Made up to 50 ml in 1X PBS (without CaCl2 and MgCl2) and stored at 4 °C. 
 Specific Reagents 
2.1.4.1 PCR 
• DreamTaq DNA Polymerase, 5 U/µL (Thermo Scientific™) 
• 10X DreamTaq Buffer, includes 20 mM MgCl2 (Thermo Scientific™) 
• Primers, 25 nmol (Full list in Appendix A.2, Table A.8) 
• dNTPs, 100 mM (Thermo Scientific™) 
• Midori Green Advance DNA/RNA stain (Nippon Genetics) 
2.1.4.2 Reverse transcriptase-PCR 
• Quick-RNA™ Miniprep Kit (Zymo Research) 
• SuperScript III First-Strand Synthesis SuperMix (Invitrogen™) 
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• Hotshot Diamond PCR Mastermix (Clent Life Science) 
2.1.4.3 Gel Electrophoresis 
• Agarose 
• 1X Tris-acetate-EDTA (TAE) 
• Quick-Load® Purple 1 kb DNA Ladder (New England Bioscience) 
• EasyLadder I (Bioline) 
2.1.4.4 Sanger Sequencing 
• ExoSAP-IT™ PCR Product Cleanup Reagent (Applied Biosystems™) 
• BigDye™ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems™) 
• 0.25 M EDTA 
• Deionised Hi-Di™ Formamide (Applied Biosystems™) 
2.1.4.5 Cloning 
• TOPO® TA Cloning® Kit (Invitrogen™) 
• Gateway™ LR Clonase™ II Enzyme mix (Invitrogen™) 
• Gateway™ BP Clonase™ II Enzyme mix (Invitrogen™) 
2.1.4.6 Protein Quantification 
• Quick StartTM Bradford Protein Assay (Bio-Rad) 
2.1.4.7 Western Blotting (WB) 
• NuPAGE™ LDS Sample Buffer (4X) (Invitrogen™) 
• 2-Mercaptoethanol 
• NuPAGE™ 4-12 % Bis-Tris Protein Gels (Invitrogen™) 
• NuPAGE™ MES SDS Running Buffer (Invitrogen™) 
• NuPAGE™ Transfer Buffer (Invitrogen™) 
• Invitrolon™ PVDF/Filter Paper Sandwich (Invitrogen™) 
• Precision Plus Protein™ All Blue Pre-stained Protein Standards (Bio-Rad) 
• SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo 
Scientific™) 
• Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific™) 
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2.1.4.8 Co-Immunoprecipitation 
• GFP-Trap® Magnetic Beads (Chromotek) 
2.1.4.9 Immunofluorescence 
• Matrigel Matrix (Corning) 
• “Marvel” Non-fat Dried Skimmed Milk (Premier Foods) 
• ProLong™ Gold Antifade Mountant (Invitrogen™) 
2.1.4.10 Live Cell Imaging 
• µ-Dish, 35 mm, High Glass Bottom dish (ibidi) 
• DMEM/F-12, with-out Phenol Red (Gibco™) 
• HEPES Buffer 
 Tissue Culture Reagents 
• Dubecco’s Modified Essential Medium (DMEM) (Thermo Scientific™) 
• DMEM/F-12, GlutaMAX™ Supplement (Gibco™) 
• Opti-MEM™ Reduced Serum Medium (Gibco™) 
• Foetal Bovine Serum  
• Trypsin 
• 1X PBS (without Calcium Chloride and Magnesium Chloride) 
• Lipofectamine™ 2000 Transfection Reagent (Invitrogen™) 
• Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen™) 
• ON-TARGETplus siRNA SMARTpools (Dharmacon) (Appendix A.1)  
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2.1.5.1 Cell-Lines 
All cell lines were sourced from American Type Culture Collection® (ATCC®). 
Any other cell lines used in this thesis were derived from these cell-lines. All cell 
lines were tested every 3 months for mycoplasma. Cells were used for 
screening between passage 15-25. mIMCD3 and RPE-1 mother cell-lines were 
previously verified using arrayCGH (266) and RNA-sequencing under different 
growth conditions. SRA references for RNA sequencing data:  
• serum starved mIMCD3 cells: SRX1411364  
• proliferating mIMCD3 cells: SRX1353143 
• serum starved RPE-1 cells: SRX1411453 
• proliferating RPE-1 cells: SRX1411451 
This confirmed the presence of all RNAi machinery in both cell lines and allele 
numbers before CRISPR/Cas9 editing. Cells were not re-sequenced post 
CRISPR/Cas9 editing. 
Table 2.2 Cell-Lines 
Cell line species, origin and growth medium are listed. All cells were grown 
as standard in 10 % [v/v] FBS and serum starved at 0.2 % [v/v] FBS. 
Cell-Line Catalogue 
No. 
Species Medium Origin 
hTERT RPE-1 CRL-
4000™ 
Human DMEM/F12 hTERT immortalised retinal 
pigment epithelial cells 
HEK293T CRL-
11268™ 
Human DMEM Embryonic kidney cells 
containing the SV40-T antigen 
mIMCD3 CRL-
2123™ 
Mouse DMEM/F12 Inner medullary collecting duct 





Human DMEM Modified HEK293T that stably 
express amphotropic envelope 
protein and gag-pol. 
 
 Microbiology Reagents 
• “α-Select Gold” DH5α Chemically Competent E. coli Cells (Bioline) 
• Ampicillin sodium salt  
• Kanamycin Sulphate (Fisher Scientific)  
• Spectinomycin dihydrochloride (Fisher Scientific) 
• 5-bromo-4-chloro-3-indolyl-βD-galactopyranoside (X-gal) 
• Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
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• QIAprep Spin Miniprep Kit (Qiagen) 
• QIAfilter Plasmid Maxi Kit (Qiagen) 
2.1.6.1 Luria-Bertani Medium (LB) 
• 1 % [w/v] Tryptone (VWR Chemicals)  
• 0.5 % [w/v] Yeast Extract  
• 10 mM NaCl  
Make up to 1 L in dH2O. For LB Agar 15 g Agar-agar (Merck Millipore) was 
added. Autoclaved to sterilize before use. *supplied by  
2.1.6.2 Super Optimal Broth with Catabolite Repression (SOC) 
• 2 % [w/v] Tryptone (VWR Chemicals) 
• 0.5 % [w/v] Yeast Extract  
• 10 mM NaCl 
• 2.5 mM KCl 
• 10 mM MgCl2 
• 10 mM MgSO4 
• 20 mM Glucose  
Make up to 1 L in dH2O. Autoclaved to sterilize, aliquoted and stored at –20 °C. 
Defrosted at room temperature before use. 
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 Antibodies and Stains 
2.1.7.1 Primary Antibodies 
Table 2.3 List of primary antibodies 
List of all the primary antibodies used throughout this thesis and optimized 
dilutions used in immunofluorescence (IF) and immunoblotting on western 
blots (WB) are shown. All antibodies listed have species reactivity in both 
human and mouse samples. *CEP290 mouse monoclonal IgG2a (Clone 
IC3G10) was a gift from Ciaran Morrison, National University of Ireland 
Galway. **Living Colors® A.v. Monoclonal Antibody (JL-8). ***TMEM216 












Mouse  Sigma T6793
-.5ML  
Milk IF 1:4000 
ARL13B  N/A Rabbit  Proteintech 17711
-1-AP  
Milk IF 1:2000 
WB 1:5000 
β-Actin  AC-15 Mouse  Abcam  Ab627
6 
Milk WB 1:10000 
CEP290 *  Mouse  N/A N/A BSA IF 1:1000 
WB 1:200 
FLAG M2 Mouse Simga F3165 Milk WB 1:1500 
GAPDH N/A Rabbit CST 2118 BSA WB 1:5000 
GFP ** JL-8 Mouse Clontech 63238
0 
Milk WB 1:5000 
γ-Tubulin  C-20 Goat  Santa Cruz  sc-
7396  
Milk IF 1:50  
γ-Tubulin  GTU-
88 
Mouse  Sigma T6557 Milk IF 1:1000 
γ-Tubulin  N/A Rabbit  Abcam Ab137
822 
Milk IF 1:1000 
IFT88  N/A Rabbit  Proteintech 13967
-1-AP  




N/A Rabbit CST^ 8505 BSA IF 1:50 
P-myosin light 
chain II (Ser19) 
N/A Rabbit CST 3671 BSA IF 1:50 









Mouse  Sigma T9822 Milk IF 1:1000 
ROCK1 N/A Rabbit CST 4035 Milk WB 1:1000 
ROCK2 N/A Rabbit Bethyl A300-
046A 
Milk WB 1:1000 
RPGRIP1L  N/A Rabbit  Proteintech 55160
-1-AP 
BSA IF 1:500  
WB 1:1000 
TMEM67  N/A Rabbit  Proteintech 13975
-1-AP 
Milk WB 1:1000 




Mouse  Sigma  V4505 Milk WB 1:5000 
 
2.1.7.2 Secondary antibodies 
Table 2.4 List of secondary antibodies 
Table showing all the secondary antibodies used throughout this thesis. 
Table outlines the target, species raised in, conjugate and optimized 
dilutions used in in immunofluorescence (IF) and immunoblotting on 
western blots (WB). Anti-bodies could be used in either Milk or BSA 
blocking solutions, blocking solution would correlate to match that used 
during the primary antibody incubation.  
Target Raised 
in 
Conjugate Vendor Cat. # Dilution 
Mouse 
IgG  
Goat  Alexa Fluor® 488  Invitrogen A1102  IF 1:2000  
Mouse 
IgG  
Goat  Alexa Fluor® 568  Invitrogen A11031  IF 1:2000  
Mouse 
IgG  
Goat Alexa Fluor® 647  Invitrogen A28181 IF 1:2000 
Mouse 
IgG  
Goat  Horseradish 
Peroxidase (HRP)  
Dako, Agilent 
Technologies  
P0447  WB 1:10000  
Mouse 
IgG  
Donkey  Alexa Fluor® 555  Invitrogen A31570  IF 1:2000  
 - 75 - 
Rabbit 
IgG  
Goat  Alexa Fluor® 488  Invitroge  A11034  IF 1:2000  
Rabbit 
IgG  
Goat  Alexa Fluor® 568  Invitrogen A11036  IF 1:2000  
Rabbit 
IgG  
Goat  Horseradish 
Peroxidase (HRP)  
Dako, Agilent 
Technologies  
P0448  WB 1:10000  
Rabbit 
IgG  
Donkey  Alexa Fluor® 488  Invitrogen A21206  IF 1:2000  
Goat 
IgG  
Donkey  Alexa Fluor® 633  Invitrogen A21082  IF 1:2000  
Goat 
IgG  
Donkey  Alexa Fluor® 350  Invitrogen A21081  IF 1:2000  
 
2.1.7.3 Cell Stains 
Table 2.5 List of cell stains 
Cell stains with their excitation and emission values. Dilutions listed were 





Vendor Catalogue # Dilution 
DAPI  358/461  Nucleus/DNA  Invitrogen™ D1306   IF 1:1000 
TOTO®-
3 Iodide  
642/660  Nucleus/ 
Nucleic Acids  







Invitrogen™ A12379 IF 1:100 
2.2 Methods 
Room temperature (RT) refers to a variable temperature between 20-22 °C. The 
following abbreviations are used: hours (hrs), minutes (mins), seconds (s), 
relative centrifugal force (rcf), revolutions per minute (rpm). 
Experimental replicates refers to repeats of experiments that were carried out 
using different reagents on different days (new vial of cells, freeze thaw or vial 
of reagents, new dilutions of chemical etc.), whereas technical replicates refers 
to repeats of experiments done at the same time on the same day, with the 
same reagents. 
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 Polymerase Chain Reaction (PCR) 
PCR reactions were made up of 1 µl of purified genomic DNA (20 ng/µl), 0.5 µl 
of forward and 0.5 µl of reverse primers (10 µM each) (Appendix A.2, Table 
A.8), 5 µl dNTPs (2.5 mM of each dNTP), 5 µl 10X DreamTaq Buffer, 0.2 µl 
DreamTaq DNA Polymerase, made up to 50 µl with dH2O. PCR reactions were 
run at 95 °C for 1 min followed by 35 cycles of 95 °C (30 sec), primer optimised 
annealing temperature (30 sec), 72 °C (1 min) and then followed by a final 
extension of 5 mins at 72 °C. Completed reactions were held at 4 °C then 
analysed on a 1.5 % agarose [w/v] gel stained with Midori Green Advance 
which was run at 120 V for 1 hr in an electrophoresis tank with 1X TAE. 
 Reverse transcriptase-polymerase chain reaction 
2.2.2.1 RNA extraction 
RNA was extracted from up to 5x106 cells using a Quick-RNA™ Miniprep Kit 
(Zymo Research). Cells were pelleted by centrifugation at 200 x rcf for 5 mins. 
Then resuspended in PBS and re-pelleted. The cell pelleted was resuspended 
in 300 l of RNA lysis buffer, transferred to a Spin-Away™ Filter and centrifuged 
for 30 sec at 13000 x rcf. The flow through was mixed 1:1 (v:v) with 100 % 
ethanol, transferred to a Zymo-Spin™ IIICG Column and centrifuged for 30 sec 
at 13000 x rcf. RNA bound to the column was DNAse I treated for 15 mins and 
then washed with RNA prep and wash buffers before being eluted in 100 μl of 
DNase/RNase-Free Water. RNA concentration was then quanitified using a 
NanoDrop™ 3300 Fluorospectrometer (Thermo Scientific™). 
2.2.2.2 Generating cDNA 
1 μg of whole cell RNA extract was mixed with 1 μl of random hexamers (50 
ng/l), 1 μl of annealing buffer and made up to a total of 8 μl with nuclease free 
dH2O. This was then incubated at 65 °C (5 mins) and then immediately placed 
on ice. 10 μl of 2X First Stand Reaction Mix and 2 μl SuperScript™ 
III/RNaseOUT™ Enzyme Mix where then added to the reaction. The reaction 
was vortexed and centrifuged to ensure it was well mixed before incubation at 
25 °C (10 mins), followed by 50 °C (50 mins), and then 85 °C (5 mins). cDNA 
was then stored at -20 °C until use.  
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2.2.2.3 Reverse transcriptase-PCR 
cDNA was diluted 1 in 10 with dH20. Then PCR reactions were made up of 1 µl 
of diluted cDNA, 0.5 µl of forward and 0.5 µl of reverse primers (10 µM each) 
(Appendix A.2, Table A.9), 3 µl HotShot PCR master mix and 5 µl of dH2O to 
make a 10 µl reaction. PCR reactions were run at 95 °C for 1 min followed by 
50 cycles of 95 °C (30 sec), primer optimised annealing temperature (30 sec), 
72 °C (1 min) and then followed by a final extension of 5 mins at 72 °C. 
Completed reactions were held at 4 °C then analysed on a 2 % agarose [w/v] 
gel stained with Midori Green Advance which was run at 120 V for 1 hr in an 
electrophoresis tank with 1X TAE. 
Band intensities were to normalised to GAPDH controls to estimate the total 
mRNA expression level in each sample. 
 Enzymatic Clean-up of PCR Products 
PCR products were purified using ExoSAP-IT® PCR Product Clean-up by 
following the manufacturer's recommended protocol to digest excess primer and 
dephosphorylate nucleotides to allow for downstream sequencing reactions. 
 Sanger Sequencing 
Sequencing reactions were made up of 0.5 µl of BigDye Terminator Kit V3.1, 2 
µl BigDye Sequencing Buffer (5X), 1 µl of purified PCR product or 250 ng of 
purified plasmid DNA, 1 µl of sequencing primer (final concentration 0.2 µM) 
made up to 10 µl in dH2O. Sequencing reactions were run at 96 °C (1 min) 
followed by 45 cycles of 96 °C (10 sec), 50 °C (5 sec), 60 °C (4 mins) and then 
held at 4 °C until precipitation. Sequencing reactions were transferred to a 96-
well sequencing plate for precipitation. Reactions were precipitated by adding   
1 µl of 0.25 M EDTA and 30 µl of 100 % ethanol to each reaction before being 
centrifuged at 2750 x rcf for 30 mins at 4 °C. Plates were inverted to remove the 
supernatant, then pellets were washed in 60 µl of 70 % [v/v] ethanol/dH2O and 
centrifuged at 2750 x rcf for 15 mins at 4 °C. Plates were inverted onto tissue 
and centrifuged at 10 x rcf for 10 secs to remove residual EtOH. Pellets were 
left to dry at 37 °C for 5 mins before being re-suspended in 10 µl of deionised 
Hi-Di™ Formamide. Sequencing reactions were run on an ABI 3130xl Genetic 
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Analyzer and base-called using Sequencing Analysis Software 6 (Applied 
Biosystems). 
 T7 Endonuclease Mutation Assay 
T7 endonuclease assay was used to identify CRISPR/Cas9 edited cell lines 
with heterozygous and compound heterozygous mutations in the targeted gene 
(Figure 2.1). The target gene was amplified by PCR and analysed as in Section 
2.1.4.1. PCR products were then denatured at 95 °C and slowly reannealed by 
decreasing the temperature -2 °C/sec until 85 °C, then at a rate of -0.1 °C/sec 
until reaching 25 °C. 10 µl of reannealed PCR products were then incubated for 
15 mins at 37 °C with; 1.5 µl of NEB Buffer 2 and 0.5 µl of T7 endonuclease (15 
µl total reaction volume). Digested PCR products were then run on a gel to 
analyse the presence of mutations as T7 endonuclease cleaves hetero-duplex 
DNA. 
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Figure 2.1 T7 Endonuclease assay to detect heterozygous mutations 
Schematic of the T7 endonuclease assay. CRISPR/Cas9 targeted DNA is 
amplified by PCR. Any mutations present are likely to be heterozygous or 
compound heterozygous. This generates a mixed pool of PCR product. The 
PCR product is reannealed slowly to allow mismatch DNA (heteroduplexes) 
to form. T7 endonuclease recognises and cleaves these heteroduplexes 
which can then be resolved by gel electrophoresis. Therefore DNA 
digestion represents a mutation present in the targeted gene of that clone, 















1  2  3 
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 Cloning 
2.2.6.1 TA Cloning 
Biallelic compound heterozygous mutations that could not be distinguished by 
initial exon sequencing were taken forward for TA Cloning to sequence each 
allele individually. 
TOPO® TA Cloning® Kit was used following the manufacturer’s recommended 
protocols to clone 4 µl of PCR product (approx. 20-50 ng) of the targeted exon 
into the pCR™ 2.1-TOPO® vector. After 30 mins reaction time, cloning 
reactions were transformed into 25 µl of DH5α chemically competent E. coli and 
plated onto kanamycin (50 µg/ml) LB Agar plates with 40 µl of 40 mg/ml X-gal 
and 40 µl of 100 mM IPTG. Blue/white screening was used to select colonies 
with successfully cloned vectors and inoculations of white colonies were 
cultured in 5 ml of LB-kanamycin (50µg/ml) for 16 hr overnight.  
2.2.6.2 Gateway Cloning 
Expression vectors for co-immunoprecipitation experiments were made using 
Gateway® technology. Following the manufacturer’s protocol, 150 ng of pENTR 
clones, containing full-length coding sequences (CDS) of genes to be 
expressed, was mixed with 150 ng of pDEST vectors that contained different C-
terminal and N-terminal tags. The plasmids were then made up to a total of 8 µl 
in TE Buffer, pH 8. 2 µl of the LR clonase was added to make a 10 µl reaction 
which was incubated at 25 °C for 1 hr. The reaction was stopped by adding 1 µl 
of 2 μg/μl proteinase K solution and was incubated for 10 mins at 37 °C. 
Cloning reactions were transformed and cultured as in section 2.2.6.1 but 
without blue/white selection. 
pDONR plasmids were made from linearized pDEST clones as above, but using 
BP clonase. 
2.2.6.3 Plasmid DNA extraction 
Cloned vector DNA was extracted from 1 ml of each 5 ml culture using a 
QIAprep Spin Miniprep Kit (Qiagen) following the manufacturer’s protocol. Once 
sequence verified, cultures were expanded to 200 ml and plasmid DNA was 
extracted with a QIAfilter Plasmid Maxi Kit (Qiagen) following the manufacturers 
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protocol and re-suspended in 300 µl of the provided Elution Buffer to make 
plasmid stocks. DNA yields were measured using a NanoDrop™ 3300 
Fluorospectrometer (Thermo Scientific™).  
 Immunofluorescence Microscopy 
1x105 cells were plated onto Matrigel Matrix coated 13 mm round sterile 
coverslips (No. 1.5; Scientific Laboratory Supplies) in a 12 well plate in 
DMEM/F12 0.2 % FBS. Cells were serum starved for 48 hr before fixing.  
Immunostaining conditions including fixation, block and antibody concentrations 
were optimised for each antibody or stain individually (Table 2.3, Table 2.4, 
Table 2.5). Cells were fixed with chilled methanol (MeOH) for 5 mins at -20 °C 
or in 10 % formalin for 15 mins followed by 5 mins permeabilization with 0.05 % 
Triton X-100 in phosphate buffered saline (PBS). Coverslips were then blocked 
for 10 mins in 1 % [w/v] Marvel/PBS or 1 % [w/v] BSA/PBS. Coverslips were 
incubated with primary antibodies (diluted in 1 % [w/v] Marvel/PBS, or 1 % [w/v] 
BSA/TBS) in a humidified chamber for 1 hr, washed 3 times in 1X PBS and then 
incubated in secondary antibodies and cell stains diluted in 1 % [w/v] 
Marvel/PBS for 1 hr in a humidified chamber. Coverslips were then washed 5 
times with PBS and mounted onto glass slides with ProLong™ Gold Antifade 
Mountant (Invitrogen™). Slides were left to cure overnight at RT. Slides were 
then stored in the dark at 4 °C and imaged within 1 week.  
2.2.7.1 Confocal Microscopy 
Confocal images were captured as manually acquired z-stacks of the same size 
using a Nikon A1R Confocal Laser Scanning Microscope, controlled by the NIS-
Elements C software. Image acquisition was optimised on wild-type negative 
control cells for each experiment. The same laser intensity and image gain 
settings were maintained when imaging each set of experimental coverslips, to 
ensure fluorescence intensity was comparable between cell lines or conditions. 
All fields of view (FOV) were chosen at random or based on DAPI staining 
alone to avoid bias that could occur from observing staining of ciliary proteins. 
Single planes and z-stacks were captured using a 63X oil objective as 
1024x1024 pixel images.  
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2.2.7.2 Analysis of Immunofluorescence images 
Summative and maximum intensity projections, 3D reconstructions, and merged 
images of z-stacks were reconstructed in FIJI image software or Columbus 
software 
2.2.7.2.1  Cilia length and incidence 
Confocal images were analysed for cilia length and incidence using FIJI image 
software (268). Regions of interest (ROI), the cilia, were then either manually 
highlighted or automatically detected using a macro (Appendix B). ROIs were 
analysed for quantitative measurements of total number of ROIs, cilia length, 
and measures of total fluorescence. Nuclei number were also counted so that 
cilia incidence could be calculated as a percentage of total cell number per 
FOV. This was also done by either manual counting or was integrated into the 
same macro as above for automated counting. 
2.2.7.2.2  3D reconstruction 
3D analysis was done using the “3D Object Counter” v2.0 plugin (269). Images 
were thresholded and rendered as individual 3D ROI to allow all dimensions to 
be quantified including cilia volume as used in Chapter 5. 
2.2.7.2.3  Co-localisation 
Regions of interest (ROI) where then either manually highlighted or thresholded 
for using the mask function throughout a stack on using the “3D Object Counter” 
v2.0 plugin (269). 3D ROI regions only were then analysed for co-localisation 
between two channels using the “Coloc 2” plugin (270) using Costes statistical 
significance test, PSF 3.0 for 10 iterations. Other images were loaded into 
Columbus software and were analysed using the co-localisation building block 
from Perkin Elmer to specifically analyse co-localisation in ciliary ROIs (Defined 
“spots”). Both methods presented data using Pearson's correlation.  
2.2.7.2.4  Image Structure 
High-throughput images of MLC and phosphorylated MLC staining were 
analysed in 2D using Columbus software. Cell boundaries were defined and 
image texture was measured specifically within these boundaries excluding the 
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nucleus. Image texture was calculated using the “Calculate Texture Properties” 
building block. The method applied a Gabor Filter at a scale of 2 pixels, 
wavelength 8 and normalisation was calculated by region intensity. Texture 
values were then multiplied by 1000 for ease of interpretation when graphically 
displayed. 
 Whole Cell Protein Extraction  
Cells were grown to confluence in a single well of a 6-well plate, with or without 
siRNA knock-down, plasmid over-expression or drug treatment, then washed 3 
times in cold PBS. Cells were re-suspended in 50 µl of lysis buffer for western 
blotting (Section 2.1.3.1) using a cell scraper and pipette mixing. The lysed 
suspension was then added to an chilled 1.5 ml microfuge tube and underwent 
a freeze-thaw cycle at -80 °C. The lysis suspension was then clarified by 
centrifugation at 12000 x rcf for 15 mins at 4 °C. The supernatant was then 
transferred into a new ice-cold microfuge tube and the pellet discarded. 
Protein concentrations of whole cell extracts (WCE) were measured using 
Quick StartTM Bradford Protein Assay. 2 µl of WCE or 1 µl of BSA standards 
(0.5, 1, 5, 7.5, 10, 1 5µg/µl) were added to 1 ml of 1X Dye Reagent in microfuge 
tubes and vortexed. Samples were incubated for 5 mins at RT, transferred to 
cuvettes and absorbance of standards and samples was read at 595 nm in a 
spectrophotometer. Sample absorbance was then compared to the BSA 
standard curve and divided by 2 to give the WCE protein concentration in µg/µl. 
 SDS PAGE and Western Blotting 
15 μg of diluted WCE was mixed with LDS Sample Buffer (4X), freshly prepared 
with 2.5 % [v/w] β-mercaptoethanol, to final 1X concentration. Samples were 
loaded in separate wells alongside one lane containing 15 μl of Precision Plus 
Protein™ Standards ladder into 4-12 % Bis-Tris gels and run at 120 V for 
90mins in MES SDS Running Buffer containing 15 % methanol. 
Proteins were then transferred from the gel to an PVDF membrane that had 
been activated for 20 sec in 100 % MeOH. The transfer was run at 30 V for 90 
mins in 1X Transfer Buffer (10 % MeOH) in an electrophoresis tank packed with 
ice. After transfer, membranes were blocked in 10 % [w/v] blocking solution 
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(blocking solution was optimised for each antibody individually, either Marvel or 
BSA was diluted in PBST or TBST) for 30 mins at RT. Primary antibodies were 
diluted in 5 % [w/v] blocking solution and incubated with the membrane in a 
falcon tube on a rolling shaker for 1 hr at RT or overnight at 4 °C. 
Membranes were washed 6 times in PBST or TBST for 2 mins before being 
incubated in secondary antibody (in 5 % [w/v] blocking solution) for 1 hr at RT. 
Membranes were washed 6 times in PBST or TBST for 3 mins. Femto 
Maximum Sensitivity Substrate (Diluted Luminol/Enhancer:Stable Peroxide 
Buffer 1:1) was added to membranes and used for visualizing immuno-stained 
proteins. Blots were imaging using a ChemiDocTM MP Imaging System (BIO-
RAD) and exposure time was optimised for each blot individually. If membranes 
required re-blotting, they were either cut to remove the region of the membrane 
that had already been probed or chemically stripped for 10mins in Restore™ 
PLUS Western Blot Stripping Buffer and then washed in before blocking and re-
staining. 
Bands were identified and when required protein levels were quantified to a 
control reference band using Image Lab software (Version 5.2.1 Build 11) (BIO-
RAD). Protein measurements were then normalised to the loading control 
quantifications. 
 Co-immunoprecipitation 
WCE were prepared as in section 2.2.8. Immunoprecipitation of GFP-fusion-
proteins was done using GFP-TRAP magnetic beads (ChromoTek). 1 µg of 
each WCE was diluted to a final volume of 500 µl with Dilution Buffer. Per 
immunoprecipitation, 20 µl of GFP-Trap magnetic bead slurry was equilibrated 
in ice-cold 500 µl dilution buffer, magnetically separated and washed a further 2 
times in 500 µl ice-cold dilution buffer. Diluted cell lysate was added to 
equilibrated beads and incubated for 2 hr 4 °C on a rotating shaker.  
Supernatant was cleared by magnetically separating the beads and was then 
discarded. The beads were washed three times with 500 µl of ice-cold wash 
buffer. The beads were re-suspended in 50 µl 4X LDS Sample buffer (2.5 % -
mercaptoethanol) and boiled 10 mins at 95 °C. The beads were then 
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magnetically separated and 20 µl of supernatant was analysed by SDS-PAGE 
as described in section 2.2.9. 
 Cell Culture 
Wild-type hTERT RPE-1 and mIMCD3 cultures, including all derived cell lines, 
were grown in DMEM/F12 – GlutaMAX™ with 10 % Foetal Bovine Serum 
(FBS). HEK293T cells were grown in DMEM with 10 % FBS. Cells were 
cultured under standard conditions (37 °C, 5 % CO2) and passaged twice a 
week at a 1:12 ratio. 
 Fluorescent Activated Cell Sorting (FACS) 
Cells expressing GFP from a transient transfection or stable viral transduction 
were grown to confluence in a T25 flask. Cells were washed in PBS and 
trypsinised in 0.05 % Trypsin/PBS for 5 mins, or until a single cell suspension 
was reached. Cells were re-suspended in DMEM F12 10 % FBS and spun at 
200 x rcf for 5 mins. The supernatant was discarded and the cells were 
suspended in 1 ml of FACS buffer (Section 2.1.3.6).  
2.2.12.1 Cell Counts 
10µl of cell suspension was added to 10 µl of 0.4 % Trypan Blue Stain and 
transferred to a Countess® Cell Counting Chamber Slides for cell counts and 
viability. The cell suspension was then passed through a 70 µm filter into an 
FBS coated polypropylene 5 ml sterile FACS tube. Cells were then stored on 
ice before sorting. 
2.2.12.2 FACS  
A single cell index sort was used to isolate single GFP-expressing cells. Cell 
sorts were gated to removed doublets, debris and to select for the top 10 % of 
GFP expressing cells. Sorting was done on an Influx 6 Way Digital 
Fluorescence Activated Cell Sorter (BD Biosciences) by staff of the St James's 
Campus Infrastructure and Facilities (SCIF) into 100 µl of FACS Collection 
Media (DMEM F12, 50 % Conditioned Media, 20 % FBS, 1 % 
penicillin/streptomycin). Plates containing single cells were then left between 2-
3 weeks to clonal growth and to establish cell lines. 
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  Generation of RPE-1 Derived Cell-Lines 
2.2.13.1 CRISPR/Cas9 Genome Editing 
All CRISPR/Cas9 edited cells used in this project were generated before the 
start date of this project by myself in my role as a Research Assistant. 
gRNAs were designed using an online tool CRISPR Design provided by the 
Zhang Lab, MIT 2015 (No longer available) to the first coding exon of targeted 
genes (Appendix C, Table C.1). The highest ranked guide sequence, with 
added overhangs for cloning, were bought as forward and reverse HPLC-
purified oligos from Sigma-Aldrich. Oligos were annealed and subsequently 
cloned into the pX458 CRISPR/Cas9 expression vector using the BbsI 
restriction site and enzymatic ligation assisted by nucleases (ELAN) technique 
(271). 
2.5 µg of cloned vectors were forward transfected into 1x106 hTERT RPE-1 
cells with 7.5 µl of Lipofectamine 2000 (Invitrogen™) following the 
manufacturer’s protocol. Transfected single cells were sorted by FACS into 96-
well plates 24 hrs post-transfection (as in section 2.2.12). Single cell colonies 
were cultured to confluence and the CRISPR targeted region, in genomic DNA 
extracted from colonies, was amplified by PCR (Section 2.2.1) and sequenced 
(Section 2.2.3 and 2.2.4) for analysis. 
2.2.13.2 Viral Transduction for stably expressing cell lines 
2.2.13.2.1  Lentiviral Transduction 
LifeAct-GFP Lentiviral particles were made by Dr. Chiara Gallioni using 2nd 
generation lentiviral protocols. HEK293T cells were transfected with LifeAct-
GFP lentiviral vector, pMD2.G (VSV-G envelope expressing plasmid, a gift from 
Didier Trono; Addgene plasmid # 12259) and psPAX2 (packaging plasmid, a 
gift from Didier Trono; Addgene plasmid # 12260). Media was changed after 24 
hrs and DMEM 10 % FBS was added. A further 48 hrs post transfection the viral 
supernatant was collected and filtered through a 0.22 µm filter, then stored at -
80 °C in aliquots until use. 
RPE-1 cells were grown to 50 % confluency in a T75 flask. 8 µg/ml of polybrene 
was added to 3 ml of lentiviral supernatant (viral particles in DMEM Media 10 % 
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FBS) to make a transduction mix. The cells were washed in PBS and 3 ml of 
transduction mix was added drop wise to cells, then left to incubate overnight. 
16 hrs later the cells were washed in PBS and 12 ml of fresh DMEM F12, 10 % 
FBS media was added. The cells were left to grow and passaged 3 times as in 
section 2.2.11. before running though FACS selection (as in section 2.2.12) to 
establish a clonal cell line. 
2.2.13.2.2  Retroviral Transduction 
Retroviral particles of pBABE GFP-ROCK2-ER (Ximbio #152723), pBABE GFP-
ROCK2.KD-ER (Ximbio #152724), pBABE GFP-ER (Ximbio #152725) (Gifts 
from Prof. Mike Olson, University of Glasgow), were made by transfecting 12 µg 
of pBABE plasmids into Phoenix Ampho cells at 50 % confluence in a T75 flask. 
24 hrs post transfection media was changed for fresh DMEM 10% FBS. 48 hs 
post transfection retroviral particles were collected and filtered through a 0.45 
µm filter. 1 ml aliquots of virus were stored at -80 C until use. 
RPE-1 cells were transduced with retrovirus us described above in section 
2.2.13.1. 
 siRNA knock-down 
All knock-downs were performed with SMARTpool: ON-TARGETplus siRNAs 
(Dharmacon) (Appendix A.1) and were species specific. Cells plated for whole 
cell extracts were plated in 6-well plates and reverse transfected with 5µl of 20 
µM siRNA and 3 µl of Lipofectamine® RNAiMAX. Cells plated for 
immunofluorescence microscopy were plated in 12-well plates on coverslips 
and transfected with 2.5 µl of 20 µM siRNA and 1.5 µl of Lipofectamine® 
RNAiMAX. 
RPE-1 or mIMCD3 cells were trypsinised and re-suspended in DMEMF12, 0.2 
% FBS. Cells were counted as in 2.2.12.1 and diluted to a final concentration of 
1x105 cells/ml. siRNA and Lipofectamine® RNAiMAX was added separately to 
250 µl of Opti-MEM, reagents were incubated for 5 mins at RT before 
combining and incubating for a further 20 mins at RT. After the incubation 
transfection regents were added to each well of the culture plate the diluted cell 
suspension was added on top of the regents to give final cell counts of 2x105 
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cells/well in 6-well plates and 1x105 cells/well in 12-well plates. Cells were then 
incubated for 72 hrs before being used to prepare WCEs or for 
immunofluorescence microscopy. 
 Inhibitor Treatment of RPE-1 Cells 
2.2.15.1 Chemical Inhibitors 
Table 2.6 List of chemical inhibitors 
Chemical inhibitors and their molecular targets. All chemicals were tested in 
dose response curves to show their effects on ciliogenesis and so an 
optimised concentration is not listed. All the chemicals listed were stored at 





Vendor Catalogue # 
KD025 ROCK2 Kinase 
domain 













Blebbistatin Myosin ATPase 
activity 
0-10 16hrs Calbiochem 203390 
 
 
Different components of the ROCK2 actin regulation pathway were targeted 
with specific inhibitors listed in Table 2.6. RPE-1 or mIMCD3 cells were plated 
in DMEM F12 ,10 % FBS for either confocal microscopy (1x105 cells per well in 
a 12-well plate, on coverslips) or for high-throughput staining (2x103 RPE-1 
cells or 1.6x103 mIMCD3 cells per well in a 96-well plate). After the cells had 
settled and fully adhered the media was changed to DMEM F12, 0.2 % FBS 
with varying concentrations of each inhibitor or DMSO for a dose response 
curve. Cells were incubated in each inhibitor for varying lengths of time to 
determine the time frame of action of each inhibitor. For longer treatments the 
media and inhibitor was changed every 24 hrs. After treatment, cells were 
prepared for imaging as in section 2.2.7. 
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 siRNA Screening 
2.2.16.1 Primary genome screen filtering to generate datasets 
The primary whole genome dataset was downloaded as an Microsoft Excel file 
from https://doi.org/10.1038/ncb3201, Supplementary Table 1. Excel filtering of 
z-scores was used to determine hits based on phenotype quantifications. siRNA 
sequences were provided by Dharmacon and then transcript specificity was 
tested using Basic Local Alignment Search Tool (BLAST). 
2.2.16.1.1  Enrichment Analysis 
Enrichment analysis was carried out using STRING online analysis tool (272) 
(https://string-db.org/). Hit lists were copied into the multiple proteins tool and 
interaction maps were then analysed. Enrichment of pathways, domains, 
protein function or biological processes within the hit list was analysed by 
comparing to the whole genome. Gene ontology (GO) terms, Kyoto 
Encyclopedia of genes and genomes (KEGG) pathways, and UniProt key words 
were then used to interpret the types of enrichment that were present in the hit 
lists. Enrichment and false discovery rate was calculated as described in 
Franceschini et al., 2013 (273). 
2.2.16.2 Screen plates 
Screens used 1 µM SMARTpool: ON-TARGETplus siRNAs for hTERT RPE-1, 
and derived, cell lines and 2µM SMARTpool: ON-TARGETplus siRNAs for 
mIMCD3 screens (Appendix A.1).  
Plates in the second combinatorial screen were coated with Matrigel® Matrix 
basement membrane to minimise cell loss during washing steps, as seen in the 
first combinatorial screen, thus reducing plate-to-plate variation. 43.5 µl of 
Matrigel® (11.5 mg/ml) was defrosted on ice and diluted in 5ml of ice-cold Opti-
MEM™ (final concentration 100 µg/ml). 50 µl of diluted Matrigel® was added to 
each well of the 96-well ViewPlate and incubated for 1 hr at RT in aseptic 
conditions. Wells were then washed twice in 100 µl of 37 °C Opti-MEM™. Any 
effect that the Matrigel®  has on cilia incidence would be controlled for in the 
screen as each cell line was normalised to its own negative controls and 
compared only to the wild-type cells in that technical replicate. 
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2.2.16.3 siRNA transfection in 96-well plates 
Confluent T75 flasks of cells were washed in PBS and then incubated in 1 ml of 
0.05 % Trypsin at 37 °C for 5 mins. 5 ml of DMEM-F12 10 % FBS was added to 
the flask to re-suspend the trypsinized cells. The cell suspension was then 
transferred to a 15 ml Falcon tube and spun in a bench top centrifuge at 250 x 
rcf for 5 mins. The supernatant was discarded and cells were re-suspended in 3 
ml Opti-MEM™. 
5 µl of 1 µM (hTERT RPE-1 screens) or 2.5 µl of 2 µM (mIMCD3 screens) 
SMARTpool: ON-TARGETplus siRNA was added to each well of the 96-well 
ViewPlate. Negative control wells contained an equivalent volume of or 1X 
siRNA Buffer (Dharmacon) A master mix was made of n+2 (number of wells) 
of 0.2 µl of Lipofectamine® RNAiMAX and 14.8 µl (hTERT RPE-1 Screens) or 
17.3 µl (mIMCD3 Screens) of Opti-MEM™ per well and incubated for 5 mins at 
RT. Transfection reagent master mix was then added to each well on the 96-
well plate. Plates were gently mixed on a rotary shaker for 5 mins before a 
further 20-60 mins incubation at RT (incubation time was consistent within 
individual biological replicates but may have varied between biological 
replicates). 
Cell counts were analysed as in section 2.2.12.1 using the Countess®. Cell 
suspensions were then diluted to final concentration 2x105 cells/ml (hTERT 
RPE-1 Screens) or 1x105 cells/ml (mIMCD3 Screens) in Opti-MEM™. 80 µl of 
each diluted cell suspension was added to each well according to associated 
plate maps (Appendix D) to give final cell counts per well of 16000 cells/well 
(hTERT RPE-1 Screens) and 8000 cells/well (mIMCD3 Screens). Only mIMCD3 
cells were plated using a XRD-384 Automated Reagent Dispenser (FluidX™ 
Ltd), hTERT RPE-1 cells and derived cell lines were manually plated using a 
multichannel pipette. Plates were then left for 1 hr at RT in aseptic conditions to 
allow cells to settle before incubation at 37 °C for 72 hrs, minimising edge 
effects and ensuring an even distribution of cells across each well. 
2.2.16.4 Immunostaining of 96-well plates 
72 hr post transfection plates were inverted to remove media and wells were 
washed for 10 mins in 100 µl PBS supplemented with CaCl2 (0.49 mM) and 
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MgCl2 (0.9 mM). Plates that were to be immune-stained with anti-acetylated 
alpha tubulin were incubated on ice for 30 mins prior to washing with PBS. 
Plates were inverted to remove PBS and blotted on tissue to remove excess 
and placed on blue ice blocks. 50 µl of chilled methanol was added to each well 
and plates were incubated at -20 °C for 5 mins followed by a 50 µl wash in PBS. 
Cells were then blocked with 50 µl of milk blocking solution (1 % w/v in PBS) for 
5mins before primary antibody incubation. 
All antibodies were diluted (section 2.1.7) in 1 % [w/v] in milk/PBS and spun at 
13000 x rcf for 5 mins before use. Blocking solution was removed and 50 µl of 
primary antibody dilution was added to each well. Plates were incubated for 90 
mins on an orbital shaker at 12 rpm. Wells were washed 3 times in PBS before 
being incubated in 50 µl of secondary antibody for 90 mins on an orbital shaker 
at 12 rpm. Wells were washed a further 6 times in PBS before being stored in 
100 µl of PBS at 4 °C until imaging. 
2.2.16.5 High-throughput imaging of screen plates 
Plates were warmed to RT before imaging. Six fields of view were captured 
using an Operetta® High Content Imaging System and Harmony® software 
(Perkin Elmer) for each well. Image acquisition was optimised on wild-type 
negative controls. FOV were set in same pattern across every well (avoiding the 
centre of the well) for every plate that was imaged. All images were taken using 
a 20X air objective. 
 Analysis of Screen Plates 
All screens were performed in triplicate (3 experimental replicates – the same 
cell lines but the whole experiment was repeated on separate days, stained with 
fresh dilutions etc.) which is standard for siRNA screening (274). Furthermore, 
hits must always be verified with downstream validation after screening 
conditions as high-throughput conditions may not be optimal for each 
siRNA/knock-down. 
Combinatorial screens were also carried out with two technical replicates for 
each experimental replicate. Although three experimental replicates were 
performed for the combinatorial screen, loss of cells in some conditions meant 
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that data could only be collected for two experimental replicates. This was 
considered sufficient for a proof of concept screen. The combinatorial screen 
also contained some internal biological replicates as some CRISPR/Cas9 
edited cell lines had mutations in the same genes. 
2.2.17.1 Columbus Image Analysis 
Image data was imported into Columbus™ Image Data Storage and Analysis 
System for high-throughput analysis. Recognition protocols were written with 
the provided software building blocks (Appendix E). Recognition protocols were 
optimised on wild-type negative controls to recognise nuclei, cytoplasm and cilia 
(Figure 2.2).  
 
Figure 2.2 High-throughput Operetta Imaging and Columbus™ 
Recognition Protocol 
Cells were imaged in 3 channels, each channel imaging at the optimal focal 
plane. B) Images were imported from Harmony® software to Columbus™ 
software C) ‘Find nuclei’ protocol recognition block was used in the DAPI 
channel to define nuclei. D) The cell body was defined using ‘Find 
cytoplasm’ by recognising TOTO-3 staining. E) Cells that were not 
completely within the field of view were removed from the analysis. F) ‘Find 
spots’ protocol was optimised to detect the maximum number of cilia 
without including background staining. Spot recognition was optimised 
based on spot radius, contrast, uncorrected spot to region intensity, 
distance between 2 spots and the spot peak radius. Spots were detected by 
ALR13B staining in the 488 nm channel. The population of cells with a 
single spot is then calculated from the calculated data and used to 
represent ciliary incidence. Cells with 2 or more spots were also calculated 
for comparison. Scale bar = 50 µM 
 
Cell counts, ciliary incidence, cilia spot size and cilia spot intensity were then 
calculated as an average across all 6 FOV per well. 
2.2.17.2 Preliminary Analysis 
Heat maps of cell number are assessed for seeding errors or for loss of cells 




Imaging	planes	 Input	Image Find	Nuclei Find	Cytoplasm Exclude	Border	
Objects
Find	SpotsA
B C D E F
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analysis as these outliers skewed the data. Further qualitative analysis removed 
data points based on the quality of immunostaining and image focus for each 
well (Figure 2.3). 
 
Figure 2.3 Qualitative assessment of combinatorial screen plates 
A) Example heat maps shows a series of 5 control wells (highlighted in red 
rectangle) that have very high cell number compared to the corresponding 
controls in plate 2 or column 12. These wells were then examined for 
seeding errors or processing errors. siPlk1 controls are also highlighted for 
cell number (red boxes) as these should have a very low cell number, the 
medium blue colour suggests a low transfection efficiency and would result 
in the entire plate being removed from analysis. B) Field of view (FOV) 
taken from a combinatorial screen plate that shows cell loss in a well. The 
high-throughput washing protocol caused lifting of the monolayer of cells. 
Lifted cells would then be aspirated and lost before imaging. C) Imaging 
artefact or possible piece of dust that is obscuring the FOV. D) Staining for 
cytoplasm with TOTO-3 failed and so cell boundaries could not be set by 
the automated recognition protocol. For any well if more than 50 % of cells 
were lost due to washing or unable to be analysed this well was excluded 
from the analysis to prevent outliers 
 
Finalised data sets were then assessed for reproducibility between technical 
replicates by calculating the coefficient of determination (R2), plates with R2   
>0.5 were considered reproducible. Positive and negative controls in each plate 
were then tested to be significantly different using a z-score comparison. If 
Staining Quality 
Cell Loss 
Plate 2 Plate 1 
Whole Cells Number of Objects 
% cells with a single cilium 
Cilia – Spot Area [px
2
] – Mean per well 
Image Quality A) B) 
C) 
D) 
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calculated means of positive and negative controls were more than 1.5 standard 
deviations apart, then the plate was taken forward for full analysis. 
2.2.17.3 Statistical Analysis 
Wells that did not pass preliminary analysis were excluded from further 
analyses and robust z-scores were calculated from the remaining data. Robust 
z-scores were used in place of a standard z-score as this statistical 
normalisation takes into account experimental variation. The robust z-score 
represents the number of median absolute deviations data point x is away from 
the median of the negative controls. 




Where 𝓂 = median values of the measured phenotype of the negative controls 
𝑀= median absolute deviation of the measured phenotype of the negative 
controls 
And therefore on a normal distribution curve, of data point 𝑥 compared to the 
negative controls 
−1.96 ≥ 𝑅𝑜𝑏𝑢𝑠𝑡 𝑍 𝑜𝑓 𝑥 ≤ +1.96  is equivalent to  𝑝 = 0.05 
2.2.17.3.1  Secondary siRNA screens 
Negative controls were pooled, (siScrambled pooled with RNAiMax transfection 
reagent only wells). These pooled negative controls were used to calculate 
robust z-scores for each quantified phenotype within each biological replicate of 
the screen. Transfection control (siPlk1) and ciliary controls (siIft88 and 
siRpgrip1l) were then confirmed to be significantly different from negative 
controls on each screen plate (robust z-scores ≤ -1.96). Once each plate was 
validated for analysis, average robust z-scores were for experimental wells 
were calculated (n=2). Average robust z-scores for 3 phenotypes were 
assessed: cell number (zcell), cilia incidence (zcilia) and percentage of cells with 2 
or more cilia (z2MCilia). Hits were then filtered based on robust z-score values to 
identify validated hits. 
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2.2.17.2  Combinatorial screens 
Robust z-scores were calculated for each cell line within in biological replicate 
of a screen and averaged across 2 technical replicates. The mean robust z-
score across all biological replicates (n=3, n=2 for some conditions) was then 
calculated with standard error of the mean and presented graphically for 
analysis. The average robust z-score provides evidence the knock-down 
causes a significant change in phenotype compared to the negative controls in 
that cell line alone. The difference between two z-scores (∆Z) was used to 
assess the type of genetic interactions inferred from the screens. The ∆𝑍 then 
provides evidence that the change seen is significantly different to the knock-
down of gene x in the wild-type mother cell line. 
∆Z =  𝑍𝑥 − 𝑍𝑥𝑦 
Where 𝑍𝑥= Robust 𝑍 of wild-type RPE-1 that has been treated with an siRNA 
against gene 𝑥 
𝑍𝑥𝑦 = Robust 𝑍 of a cell line, with mutation in gene 𝑦 that has been treated with 
an siRNA against gene 𝑥 
The synthetic genetic interactions inferred from the screen were defined as: 
Additive = −1.96 ≥ 𝑅𝑜𝑏𝑢𝑠𝑡 𝑍 ≥ 1.96 and 1.96 ≥ ∆𝑍 ≥ −1.96.  
Synergistic = −1.96 ≥ 𝑅𝑜𝑏𝑢𝑠𝑡 𝑍 ≥ 1.96 and ∆𝑍 ≤  −1.96 
Antagonistic = −1.96 ≥ 𝑅𝑜𝑏𝑢𝑠𝑡 𝑍 ≥ 1.96 and ∆𝑍 ≥ 1.96. 
2.2.17.4 Prioritising hits for validation 
In all screens, only the strongest hits were taken forward for further validation. 
This was partially due to the time constraints of investigating each hit 
individually. Many hits were instantly discounted for follow up investigation due 
to a lack of validated reagents. Specific literature searching to find a potential 
ciliogenesis role would introduce a bias into the screening system, therefore just 
the top hits/interactions from each screen were taken forward and all literature 
searching was used to further justify each hit during validation and help develop 
a hypothesis for their role in ciliogenesis. 
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Chapter 3  
Results: ROCK2 regulates ciliogenesis in RPE-1 cells 
through actin remodelling and acto-myosin contractions 
3.1 Introduction 
A whole genome, cell-based, high-content small interfering RNA (siRNA) screen 
and secondary validation screens were performed in ciliated cell lines to identify 
potential new ciliopathy genes and functional modules associated with 
ciliogenesis (266). The screens measured cilia incidence, cilia intensity and 
nuclear morphology, taking forward hits that reduced cilia incidence for further 
validation (Figure 3.1A). Primary morphological and numerical data from the 
whole genome screen allowed 4 further hit lists for different phenotypes to be 
identified. The 3 hit lists included genes that: (i) increased cilia incidence; (ii) 
increased the percentage of cells with 2 or more cilia; and (iii) significantly 
changed average cilia staining intensity (Figure 3.1B).  
 
Figure 3.1 Quantifiable phenotypes that can be analysed from the whole 
genome screen data set 
Schematic diagram comparing the phenotypes assessed in the original 
whole genome screen (A) and then subsequent phenotypes that could be 
analysed from the quantified data. (B) Cilia counts could be used to 
identify hits that increase cilia incidence or increase the percentage of cells 
with more than one cilium. Spot intensity measurements were also used as 
a proxy measurement of cilia length. Cell counts with associated cilia 
counts could identify possible cell cycle controls that decrease cell number 
and cilia number. 
 - 97 - 
These hit lists provided candidate gene lists for secondary screening to identify 
components implicated in ciliary structure and function, the regulation of 
ciliogenesis, or links between ciliogenesis and the cell cycle. By repurposing the 
whole genome screen data in this way, there was potential to identify novel 
pathways and genes that contributed to the molecular control of cilia, without 
the bias inherent when selecting specific libraries or gene subsets. 
The majority of the research that seeks to understand ciliary biology and the 
molecular pathology of ciliopathies has focused on patient mutations and 
experimental gene disruption that ablates, or impairs ciliogenesis. Positive 
regulators of ciliogenesis such as transition zone (TZ) or intraflagellar transport 
proteins (IFT), which cause ciliopathies such as Joubert Syndrome or skeletal 
dysplasias, have therefore been the research area for many groups because 
mutations in these genes cause ciliary loss. However, few recent studies have 
noted the importance of identifying mechanisms or pathways that increase 
ciliogenesis through functional loss of negative regulators as these could 
present potential therapeutic targets for ciliopathies (96, 260, 275). Across 
ciliary research generally a growing number of cellular pathways have been 
shown to contribute to the complex maintenance and regulation of ciliogenesis 
and disassembly, including the ubiquitin-proteasome (276) and actin 
remodelling systems (Reviewed in (54, 277, 278)). Thus, an unbiased approach 
using siRNA screening could identify novel genes and pathways that contribute 
to the molecular control and maintenance of cilia formation. 
 Chapter Aims and Objectives 
Aim: To improve ciliopathy patient quality of life through greater understanding 
of their genetic disease and though identifying potential therapeutic pathways. 
Specifically, this chapter aims to identify novel negative regulatory pathways of 
ciliogenesis as these have the potential to be therapeutic targets in ciliopathies.  
Hypothesis: Ciliogenesis and the cell cycle are intrinsically linked in both timing 
and role in progression of a cell towards division. If the cell cycle has several 
positive and negative regulatory pathways for the timely and precise 
progression though each stage of the cycle, which have been well defined, 
ciliogenesis would also require strict positive and negative regulatory pathways. 
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Most research has highlighted positive regulatory pathways in ciliogenesis, 
therefore there are key negative regulators that are still to be identified.  
Experimental Objectives: 
• To generate a data set from existing whole genome reverse genetic 
screening data of potential hits that increase cilia incidence 
• To carry out secondary screening to validate hits and identify candidates 
to take forward for further investigation 
• Further validation of hits in human cell line models 
• Elucidate the mechanistic links between validated hits and regulation of 
ciliogenesis 
3.2 Primary whole genome siRNA screen hits that increase 
cilia incidence 
Three stringent filtering steps were used to identify hits that increased cilia 
incidence from the whole genome data set (Figure 3.2). Firstly, the data set was 
filtered to identify hits that reproducibly increased cilia incidence: in other words, 
the siRNA knockdown had a zcilia score 1.96 in both biological replicates of the 
screen.  
The second filter was used to remove any hits that significantly increased or 
decreased cell number (-1.96<zcell<1.96). The final filtering step controlled for 
siRNA quality by removing siRNA pools that has published off-target effects. 
Enrichment analysis showed that the final hit list was significantly enriched for 
genes associated with “Intracellular non-membrane bound organelle” (GO: 
0043232 Cellular Component) (Table 3.1). This Gene Ontology (GO) term is 
defined as: “Organized structure of distinctive morphology and function, not 
bounded by a lipid bilayer membrane and occurring within the cell. Includes 
ribosomes, the cytoskeleton and chromosomes” (279). However the 83 hits did 
not highlight any obvious pathways or gene networks in a STRING analysis 
(Figure 3.3) (280).  
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Figure 3.2 Filtering steps used to identify hits that increase cilia incidence 
from whole genome screen data. 
A) The workflow of filtering steps that were used to create the increasing 
cilia hit list. Three filtering steps were used that were to ensure high 
specificity over sensitivity. Therefore hits could be taken forward for 
validation in human cell lines. B) Scatter graph shows average robust z-
score for cilia incidence of each siRNA knock-down across the whole 
genome screen. Dark grey points indicates hits that passed Filter 1, pink 
points that passed Filter 2, and red points highlight the final 83 hits to be 
taken forward for secondary screening. (8907 data points are outside y-





Hits must have a human homologue, 
siRNA must have no published off-target 
effects and target all transcripts.  
No. of hits 
83 
A) Whole Genome Data Set: 
 19097 Data Points 
Filter 2 
No effect on cell number 
Criteria 
z-Score of cell number must be 2>x>-2 
in both biological replicates 
No. of hits 
135 
Filter 1 
Increased Cilia Incidence 
Criteria 
z-Score of Cilia incidence must be >2 
in both biological replicates 
No. of hits 
240 
B) 
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Table 3.1 Gene enrichment during filtering steps to identify hits that 
increase cilia incidence 
Filter 1 returned hits that significantly increased cilia incidence in both runs 
of the whole genome screen. This gene list was significantly enriched for 
olfactory transduction and rhodopsin-like G protein-coupled receptor 
(GPCR) protein domains. The same pathways were more significantly 
enriched after Filter 2, with additional enrichment of GPCRs. The final 
enrichment step (Filter 3) removed significant enrichment in the previously 
identified pathways and the final hit list was only enriched in the Gene 











04740 Olfactory Transduction 30/240 0.000184
INTERPRO Protein Domains and Features 
IPR000725 Olfactory Receptor 29/240 0.00984
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IPR000276 G protein-coupled receptor, 
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Figure 3.3 STRING analysis of the final 83 hits for secondary screening 
STRING analysis (https://string-db.org/) (272) did not identify any 
significantly enriched pathways amongst the filtered final 83 hits taken 
forward for secondary siRNA screening. This does not reflect the potential 
of the data set to identify valuable hits and is more likely a reflection on the 
lack of sensitivity in the filtering steps used. Pink lines represent 
experimentally determined interactions, light blue lines represent 
interactions found in curated databases, black lines represent genes that 
are co-expressed, yellow lines represent genes that are co-mentioned in 
published abstracts. 
This was likely due to the stringent filtering. This stringency comes from 
ensuring that zcilia values were >2 in both runs of the primary whole genome 
screen rather than just analysing the average zcilia of the runs. If only average 
zcilia was used, this would have provided 596 hits, whereas the more stringent 
filter returned 240 hits. Likewise, if average z-scores were used for not only 
filtering step 1 but also filtering step 2, this would have returned 445 hits rather 
than the 135 returned with more stringent filtering. Thus the filters employed 
here ensured specificity over sensitivity. 
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3.3 Increasing cilia incidence secondary screen 
The secondary screen followed the same optimised protocol as the whole 
genome screen in mouse inner medullary collecting duct cells (mIMCD-3) (266) 
but used a different chemistry of siRNAs that have reduced off-target effects 
(281) and used a different batch of anti-Ac--tubulin antibody. Cell seeding 
density, fixation and antibody concentration were validated and re-optimised for 
secondary screening. 
The 83 hits to be validated (Appendix A.1.1, Table A.1) were plated across two 
96-well plates with re-tested and validated controls (Figure 3.4). Although there 
were no positive controls for increased cilia incidence across the screen, the 
use of robust z-scores allowed all hits to be normalized and compared to 
negative controls. Furthermore, the recognition protocol for primary cilia was re-
optimized and validated within this screen, ensuring that positive control siRNAs 
(that decreased cilia incidence) were significantly different to negative controls 
(Figure 3.4).  
Heat maps of the raw screen data were used for initial qualitative analysis to 
assess any obvious seeding, staining, or processing errors (Figure 3.5). Wells 
treated with siPlk1 (A1, A12) showed very low cell counts and cilia incidence, a 
qualitative indication of the transfection efficiency on each plate. The heat map 
for run one, plate two, showed very high cell numbers in parts of row A and row 
H (Figure 3.5, red highlight). This could reflect a mechanical seeding error in 
which more cells were plated in these wells, or be an edge effect that arose 
during incubation of the plates. These wells were all negative controls (treated 
with RNAiMAX transfection reagent only) and so were removed from the 
analysis pipeline to prevent skewing the statistical analysis. Once removed, the 
quantified data of the 2 biological replicates was compared. The correlation 
between runs showed evidence of good reproducibility in the screen set up and 
data for both cell counts and cilia incidence (Figure 3.6). 
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Figure 3.4 Control siRNAs are robust in the increase cilia incidence 
secondary screen 
A) Transfection efficiency in the screen was assessed with siPlk1, as 
knock-down of Polo-like kinase 1 (Plk1) inhibits cell proliferation. Mean 
robust z-score for cell number (Zcell) across the 2 runs of the screen was -
10.758, indicating that transfection efficiency of siRNAs across the screen 
was high. B) Positive control siRNAs for loss of cilia, siRpgrip1l and siIft88, 
were used to validate the accuracy of the cilia recognition protocol. Mean 
robust z-scores for cilia incidence were -2.605 and -5.523, respectively, 
indicating that the recognition protocol allowed accurate cilia identification 
and differentiation between hits of different strengths. Statistical 
significance was calculated using robust z-scores to compare negative 
with positive control siRNAs. 
 
Figure 3.5 Heat Maps from the increased cilia incidence secondary screen 
Heat maps for cell number and cilia incidence from screen run one. The 
heat maps were assessed for cell seeding errors, staining or recognition 
protocol errors. Low total cell numbers associated with the siPlk1 control 
can be seen in wells A1 and A12 (examples highlighted in green). Wells 
excluded from the analysis for possible seeding errors (examples 
highlighted in red) with significantly higher cell count. The wells chosen to 
be removed from analysed screen plates were all negative controls, 
treated with RNAiMAX transfection reagent only, so did not affect 
identification of validated hits. 
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Figure 3.6 Correlation between runs of the increased cilia incidence 
secondary screen 
Scatter graphs showing the correlation between the 2 biological replicates 
of the Increased Cilia Secondary Screen. A) zcell of biological replicates 1 
and 2 of the secondary screen were plotted to show correlation between 
runs. Pearson’s correlation coefficient (R2) between runs was 0.6366. B) 
Pearson’s correlation coefficient for zcilia was 0.7156, indicating that the 
screen was highly reproducible. 
 Hits from the secondary screen 
Pooled negative controls were used to calculate robust z-scores within each 
plate of the screen. The average zcilia was used to select hits that significantly 
increased cilia incidence. Hits were defined by a cut-off of average zcilia 1.96. 
Eight of the 83 screened siRNAs were validated as hits (Table 3.2 & Figure 
3.7). There was a clear qualitative increase in cilia staining intensity and cilia 
incidence seen across each field of view captured for the top 4 hits when 
compared to negative controls (Figure 3.8). The total of 8 hits meant the screen 
had a validation rate of 9.6%. The final data set had 2/176 negative controls 
with an average zcilia 1.96 and the screen therefore had a false positive rate of 
1.1%. The false negative rate could not be calculated, but hits in both the whole 
genome and secondary screens may have been missed due to false negatives. 
The top hit from the screen was Rock2, with an average zcilia of 3.796, 
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Table 3.2 Validated hits from the increase cilia incidence secondary 
screen 
Validated hits from the increase supernumerary cilia secondary screen. 
The average z-scores (rounded to 3 decimal places) from 2 biological 
replicates are shown for cilia incidence (zcilia) and cell number (zcell). Hits 
are ordered from highest to lowest based on the zcilia score. 
 
 
Figure 3.7 Scatter graph of zcilia scores from the increase cilia incidence 
secondary screen 
The average robust z-score for cilia incidence (zcilia) of both biological 
replicates of the screen was plotted. 8/83 hits (red points) were validated 
with average zcilia >1.96. The top 4 hits from the screen are labelled, each 
with zcilia values as follows: Rock2 (3.796), Stx19 (3.458), Fancd2os 
(2.819), Bcl10 (2.490). These hits were then considered for tertiary 
validation in a human ciliated cell line. Statistical significance of hits 
calculated with robust z-scores normalising to pooled negative controls.   
 - 106 - 
 
Figure 3.8 Immunofluorescence high content imaging of the top hits from 
the increased cilia incidence secondary screen 
Single fields of view were taken from the screen plates of the second 
biological replicate of the screen to compare control siRNAs to the top 4 
hits from the screen. There is a clear qualitative increase in cilia incidence 
seen in siRock2, siStx19, siFancd2os and siBcl10 knock-down cells 
compared to the siScr negative control. The positive control for cilia loss 
(siIft88) is also shown for comparison. Merge images show DAPI (blue), 
TOTO-3 (pink) and Ac-α-tubulin (green) staining. 
The limitations of available reagents and time encouraged the tertiary validation 
of only the top hit from the screen. The current literature and databases were 
reviewed in order to assess the potential role of each gene in ciliogenesis and 
to ensure justification for the validation of the top hit, RhoA-Associated Protein 
Kinase 2 (ROCK2). 
3.4 ROCK2 
ROCK2 has not been directly shown to be a negative regulator of ciliogenesis in 
previous studies, but downstream actin remodelling pathways activated by 
ROCK have provided indirect evidence for the importance of actin remodelling 
in controlling cilia incidence and length (92-94) Thus, the current published 
evidence suggests that a highly complex network of pathways and regulators 
control the actin cytoskeleton’s role during ciliogenesis. Further investigation 
into these mechanisms could give further clarity and insight into this process 
during ciliogenesis. 
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 Validation of knock-down and phenotype 
The SMARTpool siRNAs used in secondary screening and for tertiary 
investigation were validated to cause a significant decrease of ROCK2 protein 
levels in 2 ciliated cell models, on average giving an 80% knock-down as shown 
by western blot (Figure 3.9). 
   
Figure 3.9 Western Blots validate loss of protein by siRNA knock-down of 
ROCK2 
A) Western blots validated loss of both mouse and human ROCK2 
following siRNA knockdowns in mIMCD3 and RPE-1 cells respectively. B) 
Quantification of western blot densitometry measures for technical 
replicates of knock-downs for each cell line. Quantifications of ROCK2 
levels were normalised to -actin. Statistical significance of pairwise 
comparisons was calculated with an unpaired, two-tailed, Student’s t-test. * 
=p<0.05, ** =p<0.01. Error bars represent S.D and WCE stands for whole 
cell extract. 
Tertiary screening of ROCK2 knock-downs was done in a human cell model to 
confirm the phenotype across different model organisms. Knock-down of 
ROCK2 in human retinal pigment epithelial cells (RPE-1) showed a marginal 
increase in cilia incidence across 3 averaged biological replicates. This did not 
reproduce the strong increase in cilia incidence seen in secondary screening for 
the mIMCD3 mouse cell line (Figure 3.10). RPE-1 cells treated with siROCK2 
did, however, show a large and significant increase in cilia length, increasing on 
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Figure 3.10 ROCK2 knock-down in human hTERT-RPE-1 cells increases 
cilia length 
A) Immunofluorescence confocal microscopy of RPE-1 cells following 
knockdown of siROCK2 shows increased cilia length across the cell 
population, compared to cells treated with siRNA scrambled (siScr) 
negative control. An example cell is highlighted in each condition, with the 
length of cilia indicated. B) Average cilia length for negative controls was 
2.91m and in siROCK2 treated cells was 3.92m (n=3 biological 
replicates, minimum of 40 cilia measured per replicate).C) Quantified data 
shows there is no significant difference in cilia incidence between negative 
control cells and cells treated with siROCK2 (n=3, p=0.5310). Data was 
confirmed to be normally distributed using D'Agostino-Pearson omnibus 
K2 test. Significance was then calculated for B) and C) with an unpaired 
two-tailed Student’s t-tests. **** = p<0.0001. Error bars represent S.D. 
 Overexpression of mRock2 inhibits ciliogenesis 
A GFP-mRock2 construct validated by western blot (Figure 3.11A) was 
transfected into RPE-1 cells to assess if over-expression of Rock2 caused a 
loss in cilia incidence or length. Cells expressing GFP-mRock2 were compared 
to cells expressing untagged GFP or un-transfected cells. There was a 
significant decrease in cilia incidence in cells expressing GFP-mRock2, 
compared to the cells expressing only GFP or the un-transfected populations. 
Cells expressing GFP-mRock2 also had significantly shorter cilia than cells 
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Figure 3.11 Cilia incidence in RPE-1 cells expressing GFP-mRock2 
A) Western blot to confirm overexpression of GFP-mRock2. Membrane 
immunoblotted against GFP. A band at 27kDa, likely to be GFP cleaved 
from Rock2, can also be detected. B) Cilia incidence and cilia length were 
determined for RPE-1 cells transiently transfected with either GFP-
mRock2 or an untagged GFP construct. N=3 experimental replicates with 
at least 100 cells counted per condition in each replicate C) RPE-1 cells 
expressing GFP-mRock2 had a significantly lower cilia incidence 
compared to cells expressing GFP only. D) Cells expressing GFP-mRock2 
also had significantly shorter cilia compared to controls, suggesting a 
dominant negative effect of protein over-expression. Data in C) was 
confirmed to be normally distributed using D'Agostino-Pearson omnibus 
K2 test and not normally distributed in D). Significance was then was 
calculated with an unpaired, two-tailed Student’s t-test (cilia incidence) and 
a Mann-Whitney U test (cilia length). * = p<0.05, ** = p<0.01. Error bars 
represent S.D. 
 Rock2-/- mouse has ciliary defects 
As both cell lines tested showed a significant ciliogenesis phenotype with a 
transient Rock2 knock-down, it was of interest to confirm if a full animal knock-
out model of Rock2 would also show a ciliogenesis phenotype since transient 
knock-downs and constitutive, global knock-out models frequently manifest 
different phenotypes. For example, in some knock-out models compensatory 
mechanisms and genetic interactions can rescue phenotypes that are not 
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observed in the transient knock-down cell models (reviewed and summarised in 
(238, 282)).  
The Rock2-/- knock-out mouse has a more severe phenotype than the Rock1-/- 
mouse. Most embryos only survived to E13.5 due to placental failure but 
surviving mice, although smaller than wild type controls, did not show any 
histological differences (283). Follow-on work investigating cilia formation during 
angiogenesis in the Rock2-/- mice also noted some ciliary defects including 
longer cilia in embryonic fibroblasts (Figure 3.12), a different distribution of cilia 
across cell types in blood vessel lumens, and an overall reduced cilia number in 
tissues (265). 
 
Figure 3.12 The Rock2-/- mouse has longer cilia than wild-type controls 
Embryonic fibroblasts (MEFs)  taken from mutant and wild-type mice were 
serum starved and then stained for cilia using ARL13B as a marker. Cells 
from the Rock2-/- mice had significantly longer cilia compared to the wild-
type controls. Significance calculated with an unpaired, two-tailed 
Student’s t-test.** = p<0.01. Error bars represent S.D. This figure was 
provided by Dr. Gary Grant and partly presented in his thesis (265).  
 
 ROCK1 does not have the same role as ROCK2 in ciliogenesis 
The whole genome siRNA screen data suggested that Rock2 but not Rock1 
was involved in the negative regulation of ciliogenesis in mIMCD3 cells 
(average zcilia for siRock1 from the primary screen data set = 0.863863). 
Previously published work gave evidence that ROCK1 knock-down increases 
cilia incidence in RPE-1 cells (98). However, in previous experiments presented 
in this thesis, ROCK1 activity was not able to compensate for loss of ROCK2. 
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These different roles for the ROCKs have been described in other molecular 
mechanisms, despite the 93% homology in their kinase domains (284). 
Therefore, to test if Rock1 was a true false negative hit from the whole genome 
screen, validated knock-downs (Figure 3.13) were carried out in both mIMCD3 
and RPE-1 cells.  
IMCD3 cells treated with siRock1 showed a ciliogenesis phenotype, with a 
moderate decrease in cilia incidence and a significant increase in average cilia 
length, from 2.7m in negative controls to 3.7m (Figure 3.14 A). RPE-1 cells 
showed no significant changes in cilia incidence or cilia length between 
negative controls and cells treated with siROCK1 (Figure 3.14 B). Since 
residual ROCK2 cannot compensate for ROCK1 knock-down, and vice versa, 
this highlights the distinct roles of these proteins in ciliogenesis, confirming 
findings in other cellular pathways. Thus, the hypothesis going forward, was that 
only the kinase activity of ROCK2 was a negative regulator of ciliogenesis. 
 
Figure 3.13 Validation and specificity of ROCK siRNAs 
A) siRNAs targeting both human and mouse ROCK1 are efficient and 
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Figure 3.14 Loss of ROCK1 does not phenocopy loss of ROCK2 
A) IMCD3 cells treated with siRock1 or a scrambled negative control 
siRNA. A moderate decrease in cilia incidence was seen across cell 
populations (n=3 technical replicates, p=0.3724). A significant increase in 
average cilia length from 2.7m to 3.7m was noted (n=3, at least 50 cilia 
measured per technical replicate). B) RPE-1 cells showed no significant 
changes in ciliary phenotypes compared to negative controls when treated 
with siROCK1. Data for cilia incidence was confirmed to be normally 
distributed using D'Agostino-Pearson omnibus K2 test whereas cilia length 
data was not normally distributed. Statistical significance of pairwise 
comparisons was then calculated with Student’s two-tailed t-test (for cilia 
incidence) and the Mann-Whitney U-test (for cilia length) ****=p<0.0001. 
Error bars represent S.D. 
 ROCK2 kinase activity negatively regulates ciliogenesis 
Evidence presented thus far from an in vivo mouse and 2 in vitro cell models 
indicated that ROCK2 was a negative regulator of ciliogenesis. To decipher the 
functional role that ROCK2 played in ciliogenesis, the known kinase activity of 
the protein was specifically tested for a functional role in this process. 
Previous work with ROCK inhibitors in ciliary research have used non-specific 
inhibitors such as Y27632 (119, 285), noted more commonly for cilia elongation, 
or GSK 429286 (286), which was able to rescue loss of cilia in a Rho GTP 
Activating Protein (Arhgap35) mutant mouse embryonic fibroblast (MEFs) 
model (286). These studies did not aim to dissect the specific functional roles of 
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inhibition in restoring cilia in ciliopathy cell models. Despite its use in previous 
ciliary studies, because Y27632 chemically inhibits both ROCK1 and ROCK2 in 
addition to other kinases (287) it was judged to be unsuitable for this project. In 
contrast, KD025 is a relatively new drug that selectively binds and inhibits 
ROCK2 with a minimal effect on ROCK1 in a cell-free system (IC50= 105 nM 
and IC50 = 24 µM, respectively). Since KD025 is a competitive ATP inhibitor, 
when used in cellulo KD025 is expected to be between IC50 = 1-10µM for 
ROCK2 and greater than 200µM for ROCK1 (288), allowing the reasonable 
assumption that only ROCK2 is selectively inhibited in the experiments 
described below. 
RPE-1 cells were treated with KD025 for either 2 or 48 hours to confirm the 
efficacy of the drug. ROCK2 kinase activity was assessed by quantifying 
changes in phosphorylated MLC. Initially, western blots were used analyse 
phosphorylated MLC. Unfortunately, despite optimisation of all antibodies, 
biological replicates were not reproducible with some blots not showing 
consistent patterns or, indeed, any bands during imaging (Appendix F). Instead, 
an immunofluorescence staining and high content imaging method was 
therefore developed. Due to the previous antibody variability observed for 
western blotting, total fluorescence measurements were avoided. Instead, the 
presence of active acto-myosin (myosin is active when MLC is phosphorylated), 
which can be seen as thin fibre like structures in immunofluorescence 
microscopy, were assessed using and automated image structure analysis. 
Inactive, unphosphorylated myosin staining appears speckled cytoplasmic 
staining. These staining patterns were consistent in both the human and mouse 
cell lines (Appendix G.2). The image structure analysis was used to quantify the 
presence of regular structures, such acto-myosin fibres made from 
phosphorylated MLC. This quantification, in arbitrary units, was then used as an 
indirect measure of ROCK2 kinase activity on MLC (Figure 3.15). 
KD025 treatments led to a decrease in visible acto-myosin fibres and specific 
staining of phosphorylated MLC in both RPE-1 (Figure 3.15 and Appendix G.1) 
and mIMCD3 cells (Appendix G.2). 48 hours KD025 treatment caused a trend 
that showed reduced image structure with increasing concentrations of KD025, 
with a significant loss of image structure (visualized by the presence of acto-
myosin fibres with bi-phosphorylated (Thr18, Se19) MLC (pp-MLC)) following 
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5m KD025 treatment. 2 hour treatment also showed a trend of fewer fibre 
structures with increasing concentration of KD025. Similar results were 
observed in miMCD3 cells, but there were significant decreases in image 
structure across all antibody stains tested (Appendix G.2).  
The specific ROCK2 phosphorylation site in MLC is unclear. It is known that 
MLC is preferentially phosphorylated by ROCK at Ser19 before Thr18 (289). 
However, the literature remains unclear if ROCK1 and ROCK2 both 
phosphorylate these sites in all cell types and if preferential phosphorylation is 
initiation or pathway-specific. 
The specificity of the chemical inhibitor KD025 towards ROCK2 was confirmed 
in this thesis by showing that it caused a dose-dependent response in acto-
myosin fibre structure. Treatment of cells with KD025 indicated that the kinase 
activity of ROCK1 cannot compensate the loss of ROCK2 activity. However, 
ROCK1 knock-downs in previous publications (98) and in IMCD3 cells (Figure 
3.14) still had a ciliogenesis phenotype when assessing ciliary length. This 
therefore questions the true contribution of each kinase to ciliogenesis in the 
mouse and human model systems. 
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Figure 3.15 KD025 inhibits the kinase activity of ROCK2 and reduces the 
presence of acto-myosin fibres in RPE-1 cells 
A) Representative high-throughput images of RPE-1 cells treated for 2hrs 
with KD025. Single cells are shown in magnified high contrast insets to 
highlight the presence or absence of fibre structures (indicated by 
arrowheads). No fibre structures can be seen in the negative control 
myosin light chain II (MLC) staining across all concentrations of KD025 
treatment. There is a qualitative reduction in specific staining of fibre-like 
structures as the concentration of KD025 increases for both mono-
phosphorylated (Ser19) MLC (p-MLC) and bi-phosphorylated (Thr18, 
Ser19) MLC (pp-MLC) stained cells. B) When quantified, the 2hr treatment 
showed a gradual loss of image structure. C) The 48hr KD025 treatment 
also showed a decrease of image structure with increasing concentrations 
of inhibitor, and significant changes at 5M. Differences in baseline control 
MLC structure likely due to experiments being carried out independently 
with different batches of antibody. Data in B) and C) was confirmed to be 
normally distributed using D'Agostino-Pearson omnibus K2 test. 
Significance was then calculated with a two-way ANOVA with Dunnett’s 
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KD025 was tested on RPE-1 cells that had been transduced with lentivirus 
constructs expressing GFP-LifeAct and maintained as a polyclonal cell line 
(henceforth referred to as RPE-1:LifeAct). 
These cells were used to observe changes in cilia phenotypes and actin 
morphology as artefacts were noted when using other actin stains such as 
phallodin (Puncate background staining as seen in Figure 3.20A and Figure 
3.21B). In RPE-1:LifeAct cells serum-starved and treated with KD025 for 48 
hours, cilia incidence was significantly increased at all concentrations tested 
and cilia length was significantly increased at concentrations ≥2.5µM (Figure 
3.16). RPE-1 cells serum-starved for 24 hours and then treated with KD025 for 
a further 2 hours in serum starvation media showed no significant changes in 
cilia incidence or length. However, average cilia incidence in DMSO (vehicle)-
treated cells was 45% whereas cells treated with 0.5µM KD025 had an average 
cilia incidence of 60%. mIMCD3 cells treated with KD025 also showed 
significant increases in cilia incidence and length following 48hrs 0.5M KD025 
treatment, but showed no significant changes to cilia incidence after 2hrs 
KD025 treatment. As seen in the RPE-1 cells, the IMCD3 cells treated for 2hrs 
had average cilia incidence following DMSO (vehicle) treatment of 50%, 
whereas cells treated with 0.5µM KD025 had average cilia incidence of 61%. 
(Appendix G.3). This data suggests that the serine/threonine kinase activity of 
ROCK2 is directly implicated in modulating ciliogenesis and is not compensated 
for by residual ROCK1 activity. This also gives insight into the timeline of 
ciliogenesis, suggesting that cilia formation does not occur within 2 hours of 
disruption of the cytoskeleton and axoneme elongation must also take over 2 
hours treatment to be significantly impacted. 
48hr 5M KD025 treatment caused a 22% increase in average cilia length (from 
2.47 to 3.01) which was comparable although not as large an increase as seen 
by siRNA knock-down of ROCK2 (Figure 3.10) which caused a 26.5% increase 
in average cilia length from negative siScr controls (from 3.12 to 3.95). 
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Figure 3.16 KD025 treatment increased cilia incidence and length in RPE-1 
A) RPE-1:LifeAct cells treated with KD025 in serum starvation media for 
48 hrs had increased cilia incidence compared to DMSO-treated negative 
control cells. There was also a significant increase in cilia length in cells 
treated with 2.5 M or 5 M KD025 over 48 hrs compared to the DMSO 
control. However, there was a clear reduction in cell number and change in 
cell morphology. B) 2 hr treatment with KD025 after 24 hrs serum 
starvation did not cause significant changes to either cilia incidence or cilia 
length in RPE-1 cells. Data for cilia incidence was confirmed to be 
normally distributed using D'Agostino-Pearson omnibus K2 test whereas 
cilia length data was not normally distributed. Significance was then 
calculated using one-way ANOVAs with Dunnett’s test for multiple 
corrections (cilia incidence) and Kruskal-Wallis tests with Dunn’s multiple 
comparisons test (cilia length). *=p<0.05. **=p<0.01, ***=p<0.001, 
****=p<0.0001. # Is the control all data sets were compared to. Error bars 
represent S.D.  
A) RPE1:LifeAct  
ARL13B   LifeAct-GFP   DAPI 
B) RPE-1  
ARL13B   DAPI 
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KD025 showed that it is specific loss of kinase activity that affects ciliogenesis. 
The siRNAs used previously were therefore also tested to show if the same 
mechanistic changes could be linked to the ciliary phenotype. siRNA knock-
down of ROCK2 in both RPE-1 and mIMCD3 cell lines showed decreased acto-
myosin structures when staining for bi-phosphorylated MLC (pp-MLC) (Figure 





Figure 3.17 Knock-down of ROCK2 by siRNA inhibits the kinase activity of 
ROCK2 and reduces the presence of acto-myosin fibres 
siRNAs for Rock1 and Rock2 were tested in both IMCD3 (A) and RPE-1 
(B) cells. There was a significant loss of image structure seen in both 
knock-down conditions when assessing bi-phosphorylated (Thr18,Ser19) 
myosin light chain II (pp-MLC). However, there was only a significant 
change in mono-phosphorylated MLC (p-MLC) in mIMCD3s with Rock1 
knock-down. This represents a decrease in MLC activation and loss of 
acto-myosin fibres in siRNA knock-downs of Rock1 and Rock2. Overall 
there was a trend of decreased structure in both cell types under both 
knock-down conditions. Data was confirmed to be normally distributed 
using D'Agostino-Pearson omnibus K2 tests. Significance was the 
calculated using two-way ANOVAs with Dunnett’s multiple comparisons 
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A complementary experiment was designed to validate the role of ROCK2 
kinase activity in the observed ciliary phenotypes and rule out any possible 
novel or structural role of ROCK2 that we had not yet identified. This used a 
time-course of ciliogenesis with conditionally-activated form of ROCK2. A fusion 
construct comprising the ROCK2 KD fused to an N-terminal green fluorescent 
protein (GFP) and a C-terminal oestrogen receptor (ER) domain was used 
(GFP-ROCK2-ER). Negative controls included a validated kinase-dead (k/d) 
ROCK2 KD (ROCK2k/d) and a GFP-only construct, each fused to an ER domain 
(GFP-ROCK2k/d-ER, GFP-ER). The ROCK2 fusion proteins (kindly gifted by 
Prof. Mike Olson, Ryerson University, Canada) are expressed but the KD is 
inactive until treatment with 4-hydroxytamoxifen (4-HT) which binds the ER 
domain, releasing it from the KD, thus providing controlled activation of ROCK2 
(290). RPE-1 cells were retro-virally transduced to stably express the fusion 
constructs and single cell clones were selected. Eight GFP-ER, 8 GFP-
ROCK2k/d-ER and 6 GFP-ROCK2-ER expressing clones had stable growth in 
culture and were tested for GFP expression and cilia incidence (Figure 3.18). 
From this data, 2 GFP-ER, 3 GFP-ROCK2k/d-ER and all the GFP-ROCK2-ER 
clones were taken forward for further validation. As the GFP-ROCK2-ER clones 
all had very low cilia incidence it was decided to base clone selection on the 
ROCK2 activity, assessed by phosphorylation of myosin light chain (MLC). The 
ROCK2 antibody used for western blotting was not suitable for 
immunofluorescence (IF) and so cells expressing the fusion constructs could 
not be co-stained for ROCK2 to look for increased expression. Only the GFP 
within the fusion constructs could be detected by IF. 
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A) RPE-1 GFP-ER Clones 
 
B) RPE-1 GFP-ROCK2KD-ER Clones 
 
 C) RPE-1 ROCK2-ER Clones 
     
Figure 3.18 Expression and cilia incidence of RPE-1 cells stably 
transfected with ROCK2 kinase domain fusion proteins 
A) RPE-1 clones expressing GFP-ER. Clone 7 and 10 did not have 
detectable cilia incidence. Clones 4 and 5 had the highest cilia incidence 
and so were taken forward for further validation. B) RPE-1 clones 
expressing GFP-ROCK2k/d-ER. Clones 1 and 4, despite previously stable 
cell growth, did not continue to grow in culture and were not considered for 
further validation. Clone 9 was disregarded due to low GFP expression. 
Clones 3, 5, and 8 had the highest cilia incidence and were taken forward 
for further validation. C) RPE-1 clones expressing GFP-ROCK2-ER had 
low levels of cilia incidence and so all were taken forward to identify the 
clone with the highest ROCK2 kinase activity. Images were all taken at 
equivalent laser power and presented as maximum intensity projections 
(MIPs) of equal size z-stacks. Cilia incidence and GFP expression was 
assessed qualitatively. All merge images show the fusion construct GFP in 
green, cilia in red and nucleus (DAPI) in blue. D) Western blots showed no 
detectable GFP expression with 30g whole cell extract (WCE) loaded on 
to an SDS-PAGE gel. 
D) 
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The chosen clones were then tested for their kinase activity to confirm 
increased activity in GFP-ROCK2-ER cells and lack of activity in the negative 
control cell lines (GFP-ROCK2k/d-ER & GFP-ER). GFP was only detectable in 
the GFP-ROCK2-ER clones by confocal microscopy (Figure 3.18). As there 
were no detectable levels of the fusion proteins following western blotting, it was 
assumed that any changes in MLC phosphorylation would also be undetectable 
or quantifiable. Therefore, due to time constraints and the commitment required 
for cell line validation, this experiment was not taken forward. 
 Loss of ROCK2 does not cause cilia disassembly defects 
As the population of cells had an increase in cilia incidence it was important to 
rule out the possibility ROCK2 was affecting ciliary disassembly or ciliary 
retention rather than impacting ciliogenesis, or to clarify whether it had a role in 
both processes.  
To test this, RPE-1 cells were plated in a high-throughput format and treated for 
72 hrs with siROCK2 in serum starvation conditions. Half of the experimental 
wells were then treated with 10 % serum for the final 24 hrs to induce ciliary 
resorption and cell cycling. Cells with ROCK2 knock-down had a significant 
decrease in cilia incidence when treated with serum compared to those that 
were serum starved. In both conditions, cells treated with siROCK2 had 
comparable cilia incidence to the scrambled siRNA treated controls. This data 
suggests that loss of ROCK2 does not affect ciliary resorption and that ROCK2 
is likely acting in the initiation of and/or initial stages of ciliogenesis. 
The confluency of the RPE-1 cells in the 96-well plate set up used in this 
experiment likely limited the effect of serum addition for the final 24hrs of the 
siRNA knock-down. As the RPE-1 cells reach confluency contact inhibition 
causes the cells to slow or stop cycling, increasing the overall percentage of 
cells within the population that would have a primary cilium. Despite this, there 
was a 29% decrease in cilia incidence with the addition of serum. 
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Figure 3.19 ROCK2 siRNA knock-down does not cause ciliary 
disassembly defects 
RPE-1 cells were transfected high-throughput with siROCK2 or negative 
control scrambled siRNA and serum starved for either 72 hrs or 48 hrs, 
followed 24 hrs with 10 % serum to induce cell cycling and cilia resorption. 
RPE-1 cells treated with siROCK2 had no significant change in cilia 
incidence compared to cells treated with siScr control. RPE-1 cells treated 
with siROCK2 or siScr had a significant decrease in cilia incidence with the 
addition of 10 % serum, compared to cells that were only serum starved. 
This suggested that there was not a ciliary disassembly defect in cells with 
depleted expression of ROCK2. Data was confirmed to be normally 
distributed using a D'Agostino-Pearson omnibus K2 test Significance was 
then calculated with a two-way ANOVA with Sidak’s multiple comparisons 
test. * = p<0.05, **** = p<0.0001. Error bars represent S.D. 
 
 F-actin stability and acto-myosin contractions modulate 
ciliogenesis 
The downstream pathways of ROCK2 phosphorylation required further 
investigation to elucidate their specific contributions to ciliogenesis. As 
discussed, LIMK2 is phosphorylated by ROCK2 and has been previously linked 
to ciliogenesis through F-actin stabilisation (96, 98). To validate this previously 
published work, RPE-1 cells were treated with cytochalasin D, a chemical 
inhibitor that binds actin monomers and causes destabilisation of F-actin (291), 
mimicking the molecular effect of LIMK2 inactivation. It has also been shown to 
reduce ROCK activity though a cytoskeletal tension feedback loop (292). 
Cytochalasin D treatment of RPE-1 cells for 16 hrs significantly increased both 
cilia incidence and cilia length when compared to DMSO (vehicle) negative 
controls (Figure 3.20). 2 hr treatment followed the same trend, but did not show 
significant differences, as has been reported previously where cilia were only 
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Figure 3.20 Chemical destabilisation of F-Actin increases cilia incidence 
A) RPE-1:LifeAct cells were treated for 16 hrs with cytochalasin D or 
DMSO as a vehicle negative control in serum starvation media (0.2 % 
FBS), or RPE-1 cells were treated with cytochalasin D for 2 hrs after 24 hr 
serum starvation. Effects on cilia incidence and length were assessed by 
confocal microscopy and quantified. B) Cells treated with 0.5 M 
cytochalasin D for 16 hrs had a significant increase in cilia incidence and 
cilia length. C) RPE-1 cells were treated with cytochalasin D for 2 hr and 
showed a marginal increase in cilia incidence and average cilia length. 
Phalloidin staining in these images showed a large punctate artefact 
across all biological replicates and fields of view (Marked with * in DMSO 
condition). This was not considered biologically relevant and actin staining 
was not quantified. Data for cilia incidence was confirmed to be normally 
distributed using D'Agostino-Pearson omnibus K2 test whereas cilia length 
data was not normally distributed. Significance was calculated using one-
way ANOVAs with a Dunnett’s multiple comparisons tests (cilia incidence) 
and Kruskal-Wallis tests with Dunn’s multiple comparisons tests (cilia 
length). *=p<0.05, ****=p<0.0001. # indicates the control to which all data 
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Cytochalasin D induced significant changes to cilia length after just 2 hrs of 
treatment. This has not been tested before and reiterates the conclusion drawn 
from KD025 treatment (Figure 3.16) of a fast and dynamic process that 
overrides other regulatory pathways in the cell to allow increased ciliogenesis in 
an unsynchronised population of cells. 
The second ROCK2 activated pathway that was tested was induction of acto-
myosin contraction, which was selectively inhibited with blebbistatin. 
Blebbistatin selectively targets an ATPase intermediate of myosin II, blocking 
the myosin heads and resulting in low actin affinity, thus reducing acto-myosin 
contraction (293). Myosin heavy chains have also previously been implicated in 
ciliogenesis. Evidence has shown that non-muscle Myosin IIB (Myh10) 
increases actin dynamics through an antagonistic interaction with Myh9 and a 
direct interaction with microtubule acetyltransferase Mec17 (101). Myh10 siRNA 
knock-downs have also been shown to impair ciliogenesis and reduce the 
apical localisation of ezrin (which is required for centriole docking in multi-
ciliated cells (294)). MYH10 has also been implicated in reduced apical 
migration of centrioles. RPE-1 cells with MYH10 siRNA knock-down had a 
significant decrease in cilia incidence and centrioles in these cells were shown 
to have a more basal localisation than controls which could be rescued with 
expression of siRNA resistant MYH10 (100).  
RPE-1:LifeAct cells treated with up to 2.5 M blebbistatin for 16 hrs had a 
significant increase in cilia incidence compared to cells treated with DMSO. 
Blebbistatin concentrations ≥5 M induced apoptosis or mitotic failure, thus 
presumably any changes in cilia incidence were masked by this cytotoxicity. 
However, cilia length increased in a dose-dependent manner and was 
significant in cells treated with 5 M blebbistatin when compared to DMSO 
(Figure 3.21). As blebbistatin showed cytotoxic effects after 16 hr treatment, the 
experiment was repeated with a 2 hr incubation. Cells were initially serum 
starved for 24 hrs and then fixed following 2 hrs further serum starvation with 
varying concentrations of blebbistatin. This work showed no significant changes 
to cilia incidence but there were significant increases to cilia length in cells 
treated with 2.5 M blebbistatin compared to DMSO (Figure 3.21).   






Figure 3.21 Chemical inhibition of acto-myosin contraction increases cilia 
incidence and length 
A) RPE-1:LifeAct cells were treated for 16 hrs with blebbistatin or DMSO 
vehicle negative control in serum starvation media (0.2 % FBS). Cells 
treated with blebbistatin between 0.5 M and 2.5 M for 16 hrs had a 
significant increase in cilia incidence. Across all concentrations, there was 
no significant increase in cilia length. B) Wild-type RPE-1 cells were 
treated with blebbistatin for 2 hr after 24 hr serum starvation. Treated cells 
did not show any changes in cilia incidence across all drug concentrations. 
However, there was a significant increase in average cilia length in cells 
treated with 2.5 M blebbistatin. Phalloidin staining showed large 
punctate artefacts across all biological replicates (marked with * in DMSO 
condition). This was not considered biologically relevant and actin staining 
was not quantified. Data for cilia incidence was confirmed to be normally 
distributed using D'Agostino-Pearson omnibus K2 test whereas cilia length 
data was not normally distributed. Significance was tested using one-way 
ANOVAs with Dunnet’s multiple comparisons tests (cilia incidence) or 
Kruskal-Wallis tests with Dunn’s multiple comparisons tests (cilia length). 
**= p<0.01, ***= p<0.001, ****= p<0.0001. # Is the control to which all data 
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The differences in ciliary phenotypes at the 2 time points was not further 
investigated thus no individual time point exactly phenocopied the ROCK2 
siRNA knock-down (Figure 3.10). Individually only one downstream pathway of 
ROCK2 is being targeted with the inhibitor treatments, whereas ROCK2 knock-
down would affect all downstream pathways. Hence, when the data for both 
time points for blebbistatin and cytochalasin D treatments are collated, this 
provides a satisfactory reflection of the ROCK2 knock-down phenotype, 
showing both an increase in cilia incidence and length over the timescale 
measured. 
 Overexpression of a constitutively inactive MLC increases cilia 
incidence 
MLC fusion constructs of rat myosin light chain 9 (Myl9) with an N-terminal GFP 
tag were used to further test the role of MLC and acto-myosin contractions in 
ciliogenesis. A double-mutant construct with alanine replacements at Thr18 and 
Ser19 (MLCTASA) was used as a non-phosphorylatable MLC mutant. This 
mutant had been previously characterised, and expression of the mutant was 
shown to reduce actin filament bundles or stress fibres which are required for 
contractility (295). The non-phosphorylatable mutant is a constitutively inactive 
form of MLC. ROCK2 directly activates MLC by phosphorylation. So it was 
predicted that overexpression of this MLC mutant would phenocopy a ROCK2 
knock-down by replacing the majority of endogenous MLC through a dominant 
negative mechanism. 
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 Figure 3.22 Constitutively inactive MLC increased cilia incidence 
A) RPE-1 cells were transfected with wild-type or non-phosphorylatable 
(MLCTASA), GFP-tagged Myosin Light Chain (MLC). These were compared 
to RPE-1 cells transfected with an un-tagged GFP construct. B) Cells that 
over-expressed active MLC had a moderate decrease in cilia incidence 
(n=3, p=0.0866) whereas cells expressing MLCTASA had a significant 
increase in cilia incidence compared to the negative control (n=3, 
p=0.0174). C) There were no significant changes to cilia length in any of 
the cell populations tested. Data for cilia incidence was confirmed to be 
normally distributed using D'Agostino-Pearson omnibus K2 test whereas 
cilia length data was not normally distributed. Significance calculated with 
unpaired, two-tailed Student’s t-tests (cilia incidence) and Mann-Whitney U 
tests (cilia length). *  p<0.05. Error bars represent S.D. 
 
 Inhibition of ROCK2 can rescue loss of cilia in RPE-1 cells with 
IFT88 knock-down. 
As evidence thus far showed ROCK2 to be a negative regulator of ciliogenesis, 
it was tested if it could be a potential therapeutic target for rescuing cilia 
incidence in ciliopathy cell models. IFT88 and RPGRIP1L knock-downs gave 
robust loss of cilia phenotypes (Figure 3.4) through 2 different mechanisms: 
loss of intraflagellar transport and disruption of the transition zone, respectively. 
These knock-downs were used to model a ciliopathy-like phenotype in both 
mIMCD3 and RPE-1 cells in a high content imaging experiment. mIMCD3 cells 
A) 
B) C) 
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only responded with a significant increase in cilia incidence to KD025 treatment 
in the negative control cells treated with scrambled (siScr) siRNA. Remarkably 
however, IFT88 knock-down in RPE-1 cells saw a complete recovery of cilia 
incidence after KD025 treatment. Cells with RPGRIP1L knock-down did not 
show any recovery of ciliary incidence (Figure 3.23). 
 
Figure 3.23 KD025 treatment rescues cilia incidence in ciliopathy gene 
knock-downs 
Cells were treated in a high content imaging format with siRNAs to induce 
cilia loss over 72 hrs. Cells were then left untreated or treated with 1 M 
KD025 for the final 48 hrs. A) mIMCD3 cells with siIft88 and siRpgrip1l 
knock-downs had significant loss of cilia compared to siScrambled (siScr) 
controls: average robust z-score for cilia incidence (zcilia) was -4.30 and -
4.91, respectively (equivalent to p<0.0001). There was a significant 
increase in cilia incidence, in siScr controls treated with KD025 (zcilia= 
4.56). However, there were  no changes in cilia incidence in cells with 
either Ift88 or Rpgrip1l knock-down when treated with KD025. B) RPE-1 
cells also showed significant loss of cilia in cells with IFT88 or RPGRIP1L 
knock-down compared to negative controls, with zcilia of -4.15 and -5.40, 
respectively. There was also a significant increase in cilia in the negative 
controls treated with KD025 (zcilia= 3.25) and a complete rescue of cilia in 
the IFT88 knock-down cells treated with KD025 (zcilia= 0.0016). There was 
no rescue of cilia incidence in RPGRIP1L knock-down cells treated with 
KD025. Experimental work by Dr. Claire E. L. Smith. Significance 
calculated by change in average z-score. Where difference between two 
compared averages is >2.58  **= p<0.01, or >3.89 ****= p<0.0001. Error 
bars represent S.E.M.  
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3.5 Discussion 
The 4 main objectives of this part of the project were met; a new data set of 
potential genes involved in the negative regulation of cilia incidence was 
generated from a primary whole genome siRNA screen data set. A secondary 
screen was completed in mIMCD3 cells to identify hits that increased the 
incidence of cilia across cell populations. The top hit of this screen, Rock2, was 
validated in the human RPE-1 cell line and further investigation into its 
mechanistic function was carried out.  
 The secondary screen 
3.5.1.1 Generating a list of hits that increased cilia incidence 
The filtering method used to generate the final hit list was designed to remove 
as many false positive hits as possible. However, this inevitably meant some 
true hits were filtered out. There is inherent variability across cell-based 
screening and many siRNAs caused a significant increase in one run of the 
primary whole genome screen but did not have a substantial effect on run 2 of 
the screen, or vice versa. This could be due to the normalisation used for each 
batch of experimental plates in the screen, or due to due to other technical 
factors such as plating or transfection efficiency of individual wells or plates.  
This is therefore not a definitive list of hits that increase cilia incidence. This can 
be stated with some certainty since independently identified and validated hits 
such as LIMK2, GSN and ACT3, were not supported by the primary whole 
genome screen data and therefore did not pass the filtering used to select hits 
for secondary screening (Table 3.3). However, the independently identified hits 
were identified in human cell lines, whereas the primary genome screen data 
used in this thesis was from a mouse cell line. This highlights the possible 
differences between the 2 models, or the relative evolutionary importance of 
ROCK2 between species. 
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Table 3.3 Previously identified actin regulators of ciliogenesis did not 
increase cilia incidence in primary whole genome screen data 
The 7 genes listed were identified and validated in independent 
laboratories using RPE-1 cells. However, all the listed actin regulation 
components decreased or did not affect cilia incidence when knocked-
down with siRNA. Over half of the knock-downs caused significant loss of 
cilia in at least one run of the primary whole genome screen (red text). 2/8 
of the hits robustly and significantly decreased cilia incidence with zcilia  -
1.96 in both runs of the screen. From this data set, none of these hits 
would have been detected as negative ciliogenesis regulators. However, 
Cfl1 which codes for Cofilin, an actin severing protein did significant 
decrease cilia incidence and fits with the model of actin remodelling 
regulation of ciliogenesis presented in this thesis. 
 
3.5.1.2 B-cell Lymphoma Leukemia 10’s (Bcl10) potential role in 
ciliogenesis 
The average robust Zcilia for B-cell Lymphoma Leukemia 10 (Bcl10) knock-down 
was 2.490, equivalent to p=0.013. There were no previously published studies 
identifying Bcl10 as a ciliogenesis modulator, although there is a possible link 
between Bcl10 and motile multi-ciliogenesis. Bcl10 activates nuclear factor B 
(NFB), a family of stimuli-induced transcription factors (296). Separately, NFB 
has been linked to increased cilia incidence in nasal epithelium through 
regulation of p63. Inhibition of NFB or siRNA knock-down of p63 increased 
microvilli and cilia incidence on human nasal epithelial cells (297). Therefore, it 
is not unreasonable to predict that loss of Bcl10 by siRNA knock-down could 
cause inactivation or lower activation levels of NFB and, downstream, cause 
an increase in cilia incidence through reduced p63 expression. However, multi-
ciliated cells are known to have very different ciliogenesis pathways compared 
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to primary ciliogenesis. Without a clear hypothesis for primary ciliogenesis, 
Bcl10 was not taken forward for further investigation. 
3.5.1.3 Fanconi Anemia Opposite Strand Transcript Protein’s (Fancd2os) 
potential role in ciliogenesis 
The average robust zcilia for Fanconi anemia opposite strand transcript protein 
(Fancd2os) knock-down was 2.819, equivalent to p=0.0048. Facnd2os is highly 
expressed in the testis and also expressed in the kidney (298). However, very 
little is known about the function of any encoded protein and it has not been the 
focus of any published investigation. Some descriptions have been published 
about its localisation and possible role in the testis (299, 300) but the molecular 
structure of the protein or localisation within other cell types is still unknown. 
Without any information, a hypothesis about its role in ciliogenesis could not be 
made and so it was not taken forward for further validation and investigation. 
3.5.1.4 Syntaxin 19’s (Stx19) potential role in ciliogenesis 
Syntaxin 19 (Stx19) is a poorly characterised glutamine-donating soluble NSF 
attachment proteins receptor (Q-SNARE) that is homologous to syntaxin 11 
(38% homology) (301). Syntaxins are involved in protein trafficking and 
membrane dynamics. Syntaxin 19 localises to the plasma membrane and 
recycling endosomes in HeLa cells, and although Stx19’s exact function 
remains unknown it has been shown to co-localise with and regulate Rab8-
positive vesicles (302). Rab8 is a small GTPase that is involved in intracellular 
membrane trafficking and is essential for ciliogenesis. Rab8 is activated by co-
ordination with Rab11 and Rabin8, both enriched at the base of the primary 
cilium (303). Rab8 activation leads to cilia elongation and it recruits ciliary-
specific membrane proteins such as Smoothened to the cilium, with fusion of 
Rab8-positive vesicles with the periciliary membrane (304). 
Overexpression of GPF-STX19 prevented Rab8 vesicles from fusing with the 
plasma membrane, suggesting STX19 regulates trafficking and fusion of these 
vesicles in a dominant negative fashion (302). Current evidence suggests that 
STX19 works in opposition to the v-SNARE VAMP3 to negatively regulate the 
fusion of Rab8 vesicles with the periciliary region (304). Therefore, it could be 
hypothesised that loss of STX19 would allow more Rab8 vesicle fusion during 
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ciliogenesis, allowing for cilia to be more readily formed and perhaps also likely 
to be longer. 
However, Stx19 is still reasonably uncharacterised and so further investigation 
of this hit was considered to be out of the scope of this project, but would be of 
interest to take forward for further investigation at a later date. 
3.1.1.1 ROCK2 is a top hit and not ROCK1 
ROCK2 had not been directly shown to be a negative regulator of ciliogenesis in 
previous studies, but downstream actin remodelling pathways activated by 
ROCK have provided indirect evidence for the importance of actin remodelling 
in controlling cilia incidence and length (92-94) Thus, the current published 
evidence suggests that a highly complex network of pathways and regulators 
control the actin cytoskeleton’s role during ciliogenesis. However, the isozyme 
of ROCK2, ROCK1 was not shown in the secondary screen or downstream 
work to have a significant role in ciliogenesis.  
RhoA-associated protein kinases (ROCK) are part of the AGC serine/threonine 
kinase family. ROCK2 is a homologue of ROCK1 and these proteins display 
67% homology across the full length of their amino acid sequences (284). They 
have an N-terminal kinase domain (KD) for which they share 92% homology 
(284), a central coiled-coiled region including a RhoA binding domain (RBD), 
and a C-terminal plekstrin homology domain and cysteine rich C1-domain (114). 
Both ROCK1 and ROCK2 form and act as homodimers (305-307) through 
interaction from the N-terminal extension of the KDs to the coiled-coiled 
domains. The homodimers therefore have dimerised KDs which are able to 
phosphorylate monovalent and possibly dimerised substrates (305). ROCK1 
and ROCK2 homodimers have an auto-inhibitory structure that blocks their 
kinase activity, keeping them in an inactive conformation. They act as a 
molecular switch and upon binding of RhoA-GTP to the RBD, a conformational 
change releases the C-terminal region from blocking the KD and thus activates 
the proteins (308) (Figure 3.24). 
A) 
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Figure 3.24 ROCK2 protein domains and activation 
A) Schematic diagram of mouse ROCK1 and ROCK2 protein domains, 
modified from (309) Figure 1 with copyright permissions. ROCK 
structure and modes of regulation. Use licensed under the Creative 
Commons Attribution 4.0 International License. B) Schematic diagram 
of the activation and conformational changes of ROCK2. ROCK2 has 
an auto-inhibitory structure where the kinase domain (KD) activity is 
blocked by the RhoA-binding domain (RBD). ROCK2 is activated by 
RhoA-GTP which binds to the RBD. Once bound, there is a 
conformational change that releases the kinase domain to allow 
phosphorylation of targets. 
 
When activated by RhoA-GTP, ROCKs (both ROCK1 and ROCK2) 
phosphorylate a large number of proteins and activate several downstream 
pathways to regulate actin remodelling and dynamics. They have therefore 
been highly investigated for their role in cell adhesion (292, 310), stress fibre 
and focal adhesion formation (311, 312), and cell motility/migration (reviewed in 
(313)). ROCK controls these cellular mechanisms by directly phosphorylating 
key actin regulators. ROCK phosphorylates LIMK2 (314), which in turn 
phosphorylates cofilin to modulate F-actin stabilisation (315). ROCK also 
phosphorylates MLC (289) and MYPT1 (316), to control acto-myosin 
contraction and the formation of stress fibres (317). Further to this ROCK also 
phosphorylates EZR regulating the linking of the actin cytoskeleton to the 
plasma membrane (318). 
These apparent differences between the isozymes in other molecular 
mechanisms highlights several ways in which the specificity of ROCK2 can exist 
B) 
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over ROCK1 in the negative regulation of ciliogenesis. However, more clarity 
into the differing roles in ciliogenesis could be tested with ROCK1 specific 
inhibitors and with the development of the cell lines described in Figure 3.18. 
 Limitations 
3.1.2.1 Screening 
The primary whole genome screen was carried out in mIMCD3 cells. Upon 
reflection, given the inconsistencies between cell types and the data from the 
primary whole genome screen not correlating with independently-verified hits 
(Section 3.5.1), a genome screen data set from RPE-1 cells may have been 
more relevant. Previous ciliary whole genome screen data sets from RPE-1 
cells (93, 96) could have also been re-tasked separately, or correlated with the 
primary genome screen data used throughput this thesis. Including several 
screening datasets would have increased statistical power when identifying true 
positive hits that are conserved between both mouse and human, or across 
different tissue types. This strategy could highlight more clinically-relevant 
therapeutic targets for ciliopathy patients.  
There was a reasonably low validation rate in the secondary screen. This could 
be due to a high number of false negatives in the whole genome screen data or 
the stringent filtering steps used to generate the secondary screen hit list. 
However, as previously noted this stringent filtering ensured a robust 
methodology and data set to test, with the downside of likely missing other hits. 
It should be noted that the whole genome screen data (Section 3.5.1) does not 
identify the same hits as independently published data, so it is possible that the 
whole genome screen had a high false negative rate. 
3.1.2.2 Drug specificity and potency 
The specificity of the inhibitor KD025, although previously tested and verified 
(288), was not confirmed as part of this thesis. Therefore the statements made 
are based on an assumption that KD025 is truly specific to ROCK2 since it does 
not exactly reiterate the siRNA knock-down phenotype. The siRNA knock-down 
did not cause a significant increase in ciliary incidence 72 hrs post siRNA 
transfection (Figure 3.10), whereas 48 hrs KD025 treatment did show a 
significant increase in cilia incidence at all concentrations (Figure 3.16). It is 
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possible that these differences in time points are influencing the phenotypes 
measured. siRNA treatments were for 72 hrs and although an approximately 
80% total protein reduction was confirmed by western blots over this time, it 
may require longer for the knock-down to have the same level of inhibition as 
KD025 which acts instantly (Figure 3.9). Indeed, given the catalytic nature of 
kinase activities complete blockade of ROCK2 activity by siRNA treatment 
seems unlikely, a major reason for identifying small molecule inhibitors of this 
kinase to facilitate the mechanistic work presented here. 
The potency of both cytochalasin D and blebbistatin were also only qualitatively 
assessed by observing changes in the actin cytoskeleton and overall cell 
morphology. There was no quantified measure to show the inhibition of either 
actin polymerisation or acto-myosin contraction, respectively.  
3.1.2.3 Live actin imaging and actin stains 
The polyclonal RPE-1 cell line expressing GFP-LifeAct was used to qualitatively 
assess the potency of drug treatments through changes to the actin 
cytoskeleton. What was not initially taken into account was that LifeAct 
expression alone can change actin dynamics, so requires optimisation, and it 
does not bind to specific actin structures (reviewed in (319)). Phalloidin was 
therefore also used on fixed cells to confirm this data, despite the non-specific 
staining and imaging artefacts occasionally seen with this stain (Figure 3.20A 
and Figure 3.21B) 
3.1.2.4 ROCK2 over-expression 
The data presented in Figure 3.11 showed the opposite phenotype to that noted 
with the siRNA knock-down of ROCK, providing evidence that the phenotype 
observed with siRNA knock-down was specific to ROCK2 and not an off-target 
effect. However a dominant negative effect on ciliogenesis with GFP over-
expression alone was noted in RPE-1 cells. Thus, it must be considered that 
GFP-mROCK could also be acting through a separate dominant negative effect 
to decrease ciliogenesis, rather than the proposed mechanism of actin 
remodelling. It is also possible that over-expressed mROCK was affecting 
overall cell viability through global sequestering of RhoA. 
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3.1.2.5 Phospho-Myosin Light Chain Antibodies 
The antibodies used to confirm the inhibition of ROCK2 did not give 
reproducible results by western blot (Appendix F) and instead were used for 
high-content image analysis. The raw image analysis was based on the 
presence of acto-myosin fibre-like structures, but unfortunately co-staining with 
phalloidin to visualise actin had interfering background staining. This staining 
was not considered to be biologically relevant but it meant that actin co-
localisation with the phospho-MLC staining could not be quantified. A clear and 
strong qualitative change in both staining intensity and the presence of fibres 
could be seen across the raw image data, but quantified data only showed 
marginal changes. This may be due to the lower image quality that is generated 
by high content imaging, or it could indicate that the analysis method needs 
further optimisation.  
3.1.2.6 Cell confluency affects ciliogenesis 
It is well documented that confluence of cells in culture affects their ability to 
ciliate. Thus all experiments were plated with the same cell number to minimise 
any effect of cell confluence on ciliogenesis. 48 hrs and 16 hrs drug treatments 
affected cell number due to cell death or inhibition of cell cycle progression, but 
nevertheless were able to induce significant increases in ciliogenesis. However, 
the role of acto-myosin contraction in ciliogenesis has been shown to be greatly 
affected by cell shape and therefore also confluency (320). 
RPE-1 cells grown on a micro-pattern of different sizes enable different levels of 
cell spreading. Cells grown in smaller micro-patterns ciliated more readily than 
cells that were more spread and flat. These flatter cells were treated with 
blebbistatin, causing a significant increase in cilia incidence (321), in agreement 
with the data presented in Figure 3.21. However, a second study has shown 
that RPE-1 cells grown on smaller micro-patterns had a much rounder shape, 
and that centrosome migration and presumably ciliogenesis was reduced by 
blebbistatin treatment (322). This is consistent with the hypothesis that acto-
myosin contraction is required for the assembly of microtubule bundles that 
provide the driving force for centrosome migration (322). This was not tightly 
controlled for in this work as although cells were consistently seeded at the 
same density, blebbistatin treatment was not tested at variable cell densities. 
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Therefore, this observation may be specific to RPE-1 cells grown in a thin 
monolayer and may be different for other cell types that have a rounder shape 
and greater height. 
3.1.2.7 Interpretation of drug treatment time points 
A comparison between 2, 16 and 48hrs for drug treatment should be made with 
caution. Each experiment was completed with a different batch of RPE-1 cells 
as independent experiments. This would likely affect the baseline cilia incidence 
in each of the DMSO control conditions (as seen when comparing 2 and 16hrs 
DMSO treatment for blebbistatin (Figure 3.21)), As the time points were not 
collected as part of the same experiment the affect and timing on overall 
ciliogenesis is hard to interpret. A possible way to overcome this would be to 
look at average fold change, percentage change in cilia incidence and length or 
to normalise the data. However, the investigation into the timing of ciliogenesis 
and the effect of each drug was out of the scope of this project and so data was 
not analysed in this way.  
 Future Experiments 
3.1.3.1 Rescue experiment 
The specify of the ROCK2 siRNA could have been validated with an 
overexpression construct that is not targeted by the siRNA. This would then 
rescue cilia incidence down to WT levels. The same experiment could be 
completed with a construct for ROCK1. These are possible future experiments 
to provide further evidence in support of the specificity of ROCK2 to 
ciliogenesis. 
3.1.3.2 ROCK2 localisation 
As an antibody suitable for immunofluorescence detection was not available, it 
would be of interest to specifically track ROCK2 through the cell cycle and 
confirm it’s localisation in these cell types compared to ROCK1. It would be of 
particular interest to observe if and when ROCK2 localises with centrosomes as 
this may suggest localised changes to actin remodelling, rather than global 
remodelling, promote ciliogenesis. This could also be done through live cell 
imaging of ROCK2 if the cell lines presented in Figure 3.18 were remade and 
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validated. ROCK2 may be localised to the base of the cilium where it negatively 
regulates ciliary length by preventing vesicle trafficking of ciliary vesicles. 
Fluorescence recovery after photobleaching (FRAP) of ciliary vesicles could be 
used to determine if there is a change in the speed of trafficking to the cilium 
when ROCK2 is inhibited and the result would provide insights into the 
dynamics and timing of ciliogenesis. Experiments using the KD025 inhibitor on 
synchronised cells could also be used to more finely define the timing of 
signalling which causes the inactivation of ROCK2 and allows for dynamic actin 
and ciliogenesis to occur.  
3.1.3.3 Ciliary function  
Longer cilia have been shown to have diluted signalling and reduced 
functionality. As cilia length increased in both cell models tested with ROCK2 
knock-down, ciliary function tests should be carried out. Further investigation 
could include testing the Shh pathway with a Gli reporter assay, or observing 
translocation of Smoothened into the cilium upon Shh activation following SAG 
treatment. It may be that, as there is increased vesicle trafficking as suggested 
by Kim et al. (98), that there is also an increased delivery of signalling 
receptors, so longer cilia may remain functional. Conversely, signalling may be 
slower as receptors and signals will have further to travel through a longer 
cilium and are diluted along the longer ciliary membrane. In turn it would also be 
of importance to confirm rescue of ciliary function and not just ciliary incidence 
in the RPE-1 cells after IFT88 knock-down and KD025 treatment (Figure 3.23). 
3.1.3.4 Acto-myosin contraction 
As discussed in section 3.1.2.6, cell shape and confluency affects the impact of 
blebbistatin treatment on ciliogenesis. Future work should corroborate these 
results for RPE-1 cells grown on micropatterns, or assess the effect of 
blebbistatin on cell-line types relevant to disease manifestation in ciliopathies 
such as kidney, liver or bone cell-lines.  
It should also be determined which signalling pathways are activated when 
acto-myosin contraction is inactive, and how these contribute to ciliogenesis. As 
has been shown previously for F-actin and the role of Hippo signalling on 
vesicle trafficking (92), the signalling pathways and mechanistic insights into 
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acto-myosin contractions during ciliogenesis could offer a new downstream 
therapeutic target of ROCK2 and potentially further our understanding of basal 
body migration and docking.  
3.1.3.5 Other hits 
Other hits in the secondary screen, such as syntaxin 19, could be followed up in 
a separate research project to further investigate its role in Rab8 vesicle 
trafficking and negative regulation of ciliogenesis. If data is re-analysed and 
compared to other whole genome siRNA screens, further hits could also be 
revealed for downstream analysis. 
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Chapter 4  
Results: RACGAP1-mediated cytokinesis is not a 
prerequisite for centriole maturation and ciliogenesis 
4.1 Introduction 
The previous chapter presented evidence that repurposing and reanalysing a 
whole genome reverse genetics screen dataset can provide novel biological 
insights. Chapter 3 provided further support that actin regulation and acto-
myosin contraction are fundamental negative modulators of ciliogenesis. In this 
chapter, the whole genome screen dataset was therefore reanalysed for 
possible negative regulators of number of cilia per cell. The primary screen 
counted individual cilia as spots (using a cilia recognition algorithm) within a 
defined cell boundary, enabling re-analysis to identify populations of cells with 
more than one cilium per cell (Figure 4.1). Therefore, the second main 
phenotype that was taken forward for secondary screening was a series of 
knock-downs that caused an increased incidence of cells with two or more cilia, 
referred to in this thesis as a supernumerary cilia phenotype. 
 
Figure 4.1 Re-analysis of whole genome screen data  
Schematic diagram comparing the phenotypes assessed in the original 
whole genome screen, which was used to identify positive regulators of 
ciliogenesis (A) and the analysis of the proposed phenotypes of negative 
regulators of ciliogenesis (B) measured from the raw screen data. As cell 
boundaries and spots (cilia staining) are defined separately it is possible to 
calculate the number of spots per cell.  
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Multi-ciliated cells are cells with many cilia, which are most commonly found as 
motile ciliated cells, such as lung epithelium and ependymal cells. Exceptions to 
this include choroid plexus cilia. or olfactory sensory neuronal cilia that, despite 
having the 9+2 microtubule arrangement, lack the dynein arms required for 
motility and are present as multi primary ciliated cells (11). Most other cell types 
have a single primary, immotile cilium (323). Ciliogenesis is notably different 
between these cell types (54, 324, 325). Multi-ciliogenesis requires large 
multiplication of centrioles for the subsequent formation of multiple cilia, 
whereas primary ciliogenesis is a process tightly controlled for only a single 
duplication. It also requires extensive ciliary resources and machinery.  
Unlike in primary ciliogenesis where centrosomes duplicate from the mother 
centriole, in multi-ciliogenesis of motile cilia the centrioles are either formed 
from the mother centriole, via a cytoplasmic structure called the deuterosome (a 
protein complex required for pro-centriole biogenesis that stem from existing 
centrioles) in the deuterosome-dependent pathway, or using a centriole-
dependent assembly pathway (326, 327) (Figure 4.2). It has been shown in 
Xenopus embryos that production of centrioles from the deuterosome is 
mediated by Multicilin (328, 329), DEUP1 (a Cep63 paralogue) (327) and 
CCDC78 (330), which in turn regulate the localisation of CEP152 (327), also a 
main regulator for centriole biogenesis in standard centriole duplication (331). 
The deuterosome is signalled to form when Notch signalling is downregulated. It 
has been shown in Xenopus multi-ciliated cells that reduction of Notch 
signalling causes transcription of Multicilin, which in turn causes increased 
expression of centriole assembly genes including DEUP1 when in complex with 
E2F4 (328). This allows biogenesis of new centrioles from the deuterosome 
structure, a poorly understood event.  
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Figure 4.2 Schematic of multi-ciliogenesis of motile cilia pathways 
Cycling cells that differentiate into multi-moitle-ciliated cells can do so one 
of via two pathways, the centriole-dependent pathway, or the 
deuterosome-dependent pathway. The centriole dependent pathway has 
similarities to normal centriole duplication and involves many of the same 
proteins including CEP63 and CEP152 to initiate amplification. This occurs 
through PLK4 activation, causing centriole biogenesis in a rosette 
formation around the mother centriole. The deuterosome-dependent 
pathway relies heavily on its main protein DEUP1 which is expressed 
through multicilin-mediated transcriptional regulation. CEP152 is recruited 
by CCDC78 and together they mediate centriole biogenesis from the 
deuterosome structure. After biogenesis the centrioles migrate to become 
basal bodies and form cilia. Schematic modified from Figure 2 of 
Reference (326) with copyright permissions. 
Once formed the centrioles migrate to the apical cell surface to form basal 
bodies as in primary ciliogenesis. The migration and docking of this mass of 
centrioles requires support and stabilisation from the actin cytoskeleton. This 
dynamic actin polymerisation is regulated by FOXJI via Ezrin and RhoA. The 
actin web that supports the multiple basal bodies is not present for primary cilia, 
but primary cilia have been shown to rely on dynamic actin remodelling for 
migration and basal body docking (103, 332).  
It has also been shown that U2OS cells, which normally form primary cilia, can 
be forced to produce supernumerary centrosomes if regulators of multi-
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ciliogenesis such as DEUP1 (327) are overexpressed. This demonstrates that 
the deuterosome-dependent pathway can over-ride normal centriole regulation. 
There are some documented ciliopathy phenotypes with supernumerary cilia in 
affected tissues, allowing us to gain possible new insight into ciliopathy disease 
mechanisms. Meckel-Gruber syndrome patients with MKS1 or TMEM67 (also 
known as MKS3) mutations have supernumerary centrosomes, spindle poles 
and primary cilia in foetal kidney cysts in addition to significantly increased 
ciliary length (333). Polycystic kidney disease is another ciliopathy caused by 
mutations in PKD1 (334). Patient primary renal epithelial cells display 
supernumerary cilia as a downstream consequence of supernumerary 
centrosomes that is associated with aneuploidy and genomic instability (334). 
Supernumerary cilia dilute ciliary signalling receptors and signalling responses 
and this dysregulated signalling is thought to be the mechanism behind cyst 
formation, however it is not fully described (335). Targeted resorption of 
supernumerary cilia has been suggested as a possible therapeutic intervention 
for autosomal dominant polycystic kidney disease in order to reduce cyst 
formation and slow disease progression (336), although this approach first 
requires a suitable drug target to be identified.  
The presence of two or more cilia in both kidney and retinal cell types would be 
of interest to gain further insight into disease pathology. Negative regulators of 
ciliogenesis or centriole maturation could give insight into ciliopathy disease 
mechanisms as supernumerary centrosomes are currently the only described 
disease mechanism seen in ciliopathies with supernumerary primary cilia. 
Overall, the details of the mechanisms that determine the formation of multiple 
primary cilia from these supernumerary centrosomes is only understood in the 
sense that supernumerary centrosomes are retained after failed cytokinesis and 
can form the supernumerary cilia (335).The authorisation pathway, or lack of a 
negative regulator, for the maturation of more than one mother centriole and 
production of excess ciliary proteins for assembly of the supernumerary cilia 
have yet to be defined. 
It is therefore of interest to identify the molecular pathways or genes involved in 
the formation of supernumerary cilia, including any potentially independent of 
the cell cycle and processes that licence the maturation of over-duplication of 
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centrosomes. These are presumably independent pathways to centrosome 
biogenesis which has previously been screened for in an independent whole 
genome siRNA screen (261). This screen identified TRIM37 as a negative 
regulator of centriole duplication (261), therefore it would be of interest to see if 
this hit can also produce supernumerary cilia or if the pathways, as 
hypothesised are independent. 
These mechanisms could also give insight into processes such as centrosome 
over duplication in cancer development, where a loss or suppression of primary 
cilia allows unregulated proliferation and migration. This has been specifically 
noted in pancreatic cancer (337, 338). Paradoxically however, supernumerary 
centrosomes can also cause cancer cell death due to abnormal mitosis when 
each centrosome forms individual spindle poles (339) and cilia have been noted 
to increase choroid plexus tumour growth through facilitation of Sonic hedgehog 
signalling (340). 
The presence of two or more primary cilia or supernumerary centrosomes are 
often noted as a disease phenotype as most normal human cells do not have 
multiple primary cilia. However, there is one cell type that has supernumerary 
centrosomes and no cilia. Hepatocytes, as they age, become tetraploid and 
retain supernumerary centrosomes (341) yet are one of the 2 cell types 
alongside red blood cells that do not produce any primary cilia (although 
published data has only reported on the hepatocytes of rat models (342, 343)). 
If these cells did have the capacity and necessity, to form cilia, due to their 
multiple centrosomes they would likely produce multiple primary cilia. However, 
this may be the exact reason that ciliogenesis does not occur in these cells; 
since multiple cilia are associated with disease, they may have inhibited 
ciliogenesis altogether to prevent this occurring. Rather than having a 
specialised signalling hub and signalling responses, once terminally 
differentiated these cells would signal through receptors on the cell membrane. 
The production of multiple primary cilia would be deleterious to the cell, as it has 
been shown in previous studies that supernumerary cilia dilute signalling 
receptors and slow signalling responses (335). 
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In summary, hits that cause supernumerary cilia in an unbiased whole genome 
reverse genetics screening dataset have the potential to identify novel pathways 
or provide further insights into ciliopathy disease mechanisms. 
 Chapter Aims Objectives 
Aim: To improve ciliopathy patient quality of life through greater understanding 
of their genetic disease and though identifying potential therapeutic pathways. 
More specifically, this chapter aims to identify the novel regulatory pathways or 
mechanisms that control the formation of a single primary cilium rather than 
multiple primary cilia.  
Hypothesis: Cells such as olfactory neurones have several primary cilia, and 
cells such as hepatocytes have multiple centrosomes but no cilia. This 
highlights that differentiated cells have the capacity to generate more than one 
primary cilium and to prevent ciliary formation entirely. Therefore there is likely a 
regulatory pathway or molecular switch that controls a cells ability to produce a 
single primary cilium or generate multiple primary cilia, that has yet to be 
identified. 
Experimental Objectives: 
• To generate a data set of potential hits that increase the incidence of cells 
with two or more cilia from existing whole genome reverse genetics 
screening data (a supernumerary cilia phenotype) 
• To carry out secondary screening and identify candidates to take forward for 
further investigation 
• To validate hits in human cell line models 
• To examine mechanistic links between validated hits and the regulation of 
ciliogenesis for a single cilium in comparison to multiple primary cilia. 
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4.2 Whole genome screen hits that increased the incidence of 
supernumerary cilia 
A primary whole genome cell-based reverse genetics visual screen data-set 
(266) was reanalysed to identify hits that significantly increased the incidence of 
supernumerary cilia, specifically measured through a high content imaging 
algorithm for “cells with two or more cilia” (Appendix E.2). Similar filtering steps 
to those used to generate the “increased cilia incidence” hit lists in Chapter 3, 
were used to remove hits that: (i) did not cause a significant phenotype in both 
biological replicates of the primary screen; (ii) affected cell number; (iii) did not 
have on-target siRNAs for all annotated transcripts; and those hits for which 
there was not a human orthologue for follow up experiments.  
Initially these 3 filtering steps were designed to generate a hit list that could 
identify a novel pathway involved in licencing supernumerary cilia that was 
unlinked to the cell cycle. However, there were only 14 hits that passed through 
all 3 stringent filtering steps (Figure 4.3). Enrichment analysis also showed that 
there was no enrichment for any Gene Ontology (GO) terms, Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathways, Protein Families 
Database (PFAM) protein domains or Integrative Protein Signature Database 
(InterPro) protein domains and features in these 14 hits. Therefore a 10% 
secondary validation rate would only highlight a single hit to investigate. 
The largest loss of hits occurred after filtering step two, which was designed to 
exclude hits that had any significant changes to cell number, as centrosome 
duplication is known to be tightly linked to cell cycle regulation (344). Without 
this filtering step, a list of 91 hits was generated (Figure 4.4) (Appendix A.1.2, 
Table A.2). The risk of not including the cell number filter and taking forward a 
longer hit list, was that known cell cycle regulators could be false positive hits 
that have no direct link to ciliogenesis. However, less stringent filtering allowed 
for fewer false negative hits to be lost.   
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Figure 4.3 Original filtering Steps used to identify hits that increase the 
incidence of two or more cilia per cell 
A) The work flow of filtering steps that were used to identify hits that 
increased the incidence of cells with two or more cilia. Three filtering steps 
were initially used to select hits that were; unlikely to give false positive 
results, could be taken forward for validation in human cell lines and could 
potentially identify novel pathways that regulate or maintain cilia. However, 
as only 18 hits passed Filter 2, this step was removed and the hits that 
passed Filter 1 and Filter 3 only were taken forward for subsequent 
screening. All 96 hits from Filter 1 also passed Filter 3. B) Scatter graph 
shows average z-score for incidence of cells with two or more cilia across 
the whole genome screen. Dark grey indicates hits that passed Filter 1, all 
of thee hits were taken forward for secondary screening. Light blue hits 
passed Filter 2 and Dark blue highlights the 14 hits that passed all three 
filtering steps. (6872 data points are outside y-axis limits). C) List of the 14 
final hits made with stringent filtering. Genes are listed with their average 







Cnih3 0.798 2.965 
Dcps -0.683 2.498 
Dnajc9 -0.074 3.332 
Hectd2 0.030 3.548 
Kif27 -1.174 2.527 
Mapk8ip3 0.306 2.457 
Mkl1 -0.818 3.475 
Phox2a -0.580 3.636 
Sox2 -1.119 2.793 
Supt7l -0.554 2.677 
Tmed6 -1.323 2.740 
Ubn2 0.088 3.242 
Vpreb3 0.952 4.088 
Vps53 -1.276 2.912 
Filter 1 
Increased Number of Cilia Per Cell 
Criteria 
Z-Score of “% of cells with ≥2 cilia” 
must be >2 in both biological replicates 
No. of hits 
96 
Filter 2 
No effect on cell number 
Criteria 
Z-Score of cell number must be 
2>x>-2 in both biological replicates 
No. of hits 
18 
Whole Genome Data Set:  




Hits must have a human homologue; 
siRNA must have no off-target effects 
and target all transcripts.  
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Figure 4.4 Adapted filtering steps to identify hits that increase the 
incidence of cells with two or more cilia 
A) The flow chart to represent the filtering steps used to generate the final 
hit list of 91 hits that were taken forward for secondary screening. This 
filtering minimizes the potential for false negative hits and is also more 
likely to be biologically relevant since it is enriched for specific GO terms 
and KEGG pathways (Table 4.1). B) Scatter graph of whole genome 
screen data highlighting the final 91 hits taken forward for secondary 
screening in dark blue. (6872 data points are below the y-axis limit of -2) 
 
As expected, the final data set was highly enriched in KEGG pathways for cell 
cycle genes. Search tool for recurring instances of neighbouring genes 
(STRING https://string-db.org/) (272) analysis identified a central network of 
G2/M transition genes and peripheral nodes involved in DNA replication (Table 
4.1 and Figure 4.5). This dataset therefore has the potential to identify new links 





Hits must have a human homologue, 
siRNA must have no off-target effects 
and target all transcripts.  
No. of hits 
91 
Whole Genome Data Set: 
19097 Data Points 
Filter 1 
Increased Number of Cilia Per Cell 
Criteria 
Z-Score of “Percentage of cells with ≥2 
cilia” must be >2 in both biological 
replicates 
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Table 4.1 Gene Enrichment in the final hit list for the increase in incidence 
of cells with two or more cilia secondary screen 
The 91 hits are enriched for genes encoding nuclear proteins (43/91). The 
data set is also significantly enriched for cell cycle genes, approximately 




PPI enrichment p-value: 0.00248
Pathway ID Pathway No. of Hits False Discovery Rate
Gene Ontology (GO) – Cellular Component
GO:0097125 Cyclin B1-CDK1 complex 2/91 0.0158
GO:0070013 Intracellular Organelle Lumen 31/91 0.0158
GO:0044446 Intracellular Organelle Part 47/91 0.0158
GO:0044428 Nuclear Part 31/91 0.0158
GO:0031981 Nuclear Lumen 29/91 0.0158
GO:0005634 Nucleus 43/91 0.0158
GO:0061695 Transferase Complex, Transferring Phosphorus-
Containing Groups
6/91 0.0189
GO:0043231 Intracellular Membrane-Bounded Organelle 53/91 0.0216
GO:0005654 Nucleoplasm 22/91 0.0244
KEGG Pathways
mmu04110 Cell Cycle 6/91 0.0011
mmu03030 DNA Replication 3/91 0.0191
UniProt Key Words
KW-0539 Nucleus 36/91 0.0064
KW-0832 Ubl conjugation 19/91 0.0464
KW-0765 Sulfation 3/91 0.0464
KW-0131 Cell Cyle 9/91 0.0464
KW-0010 Activator 9/91 0.0464
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Figure 4.5 STRING analysis of the final 91 hits for the increase incidence 
of cells with two or more cilia secondary screen 
A clear network of genes is present from the STRING analysis 
(https://string-db.org/) (272)of the final 91 hits. The central nodes (eg. 
Ccnb1, Cdk1) are involved in the G2-M transition of the cell cycle and the 
more peripheral nodes of the network (eg. Prim2, Tfdp1) are involved in 
DNA replication. The original, more stringent, hit list of 14 genes does not 
have any known interactions within the dataset when assessed using 
STRING analysis. Pink lines represent experimentally determined 
interactions, light blue lines represent interactions found in curated 
databases, black lines represent genes that are co-expressed, yellow lines 
represent genes that are co-mentioned in published abstracts. 
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4.3 Increased incidence of supernumerary cilia: secondary 
screen 
A secondary validation screen of the 91 candidate hits was performed using 
smartpool siRNAs of a different chemistry (Dharmacon ON-Target Plus siRNA). 
This screen followed the same general methodology as described in Chapter 3. 
The screen did not include a positive control for supernumerary cilia, but the 
image analysis algorithm used for high content imaging of cilia was validated by 
controls that decreased cilia incidence. The same controls used in the increase 
of cilia incidence screen were retested and found to be suitable for this 
secondary screen (Figure 4.6). 
 
Figure 4.6 siRNA negative and positive controls in the supernumerary cilia 
(increased incidence of cells with two or more cilia) secondary 
screen 
A) The average robust z-score of all the control siRNAs for cell number 
(zcell ). Average calculated across 2 biological replicates of the increased 
incidence of cells with 2 or more cilia secondary screen. The positive 
control for transfection, siPlk1, has average zcell of -18.425 which indicates 
a very high transfection efficiency across the screen. B) Negative and 
positive controls for cilia incidence validated the image analysis algorithm 
used for high content imaging of cilia. Average robust z-scores for cilia 
incidence (zcilia) for siRpgrip1l, siIft88 and siMks1 were -3.580, -3.896 and  
-4.327 respectively.   
A) 
B) 
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This secondary screen had to be repeated 3 times as one biological replicate 
failed qualitative testing (as outlined in Chapter 2, Section 2.2.17.2). Correlation 
between the final 2 biological replicates taken forward for analysis was low, with 
a Pearson’s correlation co-efficient of only 0.1716 when comparing the robust z-




Figure 4.7 Correlation between separate biological replicates of secondary 
screens for cell number and supernumerary cilia 
Scatter graphs showing the correlation between the 2 successful biological 
replicates of the supernumerary cilia secondary screen. A) Pearson’s 
correlation co-efficient (R2) is 0.3624 when comparing robust z-scores for 
cell number (zcell). B) The R2 for comparing robust z-scores for 
supernumerary cilia (z2MCilia) is 0.1716. R2 for both phenotypes are below 
0.5, suggesting poor reproducibility of the results or large experimental 
variation between biological replicates. 
 
 Hits from the secondary Screen 
After qualitative and statistical analysis, 10 hits (Table 4.2) were shown to 
significantly increase the incidence of supernumerary cilia, with average robust 
z2MCilia scores >1.96 (Figure 4.8). The total of 10 hits meant the screen had a 
validation rate of 11%. The final data set had 3/77 negative controls with an 
average z2MCilia 1.96 and the screen therefore had a false positive rate of 3.9%. 
The false negative rate could not be calculated, but hits in both the whole 
genome and secondary screens may have been missed due to false negatives. 
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Table 4.2 Validated hits from the increase supernumerary cilia secondary 
screen 
Validated hits from the increase supernumerary cilia secondary screen. 
The average z-scores (rounded to 3 decimal places) from 2 biological 
replicates are shown for cilia incidence (zcilia), incidence of cells with two or 
more cilia (z2Mcilia) and cell number (zcell). Hits are ordered from highest to 
lowest based on the z2Mcilia score. 
Gene Accession No. zcilia z2Mcilia zcell 
Racgap1 NM_012025 -9.764 10.141 -14.965 
Cdk1 NM_007659 -8.713 7.769 -13.243 
Espl1 NM_001014976 -3.625 7.455 -14.877 
BC089491 NM_175033 -0.828 4.399 -4.101 
Tfdp1 NM_009361 -0.947 3.086 -9.486 
Hectd2 NM_172637 2.138 2.940 0.775 
Ssrp1 NM_182990 -0.778 2.754 -4.041 
Lhb NM_008497 -0.474 2.233 -6.332 
Narf NM_026272 -0.714 2.195 -2.962 
Mcm7 NM_008568 -2.646 1.988 -4.349 
 
 
Figure 4.8 Scatter graph of mean z2Mcilia from the secondary screen. 
The top 10% of hits are highlighted in blue. The four labelled hits 
reproducibly increase supernumerary cilia (incidence of cells with 2 or 
more cilia) with robust z-scores z2Mcilia ≥2 for both biological replicates of 
the secondary screen. The top 4 hits and their z2Mcilia values were: 
Racgap1 (10.141), Cdk1 (7.769), Espl1 (7.455), and Hectd2 (2.940). 
Significance calculated using robust z-scores to compare knock-downs to 
pooled negative controls.   
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There were 3 clear top hits that could be taken forward for further investigation, 
all with z2MCilia >7.45, equivalent to p< 0.00001. The top 3 hits also had a clear 
qualitative difference from the negative controls when assessing raw image 
data by eye. Cell numbers were significantly reduced and raw image data 
showed a high proportion of large, multinucleated cells, suggesting cell division 
defects in these knock-down conditions (Figure 4.9). 
The 3 top hits (Cdk1, Espl1 and Racgap1) encode proteins that interact. CDK1 
phosphorylates both ESPL1 (345) and RACGAP1 (346), thus highlighting a 
functional network or pathway that, when perturbed, caused the increased 
incidence of supernumerary cilia.  
The limitations of available reagents and time encouraged the tertiary validation 
of only the top hit from the screen. The current literature and databases were 
reviewed in order to assess the potential role of each gene in ciliogenesis and 
to ensure justification for the validation of the top hit Racgap1. Further literature 
searches were carried out to devise the simplest biological hypothesis for why 




Figure 4.9 Raw image data of top hits from the increased supernumerary cilia (increased incidence of cells with two or more 
cilia) secondary screen 
Raw image data taken from the increased incidence of 2 or more cilia secondary screen. Wild-type mIMCD3s have punctate cilia 
staining in the siScr control and there is a loss of cilia in the siRpgrip1l positive control. The 3 top hits of the screen were Racgap1, 
Cdk1 and Espl1. Cilia also appeared longer when cells were treated with siCdk1. These cells were also multinucleated, with some 
cells having over 6 individual nuclei. All 3 top hits showed a significant decrease in overall cell number that was associated with an 
increase in cells with 2 or more cilia (examples indicated by white arrows). siHectd2 knockdown (z2MCilia = 2.94) was the only 
validated hit that did not show a significant change in cell number or the presence of multinucleated cells
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 Validation of siRNA knock-down 
siRNAs for use in both mouse mIMCD3 and human RPE-1 cells to knock-down 
the orthologues of RACGAP1 were validated by reverse transcriptase-PCR 
(RT-PCR). Knock-down of the RACGAP1 mRNA in both mIMCD3s and RPE-1 
cells was observed when compared to cells transfected with the scrambled 
siRNA and normalised to GAPDH mRNA levels (Figure 4.10). This validates the 
efficacy of the siRNA reagents used both in the secondary screen and for 
downstream validation work. 
 
Figure 4.10 Racgap1 siRNA validation by RT-PCR 
RT-PCR was used to validate siRNAs targeting both mouse and human 
RACGAP1. Cells were treated with siRNA for 72 hours before whole RNA 
was extracted, and cDNA generated. RT-PCR was run for 50 cycles and 
showed a decrease in Racgap1 mRNA levels when densitometry was 
normalised to GAPDH mRNA levels in the same sample. N=1 technical 
replicate. 
 
 RACGAP1 knock-down increases the incidence of 
supernumerary cilia in RPE-1 cells 
To further investigate and validate Racgap1 as the top screen hit, an siRNA 
mediated RACGAP1 knock-down was performed in human RPE-1 cells. This 
would also show if the cellular phenotype seen during secondary screening was 
consistent in a different cell model and species since, phenotypes can vary 
between different cell lines. When RPE-1 cells were treated with siRACGAP1 
there was a significant increase in the number of cells with supernumerary cilia 
Product RAGAP1 GAPDH






























































1 0.27 1 0.64 Normalised Quantification
 157 
compared to cells treated with scrambled negative control siRNA (Figure 4.11). 
Cilia originated from separate centrosomes and there was no branching or 
splitting of the axonemes seen in the captured fields of view. Nuclei also 
appeared to be much larger than in cells treated with scrambled negative 
control siRNA (data not shown), implying a 4N DNA content consistent with the 
multinucleated large cells observed in the raw secondary screen data (Figure 
4.9) arising from mitotic failure. As described for other ciliopathy disease 
mechanisms in Section 4.1, it was therefore assumed that the increase in 
supernumerary cilia following RACGAP1 knock-down could be explained by an 
increase in centrosome number following exit from a failed mitosis. Thus, the 
observed increase in cilia incidence would be a secondary, indirect 
consequence of RACGAP1 knock-down. 
 
 
Figure 4.11 RACGAP1 knock-down increases the number of cilia and 
centrosomes per cell in RPE-1 cells. 
A) Examples of primary cilia in RPE-1 cells treated with negative control 
scrambled siRNA (siScr) or siRNA targeting RACGAP1 (siRACGAP1). 
Cells treated with siRACGAP1 have more centrosomes compared to 
controls. Each cilium in these cells appears to originate from separate 
centrioles, and no cells were visualized that had either 2 cilia originating 
from a single centriole or branched/split cilia. B) The proportion of cells 
with different cilia:centriole ratios (normal ratio = 1:2). Over 40% of cells 
had either an increase in centriole number, increase in cilia number or both 
following RACGAP1 knockdown. The most frequent aberrant ratio 
comprised of a duplication of both cilia and centrosomes (2:4). Other ratios 
(2:2 and 3:4) may indicate errors of centriole maturation. Figure provided 
by Dr. Basudha Basu. N=3 technical replicates.  
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Each cilium appeared to originate from individual centrioles within single and 
separate centrosomes (as distinguishable at this resolution of microscopy), 
suggesting that there were no aberrations in centriole maturation or incorrect 
ciliogenesis from daughter centrioles. To confirm that cilia only formed from the 
mother centriole in each centrosome, the experiment was repeated with 
immunostaining for CEP164, a mother centriole marker required for ciliogenesis 
(88) (Figure 4.12). Cilia always originated from the mother centrioles marked 
with CEP164 staining. Centrosomes not marked with CEP164, daughter 
centrioles, were not seen to produce cilia in any of the fields of view. This 
suggests that centrosome duplication and maturation is happening normally 
following RACGAP1 knock-down. 
 
Figure 4.12 Supernumerary cilia originate from mother centrioles 
RPE-1 cells with RACGAP1 siRNA knock-down were stained for cilia (red), 
centrosomes (red) and CEP164 (green), a marker of the distal 
appendages in the mother centriole. This was to test if centriole maturation 
was correctly specified and that supernumerary cilia originated from 
mother centrioles marked by CEP164. All cilia in the fields of view 
captured appeared to stem from adjacent staining for CEP164. Figure 
provided  by Dr. Basudha Basu. 
 
 RACGAP1 knock-down in cycling cells 
RACGAP1 has a well-defined role in cytokinesis as discussed in section 4.4.3. 
The presence of supernumerary centrosomes observed in RPE-1 cells following 
RACGAP1 siRNA knockdown, and the prominent multi-nucleated phenotype 
observed in mIMCD3s during secondary screening, was likely due to a mitotic 
defect. 
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The data thus far, alongside the known role of RACGAP1, suggested that 
centrosome duplication and maturation is occurring normally under RACGAP1 
knock-down conditions. However, after failed cytokinesis cells would retain both 
duplicated centrosomes. These supernumerary centrosomes then correctly 
mature and mark their mother centriole with CEP164, allowing two cilia to form 
in the aneuploid cell. The signalling mechanisms for centrosome maturation 
therefore do not compensate for or are unable to identify the supernumerary 
centrosomes, allowing for maturation of the duplicated centrosomes as if they 
were in a new daughter cell. 
As the supernumerary centrosomes are a downstream effect of mitotic failure, 
the supernumerary ciliated phenotype would presumably be more apparent in 
cycling cells. This would not have been tested in previous experiments which 
were performed under conditions of serum starvation in order to induce 
ciliogenesis. To test if supernumerary cilia were more frequent in cycling cells, 
RPE-1 cells were treated with either scrambled negative control siRNA or 
siRACGAP1. For the last 24 hours prior to fixation, medium supplemented with 
10% serum medium was added to half of the technical replicates in order to 
observe any changes in the number of multinucleated cells in induced cycling 
conditions. This experiment would test for a possible ciliary resorption defect, 
where cilia were just retained on cycling cells, or prevented cell cycling.  
RPE-1 cells treated with siRACGAP1 showed a significant increase in the 
percentage of cells with supernumerary cilia after addition of serum (Figure 
4.13). RPE-1 cells treated with either scrambled siRNA control or siRACGAP1 
resumed cycling after addition of serum, as shown by an increase in nuclei 
number (Figure 4.14A). Cell and nuclei numbers suggested that although cells 
were cycling, they were becoming multi-nucleated. This is consistent with the 
phenotype seen during secondary screening in mIMCD3s. However, raw image 
data of RPE-1 cells (Figure 4.14C) showed a more subtle phenotype, with fewer 
multinucleated cells when qualitatively compared to mIMCD3s. This was likely 
due to the difference in cell cycle duration between the 2 cell lines under serum 
starved conditions.   
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Figure 4.13 RACGAP1 knock-down cells treated with serum have 
increased incidence of cells with supernumerary cilia 
RPE-1 cells were treated with siRNAs and imaged, then analysed high-
throughput to assess the incidence of cells with 2 or more cilia, with and 
without serum in the growth medium. There was no significant change in 
the percentage of cells with two or more cilia in the negative controls both 
with or without serum treatment. Cells with RACGAP1 siRNA knock-down 
had a significant increase in the percentage of cells with 2 or more cilia 
after 24hr serum treatment, compared to serum starved cells with 
RACGAP1 knock-down. By re-introducing serum and allowing the cells to 
re-initiate cycling, this further increased the incidence of supernumerary 
cilia. This suggests that the presence of cells with supernumerary cilia, 
observed following RACGAP1 knock-down, is linked to an active cell cycle. 
Data was tested for normal distribution using a D'Agostino-Pearson 
omnibus K2 test and confirmed to be normally distributed. Statistical 
significance was then calculated using an unpaired, two-tailed Student’s t-
test. Experimental work performed by Dr. Basudha Basu analysis and 




Figure 4.14 RACGAP1 knock-down cells treated with serum have 
increased numbers of nuclei per cell 
RPE-1 cells were treated in a 96 well plate with either scrambled siRNA 
negative control or siRACPGAP1. High-throughput imaging and 
quantification of cilia was used to determine the incidence of cells with 2 or 
more cilia. Technical replicates (n=2) of the knock-downs were serum 
starved for 72hours or had 10% serum added for the final 24hrs to induce 
cell cycling. A) Nuclei counts per well significantly increased in both knock-
down treatments with the addition of 10% serum showing that cell cycling 
was resumed after serum starvation. B) Although there was an increase in 
nuclei counts per well there was not a significant change with or without 
serum in the total number of cells in wells with RACGAP1 knock-down. As 
nuclei counts were also higher than cell counts, this indicates that a 
proportion of the cells in wells treated with siRACGAP1 and serum were 
multinucleated. C) Raw image data shows increased incidence of 
multinucleated cells in 10% serum supplemented medium compared to 
0.2% serum supplemented medium (indicated with white arrows). Data 
was tested for normal distribution using a D'Agostino-Pearson omnibus K2 
test and confirmed to be normally distributed. Statistical significance was 
then calculated using unpaired, two-tailed Student’s t-tests. Error bars 















This work provided evidence that following RACGAP1 knock-down, cells 
continued to cycle but failed to divide. In addition, there are no negative 
regulators or compensation mechanisms for retained supernumerary 
centrosomes and, consequently, supernumerary cilia in the cell lines examined.  
 RACGAP1 knock-down causes supernumerary cilia as a 
consequence of mitotic failure 
To confirm that a mitotic defect caused supernumerary cilia, cell cycle 
progression was assessed by live cell imaging experiments. mIMCD3 cells 
expressing GFP-LifeAct to visualise the actin cytoskeleton, or mIMCD3s stably 
expressing serotonin receptor 5HT6-GFP to visualise cilia, were used so that 
cell division and cilia formation could be tracked in real time. Live cell imaging of 
cells treated with Racgap1 siRNA showed mitotic failure, causing multi-
nucleation and formation of supernumerary cilia (Figure 4.15A). The cells 
appeared to still ingress in telophase (Figure 4.15A 180mins), a process that 
appears to be compensated for by the lack of RACGAP1, but failed to complete 
abscission. As cells continued to cycle and additional centrioles matured, the 
cells became over-ciliated with up to 4 cilia per cell after 2 failed mitotic 




Figure 4.15 Live cell imaging of mIMCD3 cells treated with siRacgap1 shows mitotic abscission failure 
A) mIMCD3 stably expressing LifeAct-GFP, to visualise actin, were treated with scrambled negative control or 
siRacgap1. Cells treated with scrambled siRNA undergo normal mitotic division. The midbody (highlighted at 120mins) 
forms, and the 2 daughter cells successfully undergo cytokinesis and are identifiable as separate cells from 240mins 
(indicated by white arrows at 420mins). Cells treated with siRacgap1 show abscission failure after mitosis. At 180min the 
cells can be seen trying to separate and do not complete cytokinesis. The indicated cells within the field of view are 
polyploid, with at least 2 nuclei per cell due to the mitotic failure. B) mIMCD3 cells stably expressing 5HT6-GFP, to 
visualise cilia, were treated with scrambled negative control or siRacgap1. In negative control cells cilia form following 
normal cell division, with 1 cilium forming in each cell. In cells treated with siRacgap1, arrowheads indicate a polyploid 
cell that attempts to undergo mitosis and after abscission failure, 4 centrosomes each produce a cilium (indicated at 
360mins). Arrows show exemplar cells that follow the description above. Live cell imaging was performed by Dr. Basudha 
Basu.
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- 164 - 
4.4 Discussion 
The 4 main aims of this part of the project were met; a new data set of potential 
genes involved in the negative regulation of supernumerary cilia was generated 
from a primary whole genome siRNA screen data set. A secondary screen was 
completed in mIMCD3 cells to identify hits that increased the incidence of 
supernumerary cilia. The top hit of this screen, Racgap1, was validated in the 
human RPE-1 cell line and further investigation into the mechanism was carried 
out with immunofluorescence microscopy and live cell imaging. 
 The secondary screen for increased incidence of cells with 2 
or more cilia 
4.4.1.1 The Final Hit List 
It was initially planned to generate a hit list that would identify hits that were 
unlinked to the cell cycle, in the hope that a novel pathway could be identified 
that regulates supernumerary cilia. Thus, the filter which removed hits affecting 
cell number was initially thought to be the most important filter. After removing 
this step, STRING and GO analysis highlighted that only 10% of hits were cell 
cycle regulators. It is possible that many of the other genes in the remaining 
90% of the data set, although are not directly linked to cell cycle previously, 
when knocked down experimentally significantly affect cell number.  
Interestingly there was no overlap between the final 96 hits for the two or more 
cilia incidence screen and the 32 candidate genes required for restricting 
centriole number that were identified in the whole genome screen carried out for 
centriole biogenesis in the Gonzcy lab (261). This highlights that the pathways 
between centriole duplication and centriole maturation are likely to be 
independent from one another. 
 Secondary screen hits 
4.4.2.1 Cyclin Dependant Kinase 1 (Cdk1) 
Cyclin Dependant Kinase 1 (CDK1) is a serine/threonine kinase that is a very 
highly conserved cell cycle regulator (347).It is known to interact with over 75 
different proteins across many cellular pathways and has key roles at each 
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stage of the cell cycle (348). The most notable of these is its role at cell cycle 
checkpoints. CDK1 levels are lowest in G1. As they start to increase this 
activates transcription factors such as E2Fs to activate DNA replication genes 
and drive the transition into S phase. CDK1 is upregulated to its highest levels 
during the cell cycle in prometaphase, when it drives the initiation of mitosis 
(349).  
Due to the clear phenotype of aneuploidy/large nuclei seen in mIMCD3 cells 
during secondary screening (Figure 4.9), it is suggested that these cells 
experienced cell cycle failure. High levels of cell loss were observed with this 
knock-down (average zcell = -13.24 
Global knock-down of CDk1 in these cells means that many stages of the cell 
cycle would be dysregulated and there would be high genome instability. It is 
unclear if one or all of these dysregulations would contribute to the 
supernumerary cilia phenotype seen. However, it is simplest to assume that 
retained centrioles from failed mitosis would produce the supernumerary cilia 
phenotype. As CDK1 has essential roles throughout the cell cycle and its knock-
down is greatly detrimental to cell health, it would be almost impossible to 
accurately validate this phenotype, even in experiments using synced cell 
cultures. 
4.4.2.2 Separin (Espl1) 
Espl1 codes for a protease also known as Separin or Separase, because of its 
essential role in chromatid separation. ESPL1 cleaves a key protein in the final 
stages of sister chromatid separation during mitosis (350). Thus knock-down of 
Espl1 will cause non-disjunction and metaphase arrest. Any surviving cells 
would then return to interphase. DNA breakage and random disjunction is the 
likeliest cause of the small micronuclei seen in Figure 4.9. 
This failure of mitosis in Espl1 knock-downs would also cause retention of 
duplicated centrosomes which, as discussed in the previous section, allows 
supernumerary cilia to form. This hit was not taken forward for further 
investigation. 
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4.4.2.3 HECT Domain E3 Ubiquitin Protein Ligase 2 (Hectd2) 
HECT Domain E3 Ubiquitin Protein Ligase 2 (HECTD2) is a predicted E3 
ubiquitin ligase but little is known about its function, molecular targets or 
regulation.  
As an E3 ligase, HECTD2 would help an E2 ligase ubiquitinate its target 
protein. Therefore, knock-down of Hectd2 by siRNA would lead to loss of 
ubiquitination on target proteins. If the ubiquitination of this target protein is 
required for it to be targeted for degradation, knocking-down the degradation of 
a positive regulator of ciliogenesis would lead to unregulated ciliogenesis. 
Ubiquitination of target proteins can also lead to changes in protein localisation. 
A Hectd2 knock-down could therefore could potentially lead to a target protein 
being mis-localised. A negative regulator of ciliogenesis that is not correctly 
targeted could also lead to unregulated ciliogenesis.  
Image data from the secondary screen may show longer cilia (Figure 4.9), but 
this is hard to assess qualitatively and cannot be accurately quantified in 
mIMCD3 cells because cilia are positioned vertically and thus are recognised as 
a single spot using the Columbus™ algorithms. However, it is possible that 
longer cilia in the mIMCD3 cells were angled or lying flat, thus were incorrectly 
detected by the recognition protocol and broken down into 2 separate “spots” 
(Figure 4.16), an artefact that had been noted in previous screens (personal 
communication with Dr. Katarzyna Szymanska, Univeristy of Leeds). 
 
Figure 4.16 Limitations of the spot recognition protocol 
Raw image data taken from the increase in the secondary screen for 
incidence of cells with two or more cilia. The optimised recognition protocol 
failed to recognise single longer cilia as a single spot and were instead 
segmented into two separate adjacent spots. 
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Therefore, as there was relatively little known about this gene and its function 
and without any available validated reagents, it was not taken forward for further 
investigation. 
 Rac GTPase activating protein 1 (Racgap1)  
Rac GTPase activating protein 1 (RACGAP1) also known as MgcRacGAP or 
CYK4, is a component of the centralspindlin complex and is required for 
successful cytokinesis. Its localisation is cell cycle dependent, but it is localised 
at the mitotic spindle during metaphase, the cleavage furrow and central spindle 
during anaphase, and then in the midbody during cytokinesis (351). 
RACGAP1 dimerises and auto-associates with a KIF23 dimer to make up a 
heterotetrameric centralspindlin complex (352). RACGAP1 and KIF23 are 
functionally interdependent, such that removal of one or the other causes 
central spindle defects (353, 354). RACGAP1 tethers microtubules to the 
plasma membrane for cleavage furrow formation (Figure 4.17A) but also has a 
role in the signalling required to form the acto-myosin contractile ring during 
anaphase though its direct interaction with ECT2 (355) (Figure 4.17B).  
With Cdk1, Espl1 and Racgap1, the logical hypothesis behind the incidence of 
supernumerary cilia was the induction of mitotic defects. Therefore, because 
both Cdk1 and Espl1 would have caused significant cell cycle defects and cell 
death, Racgap1 was the only viable hit to take forward in tertiary screening 
because some knockdown cells can survive as binucleate, allowing time for 
observation of the ciliary phenotype. Racgap1 was also the top hit in the 
secondary screen (Figure 4.8) and was a confirmed negative regulator in an 
independent whole genome siRNA screen. the previous screen (260). 
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Figure 4.17 The localisation of RACGAP1 in the centralspindlin complex 
and mitosis 
Schematic diagram shows the formation of the centralspindlin complex on 
peripheral microtubules (A) and at the central spindle (B). KIF23 binds to 
microtubules and has myosin like activity within the centralspindlin 
complex with RACGAP1. ECT2 interacts with RACGAP1 and is then able 
to activate RhoA bound to the GAP domain in RACGAP1. RhoA pathways 
initiate formation of the cleavage furrow and central actomyosin contractile 
ring. Modified from (351) Figures 1 and 4 with copyright permissions. 
 
 Limitations 
4.4.4.1 Secondary screening 
For both cell number and incidence of cell with two or more cilia there was a low 
Pearson’s correlation (R2 < 0.5) between the 2 biological replicates of the 
screen. This is despite re-optimisation of controls and recognition protocols. 
This increases the likelihood for both false positives and false negatives in the 
dataset. The low correlation and high variation between biological replicates of 
A) 
B) 
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the secondary screen could be due to the lack of a positive control to validate 
the recognition protocol. Without such a control, there is not a quantifiable way 
to determine the recognition protocols ability to detect cells with more than one 
cilium, or separate 2 very close cilia. Two adjacent cilia may not be separately 
resolved at the 20X magnification used for high content imaging leading to 
potential false negative results. This highlights the importance of tertiary 
validation of phenotypes. 
The secondary screen was also limited by the stringent filtering steps used, 
which did not account for the lack of reproducibility between hits seen in the 
primary screen (Table 6.1 and Figure 4.7). Initial filtering produced only 14 hits 
of which none were known to be related or interact. It is likely that, because the 
whole genome screen data set and recognition protocols were not optimised to 
identify 2 separate cilia per cell, there was a high margin of error for both false 
positives (possibly caused by long cilia as discussed 4.4.2.3) or false negatives 
in the primary data. However, taking datasets like this forward and repurposing 
it has been shown throughout this thesis to be a useful strategy to identify new 
hits and regulatory pathways. There are, of course, inherent limitations when 
this repurposing is for a slightly different phenotype to that for which the screen 
was optimised because the detection protocols are likely to not precisely 
analyse the new phenotype of interest. 
4.4.4.2 Imaging resolution 
During tertiary validation of RACGAP1 knock-down in RPE-1, cells with 2 
centrosomes and 2 cilia, or 4 centrosomes and 3 cilia, were noted (Figure 
4.11B). This implied that there was a defect of centriole maturation, but it could 
be argued that this was merely a technical artefact that arose from the 
limitations of resolution achievable with light microscopy. At the resolution of 
microscopy used in these experiments (Zeiss ApoTome with structured 
illumination, which has comparable or slightly improved axial resolution to 
confocal microscopy (356) which is 500nm at optimal conditions (357)), cells 
that were visualized with 2 centrioles and 2 cilia may not have had additional 
centrioles resolved due to their close proximity to punctate staining seen or 
because they were spatially obscured from imaging. This appears to be the 
simplest biological explanation for the odd ratios seen in Figure 4.11. In future 
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work, resolution could be improved by using Airyscan microscopy (400nm axial 
resolution (358)) or using a different cell model for imaging. 
Furthermore, polyglutamylated tubulin was used as a marker for centrioles. This 
specifically marked post translational modifications, which are dynamic and 
often mark a nascent cilium. Other centrioles without these post-translational 
modifications may have been missed as they would not have been stained by 
the GT335 antibody. 
4.4.4.3 Lack of HECTD2 Validated Reagents 
Possibly the most interesting hit that could have been taken forward for further 
investigation was Hectd2, since it was the only secondary screen hit that did not 
have an apparent mitotic defect. The initial aim of this screen was to identify hits 
that did not cause changes in cell number, and hence likely to be independent 
of defects in mitosis or centrosome duplication, in order to identify a novel 
pathway that led to supernumerary cilia. Hectd2 was the only hit that fit these 
initial criteria and was in the small dataset of 14 hits that passed all 3 filtering 
criteria. However, there is little known about this gene and protein and there are 
very few validated reagents available for experiments. Due to time constraints it 
would not have been feasible for new reagents to be produced and validated, 
and thus it was decided to discontinue this branch of the project. 
 Impact and Significance 
A novel role for RACGAP1 was not identified in this work, but a secondary 
downstream phenotype of RACGAP1 knock-down was identified. To our 
knowledge, this is the first described link between the centralspindlin complex 
and incidence of supernumerary primary cilia. Furthermore, HECTD2 may be a 
component of a novel regulatory mechanism that specifies cilia number. 
 Potential future work 
4.5.6.1 Cilia function tests 
It would be interesting to investigate any changes in cilia function in the multi-
ciliated cells using signalling assays. Sonic Hedgehog (Shh) signalling has been 
shown to be depleted in “super-ciliated” cells caused by Plk4 knock-down. Shh 
expression was not proportionally increased with incidence of supernumerary 
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cilia; instead, Shh receptors were proportionally diluted across the multiple cilia 
which dampened the cell’s overall Shh signalling response (335).  
Wingless-related integration site (Wnt) signalling has also been shown to be 
altered in MEFs induced to have supernumerary cilia by treatment with a DNA 
polymerase inhibitor. Single ciliated cells dampened Wnt signalling in 
comparison to non-ciliated cells, whereas bi-ciliated cells further reduced Wnt 
signalling response and caused decreased levels of nuclear β-catenin (158)  
These signalling assays could be used to assess changes in signalling with 
RACGAP1 knockdown, as the supernumerary cilia were induced using different 
techniques and targets in the previous studies. It would be beneficial to provide 
further evidence that ciliary signalling is diluted across supernumerary cilia or 
highlight if the phenotype described in this thesis does not correlate to previous 
functional data in supernumerary cilia. 
4.5.6.3 The centralspindlin complex components 
It would also be of interest to investigate Kif23 and centralspindlin regulators to 
see if knock-downs phenocopy the phenotype of Racgap1 knock-downs.  
Alongside this it would be a priority to confirm that supernumerary cilia 
formation is a secondary phenotype arising from mitotic failure and not a novel 
direct function of RACGAP1 or the centralspindlin complex. Actin remodelling 
and RhoA activation was discussed in Chapter 3 as an important component of 
ciliogenesis and Racgap1 has a direct role in actin remodelling during 
cytokinesis. This alternative mechanism would have to be tested with specific 
RACGAP1 antibodies at different stages of ciliogenesis. 
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Chapter 5  
Results: The transition zone genetically interacts with IFT88 
5.1 Introduction 
Genetic interactions between ciliary genes are already known to contribute to 
the spectrum of phenotypes observed for ciliopathies such as Bardet Biedl 
syndrome (359-362), as discussed in (Chapter 1, Section 1.5.2). As the cilium is 
highly regulated and has complex molecular signalling, it is likely that there are 
many more genetic interactions to be identified that contribute to the observed 
variability in ciliopathy phenotypes. A high-throughput methodology could 
therefore be a useful tool in screening for genetic interactions amongst ciliary 
genes to aid in our understanding of the molecular pathology behind these 
varying phenotypes. This chapter describes the development and a proof of 
concept experiment to show that the development of a large scale genetic 
interaction screen is possible if looking at ciliary phenotypes. 
Knock-outs of ciliary genes often cause severely decreased cilia incidence or a 
reduction in ciliary length, as seen in mouse derived cultures (363-365). In this 
chapter, I have hypothesised that heterozygous mutant cell-lines, that have a 
residual protein level, would still have quantifiable ciliary phenotypes. These 
heterozygous cell lines were then further perturbed to detect genetic 
interactions with small interfering RNA (siRNA), generating “double 
perturbation” conditions to identify synthetic genetic interactions (366). These 
combinatorial screens of siRNA and Clustered Regularly Interspaced Short 
Palindromic Repeats/Cas9 (CRISPR/Cas9)-edited cells acted as a primary 
screen to provide potential follow-up projects for secondary validation, whereas 
previous chapters have used a secondary screen and tertiary validation to gain 
mechanistic insight. Any potential interactions that were identified could provide 
novel insights into the genetics of ciliogenesis, ciliary maintenance or 
disassembly. 
Known ciliopathy genes coding for different structural and functional 
compartments of the cilium (Figure 5.1, Table 5.1 Genes targeted by 
CRISPR/Cas9 
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 were targeted by CRISPR/Cas9 genome editing to generate a panel of 
heterozygote genome-edited cell lines. Targets included a ciliary membrane 
protein (ARL13B), intraflagellar anterograde transport protein (IFT88) and 
transition zone proteins (CEP290, TMEM67, RPGRIP1L and TMEM216). These 
uncharacterised cell lines were validated and used in combinatorial screening 
with siRNAs targeting a separate panel of genes. Both panels were selected 
based on available reagents in the lab and were focused on the transition zone, 
a ciliary compartment shown in previous studies to be tightly regulated and 
influenced by epistatic interactions (82, 360, 367).  
 
Figure 5.1 Schematic of the primary cilium and transition zone 
The primary cilium has a complex ultrastructure with many different 
compartments. Genes that code for components of the ciliary membrane 
(ARL13B), intraflagellar trafficking (IFT88), and transition zone (CEP290, 
RPGRIP1L, TMEM67, TMEM216) were targeted with CRISPR/Cas9 
genome editing to generate heterozygous mutations. Modified from (368) 
Figure 1. Clinical features of Meckel–Gruber syndrome (MKS) and 
schematic of primary cilia structure, use licensed under the Creative 
Commons Attribution 4.0 International License.  
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Table 5.1 Genes targeted by CRISPR/Cas9 
This table summarises the genes and specific exons targeted by 
CRISPR/Cas9. Data is also provided on the known or predicted structural 
modules in the cilium and the published phenotypes for each gene. 
COACH = Cerebellar vermis aplasia, Oligophrenia, congenital Ataxia, 
Coloboma and Hepatic fibrosis. RHYNS = Retinitis pigmentosa, 
HYpopituitarism, Nephronophthisis, and mild Skeletal dysplasia. Data 
collected from Online Mendelian Inheritance in Man, OMIM® (369) and * 
IFT88 phenotype described in (370). 
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5.1.1 Chapter Aims and Objectives  
Aims: To understand the molecular mechanisms behind the spectrum of 
phenotypes seen in ciliopathy patients. 
Hypothesis: The high variation in phenotypes seen across the ciliopathy 
disease group is due to epistatic genetic interactions between ciliary genes as 
has been identified in a few familial cases of Bardet Biedl Syndrome (371). The 
inheritance of a variety of alleles, that are unidentified in traditional clinical 
mutation screening, act in an epistatic manner to affect ciliogenesis and ciliary 
function. Thus providing a molecular explanation for the spectrum of 
phenotypes and diseases seen from mutations in the same gene.  
A quick and high-throughput methodology could be used to screen ciliary genes 
and genes associated with ciliary function to identify potential epistatic 
interactions through the impact on simple ciliary phenotypes, such as ciliary 
incidence and length. 
Experimental Objectives: 
• To validate CRISPR/Cas9-edited cell lines for use in high-throughput 
screening. 
• To design, optimise and develop a high-throughput technique which is 
able to identify epistatic genetic interactions. 
• To carry out a proof of concept small scale screen, henceforward called 
a combinatorial screen, to show that the technique is feasible and has 
the potential to be developed 
• To use screen test data to identify synthetic genetic interactions between 
knockout and knockdowns of ciliary genes 
• To validate and determine the mechanistic basis for any potential genetic 
interactions inferred from the primary combinatorial screen data. 
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5.2 Validation of CRISPR/Cas9-edited cell lines 
CRISP/Cas9-edited hTERT-RPE-1 cell lines were generated in Prof. Colin 
Johnson’s group during my time as a research assistant prior to undertaking 
this thesis project. The cell lines were tested for heterozygous and compound 
heterozygous mutations by a T7 Endonuclease I Digestion Assay (T7 assay) 
(Figure 5.2). Due to the random mutation events from CRISPR/Cas9 editing, it 
was assumed that mutations on both alleles would be different. Therefore, both 
single allele and double allele mutations would give a positive result in a T7 
assay. Across all genes targeted 59 clones were identified by T7 assay to as 
having mutations in target exons. The frequency of positive results in the T7 
assay was also used to predict the overall efficacy of each of the guide RNAs 
(gRNAs) used to initially generate these cell lines (Table 5.2).  
 
Figure 5.2 T7 assay of ARL13B CRISPR/Cas9 targeted colonies 
T7 assay using re-annealed polymerase chain reaction (PCR) products of 
ARL13B exon 1 from CRISPR/Cas9 treated colonies (PCR product 590bp, 
expected cut bands approx. 440bp and 150bp). This assay was used to 
identify heterozygous and compound heterozygous mutated colonies to 
take forward for validation, examples seen for colonies 8 and 29. 
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Table 5.2 Predicted gRNA efficacies 
For each gene targeted only one gRNA was used. T7 assays were used to 
predict the efficacy of each gRNA’s ability to induce indel mutations. This 
was based on the number of positive results from the T7 assay which 
indicates either a heterozygote or compound heterozygote mutation in the 
targeted exon. The predicted gRNA efficacy is calculated using an 
equation described in (372). 
% gene modification = 100 × (1 − (1 − fraction cleaved)1/2) 
 
5.2.1 Mutation analysis of CRISPR/Cas9-edited cell lines 
CRISPR/Cas9 induced mutation positive colonies identified by T7 assay were 
taken forward for Sanger sequencing. Both Sanger sequencing (Appendix H) 
and Mutation Taster online tool (http://www.mutationtaster.org/) (373) were 
used to define heterozygous mutations and predict their pathogenicity. 
Mutations ranged from a single base-pair insertion to a 361bp deletion. 
Polyclonal cell lines were assessed using TA cloning so that all individual alleles 
within the cell population could be sequence verified. Both monoclonal and 
polyclonal cell lines that were shown to have mutations with predicted 
deleterious pathogenicity were taken forward for further validation (Table 5.3). 
Throughout this thesis these cell lines will be referred to by their gene, clone 
number, and mutation abbreviations. 
The top 20 potential off-target sites of these 10 chosen cell lines were also 
sequenced to verify the specificity of editing and to ensure that any validated 
phenotype was due only to the mutation in the targeted gene. There were no 
off-target mutations detected by Sanger sequencing in the clones taken forward 
for phenotype validation (data not shown). However, this does not 
comprehensively confirm that the clones are free of off-target mutations.  
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Table 5.3 Sequence Validated heterozygous CRISPR/Cas9-edited cell lines 
Validated mutations for the cell lines used throughout this project. The targeted 
gene, clone number and mono or polyclonal genetic status of each cell line are 
listed. Coding sequence and protein mutations are listed alongside 
abbreviations to represent the overall predicted pathogenicity (+ = wild type 
allele, - = pathogenic allele, if.del = deleterious allele, if.indel = possibly 
deleterious). *TMEM67 inversion was not fully characterised and the inversion 
starts before, and covers exon 1. 
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5.2.1.1 TMEM67 C47 Mutation Analysis 
TMEM67 C47 was the only colony for which the mutation could not be 
accurately defined. Initial colony sequencing data showed an uninterpretable 
electropherogram that did not align to any TMEM67 wild-type sequence. The 
PCR products used for this sequencing were checked and shown to be clean 
single bands at the expected size. Other PCR products from colonies in the 
same run were also sequenced and showed the expected amplified region 
across exon 1 of TMEM67. After repeated polymerase chain reactions (PCR) 
and Sanger sequencing of C47 with either failed or further uninterpretable 
results, the cell line required further analysis. New primers spanning a larger 
amplification region were designed in case primer sites were mutated or a 
larger deletion had deleted primer sites altogether. Primers of increasing further 
distance from the predicted mutation site were used. By using these primers, a 
potential inversion across exon 1 (Figure 5.3) was detected alongside a full 
wild-type sequence, although this was only detected in the forward primer 
Sanger sequencing results. Thus it was possible that the reverse primer 
sequence was being missed for this allele or was deleted entirely, so only the 
wild-type allele was sequenced. Further primers were designed to amplify a 
1.1kb region over exon 1, but Sanger sequencing of these PCR products only 
produced wild-type sequence. The cell line was taken forward to look for loss of 
protein and any robust phenotype that would allow the cell-line to be kept in the 
CRISPR/Cas9 panel, but all results were interpreted with the consideration that 
this may simply be a wild-type clone that had under gone clonal selection 
making it differ from normal wild-type controls. The possibility that this was a 
polyclonal cell line with a high proportion of wild-type cells compared to mutant 
cells, which meant sequencing was inconsistent, was also considered. 
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Figure 5.3 TMEM67 C47 +/- mutation analysis 
Using primers that extended into the intron region before Exon 1 of TMEM67, 
an inversion (red) was detected in the second allele of TMEM67 C47 (purple) 
was detected. The inversion starts at base 4982 when reading the second allele 
5’ to 3’. The inversion sequence refers to the sequence starting at 5527 in the 
reference sequence and matching the reference sequence when read 3’ to 5’. 
This inversion spanned over exon 1 but the second break point was not covered 
in the Sanger sequencing data of the reverse primers. Further primers into the 
intron sequence after exon 1 failed to generate readable electropherograms 
after Sanger sequencing and so this mutation was not fully characterised.  
Reference Sequence
Allele 1 Sequence
Allele 2 Sequence, Inversion, Inversion Break Point = 
4921 tgccaacttc gcgcagggtt ggtaacctag caaccaagca acacgagcag tgacttccgg
tgccaacttc gcgcagggtt ggtaacctag caaccaagca acacgagcag tgacttccgg
tgccaacttc gcgcagggtt ggtaacctag caaccaagca acacgagcag tgactgctgc
4981 tacccggact tgggttgtcc aatcagctca gcgaagccgc cgcagaggct gatggggggc
tacccggact tgggttgtcc aatcagctca gcgaagccgc cgcagaggct gatggggggc
tggaaatttt acatttctac gtcactaaac aatatacatg tattggggcc aggcgcggtg
Exon 1                         
5041 tggaggctgt gaggcttcca gcgtcggtac cATGGCGACG CGCGGTGGGG CTGGGGTGGC
tggaggctgt gaggcttcca gcgtcggtac cATGGCGACG CGCGGTGGGG CTGGGGTGGC
gctcacgcct gtaatcccca gcactttggg aggcggaggc gggtggatca cctgaggtca
Continues to unknown break point.
Confirmed Inversion Sequence:
5527 gctgctggaa attttacatt tctacgtcac taaacaatat acatgtattc gggccaggcg
5467 cggtggctca cgcctgtaat cccagcactt tgggaggcgg aggcgggtgg atcacctgag
5467 cggtggctca cgcctgtaat cccagcactt tgggaggcgg aggcgggtgg atcacctgag
5407 gtcagaagtt cgagactagc ctgatcaaca tggtgaaact ccatttacgg ggactagggg
Exon 1 
5347 ccgaccaagg cgggagtgtt acttttgcca gggcccaccg caaaccgtct tacCTCGGGC
Exon 1                              
5287 ATCTTGCCTC TGGTTAGCTC CACAAGGAAC ACACGAGAGG GCGGAGATAT CAAAGTACTG
Exon 1                              
5227 GTTGTTGTCG CACTTCTCCG GCTGCTGGAA AGGGAAAGAG AAGGTCTGGG CAAAGTACTG
Exon 1                           
5167 GCGAGGGAGG AACAACAGAA GGAACGCGGT CACGGCCCGG GCGGATA………
Continues to unknown break point.
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5.2.2 CRISPR/Cas9-edited cell lines have reduced levels of target 
proteins 
Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR) 
showed loss of protein or gene expression in all cell lines compared to negative 
controls (Figure 5.4). Protein levels in cells were compared to wild-type, 
passage matched, retinal pigment epithelial (RPE-1) cells treated with either 
siScr negative control or with siRNA against the CRISPR/Cas9 targeted gene 
(positive control). Quantifications were normalised to loading controls to 
estimate the protein levels in the mutant cell lines relative to the negative wild-
type control (Figure 5.4). ARL13B, CEP290 and IFT88 mutant cell lines all 
showed reduced protein levels compared to negative controls. Despite the lack 
of characterised mutation TMEM67 C47+/- also showed reduced protein levels 
relative to controls. Normalised protein or RT-PCR results matched the 
predicted pathogenicity and mutant allele frequency in all cell lines tested. 



















Figure 5.4 CRISPR/Cas9-edited cell lines have loss of targeted protein or mRNA 
A) Western blot shows loss of ARL13B protein levels in C19+/- and C71+/- cell lines compared to negative control when densitometry 
is normalised to β-Actin levels. ARL13B has predicted molecular weight 49kDa, the siRNA positive control allows correct 
identification of the band at approx. 55kDa. B) Western blot shows loss of IFT88 protein levels in IFT88 C29+/- and C31if.del/- cell lines 
compared to negative control when normalised to Vinculin loading control. C) RPGRIP1L protein levels reduced in both cell lines 
and siRNA knock-down compared to siScr negative control. Expected bad size 150kDa but bands appeared at approx. 40kDa. D) 
TMEM67 protein levels were reduced in both the siTMEM67 and TMEM67 C47+/- samples when normalised to vinculin and 
compared to siScr control E) TMEM216 mRNA levels were reduced in siRNA and edited cell line samples when normalised to 
ACTB mRNA levels and compared to siScr control. Results were interpreted across n=3 experimental replicates for western blots 
and n=1 for RT-PCT. Quantifications were therefore applicable to TMEM216 cell lines. Average protein levels presented in graphs, 
normalised to loading controls. All westerns were loaded with RPE-1 whole cell extracts. Error bars represent Standard Deviation. 
IB: RPGRIP1L 
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5.2.3 Ciliary Phenotypes 
9/10 of the CRISPR/Cas9-edited cell lines that were phenotyped and validated 
by high-throughput high content imaging had significant changes to either cilia 
length or cilia incidence compared to pooled wild-type (WT) control cells that 
had also been clonally selected (Figure 5.5 & Figure 5.6). CEP290 C53+/- did 
not show any significant change in the ciliary phenotypes measured across the 
polyclonal cell population (Figure 5.5). This is despite 2 alleles across the 
polyclonal cell population with frame-shift mutations (Table 5.3).  
IFT88 C31if.del/-  was also a deleterious mutation, despite an in-frame deletion on 
one allele. Protein levels were also higher in this cell line compared to IFT88 
C29+/- but the cilia incidence and length defects were more significantly different 
when compared to wild-type controls (Figure 5.5 & Figure 5.6). 
  
Figure 5.5 High-throughput quantification of cilia incidence and cilia spot 
size in CRIPSR/Cas9-edited cell lines 
A) 6/10 cell lines showed a significant change in ciliary incidence. ARL13B 
C71+/-, CEP290 C53+/-, IFT88 C29+/-, and RPGRIP1L C49if.del/-showed no 
significant change in ciliary incidence. TMEM67 C47+/- however showed a 
significant increase in ciliary incidence. B) 9/10 cell lines showed a 
significant decrease in cilia membrane area (measured as spot size in 
pixels squared (px2)). TMEM67 C47+/- was the only clone to show a 
significant increase in cilia size compared to wild-type controls. CEP290 
C53+/- did not have any significant change in either cilia incidence or cilia 
length. Data was confirmed to be normally distributed using a D'Agostino & 
Pearson omnibus K2 test. Significance was calculated with One-Way 
ANOVA with Dunnets test for multiple corrections. where # indicates the 
control each data set was compared to.  * = p<0.05, ** = p<0.01, ***= 
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Figure 5.6 High-throughput high content imaging of CRISPR/Cas9 mutant 
cell-lines shows qualitative changes in cilia incidence and size 
Raw image data from Operetta high-throughput imaging shows qualitative 
differences in cilia incidence and spot size. Cilia incidence appears to be 
lowest in the RPGRIP1L and TMEM216 mutant cell lines. ARL13B C71+/- 
and CEP290 C53+/- have similar ciliary staining patterns to wild-type (WT) 
RPE-1. TMEM67 C47+/- cilia appear brighter than WT RPE-1 cells, which 
could reflect increased cilia length or ARL13B expression. Confluency is 
consistent across all cell lines imaged and so changes in cilia incidence 
could not be influenced by cell density.  
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5.2.4 CEP290 C53+/- polyclonal cell line validation 
Despite sequencing suggesting deleterious mutations and western blot showing 
a significant loss of protein across the polyclonal population in the CEP290 
C53+/- cell line, high-throughput imaging showed no significant phenotype for 
cilia incidence or spot size when compared to wild-type controls. This cell line 
was shared with a collaborator, Dr. Elisa Molinari at Newcastle University, so 

















Figure 5.7 CEP290 C53+/- cell line has significantly smaller cilia compared 
to wild-type controls 
No significant change in cilia incidence was seen in the C53+/- cell line 
compared to WT controls. However, changes in cilia size leading to a 
significant decrease in average length across the population were 
observed. The presence of bulbous cilia and discontinuous ARL13B 
staining was also noted. Experimental work, analysis and figures were 
provided by Dr. Elisa Molinari, Newcastle University. Significance was 
tested with a two-tailed Student’s T-test. *** = p<0.001 B) Western blot 
shows significant loss of CEP290 in the CEP90 C53 +/- polyclonal cell line 
relative to wild-type (WT) RPE-1 controls, down to approximately 15% n=3. 








































- 186 - 
After the lack of quantifiable phenotype that was seen in high-throughput 
imaging, the cell line was tested again in Newcastle. Their work showed that 
although there was no significant difference in cilia incidence, there was a 
significant change to cilia size in the CEP290 C53+/- cell line, including the 
presence of some bulbous cilia and discontinuous ARL13B staining (Figure 
5.7). This meant that the CEP290 polyclonal mutant cell line was suitable to 
take forward for combinatorial screening, as it showed a significant ciliary 
phenotype without complete loss of cilia incidence. 
5.2.5 Polyclonal Colonies 
Two of the 10 chosen cell lines were confirmed to be polyclonal, but were still 
taken forward for phenotype validation (ARL13B C8+/-, CEP290 C53+/-). This 
was justified because the mutant allele frequency and protein levels remained 
consistent after 5 passages of the cell line. Cilia incidence and length in the cell 
populations were also consistent across 3 biological replicates of phenotyping 
(Figure 5.5, Figure 5.6, Figure 5.7)This suggests a stable population ratio of the 
different mutant cells during routine passaging. However, polyclonal populations 
may not have maintained a stable population across further passaging and 
experimental work, which was not tested for, but was considered during 
interpretation of all downstream work.  
5.3 Combinatorial Screen 
5.3.1 Set up of the Combinatorial Screen 
The panel of siRNAs used in the combinatorial screen were confirmed to knock-
down protein or mRNA levels in WT RPE-1 cells compared to a scrambled 
siRNA negative control (siScr) (Figure 5.8). Once both the heterozygous cell 
lines and siRNAs were validated, the combinatorial screen was optimised for 
seeding density, transfection efficiency and immunofluorescent staining of the 
cilia marker ARL13B. 
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Figure 5.8 Validation of the siRNA panel used in the combinatorial screen 
Validation of the IFT88 (A), RPGRIP1L (B), TMEM67 (C), TMEM237 (D), 
and TMEM107 (E) siRNAs used as the siRNA panel in the combinatorial 
screen by western blot or RT-PCR. There are reduced protein levels in all 
RPE-1 cells treated with siRNA versus the negative scrambled control (A, 
B, C, D). Equal loading can be seen in blots when comparing -actin 
levels, except in blot C), when quantified and normalised to the loading 
control there was a reduction in TMEM67 levels compared to the 
scrambled control. E) TMEM107 mRNA levels were reduced in the sample 
treated with siRNA when normalised to ACTB mRNA. WCE stands for 
whole cell extract. 
 
High cell loss was seen in the first combinatorial screen which was not present 
during optimisation experiments. Therefore during the second round of the 
combinatorial screening, which screened the CEP290 and TMEM67 mutant cell 
lines, Matrigel® was added to plates prior to seeding and transfection to 
minimise cell loss.  
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5.3.2 Primary Analysis of the Combinatorial Screen 
Heat maps were used to qualitatively assess transfection efficiency, plate 
seeding and controls. This initial primary analysis acted as a quality control 
which excluded any potentially failed screen plates, which could then be 
repeated. Heat maps also highlighted wells that had high (>50%) loss of cells 
which were therefore removed from statistical analyses. This was likely due to 
high-throughput washing steps in the protocol that disturbed the cell monolayer. 
The addition of Matrigel® coating in the second combinatorial screen reduced 
the number of wells excluded from the analysis due to cell loss, and any 
consistent cell loss was mostly confined to a single field of view within a well. 
Primary analysis also excluded wells on the basis of immunostaining quality. In 
some wells the staining quality was poor or the field of view was obscured by a 
dust fragment (Materials and Methods Figure 2.3). Once these individual wells 
were excluded from the data set, all conditions were covered by a minimum of 2 
biological replicates. The screen data was also shown to have strong correlation 
between experimental replicates, suggesting that the screen is likely to be 
reproducible (Figure 5.9).  
   
Figure 5.9 Correlation between biological replicates of the combinatorial 
screen 
A) Screen one had a Pearson’s Coefficient (R2) value of 0.7156 between 
experimental replicate 1 and 2. Despite the inherent variability expected in 
this screen set up the data could still be considered reproducible as it has 
a R2 value >0.5. B) The second combinatorial screen only screened 2 
CRISPR/Cas9-edited cell lines, CEP290 C53+/- and TMEM67 C47+/-. When 
comparing experimental replicate 1 and 2 the screen had an R2 value of 
0.8658, providing evidence that this screen was also reproducible. 






















































































A) Combinatorial Screen 1 B) Combinatorial Screen 2 
- 189 - 
After primary analysis was assessed to ensure the quality of screen data, the 
siRNA controls were assessed using average robust z-scores to determine the 
transfection efficiency for each screen plate and ensure the accuracy of the 
automated cilia recognition protocol (Figure 5.10). 
 
Figure 5.10 siRNA controls were robust in the combinatorial screen 
A) Average robust z-scores of siRNA controls in wild-type RPE-1 cells 
showed that siPLK1 and siTMEM237 significantly decreased cell number 
(zcell <-1.96) compared to negative controls. Loss of PLK1 causes cell 
death which is a reproducible and easily quantified phenotype used as the 
transfection control. The transfection efficiency was therefore estimated 
from the amount of cell death seen in wells treated with siPLK1. B) siIFT88 
and siRPGRIP1L were used as controls for cilia incidence as these genes 
are essential for ciliogenesis. Treatment of cells with these siRNAs causes 
a reproducible and significant decrease in the average robust z-scores for 
cilia incidence (zcilia <-1.96). These controls were used to validate the cilia 
recognition protocol but were also included in the analysis for identifying 
genetic interactions. Grey dotted lines mark cut-offs for significance 
equivalent to p = 0.05 (1.96< z <-1.96). Significance calculated using 
robust z-scores. 
 
To minimalize the impact of experimental variation that is inherent when using 
several cell lines in a single plate high-throughput format, robust z-scores were 
calculated for each cell line separately throughout the screen. The robust z-
scores for CRISPR/Cas9-edited RPE-1 cell lines were then compared to WT 
RPE-1 for each siRNA condition. Data for each cell line was normalised, so that 
A)  B)  
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irrespective of any genetic background or defined ciliary phenotypes, the 
negative controls (siScr) in each cell line would have an average robust z-
scores for cilia incidence (zcilia) of 0. Therefore, z-scores would represent the 
change in phenotype due to the siRNA knock-down for each cell line only. Any 
significant differences between zcilia of the knock-downs in the mutant cell lines 
and WT RPE-1 could be then attributed to the different genetic backgrounds of 
those cell lines. This difference is henceforth referred to as zcilia. Significant 
zcilia were used to identify genetic interactions between the CRISPR/Cas9-
edited genes and the genes targeted with siRNA. The same analysis was used 
to assess changes in spot size (zsize), assumed to represent cilia size. The 
statistical method is outlined in (Chapter 2, Section 2.2.17.3). 
5.4 Genetic interactions of Cilia Incidence 
The combinatorial screen provided evidence for 14 potential synergistic 
interactions, of which 2 present as a reciprocal pair. There is also evidence for 8 
additive interactions and one antagonistic interaction inferred from the screen.  
5.4.1  Additive Genetic Interactions 
Eight additive genetic interactions were identified from the cilia incidence data. 
These interactions had a significant change in cilia incidence but the change 
was not significantly greater than that seen in the WT RPE-1 cells treated with 
the same siRNA: 
1.96 ≤ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑧𝑐𝑖𝑙𝑖𝑎 ≤ −1.96  and  1.96 > 𝑧𝑐𝑖𝑙𝑖𝑎 >  −1.96  
The genetic background of the CRISPR/Cas9-edited cell line did not 
significantly change the loss of cilia caused by the siRNA knock-down, so each 
genetic background had the same proportional cilia loss. However if raw data 
were to be compared it would show a more severe phenotype than the WT cells 
treated with the same siRNA. 
ARL13B cell-lines only presented with additive genetic interactions (Figure 5.11) 
and no synergistic or antagonistic interactions were inferred from the 
combinatorial screen data. This was also the cell line that showed the highest 
variation in z-scores across biological and technical replicates of the screen.  
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Figure 5.11 Additive synthetic genetic interactions identified in ARL13B 
CRISPR/Cas9-edited cell lines. 
ARL13B mutant cell lines showed very high variability between biological 
replicates. Reducing the ability to accurately identify any potential genetic 
interactions using the combinatorial screening methodology. However, 
additive genetic interactions were suggested between ARL13B and 
RPGRIP1L. Significance calculated using Δz (described in Section 
2.2.17.3) Error bars represent S.E.M. 
 
5.4.2 Synergistic Genetic Interactions 
Twelve synergistic genetic interactions were identified from the cilia incidence 
data. These interactions had a significant change in cilia incidence that was 
significantly greater than that seen in WT RPE-1 cells treated with the same 
siRNA: 
1.96 ≤ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑧𝑐𝑖𝑙𝑖𝑎 ≤ −1.96  and  1.96 < 𝑧𝑐𝑖𝑙𝑖𝑎 <  −1.96 
Thus the genetic background of the mutant cell line meant that proportionally, 
when normalised to base levels of cilia incidence, there was a greater effect on 
the cilia incidence phenotype in the mutant cell lines compared to WT RPE-1 
cells. This suggested a synthetic synergistic interaction between the 
CRISPR/Cas9-edited gene and the gene targeted for knock-down by siRNA.  
5.4.2.1 IFT88 and Transition Zone Genes 
IFT88 is well known to be a central regulator of ciliogenesis and ciliary 
maintenance (13, 38) as part of the IFT B complex (57, 374), therefore it was 
not unexpected that it was part of many of the genetic interactions identified 
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(5/12 total synergistic interactions for cilia incidence). All of the synthetic 
synergistic interactions involving IFT88 were with transition zone genes (Figure 
5.12A). A clear triad of interactions was noted between IFT88, RPGRIP1L and 
TMEM67 as these showed partial reciprocal interactions (Figure 5.12B, C). 
IFT88 C29+/- and C31+/if.del treated with siRPGRIP1L had a zcilia of −8.32 and 
−7.50 respectively, showing a significant loss in cilia incidence. In contrast, the 
zcilia for WT cells treated with siRPGRIP1L was −3.68, significantly lower than 
the loss of cilia seen in the IFT88 cell lines (zcilia = 4.64 and 3.82 respectively, 
equivalent to p<0.00001 and p=0.000233) (Figure 5.12A). As the sum loss of 
cilia was higher than that seen in either gene individually, this was taken 
forward as a synthetic synergistic interaction between IFT88 and RPGRIP1L. 
The reciprocal interaction between IFT88 and RPGRIP1L was tested in 
RPGRIP1L C19+/- and RPGRIP1L C49if.del/- cells treated with siIFT88. The zcilia 
were −0.75 and −6.21, with zcilia  of −3.50 and 1.96 respectively (Figure 5.12B). 
Therefore the RPGRIP1L C49if.del/- also showed a synergistic interaction with 
IFT88 (p=0.05), but this was not replicated in the RPGRIP1L C19+/- cell line. 
IFT88 C29+/- and C31+/if.del treated with siTMEM67 had zcilia of −12.71 and 
−6.74 and zcilia  of 10.26 and 4.29 respectively (Figure 5.12A). These 
suggested a strong synthetic synergistic interaction. However, an interaction 
between IFT88 and TMEM67 was only partially supported by the reciprocal 
experiment. TMEM67 C47+/- treated with siIFT88 had a significant loss of cilia 
(zcilia = −2.39), but this was seen only as an additive interaction as the loss of 
cilia seen in WT cells treated with siTMEM67 was larger (zclia = −3.74) (Figure 
5.12C). 
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Figure 5.12 Genetic interactions between IFT88 and transition zone genes 
A) IFT88 mutant cell lines had significantly greater loss of cilia when 
treated with siRPGRIP1L, siTMEM67 and siTMEM237 compared to WT 
cells treated with the same siRNAs. This suggested a synthetic genetic 
interaction between IFT88 and each of these genes. B) RPGRIP1L mutant 
cell lines only showed potential genetic interactions for the RPGRIP1L 
C49if.del/- cell line, none of which were replicated in the C19+/- cell line. 
RPGRIP1L C49if.del/- showed a reciprocal synthetic synergistic interaction 
with IFT88. Synergistic interactions were also suggested with TMEM67, 
TMEM107 and TMEM237. C) The TMEM67 mutant cell line showed a 
reciprocal interaction with RPGRIP1L, an additive interaction with IFT88 
and synergistic interactions with TMEM107 and TMEM237. Significance 
was calculated using z scores, representing the number of standard 
deviations between each experimental value and the comparison value 
(described in Section 2.2.17.3) * = 1.96<z<-1.96, ** = 2.58<z<-2.58,    
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RPGRIP1L C19+/- and C49if.de/- treated with siTMEM67 had zcilia of -1.88 and 
−8.50 with zcilia  of −0.58 and 6.04 respectively (Figure 5.12B). As seen with 
siIFT88, there was no discernible genetic interaction for the RPGRIP1L C19+/- 
cell line. However, the large zcilia  value observed for C49if.de/- suggested a 
strong synergistic interaction between RPGRIP1L and TMEM67. This was 
supported by the reciprocal interaction when TMEM67 C47+/- was treated with 
siRPGRIP1L, which had a zcilia of −7.87 and a zcilia  of 3.35 Figure 5.12C). 
5.4.2.2 Synergistic interactions that increased cilia incidence 
The second combinatorial screen consistently showed that siTMEM237 
increased cilia incidence (zcilia = 2.58). However, this phenotype was not 
significant in the first combinatorial screen (zcilia = 0.20), possibly due to higher 
variation across the first screen. Three synergistic interactions that increased 
cilia incidence were suggested from the second combinatorial screen data, one 
of which was the only synergistic interaction inferred for CEP290. The increased 
cilia incidence phenotype was further significantly increased in CEP290 C53+/- 
polyclonal cells treated with siTMEM237 (Figure 5.13) and TMEM67 C47+/- cells 
treated with siTMEM237 or siTMEM107 (Figure 5.12C). The increase in cilia 
incidence was greater than that seen in WT cells treated with the same siRNA.  
 
Figure 5.13 TMEM237 knock-down increases cilia incidence 
CEP290 edited cells did not show any significant ciliary phenotype 
compared to WT RPE-1. However, when treated with siTMEM237 there 
was a significantly greater increase in cilia incidence (zcilia for WT RPE-1 = 
2.578 and for CEP290 C53+/- = 8.553). This would suggest a potential 
synergistic interaction between CEP290 and TMEM237. This was also the 
only synthetic genetic interaction suggested for CEP290 that affected cilia 
incidence. Significance was calculated using z scores, representing the 
number of standard deviations between each experimental value and the 
comparison value (described in Section 2.2.17.3). **** = 3.89<z. Error 
bars represent S.E.M. 
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5.4.3 Antagonistic Genetic Interactions 
In addition to the above genetic interactions which further perturbed or 
increased ciliary incidence, an antagonistic interaction was also inferred for 
ciliary incidence between TMEM216 and RPGRIP1L. In both TMEM216 
CRISPR/Cas9-edited cell lines there was a significantly lower cilia incidence 
compared to WT controls. When these cells lines were treated with 
siRPGRIP1L cilia incidence increased, whereas WT RPE-1 cells had a 
significant decrease in cilia incidence in response to siRPGRIP1L (Figure 5.14). 
This suggests an antagonistic interaction between TMEM216 and RPGRIP1L.  
 
Figure 5.14 A potential antagonistic interaction between RPGRIP1L and 
TMEM216 affecting cilia incidence 
TMEM216 heterozygous cell lines showed a significant loss of cilia 
compared to wild-type (WT) RPE-1 cells. Each cell line was normalised to 
siScr control in order to quantitate the differences in response to each 
siRNA treatment. There was a significant increase in cilia incidence for 
both TMEM216 edited cell lines following knock-down of RPGRIP1L, 
whereas WT RPE-1 showed a significant decrease. This suggests an 
antagonistic synthetic genetic interaction between TMEM216 and 
RPGRIP1L. Significance calculated using z scores, representing the 
number of standard deviations between each experimental value and the 
comparison value (described in Section 2.2.17.3). ** = 2.58<z<-2.58,    
*** = 3.3<z<-3.3, **** = 3.89<z<-3.89. Error bars represent S.E.M. 
 
Raw data from the combinatorial screen was used to assess the extent of the 
rescue of cilia incidence in this synthetic antagonistic interaction. This showed 
that cilia incidence increased in the TMEM216 mutant cell lines with RPGRIP1L 
knock-down compared to negative controls. However, this was not a significant 
increase and under these conditions cilia incidence was still significantly lower 
than in WT RPE1 controls (Figure 5.15). Although the raw data did not support 
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a statistically significant difference, the trend of the data suggested an 
antagonistic interaction.  
 
Figure 5.15 Validating a synthetic antagonistic interaction between 
RPGRIP1L and TMEM216 
A) Normalised raw data from the combinatorial screen showed an increase 
in cilia incidence in both TMEM216 mutant cell lines treated with 
siRPGRIP1L, but was not significant and did not rescue cilia incidence to 
WT levels. B) A secondary screen with both RPGRIP1L and TMEM216 
mutant cell lines contradicted the primary screen and indicated reduced 
cilia incidence in TMEM216 mutant cell lines treated with siRPGRIP1L. 
However, RPGRIP1L C19+/- showed a significant increase in cilia 
incidence with TMEM216 knock-down. There was also an increase in cilia 
incidence in WT RPE-1 cells treated with siTMEM216. This suggested 
TMEM216 knock-down alone increased cilia incidence and TMEM216 
does not have an antagonistic relationship with RPGRIP1L. Data was 
confirmed to be normally distributed using a D'Agostino & Pearson 
omnibus K2 test. Statistical significance was then calculated using two-
way ANOVAs with Dunnet’s multiple comparisons tests. # indicates the 
control each data set was compared to. * = p<0.05, ** = p<0.01,               
*** = p<0.001. Error bars represent S.D. 
A secondary validation experiment, with reciprocal experiments in the 
RPGRIP1L cell lines, was therefore carried out in order to test the presence of a 
synthetic antagonistic interaction. In contrast to the combinatorial screen data, 
TMEM216 mutant cell lines treated with siRPGRIP1L had a further decrease in 
cilia incidence that did not support an antagonistic interaction. However, 
RPGRIP1L mutant cell lines treated with siTMEM216 did have an increase in 
cilia incidence and were rescued to WT levels (Figure 5.15). In WT cells, 
A) B) 
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TMEM216 knock-down also had a trend of increased cilia incidence. Therefore, 
it is unlikely that the mutations in RPGRIP1L have an antagonistic affect and 
that TMEM216 knock-downs alone can increase cilia incidence in this screen 
(Figure 5.15). This data also highlighted the difference between transient knock-
downs with siRNA and stable CRISPR/Cas9 knock-outs: TMEM216 siRNA 
knock-down in WT cells increased cilia incidence whereas the heterozygote 
TMEM216 mutant cell lines had significantly fewer cells when compared to WT 
RPE1. 
5.5 Further investigation of synthetic synergistic interactions 
between IFT88, RPGRIP1L and TMEM67 
When all the inferred interactions from the combinatorial screen were 
summarised, a triad of partially reciprocal genetic interactions between IFT88, 
RPGRIP1L and TMEM67 was prominent.  
Previous research in C. elegans has also genetically linked the separate 
structural modules of the transition zone containing RPGRIP1L and TMEM67. 
The RPGRIP1L orthologue mks-5, which is part of the NPHP module (Figure 
5.1), was shown to functionally and genetically interact with the MKS module 
which includes TMEM67 (mks-3) (Figure 5.1) (375). Although a genetic 
interaction between RPGRIP1L and TMEM67 was not directly tested, the 
RPGRIP1L (mks-5) mutants failed to localise TMEM67 (mks-3) and all other 
MKS module components to the transition zone, suggesting a functional link 
between the 2 modules (375). To determine if this interaction was conserved in 
mammalian cilia, RPGRIP1L heterozygote mutant RPE-1 cells were assessed 
to identify if any other proteins within the IFT88-RPGRIP1L-TMEM67 triad were 
mis-localised in each of the CRISPR/Cas9-edited cell lines. 
5.5.1 Mislocalisation of TMEM67 in IFT88 and RPGRIP1L 
heterozygous mutants 
To test if the observed genetic interactions also mediated a functional link 
between these modules in the transition zone (NPHP and MKS modules) and 
IFT, the localisation of each protein for each of the heterozygous mutants within 
the IFT88-RPGRIP1L-TMEM67 interaction triad was determined. 
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IFT88 co-localisation with either acetylated -tubulin or -tubulin did not 
significantly change in IFT88, RPGRIP1L or TMEM67 CRISPR/Cas9 edited 
cell-lines when compared to WT RPE-1 controls (data not shown). This 
suggested that there was no functional link between maintaining the integrity of 
the transition zone and the correct localisation of IFT88. Localisation of 
RPGRIP1L also did not show any changes in localisation in the IFT88 
heterozygous mutant cell lines, however RPGRIP1L did show a greater 
increase in co-localisation with the basal body marker γ-tubulin in the TMEM67 
C47+/- cell line (Figure 5.16). This could suggest that in TMEM67 C47+/- cells, 
RPGRIP1L and the transition zone had extended more proximally towards the 
basal body, as the co-localisation with the ciliary axonemal marker acetylated α-
tubulin did not significantly change. 
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Figure 5.16 RPGRIP1L was mis-localised in TMEM67 C47+/- cell line 
A) Image data from each cell line stained for acetylated -tubulin (ciliary 
axonemal marker), RPGRIP1L and -tubulin (basal body marker). 
Examples of cilia for each cell line are highlighted (white boxes and 
marked by white arrowheads). In the TMEM67 C47+/- cell line; RPGRIP1L 
did not co-localise with the basal body to the same extent as other cell 
lines. B) When quantified this shows a significant shift in RPGRIP1L 
distally from the basal body. C) Although there is a slight increase, there is 
no significant change to co-localisation of RPGRIP1L with acetylated -
tubulin. Data was confirmed to be normally distributed using a D'Agostino 
& Pearson omnibus K2 test. Statistical significance was then calculated 
using one-way ANOVAs with Dunnet’s multiple comparisons tests, where 
# indicates the control each data set was compared to. ** = p<0.01 and 
**** = p<0.0001. Error bars represent S.D. N=3 technical replicates with 





























































































- 200 - 
TMEM67 localisation however was significantly affected in all of the cell lines 
tested. Wild-type cells showed TMEM67 in the transition zone with some distal 
localization along the ciliary membrane as previously reported (60, 376). 
However, TMEM67 showed significantly reduced co-localisation with acetylated 
α-tubulin and significantly greater co-localisation with γ-tubulin (Figure 5.17). 
This suggested that TMEM67 was restricted to the transition zone in both 
RPGRIP1L and IFT88 CRISPR/Cas9-edited cell lines. 
 
 
Figure 5.17 TMEM67 mis-localises in RPGRIP1L and IFT88 heterozygote 
mutant cell lines 
A) TMEM67 extends distally from the transition zone the ciliary membrane 
in wild-type cells. In IFT88, RPGRIP1L and TMEM67 heterozygous mutant 
cells; TMEM67 appeared as a distinct spot at the base of the cilium, with 
no distal extension B) There was a statistically significant reduction in co-
localisation of TMEM67 with the axonemal marker acetylated α-tubulin, 
despite an associated decrease in cilia length. C) TMEM67 staining 
showed an associated increased co-localisation with γ-tubulin in 
RPGRIP1L, IFT88 and TMEM67 CRIPSR/Cas9 edited cell lines. Data was 
confirmed to be normally distributed using a D'Agostino & Pearson 
omnibus K2 test. Statistical significance was then calculated using one-
way ANOVAs with Dunnet’s multiple comparisons tests, where # indicates 
the control each data set was compared to. * = p<0.05, *** = p<0.001 and 
**** = p<0.0001. Error bars represent S.D. N=3 technical replicates with 
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It is likely that the changes in localisation of TMEM67 in these cell lines was 
driven through different pathways because different ciliary modules (the IFT and 
the NPHP transition zone modules) were affected. It was also interesting to note 
that in the TMEM67 C47+/- cell line, TMEM67 localisation was significantly 
altered. There was reduced distal localization along the ciliary membrane and 
an increase in co-localisation with the basal body, indicating a shift in the 
position of the transition zone. The reduced co-localisation with the ciliary 
axoneme could be due to reduced protein levels in this cell line (Figure 5.4) or 
that overall the cilium is longer, affecting the quantified ratio of TMEM67 
localisation. 
5.5.2 Biochemical interactions between IFT88, TMEM67 and 
RPGRIP1L 
Co-immunoprecipitations were used to test if the synthetic genetic interactions 
were mediated by biochemical associations. IFT88, TMEM67 and RPGRIP1lL 
fused to epitope or protein tags in expression constructs were made using 
Gateway cloning technology (described in Chapter 2, Section 2.2.6.2). The 
constructs were validated by western blot and Sanger sequencing to 
demonstrate expression of each protein with the correct tag. Co-
immunoprecipitation experiments were initially inconclusive or uninterpretable 
due to issues with control antibodies, agarose beads or antibody specificity. 
GFP-TRAP was then used (described in Chapter 2, Section 2.2.10) as an 
alternative pull-down reagent to demonstrate a potential biochemical 
association between IFT88 and RPGRIP1L. IFT88-eYFP fusion protein 
interacted with 3xFLAG-RPGRIP1L (Figure 5.18). However, a GFP-RPGRIP1L 
construct could not be made and the reciprocal pull-down was not tested. Pull-
downs indicated that C-terminal tagged TMEM67-TAP was aberrantly small, 
suggesting that TMEM67 was cleaved from both of its C-terminal fusion tags. 
However, TMEM67-GFP pulled down 3XFLAG-RPGRIP1L and, separately, 
IFT88-eYFP pulled down TMEM67-TAP. Taken together these data suggest 
that there is a potential biochemical interaction between RPGRIP1L, TMEM67 
and IFT88, but this requires further investigation because the aberrant size of 
TMEM67 fusion proteins put into question the reliability of the data. It is 
possible, for example, that any tag cleavage from TMEM67 only occurred when 
- 202 - 
WCE or GFP-TRAP samples were prepared for SDS-PAGE. Alternatively, a 
small amount of full-length tagged TMEM67 may have been present, below the 
threshold of detection for the antibodies used in blotting, but sufficient to permit 
the pull down of interacting species. 
 
Figure 5.18 IFT88, RPGRIP1L and TMEM67 may biochemically interact 
Co-immunoprecipitation of GFP or eYFP tagged fusion proteins from 
whole cell extract (WCE) of HEK293T cells expressing combinations of the 
above constructs. A potential biochemical interaction was seen between 
IFT88 and RPGRIP1L because IFT88-eYFP pulled-down 3XFLAG-
RPGRIP1L, although the reciprocal pull down could not be tested. 
TMEM67 fusion proteins were aberrantly sized when analysed by western 
blot, migrating in the gel at the approximate molecular weights of the tags 
only (GFP 27kDa, TAP 20kDa). 
 
5.6 Genetic Interactions of Cilia Size 
The second phenotype assessed in the combinatorial screen was cilia size. 
This was measured indirectly by quantification of the spot size of ARL13B 
staining. It was suggested that spot size would be a proxy measurement of 
cilium length as RPE-1 cilia are known to be both partially intracytoplasmic and 
to lie flat in close association with the apical cell surface (33). Cilia could 
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therefore be imaged within one imaging plane and lengths measured from a 
single image plane or maximum intensity projection (37). The aim of this work 
was to identify interactions that were involved in controlling cilia length, but due 
to high experimental variation fewer genetic interaction were inferred from this 
data. This was likely due to the parameters of the recognition protocol 
(Appendix E.3) or an increase in intrinsic variation in cilia size under “double 
perturbation” conditions. The screen provided evidence for 3 synergistic 
interactions, 7 additive interactions and 2 antagonistic interactions.  
5.6.1 Antagonistic Interactions 
Across the combinatorial screen data for cilia size, 2 antagonistic interactions 
were inferred. The strongest of all these was between RPGRIP1L and 
TMEM107 (Figure 5.19). RPGRIP1L C49if.del/- had cilia spots with an average 
zsize of 2.70 when treated with siTMEM107 and zsize of −3.92. RPGRIP1L 
C19+/- cells treated with siTMEM107 had zsize of 1.47, so although not 
significantly different to RPGRIP1L C19+/- treated with siScr control, the zsize 
was −2.69 showing it was significantly different to WT RPE-1 cells treated with 
siTMEM107. WT cells treated with siTMEM107 had an average zsize of −1.22, a 
reduction in cilia size. Therefore the positive z-scores seen in CRISPR/Cas9-
edited RPGRIP1L cell lines suggested an antagonistic interaction between 
RPGRIP1L and TMEM107.  
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Figure 5.19 A synthetic antagonistic genetic interaction between 
RPGRIP1L and TMEM107 
RPGRIP1L heterozygous cell lines showed a significant increase in the 
average robust z-score for cilia spot size (zsize) when treated with 
siTMEM107 (zsize for RPGRIP1L C19+/- = 1.47, zsize RPGRIP1L C49if.del/- = 
2.70). In contrast, wild-type RPE-1 cells showed a decrease in cilia spot 
size when treated with siTMEM107 (zsize = -1.22). This suggested a 
synthetic antagonistic interaction between RPGRIP1L and TMEM107. This 
interaction was seen for both RPGRIP1L CRISPR/Cas9-edited cell lines 
and no other genetic interactions were inferred that affected cilia size in 
these cell lines. Significance calculated using z scores, representing the 
number of standard deviations between each experimental value and the 
comparison value (described in Section 2.2.17.3). * = 1.96<z<-1.96, ** = 
2.58<z<-2.58. Error bars represent S.E.M 
 
The raw data from the combinatorial screen was then assessed to determine if 
the “double perturbation” conditions showed a complete rescue in cilia size 
(Figure 5.20). There was a complete rescue of cilia size in RPGRIP1L C19+/- and 
partial rescue in RPGRIP1L C49if.del/-. This interaction was therefore chosen to be 
taken forward for further validation by confocal microscopy. 
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Figure 5.20 Raw data show siTMEM107 treatment rescues cilia size in 
RPGRIP1L CRISPR/Cas9-edited-cell lines. 
Normalised data from the screen indicated that wild-type RPE-1 cells 
showed no significant change in average cilia size with siTMEM107 
treatment. The loss of cilia membrane area seen in RPGRIP1L C19+/- was 
rescued by siTMEM107 treatment. The same phenotype in RPGRIP1L 
C49if.del/- was not completely rescued by siTMEM107 treatment, but a 
significant increase in average cilia membrane area was seen. Data was 
confirmed to be normally distributed using a D'Agostino & Pearson 
omnibus K2 test. Statistical significance was then calculated using a one-
way ANOVA with Dunnet’s multiple comparisons test. * = p<0.05, ** = 
p<0.01. Error bars represent S.D 
 
5.7 Further investigation of a synthetic antagonistic interaction 
between RPGRIP1L and TMEM107 
The interaction between RPGRIP1L and TMEM107 was of interest because it 
worked antagonistically, could potentially rescue cilia size and could have a  
direct downstream effect on ciliary function. This was also the only interaction in 
which both CRISPR/Cas9-edited cell lines showed corroborating results 
supporting an antagonistic interaction. All other interactions for cilia size were 
inferred from a single heterozygous cell line for each mutant gene.  
As the screen used high content imaging with a x40 air objective, a lack of 
resolution prevented accurate measurement of cilia size. Therefore the 
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interaction was tested again and imaged using confocal microscopy. As seen in 
the combinatorial screen TMEM107 knock-down in RPGRIP1L heterozygous 
mutant cells did not significantly change cilia incidence (Figure 5.21). However, 
this imaging did not confirm an effect on cilia length, suggesting that the original 
result was a false positive finding and that high content imaging of cilia spot size 
is a poor proxy measurement for ciliary length. In this confocal image data 
TMEM107 knock-down did not rescue ciliary length and, in fact, for RPGRIP1L 
C19+/- cells average ciliary length decreased from 2.9m to 2.6m. 
Further qualitative inspection of the image data showed a ball-like phenotype in 
the RPGRIP1L heterozygote cells lines with TMEM107 knock-down. Total 
ciliary volume was then quantified, which was consistent with the primary 
combinatorial screen data by showing a significant increase. It is highly likely 
that this increased ciliary volume and bulbous ball-like phenotype was detected 
by high content imaging as an increase in ciliary spot size.  
To ensure that the bulbous phenotype was not a structural defect of the ciliary 
axoneme, the total volume of acetylated α-tubulin staining was quantified (data 
not shown) which showed no significant changes. Qualitatively, staining of 
acetylated α-tubulin also appeared as expected. This new bulbous phenotype 
therefore could suggest an IFT-A defect as seen in Chlamydomonas (377) and 
mice (70). Alternatively, it could reflect total disruption of the ciliary gate, 
allowing diffusion of cytosolic proteins into the cilium causing the ciliary 
membrane to appear bulbous.  




Figure 5.21 Confocal microscopy reveals a cilia volume increase in 
RPGRIP1L heterozygous mutant cell-lines with TMEM107 knock-
down 
A) Cilia incidence and B) cilia length were not significantly affected by 
TMEM107 knock-down in wild-type (WT) or RPGRIP1L mutant cell lines. 
C) Qualitative assessment of images showed a bulbous phenotype in 
RPGRIP1L homozygous mutant cell lines. D) The volume of RPGRIP1L 
C19+/- cilia was rescued to WT levels following TMEM107 knock-down. . 
All data was confirmed to be normally distributed using a D'Agostino & 
Pearson omnibus K2 test. Statistical significance was then calculated 
using one-way ANOVAs with Dunnet’s multiple comparisons tests,           
** = p<0.01 and error bars represent S.D. **** = p<0.0001. Error bars 
represent S.D.  
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5.8 Discussion 
The 4 main aims of this part of the project were met; CRISPR/Cas9 mutant cells 
were validated to have a loss of protein but still presented with a quantifiable 
ciliary phenotype, a combinatorial screen was designed, tested and completed 
and was shown to be reproducible and able to identify novel genetic 
interactions. Since the work presented here was completed, it has also been 
shown that IFT88 knock-out RPE-1 cells show complete loss of cilia (378). 
Therefore showing that when assessing ciliogenesis, any genetic interactions 
with other genes would not have been quantifiable or detectable in complete 
knock-out cell lines. A triad of interactions for ciliary incidence were further 
investigated to determine the mechanistic basis for any potential genetic 
interactions inferred from the primary combinatorial screen data, and a potential 
biochemical interaction was identified. A second interaction was also followed 
up for ciliary size which identified a novel phenotype.  
5.8.1 CRISPR/Cas9-edited Cell lines 
Although significant when compared to cultured wild-type controls, the detected 
phenotypes in the CRISPR/Cas9-edited cell lines must be assumed to be sub-
clinical, as heterozygous parents of ciliopathy patients or unaffected carriers 
mostly do not manifest any discernible clinical phenotypes. However, there are 
some reports of heterozygous manifestations of Meckel syndrome presenting 
with isolated features such as polydactyly and this may be reflected in the more 
severe cellular phenotypes seen in the RPGRIP1L and TMEM216 
CRISPR/Cas9 edited cell lines (Figure 5.5). Mutations in both of these genes 
cause Meckel Syndrome. 
The phenotypes may also be tissue specific, or comprise endophenotypes that 
manifest under artificial cell culture conditions. The exception to this are 
RPGRIP1L C49if.del/- and TMEM216 C89if.del/-, which are biallelic mutations and 
could therefore manifest clinically relevant phenotypes.  
5.8.1.1 ARL13B edited cell lines 
The two heterozygous mutants for ARL13B showed approximately 50% of the 
protein seen in WT cells, consistent with the heterozygous null alleles both lines 
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carried. However, the phenotypes varied slightly: the ARL13B C8+/- polyclonal 
cell line showed a significant decrease in cilia incidence while in C71+/- 
incidence was highly variable and was therefore not considered to be 
significant. Conversely, both cell lines did show a significant decrease in cilia 
size when measured by high content imaging. This could be due to a technical 
measurement artefact, as discussed in Section 5.7 when validating the genetic 
interaction between RPGRIP1L and TMEM107. The overall reduced ARL13B 
protein levels in these cell lines could reduce apparent spot size either by 
decreasing total staining, or mis-localising along the ciliary membrane.  
Arl13b -/- mice are embryonic lethal but conditional adult knock-outs showed 
destabilised axonemes and transition zones in the specialised photoreceptor 
cilium (379). This highlights the severe phenotypes associated with ARL13B 
mutations. As the phenotypes for the ARL13B mutant cells used in the project 
were comparatively mild, it seems likely that the residual protein in the these 
cell lines was sufficient for adequate ciliogenesis and cilia function. 
5.8.1.2 CEP290 mutant cell line 
The only CEP290 mutant cell line successfully created and investigated was the 
polyclonal C53+/- cell line. This was shown to have approximately 20% less 
protein across the cell population and significantly shorter cilia when compared 
to WT cells (Figure 5.7). This is contrary to the knock-out mouse model, which 
showed reduced cilia numbers and highly elongated cilia (380). Therefore, as 
there was no significant change to cilia incidence, this could suggest that the 
polyclonal population is made up of 2 individual heterozygote cell linages. 
It may be of interest to separate this cell line into 2 monoclonal cell lines, to 
allow transition zone integrity and ciliary function to be more accurately 
investigated. It is possible that the cell line is 2 separate heterozygote lines and 
the WT alleles in both cell types are sufficient to maintain a normal ciliary 
phenotype (Figure 5.5). The CEP290 orthologue in Chlamydomonas shows 
evidence of being a key structural component of the Y-shaped linkers in the 
transition zone (381) and likely acts as a scaffold for other transition zone 
proteins to correctly localise. Therefore, monoclonal mutant cells may present 
genetic interactions with the ciliary siRNA panel used in the combinatorial 
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screen and help to decipher the hierarchy of CEP290 in transition zone 
organisation in this cell line.  
5.8.1.3 IFT88 mutant cell lines 
IFT88 is part of the IFT-B module (382), which is responsible for anterograde 
trafficking from the base to the tip of the cilium. Commonly, IFT-B mutations are 
associated with complete loss of cilia, as without anterograde transport the 
cilium is unable to recruit new protein and extend its axoneme. 
The heterozygous IFT88 mutants both presented with significantly shorter cilia 
than WT controls (Figure 5.5). However, it was interesting to note that IFT88 
C31+/if.indel had a more severe phenotype than C29+/-, as it also presented with a 
significant reduction in cilia incidence. This could indicate that the in-frame 
deletion of 2 amino acids in IFT88 was a dominant negative mutation.  
IFT88 C31+/if.indel cell line had a loss of total IFT88 protein despite no change 
being predicted from genotyping and pathogenicity analysis (Table 5.3). The 2 
amino acid change NP_001340497.1:p.(Leu125_Ser126delinsCysLys) occurs 
in an undefined domain of the protein but is close to the predicted start of a 
TPR-like helical domain (383), which therefore may affect domain or protein 
stability. 
5.8.1.4 RPGRIP1L mutant cell lines 
Both RPGRIP1L heterozygotes had a significant decrease in cilia incidence and 
a decrease in cilia length compared to WT cells (Figure 5.5), reflecting a similar 
phenotype seen in embryonic fibroblasts taken from the Rpgrip1l-/- mouse (364). 
However, the Rpgrip1l -/- mouse was also independently been shown to have 
elongated cilia compared to WT embryos, in embryonic fibroblasts and across 
other cell types (384). The data presented here supports the former study by 
suggesting that RPGRIP1L has a positive effect on cilia length. 
Regardless of observations from mouse phenotypes, RPGRIP1L C49if.del/- was 
predicted to have a more severe phenotype due to the biallelic mutations and 
predicted pathogenicity of the p.24_33del mutation. As this cell line had both 
fewer and shorter cilia than C19+/- it provides evidence that this uncharacterized 
region of RPGRIP1L has importance in the correct function of this protein. Also 
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of note was that genetic interactions were only inferred in the RPGRIP1L 
C49if.del/- cell line, possibly highlighting the important role of residual RPGRIP1L 
in the C19+/- cell line in organising and maintaining a functional transition zone; 
this protein is considered to act near the top of the hierarchical organisation of 
the transition zone. 
5.8.1.5 TMEM67 mutant cell line 
The TMEM67 heterozygote cell line had greater cilia incidence and longer cilia 
than WT cells (Figure 5.5). Tmem67-/- mice have been shown to have 
significantly fewer and shorter cilia in lung tissue (365), but longer cilia in the 
distal nephron of the kidney when compared to WT RPE-1 and heterozygous 
controls (202). Thus different cell types will likely present varying ciliary 
phenotypes. Accordingly, the increased cilia incidence and length phenotype 
seen in TMEM67 C47+/- could be a retinal-specific phenotype, which could be 
tested for in the current mouse models as retinal phenotypes have not been 
previously studied. 
However, the mutation in the TMEM67 C47+/- cell line could not be fully 
characterised, and it may therefore not be a true heterozygous monoclonal cell 
line. The phenotype quantified (Figure 5.5) may simply be due to the clonal 
selection of the cell line and not due to a mutation in TMEM67. This is a 
possibility following work independent of this thesis that generated a second 
TMEM67 heterozygote cell line in RPE-1. This new heterozygote cell line 
showed the opposite phenotype to the one presented in this chapter, with 
shorter and fewer cilia than WT controls. (Personal communication with Dr. 
Sunayna Best, University of Leeds).  
5.8.1.6 TMEM216 mutant cell lines 
The TMEM216 heterozygous cell lines had the greatest decrease in cilia 
incidence compared to WT cells of all the cell lines phenotyped in this project 
(Figure 5.5). TMEM216 is a Joubert syndrome gene and the encoded 
transmembrane protein is thought to be located in the peripheral MKS module 
of the transition zone (385) (Figure 5.1). 
It was surprising to see that heterozygotes of other ciliopathy genes had 
reasonably mild but significant phenotypes whereas the TMEM216 C42+/- cell 
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line lost more than 60% of its cilia. Furthermore, human carriers of TMEM216 
mutations do not present with any clinically relevant ciliopathy phenotypes. This 
again could highlight the limitations of cell models and how much they may vary 
from actual disease states. 
5.8.2 The combinatorial screen 
Although the primary screen presented with high variability, it was also shown to 
be reproducible with a significant correlation between biological replicates 
(Figure 5.9). The screen has also been independently validated by the fact that 
many of the genetic interactions inferred have been identified and published as 
part of other work since it was completed. This supports the value of this 
experimental set up and its ability to accurately identify genetic interactions.  
For example, TMEM107 was found to biochemically interact with other MKS 
module proteins in the transition zone (TMEM237 and TMEM216) (81). This 
biochemical interaction was reflected in the combinatorial screen data, as the 
TMEM216 mutant cell lines showed an additive interaction with TMEM107. 
As a preliminary reverse genetics screening technique this could be very useful 
for finding primary hits or interactions aimed at follow up work by screening with 
a larger panel of siRNAs. Initially, the main limiting factor for this technique was 
the generation and validation of the CRISPR/Cas9-edited cell panel. With the 
huge advances in genome editing efficiency with CRISPR (386-388) alongside 
new technological advances, targeting capacity and improved technologies for 
specific genomic changes, repeating the screen set-up would now be quicker. A 
larger panel of genes could therefore be targeted with CRISPR/Cas9. A panel 
modelling patient-specific alleles, for example, could be adopted and used in 
this technique. This would test for genetic interactions that directly affect the 
severity of patient phenotypes, thus giving a greater understanding of ciliopathy 
phenotype variations. However, the non-patient mutations used in this thesis 
are still relevant to understanding underlying ciliary biology.  
It could also be up-scaled to test for more reciprocal interactions and across an 
increased panel of CRISPR/Cas9-edited genes, making this a useful future 
technique towards understanding the many genetic and functional interactions 
seen across ciliary genes.  
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5.8.3 Additive vs Synergistic interactions 
Additive interactions from the screen could suggest that these genes, or their 
resultant proteins are working in the same functional component, protein 
complex or functional pathway; thus the difference between a single genetic 
perturbation and a double is small (eg TMEM107 and TMEM216, Figure 5.14). 
A synergistic interaction would suggest that these genes or proteins are from 
distinct modules, components or pathways that are interacting and contributing 
to ciliogenesis individually. Synergistic interactions discussed previously 
(Sections 6.5.2 and 6.5.3) have helped researchers to define different functional 
modules of the transition zone and determine their hierarchy in ciliogenesis. The 
main synergistic interactions identified in in this screen were between IFT88 
(IFTB, anterograde intraflagellar transport), RPGRIP1L (NPHP module of the 
transition zone) and TMEM67 (MKS module of the transition zone). 
5.8.4 Genetic Redundancy 
Genetic redundancy would have been indicated by a significant change in 
phenotype observed after the genetic perturbation of 2 genes, such as a 
CRISPR/Cas9 bi-allelic null treated with siRNA, but no significant change in 
phenotype when each of the 2 genes were knocked out individually. There were 
no gene combinations that displayed genetic redundancy. It is important to 
consider that true genetic redundancy cannot be assumed from the 
combinatorial screen data because there was not a complete knock-out in any 
of the CRISPR/Cas9 edited cell lines and siRNAs do not provide complete 
experimental knock-out as there are usually residual protein levels. 
5.8.5 Limitations 
5.8.5.1 Validation of Interactions 
Many of the interactions presented in this chapter require further validation, 
particularly for interactions with either TMEM67 or CEP290 because these 
genes were represented by only one validated mutant cell line. The cell lines 
available for this project were greatly limited by the quality of the technology at 
the time they were made. Since this work CRISPR/Cas9 technology has greatly 
improved in both specificity and efficiency. These cell lines were also all 
generated from the same gRNA for each gene, targeting the same exon. A 
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more robust approach would have used cell lines that were mutated with 
different gRNAs targeting different exons. This would then further support the  
hypothesis that the genetic interactions are specific to the gene targeted, and 
not an unidentified off-target effect of using CRISPR/Cas9. 
5.8.5.2 Scale of the screen 
The developed combinatorial screen technique would benefit from being up-
scaled to reduce both the technical issues in plating each cell line and the 
overall variability that was seen throughout screening. Due to the technical 
challenges in setting up the screen, it only covers a very small panel of potential 
genetic interactions, reducing the potential number of validated interactions and 
overall impact. Despite this, the high-throughput set up was shown to be 
reasonably robust and independently validated. 
5.8.5.3 Technical Limitations 
Using ARL13B as a ciliary marker could have affected the detection of 
interactions across the screen. It is well documented that mutations in transition 
zone genes cause mis-localisation of ciliary membrane proteins (389), including 
ARL13B (390). As the siRNA panel mostly focused on genes in the transition 
zone, it is possible this led to variable staining of ARL13B and thus increased 
variability across the technical and biological replicates of the screen. This could 
be mitigated by using a ciliary axonemal marker such as acetylated alpha-
tubulin, which was initially not selected as the staining was less suited for high 
content imaging than ARL13B. 
5.8.6 Potential Future Work 
Some interactions were taken forward for further validation and presented in 
this thesis but time constraints limited validation or further investigation of 
several of the potential genetic interactions. Reciprocal testing for each of the 
interacting pairs should be taken forward for further validation. It is also 
important to retest and validate the data generated with the TMEM67 C47+/- cell 
line. A second mutant clone could be used to verify the interactions inferred 
from the combinatorial screen and also be used for further validation work or 
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other investigations as the mutation in TMEM67 C47+/- was unable to be fully 
characterised. 
Ciliary function and signalling defects should be tested for in the CRISPR/Cas9-
edited cell lines. Initial testing in a Gli reporter assay using a luciferase reporter 
construct (data not shown) was highly variable and inconclusive. This could be 
re-tested using immunofluorescence microscopy to assess the translocation of 
Smoothened into the cilium upon Shh stimulation. Other ciliary function tests 
could include measurement of changes in non-canonical Wnt signalling in the 
IFT88 and RPGRIP1L mutant cell lines as an assessment of functional 
consequences from TMEM67 mis-localisation.  
As mentioned previously, the combinatorial screen may be less variable if a 
different ciliary marker was used, for example acetylated α-tubulin. This would 
hopefully validate the data presented here and highlight any false negative 
results due to variable ARL13B localisation. Furthermore, scaling up of the 
combinatorial screen could include internal repeats and reciprocal testing for 
each of the potential interacting pairs and should include ARL13B siRNA to see 
if previously published interactions can be validated using this technique. 
A test for biochemical interactions between RPGRIP1L and TMEM107 should 
be carried out to see if the genetic interaction reflects a biochemical one. This 
was initially attempted but TMEM107 constructs failed to express.  
From the follow-up investigations presented in this thesis there were also 
several new questions and lines of study. Follow up immunofluorescence 
investigations, signalling assays and possible fluorescence recovery after 
photo-bleaching (FRAP) to look at dynamics for the transition zone or 
membrane proteins, would give further insight into transition zone organisation 
and function in relation to the genetic interactions presented in this chapter.  
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Chapter 6 
Final Discussion 
6.1 Reverse genetic screening 
Although forward genetics and identification of patient mutations remains at the 
forefront of basic and clinical research into ciliopathies, reverse genetics is an 
increasingly important strategy for effective molecular research into ciliary 
biology and for biomedical research. 
As a growing number of studies identify novel roles for cilia across cellular 
mechanisms and disease pathology, the interest and impact of ciliary research 
has increased. This necessitates an unbiased approach to collate data at the 
genomic level, for all genes in a genome, in order to define their contribution to 
ciliary phenotypes. This strategy has the potential benefit in allowing surprising 
and novel functions to be identified. It may also provide further evidence to 
support previously identified pathways or ciliary gene functions. Further defining 
each gene’s role in ciliary biology would not only increase our understanding, 
but also allow us to more precisely manipulate cellular systems and to generate 
more focused hypotheses to test in further research. 
Several whole-genome siRNA screens have now been published, for at least 
two different cell models, with a range of protocols for imaging and 
quantification of different ciliary phenotypes (96, 266, 391). These data sets 
have the potential to be repurposed, as in Chapter 3 and 4 of this thesis, and 
lead to significant or novel screen hits that can provide unexpected insights into 
ciliary biology. The value of the original whole genome siRNA screen data used 
throughout this thesis was the availability of raw image data and the 
quantification of a full range of phenotypes, both ciliary and cellular. This made 
it suitable for reanalysis from the start of the project, allowing for quick 
identification of hits and increasing the time available for downstream 
investigation work to be carried out. This methodology generated two 
independent and coherent pieces of work that provide insights into molecular 
mechanisms that would otherwise have been impossible within the time frame 
of this thesis. 
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A correlated, freely available database of all previous ciliary-related siRNA 
screen datasets would be a highly valuable resource for researchers, including 
screens that have been published to assess cellular phenotypes linked to ciliary 
biology. Data from whole genome reverse genetic screens, for example 
assessing DNA damage responses (392, 393) or ciliary signalling (264), could 
all be correlated with structural ciliary phenotype screens such as the one used 
in this thesis. All published datasets have already been optimised and validated 
extensively for high-throughput screening, providing both precise and accurate 
data points that will be invaluable for future research.  
The database would have to provide evidence of the quality of image staining 
and correlate data based on each cell line being screened. This would provide 
stronger biological evidence of true positive results if data is replicated 
independently. Images could also be available so that the raw image data could 
be downloaded and reanalysed using different scripts so that 
immunofluorescent staining could be reused to assess similar but different 
phenotypes from the data.  
Other microscopy-based phenogenomic data repositories include the “Image 
Data Repository” https://idr-demo.openmicroscopy.org/, or “Mineotaur” 
http://www.mineotaur.org/. These are interactive visual analytics tools and 
repositories for imaging and microscopy datasets but do not have the 
advantage of an unbiased whole genome siRNA screen.  
6.2 ROCK2 is a key regulator of ciliogenesis and not ROCK1 
6.2.1 The different roles of ROCK1 and ROCK2 
In Chapter 3, it was confirmed that ROCK1 does not compensate for the loss of 
ROCK2 kinase activity (Figure 3.16) and that siRNA knock-downs of ROCK1 do 
not phenocopy ROCK2 knock-downs (Figure 3.14). Due to their extensive 
homology, these 2 genes were initially thought to be functionally redundant, but 
over the last 15 years increasing evidence has shown that they play distinct 
roles in regulating many cellular mechanisms.  
The ROCKs have different expression profiles across tissues and some 
differences in sub cellular localisations (reviewed in (309)), however both have 
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a cytosolic localisation and a centrosomal association (394, 395). They have 
also both been shown to localise to the plasma membrane; ROCK1 in mouse 
intestinal epithelial cells (396) where ROCK2 was undetectable by 
immunostaining; and ROCK2 in HeLa cells (397). The published localisations of 
the ROCKs were not confirmed in either RPE-1 or mIMCD3 cells for this thesis. 
Overexpression constructs used in Figure 3.11 had non-specific localisation of 
GFP signal, A better test of localisation would have been to use published 
polyclonal antibodies against both ROCK2 and ROCK1, however the antibodies 
used for western blot were tested in immunofluorescence experiments and 
shown to not be suitable (data not shown).  
Based on previous studies describing localisation (398); logic would suggest 
ROCK1 would have a more prominent role in ciliogenesis because of its 
stronger localisation to the plasma membrane and involvement in vesicle 
trafficking. However, this notion was not supported by the work presented in this 
chapter. 
Differences in the C-terminal regions of ROCK1 and ROCK2 may explain their 
different cellular localisations and functions. The plekstrin-like and C1 domains 
bind to membranes. ROCK2 was found to have high affinity for the lipids 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and phosphatidylinositol (4,5)-
bisphosphate (PIP2). ROCK2 activity was sensitive to the levels of these lipids 
in vitro. ROCK2 kinase activity increased in the presence of overexpressed 
phosphoinositide-3 kinase, which would increase the cell’s pool of PIP2 and 
PIP3. However, ROCK1 was shown to not strongly bind to either lipid type 
(399). PIP2 is known to localise to the base of cilia in C. elegans (400) and has 
been shown to translocate through the ciliary membrane upon Inositol 
Polyphosphate-5-Phosphatase E (INPP5E) inactivation in mouse neural stem 
cells (401). If localisation of PIP2 is similar in human cells, this suggests that 
ROCK2 could have a higher affinity for the base of the cilium, allowing for 
localised regulation and stabilisation of actin remodelling that would prevent 
excessive extension of the ciliary axoneme. 
Furthermore, there are several differences that have been identified in the 
regulation and activation of the ROCKs. ROCK2 activity, unlike ROCK1, is 
increased by phosphorylation of Ther967, Ser1099, Ser1133 and Ser1374 by 
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Plk1 (402). In contrast, work on focal adhesion dynamics has shown that 
phosphorylation of Tyr722 decreases ROCK2’s affinity for RhoA, which could 
be used as a fine tuning regulatory mechanism of ROCK2 activation (403). 
These phosphorylation events have not been identified in ROCK1. 
Although both isoforms of ROCK are able to bind RhoA, only ROCK1 is able to 
bind RhoE. Binding of RhoE inhibits ROCK1 activity, but RhoE is also a 
phosphorylation target of ROCK1. When RhoE is phosphorylated by ROCK1 it 
is stabilised, increasing its binding to ROCK1, thus suggesting the existence of 
a ROCK1-specific negative feedback loop (404). The differences in regulation 
allow independent activation of ROCKs and, potentially, localised fine tuning of 
ROCK2 activation to negatively regulate ciliogenesis.  
It should also be noted that ROCK1 and ROCK2 differentially phosphorylate the 
same targets. In rat embryonic fibroblasts it was shown that when ROCK1 was 
knocked down by siRNA, MLC phosphorylation at Ser19 was reduced, but this 
was not noted in ROCK2 knock-downs (399). This can be seen in Figure 3.17A 
where siRNA knock-down of Rock1 in mIMCD3 cells reduced both mono 
(Ser19) and bi-phosphorylated (Thr18/Ser19) MLC, whereas Rock2 knock-
downs only significantly reduced bi-phosphorylated MLC structure. These 
findings provide evidence of distinct roles for ROCK1 and ROCK2, supporting 
the data presented in this thesis that the regulation of ciliogenesis is primarily 
regulated by ROCK2. 
An independent secondary screen of actin remodelling factors in RPE-1 cells 
identified LIMK2 as a negative ciliogenesis regulator (92). ROCK1 and ROCK2 
were also included in this screen, which demonstrated that ROCK1 knock-down 
caused a greater increase in cilia incidence than ROCK2 knock-down, although 
both had a smaller effect on ciliogenesis than knock-down of LIMK2 and 
TESK1. Myosin light chain kinase (MLCK) was also tested in this small screen 
and its knock-down marginally increased cilia incidence. However, this was not 
investigated further as the study focused on F-actin dynamics and phenotypes 
other than cilia incidence, such as cilia morphology or length, were not analysed 
(98). 
RhoA-GTP, is the activator of ROCK2. RhoA knock-down in the primary whole 
genome screen gave an average zcilia of -3.28 and also significantly reduced cell 
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number (average zcell = -5.97). This is likely due to the global knock-down of 
RhoA, which is essential across many cellular pathways, greatly reducing cell 
viability causing significant cell and cilia loss. It therefore did not phenocopy 
Rock2 knock-down. 
6.2.2 Acto-myosin contractions and actin dynamics contribute to 
ciliogenesis 
Acto-myosin contraction is controlled by the phosphorylation of MLC which 
causes the myosin complex to adopt an active confirmation. MLC is directly 
phosphorylated by ROCK and indirectly regulated by ROCK phosphorylation of 
MLCK, suggesting an important role for acto-myosin contraction during 
ciliogenesis. It should be noted that previous studies have only investigated 
different myosin heavy chains (100, 101). Activation of myosin occurs on the 
light chains, thus upstream regulation of molecular function of these heavy 
chains would still involve ROCK phosphorylation, providing further evidence in 
support of ROCK2-mediated actin remodelling regulating ciliogenesis.  
Evidence presented in this chapter adds to previous publications highlighting 
the essential role of actin regulation in ciliogenesis. The pathway is summarised 
in Figure 6.1. The data presented in Figure 3.21 and  Figure 3.22 provide 
evidence for an important role in acto-myosin contraction in the negative 
regulation of ciliogenesis. Thus, upon inhibition of contraction or constitutive 
inactivation of MLC, ciliogenesis was significantly increased. Over-expression of 
GFP-tagged constitutively-inactive MLC(TASA) could substitute for endogenous 
MLC and thus the cellular population of MLC was inactive and prevented from 
ROCK2 phosphorylation, functionally phenocopying ROCK2 knock-down. This 
data indicated that inhibiting acto-myosin contraction caused an increase in cilia 
incidence compared to the GFP-only control. Acto-myosin contraction has 
previously been implicated in ciliogenesis. Blebbistatin rescued cilia incidence in 
RPE-1 cells following myosin heavy chain 10 (Myh10) siRNA knock-down (101), 
supporting the hypothesis that acto-myosin contraction negatively regulates 
ciliogenesis and could rescue a loss-of-cilia phenotype.  
Contradictory results have shown that blebbistatin treatment reduced 
microtubule stability and bundles in RPE-1 cells grown on micro-patterns, which 
were used to improve spatial resolution in z as it forced cells grow with a 
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rounded shape. It was reported that microtubule bundles were the driving force 
in centrosome migration from the basal membrane and that their formation was 
inhibited with blebbistatin. However, the overall effect of blebbistation on was 
not determined in this study (95). 
 
Figure 6.1 ROCK2 regulation of ciliogenesis through actin remodelling 
and acto-myosin contraction. 
RhoA is activated by GTP which can then bind to ROCK2. This causes a 
conformational change that activates ROCK2 so it can phosphorylate 
downstream targets such as LIMK2 and myosin light chain (MLC). 
Phosphorylated LIMK2 stabilises F-actin through cofilin and 
phosphorylated MLC allows contractile acto-myosin fibres to form which 
repress ciliogenesis. If ROCK2 is inhibited by KD025 or siRNA knock-
down, LIMK2 and MLC are not activated. This leads to the destabilisation 
of F-actin and deactivation of MLC which reduces acto-myosin contraction. 
These cytoskeletal changes promote ciliogenesis. 
Throughout the experiments presented in Chapter 3, blebbistatin and 
cytochalasin D treatments gave slightly different phenotypes. Blebbistatin only 
significantly changed ciliary incidence and not ciliary length after 48hrs, but did 
increase cilia length at higher concentrations after 2hrs. The individual 
phenotypes noted with inhibitor treatments raises the question of the relative 
contributions of actin remodelling and acto-myosin contractility to each process 
in ciliogenesis; when does F-actin remodelling occur during ciliogenesis? And is 
acto-myosin contraction required for both centrosome migration and axoneme 
elongation? 
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It could be hypothesised that the 2 stages of ciliogenesis have different 
contributions from the localised regulation of actin dynamics that facilitate each 
process. The first process inhibits acto-myosin contraction in parallel with 
dynamic remodelling of actin, which allows centrosome migration but without 
cellular contraction restricting the movement of the centrosome or preventing 
centriole docking due to a lack in membrane flexibility. Once docked, F-actin 
stability allows for efficient trafficking of ciliary vesicles needed to continue 
elongation of the cilium and hence also contribute to the increase in ciliary 
length that was observed following cytochalasin D treatment. These results 
corroborate previous studies that also show specific accumulation of ciliary 
vesicles with cytochalasin D treatment (98) and inhibition of centriole migration 
when expression of myosin heavy chains are disrupted through siRNA knock-
down (100). This could be tested for in live cell imaging and visualisation of both 
actin remodelling and centrosome migration. If stress fibre formation is reduced 
around the centrosome prior and during its migration to the apical membrane 
this could be evidence for the localised remodelling of actin to reduce acto-
myosin contraction. Visualisation of ciliary vesicles (for example with a 
fluorescently tagged Rab8 marker) in a similar experiment could then highlight 
dynamic actin remodelling and vesicle trafficking after docking of the basal 
body. A super resolution microscope with live cell imaging set up would be 
required for accurate and fast imaging of these cellular processes. 
Despite the current evidence presented, it is counter intuitive to think that 
vesicle trafficking increases when actin is disrupted, because it relies on 
correctly oriented F-actin filaments for the motor proteins to transport the 
vesicles along. It is possible that during normal ciliogenesis actin remodelling is 
tightly controlled and the removal of stress fibres but not branched F-actin 
facilitates vesicle trafficking. It is also likely that the fine tuning of this actin 
remodelling occurs in association with remodelling of other cytoskeletal 
components such as microtubules and septins, which have been shown to 
contribute to ciliogenesis (405, 406). It has also been shown in RPE-1 cells that 
ciliary elongation due to cytochalasin D treatment can be reduced by taxol 
mediated stabilisation of microtubules (407). However, how these interactions 
between cytoskeletal components contribute to ciliogenesis would need to be 
further investigated. 
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6.3 Cell cycle defects cause supernumerary cilia 
The work in Chapter 4 is the first description mention of a supernumerary cilia 
phenotype due to disruption of the centralspindlin complex. This shows that 
although the screen did not identify a novel pathway, the methodology was 
robust in identifying hits that can be validated for the incidence of 
supernumerary cilia. These results, in addition to the results shown in Chapter 3 
give even more value to the large data-sets from whole genome siRNA screens 
and the unexpected biological insights that can be gained from their re-analysis. 
6.3.1 Top hits caused cell cycle defects 
After filtering, the 3 top hits appeared to show some variation of cell cycle 
defects in raw secondary screen image data (Figure 4.9), as cells appeared 
enlarged or multinucleated. However, the multinucleated phenotype was more 
apparent in mIMCD3s, since these cells continue to divide even under serum 
starvation conditions, whereas RPE-1 cells significantly slow cell cycle 
progression and become quiescent under the same conditions. 
Previous reports of supernumerary cilia in ciliopathies have mostly been 
reported in foetal kidney tissue (333, 334). It may be that this tissue is more 
sensitive to these knock-downs or have compensatory mechanisms that allow 
them to avoid apoptosis under these otherwise stressful conditions.  
The top hit, Racgap1, has not been previously associated with ciliogenesis or 
ciliary biology, however the phenotype was consistent with previous studies on 
the highly conserved role of Racgap1 in cytokinesis in eukaryotes (408, 409). 
Supernumerary cilia in Racgap1 knockdowns can be concluded to be a 
secondary phenotype downstream of mitotic failure and the retention of 
duplicated centrosomes. These mitotic failures are likely due to a failure to 
assemble a centralspindlin complex, as published previously in C.elegans, 
Xenopus and zebrafish embryos with mutations in Racgap1 orthologues (353, 
410, 411). Signalling allows the older retained centrioles to develop into basal 
bodies and subsequently produce cilia. In C. elegans, mutations in the Racgap1 
orthologue allowed a cleavage furrow to form but prevented the formation of a 
central spindle, causing a subsequent failure of cytokinesis (353). This is likely 
the reason that mitosis failed in the mIMCD3 cell model following Racgap1 
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knock-down, consistent with observations made during live cell imaging (Figure 
4.15).  
What is particularly of interest is that there is no compensatory mechanism to 
prevent retained mother centrioles from maturing after mitosis failure. As cells 
return to G1 after exiting a failed mitosis, the signalling to mature mother 
centrioles does not have a checkpoint or regulatory mechanism to recognise the 
retained supernumerary centrosomes. Thus, the signalling allows for both 
mother centrioles to mature. Further to this unlicensed maturation of retained 
centrioles, the cells examined in this work also do not have any active 
regulation that prevented the formation of more than one primary cilium. 
6.3.2 The central spindlin complex is implicated in cilia regulation 
The centralspindlin complex is made up of RACGAP1 and KIF23, a kinesin 
family member that is the microtubule binding component of the centralspindlin 
complex. KIF23 is also responsible for recruitment of the guanine exchange 
factor, Ect2. The centralspindlin complex binds to microtubules during 
anaphase. Its accumulation is dependent on Aurora B, which is then able to 
phosphorylate centralspindlin and stabilise its accumulation at the spindle mid-
zone. Centralspindlin also forms on peripheral microtubules towards the cell 
membrane in order to mediate cleavage furrow formation. Once accumulated 
and stabilised, RACGAP1 interacts with phosphorylated ECT2, which in turn 
activates RhoA to initiate formation of the acto-myosin contractile ring and 
cleavage furrow for telophase. 
Although only Racgap1 was taken forward for secondary screening in this 
thesis, data from the  primary whole genome screen for many of the 
centralspindlin regulators and components support the data presented for 
Racgap1. ECT2 and RhoA are essential for correct localisation and local 
activation of cleavage furrow formation and the acto-myosin contractile ring 
(355). However, siRNA knock-downs of either of the genes encoding these 
proteins do not phenocopy Racgap1 knock-down (Table 6.1). This could be due 
to RhoA’s roles across many other cellular mechanisms and actin regulation, 
and acute global knock-down is deleterious to overall cell health. Aurora B, 
however, is essential for the accumulation of the centralspindlin complex and is 
upstream of this pathway. siRNA knock-down of Aurkb therefore appears to 
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phenocopy Racgap1 knock-down by causing an increase in supernumerary cilia 
(Table 6.1). Retrospectively, Kif23 and Aurkb were good candidates for 
secondary screening as they have highly significant Z2MCilia values (equivalent to 
p<0.001). However, they did not show consistent results in the primary whole 
genome screen and were excluded because of low z-score values in biological 
replicate 2 (Table 6.1). These are likely to be false negative results and again 
highlight the importance of sufficiently stringent filtering steps used to generate 
the secondary screening hit list. 
Table 6.1 Whole genome screen data of centralspindlin components and 
regulators 
The 2 components of the centralspindlin complex (Kif23 & Racgap1) when 
knocked down by siRNA cause a significant increase in supernumerary 
cilia, as shown by the average robust z-score for incidence of cells with 2 
or more cilia (Z2MCilia). Both Kif23 and Aurkb were not taken forward for 
secondary screening because in the second run of the whole genome 
screen they did not show a significant increase in cells with supernumerary 
cilia. Green represents numbers greater Z2MCilia >1.96 and red represents 
numbers <1.96. 
 Run 1 z-score Run 2 z-score z2MCilia 
Kif23 5.556383 1.014768 3.285575 
Racgap1 3.637513 3.931008 3.784261 
Ect2 -0.76198 -1.15997 -0.96097 
RhoA -1.13110 -0.58016 -0.85563 
Aurkb 4.975328 1.896057 3.435692 
 
Kif23 has also been noted as a potential ciliary gene by high-throughput 
computational prediction analysis (412). It is also known to localise to the base 
of the cilium in RPE-1 cells and with a ciliary rootlet marker in multi-ciliated 
Xenopus epithelium (413). To our knowledge, the centralspindlin complex has 
not been localized to any ciliary or associated structures, and this thesis 
ascribes the supernumerary cilia phenotype as a secondary downstream 
consequence of mitosis failure. However, since mitotic progression was not 
directly tested, it is possible that there is another uncharacterised, direct role of 
the centralspindlin complex in primary ciliogenesis. 
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6.4 Hectd2’s potential role in ciliogenesis 
Interestingly, only 1 of the 10 hits from the supernumerary cilia screen did not 
have a statistically significant decrease in cell number: siHectd2 treatment had 
an average z2Mcilia of 2.94 and average zcell of 0.775 (Table 4.2).  
Hectd2 is an obvious hit to take forward for further investigation as it does not 
significantly change cell number and has no obvious mitotic defect. Thus, initial 
experiments would need to validate the phenotype in RPE-1 cells and identify if 
the cilia stem from single or multiple centrioles. However, as it is an 
undescribed E3 ubiquitin ligase, the substrates and activating E2 ubiquitin 
conjugating enzyme would also need to be identified in order to fully understand 
its mechanism of action. From the 35 known active E2 ligases (414), the only 
E2 identified as a hit from the whole genome primary screen of ciliogenesis with 
an average z2MCilia >1.96 was Ube2b. The similarities in phenotypes suggest 
that Ube2b is a candidate E2 for Hectd2. However, it is much harder to predict 
the target(s) of Hectd2 (reviewed in (415)) and to define whether any 
subsequent ubiquitination mediated by it would be to mark the target for protein 
degradation, localisation or change in function, each dependant on which lysine 
residues are ubiquitinated.  
The ubiquitin/proteasome system (UPS) has recently come to light as an 
important regulator of ciliogenesis with many components specifically localising 
to the base of the cilium (416, 417). E3 ligases have been shown to be involved 
in several stages and mechanisms of ciliogenesis and ciliary signalling. For 
example, UBR5, a HECT Domain containing E3 ubiquitin ligase, was identified 
as a positive regulator of ciliogenesis. siRNA knock-down of UBR5 completely 
ablated cilia in RPE-1 cells and UBR5 interacted with CSPP1, a centriolar 
satellite protein. The ubiquitination of CSPP1 was required for the correct 
localisation and stabilisation of centriolar satellites for ciliogenesis (418). By 
contrast, the CUL3-KCTD10 complex acts as an E3 ubiquitin ligase, with 
KCTD10 localising to the mother centriole and targeting CEP97 for degradation. 
Once CEP97 was removed this allowed CP110 to also be removed from the 
mother centriole to signal the timely initiation of ciliogenesis in G1 (419). 
Hectd2 knock-downs, in the whole genome screen used in this project, only had 
a significant effect on the incidence of supernumerary cilia and had no 
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significant effect on overall cilia incidence or cell number. However, data from a 
separate whole genome reverse genetics screen (260), designed to identify 
modulators of ciliogenesis and cilium length, identified HECTD2 as a putative 
negative regulator of ciliogenesis. Knock-down of HECTD2 in their study 
caused a marginal increase in cilia incidence, albeit with only one of 4 siRNAs 
used against HECTD2. HECTD2 was considered as a putative regulator in this 
screen because it fulfilled their arbitrary cut off criteria of showing more than 10 
cells with cilia greater than 6μm in length across the image data captured. The 
screen did not specify or have any data to show the incidence of supernumerary 
cilia, but it does support the result of the secondary screen performed here 
which suggests that HECTD2 is a negative regulator of ciliogenesis. However, 
this was not a hit in the increase cilia incidence screen data presented in 
Chapter 3 as it had an average of -0.595, showing no significant change to cilia 
incidence compared to controls. Unfortunately ciliary length was not quantified 
due to the set-up of the primary screen and as discussed in Chapter 4 it may be 
that the increase in cilia length was incorrectly measured as two or more cilia 
due to recognition protocol errors. 
Possible interactors of HECTD2 were identified from literature searches and 
databases (420-423) but none had clear roles in ciliogenesis, centrosome 
duplication or the cell cycle. The interactors PIAS1 (424) and PPARγ (425) are 
linked to Hedgehog signalling regulation but not ciliogenesis, while many of the 
suggested interactors were less well characterised than HECTD2. 
If validated antibodies were available, then immunofluorescence could be used 
to identify the subcellular location of Hectd2 throughout the cell cycle and 
stages of ciliogenesis. Its localisation could also suggest possible ubiquitination 
targets of Hectd2. Western blotting of cell cycle halted cell cultures could clarify 
whether Hectd2 levels vary in a cell-cycle dependent manner. Furthermore, 
immunohistochemistry could be used alongside mRNA studies to define the 
tissue distribution of Hectd2 expression.  Thus, although there are many 
avenues that can be taken to explore and define the function of Hectd2, 
reagents such as antibodies would need to be validated making this a large and 
extensive research project. 
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6.5 Genetic epistasis from transition zone genes contribute to 
the regulation of ciliogenesis  
The combinatorial screen proved to be an effective technique to identify genetic 
interactions that affect ciliary incidence. Some further optimisation and use of 
new CRISPR/Cas9 techniques introduced in 1.6.7 provide the opportunity to 
scale up the screen and improve the high variability seen across the preliminary 
data. Despite that variability, the screen was able to highlight several potential 
genetic interactions for both ciliary incidence, summarised in Figure 6.2 and a 
few interactions for ciliary size, summarised in Figure 6.3 
 
Figure 6.2 Summary of genetic interactions for cilia incidence 
Diagram that summarises all of the genetic interactions for cilia incidence 
that were identified from combinatorial screen data. The arrow direction 
shows the siRNA knock-down and points to the CRIPSR/Cas9 edited cell 
line in which the knock-down was performed. The thickness of each arrow 
represents the strength of the interaction inferred from robust z-scores (and 
expressed as p-values). Synergistic interactions are represented by red 
arrows, antagonistic by green and additive by black. There is a clear triad of 
reciprocal interactions that is highlighted between IFT88, RPGRIP1L and 
TMEM67. 
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Figure 6.3 Summary of genetic interactions of cilia size 
This diagram summarises all of the genetic interactions impacting on cilia 
size that were inferred from combinatorial screen data. The direction of the 
arrow shows the siRNA acting on the different genetic backgrounds of each 
cell line. The thickness of each arrow represents the strength/significance of 
the interaction. Synergistic interactions are represented by red arrows, 
antagonistic by green and additive by black. Highlighted in bold is the 
antagonistic interaction between RPGRIP1L and TMEM107. 
 
6.5.1 Lack of synergistic interactions identified with ARL13B 
identified through combinatorial screen test data 
It was surprising that data from the ARL13B mutant cell lines only inferred 
potential additive genetic interactions rather than synergistic interactions. 
Several synergistic interactions have been presented for ARL13B in past 
studies. Previous work in C. elegans has suggested that the ARL13B 
orthologue (arl-13) genetically interacts with both ciliary transport and transition 
zone proteins. Double mutants of arl-13 and nph-4 or bbs-8 (orthologues to 
human transition zone genes NPHP4 and BBS8, respectively) and double 
mutants of arl-13 with osm-3 or che-11 (orthologues to human ciliary transport 
genes KIF17 and IFT140, respectively) showed more severe ciliary morphology 
defects compared to single mutants. Double mutants of arl-13::bbs-8 also 
showed reduced numbers of IFT particles, linking the transition zone and IFT 
which will be separately discussed. The data suggests arl-13 genetically 
interacts with these genes to maintain cilia and IFT function (426). However, the 
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above interactions were associated with anterograde transport, whereas the 
combinatorial screen included IFT88, which is involved in anterograde transport.  
In a separate study, arl-13 was also shown to be involved in not just 
anterograde transport, but the docking of both IFT-A (anterograde) and IFT-B 
(retrograde) particles (427). In Arl13b-/- mutant mice it has also been suggested 
that IFT is generally mis-localised and impaired (379). This only presented as 
an additive interaction in the ARL13B heterozygote cell lines with IFT88 knock-
down. This suggests that IFT88 is higher up in the hierarchy of ciliary formation, 
as the knock-down was proportionally equivalent in both cell lines and was 
unaffected by a reduction in ARL13B protein levels. It is therefore possible that 
an ARL13B knock-down in the IFT88 CRISPR/Cas9-edited cell lines may show 
a synergistic interaction, destabilizing the residual levels of IFT88. 
It may be that other genetic interactions that are present with ARL13B would 
only be observed if CRISPR/Cas9-edited cell lines were treated with ALR13B 
siRNA, which was not part of the screen panel. It is therefore likely that some 
false negatives were missed in the screen. 
6.5.2 Interactions between IFT88 and the Transition Zone 
A clear triad of interactions was inferred between IFT88, RPGRIP1L and 
TMEM67 because these were supported by reciprocal experiments (Figure 
5.12). IFT proteins are already well known to interact with the BBSome for 
loading cargo for ciliary transport (428-430) and in the Hedgehog signalling 
pathway for changes in ciliary localisation (65, 431). 
The RPGRIP1L orthologue in C. elegans has also been shown to genetically 
interact with IFT-A protein IFT-139 (432). This study suggests that core IFT-A 
proteins promote entry of the MKS module into the cilium and are therefore 
required for ciliogenesis. This work also describes a role for IFT-A in 
maintaining the correct MKS module localisation in the transition zone (432), a 
notion independently supported by work that shows IFT-A dynein has 
interactions with the transition zone (72). In comparison, little evidence has 
been published for a genetic or functional link between the transition zone and 
proteins in the IFT-B module, specifically IFT88. 
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However, recent evidence supports a functional interaction between IFT-B and 
the transition zone in maintaining the ciliary gate. In Chlamydomonas rpg1-l 
(RPGRIP1L) mutants, a dysfunctional ciliary gate is seen that allows flooding of 
cytoplasmic/non-ciliary proteins into the cilium. In contrast fla11-1 (IFT172) 
mutants had significantly reduced levels of IFT and ciliary membrane proteins, 
suggesting that it has a role in retention of proteins that pass the ciliary gate. 
Consequently, both IFT-B and RPGRIP1L have to work together to maintain a 
functional ciliary gate (433). Nevertheless, the present study is the first work to 
suggest a synthetic synergistic interaction between IFT-B and 2 transition zone 
proteins, RPGRIP1L and TMEM67.  
Interactions between IFT88 and TMEM67 were not shown to be reciprocal, as a 
synergistic interaction was shown in the IFT88 cell line but an additive 
interaction was seen in the TMEM67 cell line. This may be partly explained by 
the base-line level of cilia incidence in the TMEM67 mutant cell line, which is 
significantly greater than WT cells (Figure 5.5). Consequently, the knock-down 
of IFT88 would have to overcome the phenotype of increased cilia seen in this 
cell line, masking the synergistic interaction. 
Reciprocal interactions were also inconsistent with RPGRIP1L. This may be 
due to the important role of RPGRIP1L in ciliogenesis and its role higher up in 
the hierarchy of transition zone organisation (79, 375, 434). C19+/-  likely has 
enough functional RPGRIP1L to compensate and maintain a level of cilium 
formation, despite the IFT88 knock-down, whereas residual protein levels in the 
C49if.del/- cell line (Figure 5.4) may not be functional or able to maintain cilia due 
to the p.24_33del mutation. This suggests that the interaction is not detectable 
in heterozygotes and would only be inferred in knock-outs or conditions with no 
functional RPGRIP1L protein. The functionality of RPGRIP1L in these cell lines 
would have to be tested by observing any mis-localisation of other transition 
zone proteins to support this hypothesis. 
6.5.2.1 TMEM67 mis-localises in IFT88 and RPGRIP1L heterozygous 
mutants 
Many transition zone proteins mis-localise in RPGRIP1L mutants, as has been 
shown in C. elegans (435) and human fibroblasts (389). The mis-localisation 
and proximal restriction of TMEM67 in RPGRIP1L heterozygote cell lines 
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suggests that WT RPGRIP1L may licence the entry of TMEM67 into the ciliary 
membrane. In contradiction to this, previous work in C. elegans suggest that 
mks-5 (RPGRIP1L) restricts mks-3 (TMEM67) localisation to the transition 
zone, because mks-5 mutants showed mks-3 dispersed along the ciliary 
axoneme (375). This may however a phenotypic difference between a 
heterozygote and a complete knock-out, or a species specific difference. This 
could be tested for in RPGRIP1L-/- RPE-1 cells. 
If RPGRIP1L is licencing distal TMEM67 localization into the ciliary membrane, 
possibly as a role of the diffusion barrier at the transition zone (435), this may 
have a functional consequence as TMEM67 has been shown to contribute to 
non-canonical Wnt signalling (436). Complete knock-outs of TMEM67 have also 
previously been shown to affect the localisation of membrane proteins such as 
Arl13b and Smo in mouse embryonic fibroblasts (385), so it would be of interest 
to see if mis-localisation of TMEM67 alone would show  similar functional 
consequences.  
Separately, TMEM67 restriction to the basal body in the IFT88 heterozygotes 
could be due to loss of an active transport of TMEM67 along the membrane. It 
has previously been discussed that transition zone proteins that mis-localise or 
are mis-assembled are actively recovered and returned to the transition zone by 
IFT-A (72). Independently it has been hypothesised, from data in C. elegans, 
that transition zone proteins are actively trafficked into cilia by anterograde IFT-
B alongside evidence for IFT-A regulation of MKS module localisation (432). 
This independently supports the data in the IFT88 heterozygous mutants 
presented here and suggests that there is active anterograde transport of 
TMEM67 along the membrane, thus the localisation seen in WT cells along the 
length of the ciliary membrane would not be due to passive diffusion. This could 
be the case for many other ciliary membrane proteins and therefore be a key 
part of correct signalling through cilia. This phenotype could potentially be 
tested for with an optimised fluorescence recovery after photo bleaching 
(FRAP) experiment to look at the recovery rates of these membrane proteins 
after bleaching the transition zone, where rapid recovery would suggest 
diffusion rather than active transport as hypothesised from the data presented 
here.  
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6.5.3 Antagonistic interaction between RPGRIP1L and TMEM107 
Follow-up experiments from the combinatorial screen did not validate the 
antagonistic interaction between RPGRIP1L and TMEM107. It is likely that the 
ball-like phenotype described in Figure 5.21 increased the overall spot size 
detected in the primary combinatorial screen, thus making this hit a false 
positive antagonistic interaction. However, this novel phenotype suggests a 
synergistic interaction, and a possible functional interaction between RPGRIP1L 
and TMEM107 since TMEM107 knock-down alone does not significantly 
change ciliary phenotypes in WT cells (Figure 5.20). The ball like-phenotype 
that was noted could be a possible retrograde IFT defect or un restricted entry 
of cytosolic proteins that were able to diffuse across a faulty ciliary gate. 
RPGRIP1L has been genetically and functional linked to anterograde IFT (72, 
432), therefore it is possible this interaction may, in part, be mediated by 
TMEM107.  
This synergistic interaction has also been reproduced in C. elegans, with 
mks5::tmem107 double mutant showing a far more severe phenotype than 
either single mutant. This interaction is specific to mks-5 (RPGRIP1L), as the 
same phenotype was not noted in the control double mutant, cep290::tmem107 
(Personal communication with Professor Oliver Blacque, University College 
Dublin). However, it remains unclear why there is a synergistic interaction when 
transition zone proteins fail to be correctly localised or recruited in mks-5 mutant 
worms.  
It has been noted previously in mouse IMCD3 cells with TMEM107 knock-down 
that there is no change in localisation of RPGRIP1L relative to the basal body 
(81). However, TMEM107 localisation has not been tested in the RPGRIP1L 
mutant cell lines. TMEM107 has been shown in C. elegans to be located in an 
intermediate layer of the transition zone (81), suggesting a unique function 
independent of other TMEM proteins. This is also reflected in the combinatorial 
screen data, as both TMEM67 and TMEM237 do not have a similar functional 
interaction with RPGRIP1L and there were no significant changes to ciliary size 
in these “double perturbations”. 
RPGRIP1L CRISPR/Cas9 edited cell lines showed mis-localisation of TMEM67, 
and since RPGRIP1L is a master organiser of the transition zone there are 
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likely to be other mis-localised transition zone proteins in these cells. A 
disorganised transition zone may not be correctly tethered to the ciliary 
membrane, allowing the cytosolic proteins to diffuse in and cause the ball-like 
phenotype. Which could be tested with expression of a GFP construct, 
observing any diffusion of free GFP into the cilium or possibly using FRAP to 
assess the dynamics of GFP diffusion into the cilium. It may also be that excess 
membrane is produced due to a dysregulated ciliary gate, allowing flooding of 
other ciliary signalling and membrane proteins to increase the ciliary membrane 
size. This leads to the hypothesis that TMEM107 has key roles in tethering the 
ciliary membrane or in the control of the ciliary gate. 
6.6 Future tools for ciliary research 
Huge advances have been made in microscopy techniques with the 
development of super resolution and high-throughput microscopy. The 
molecular architecture and organisation of the cilium is still to be accurately 
defined despite initial work with super-resolution microscopy starting to 
elucidate this complex structure (60), it is likely that these techniques will lead to 
a far greater understanding of protein localisation and organisation in the 
primary cilia in the coming years. 
Another exciting technology that could benefit ciliary research is biotin ligase 
(BioID) and ascorbate peroxidase (APEX) proximity biotinylation labelling 
techniques. These techniques are being used to build an interaction landscape 
of the ciliome by tagging key proteins with either BioID or APEX to then 
biotinylate all proteins within proximity to the tagged protein of interest. These 
biotinylated proteins are then purified and characterised to identify potential 
interactors or proteins structurally close to the tagged protein (40, 41). Rapid 
(so-called “turbo”) BioID over short (<1hr) time-scales is also being used to 
identify interactions involved in the different stages of ciliogenesis and how 
interactions change with mutant proteins (personal communication with Dr. 
Katarzyna Szymanska). 
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6.7 Future work 
6.7.1 Drug repurposing 
As there are no clear guidelines on the treatment of ciliopathies, management 
prioritises alleviation of symptoms as the underlying genetic disorder cannot be 
treated. The work in Chapter 3 of this thesis highlights ROCK2 as a potential 
therapeutic target for ciliopathies. For example, KD025 treatment was able to 
rescue cilia incidence in siIFT88 knock-down conditions. As discussed in 
Chapter 3, KD025 is currently still undergoing safety and efficacy testing in 
phase 2 clinical trials for several skin diseases: chronic Graft Versus Host 
Disease (cGVHD) (ClinicalTrials.gov Identifier: NCT02841995), Idiopathic 
Pulmonary Fibrosis (ClinicalTrials.gov Identifier: NCT02688647), Diffuse 
Cutaneous Systemic Sclerosis (ClinicalTrials.gov Identifier: NCT03919799) and 
previous Phase II testing for Severe Psoriasis Vulgaris (437). Initial results from 
all trials are promising. It will, however, require several more years of clinical 
testing and additional Phase III clinical trials before it could be potentially 
delivered as a therapeutic for patients. Once approved the drug could be 
repurposed for ciliopathy patients. 
Drug discovery is not only expensive and time-consuming but has high attrition 
rates, particularly at the safety stages of clinical testing, despite extensive pre-
clinical research (438). Repurposed drugs such as KD025 or other ROCK2-
specific inhibitors could be tested in pre-clinical organoid models of retina or 
kidney in order to confirm a potential therapeutic effect, before taking them 
forward for clinical safety testing in humans. Hence repurposing drugs offers a 
chance of much lower attrition rates and faster approval for use in rare diseases 
in addition to lower development costs. However, drug repurposing still has 
many challenges such as patent rights. This can impact a pharmaceutical 
company’s incentive to repurpose drugs, particularly for those that are generic 
and “off patent”. This is especially important if there is already publicly 
accessible research that investigates the novel uses of the drug, or it’s novel 
use has already been unofficially adopted in clinical practice as this impacts the 
ability to get a patent for the newly-proposed use (439, 440). However, with 
novel intellectual property, a method of use patent can easily be applied for 
repurposing “off patent” drugs.  
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Drug repurposing is an ideal approach for ciliopathies, as it is not financially 
viable to target each disease type individually. A drug developed to target a 
single ciliopathy would be classed as an “orphan” drug because of its very 
limited clinical use. Orphan drugs are not profitable to produce and so usually 
require government funding to assist production. Drug repurposing however 
avoids this issue as the drug is already in production for, with a known drug 
target and mechanism of action. 
However, although drug repurposing could provide an easier route to a 
therapeutic for ciliopathies targeted drug design is still valuable. Ciliopathies as 
a group of diseases, are relatively common and present a large clinical burden. 
Therefore, a drug targeting ciliary function rather ciliopathy symptoms, as those 
currently in clinical trial, has the potential to have greater clinical impact and be 
profitable to produce. 
6.7.1.1 Drug repurposing of ROCK inhibitors 
There are few ROCK inhibitors in current clinical use, and none that have been 
approved for use by the European Medicines Agency (EMA) and U.S. Food & 
Drug Administration (FDA). Non-specific ROCK inhibitors include hydroxyfasudil 
(currently only approved for use in China and Japan) and the fasudil derivative 
ripasudil (currently only approved for use in Japan) which are potential drugs 
that could be repurposed for ciliopathy patients. Fasudil is of interest as it was 
initially approved for use in China and Japan to treat cerebral vasospasm. It has 
also been repurposed once before and went through a phase 2 clinical trial in 
China for use in amyotrophic lateral sclerosis (ALS) in 2013. However, the trial 
has yet to be published or completed (ClinicalTrials.gov Identifier: 
NCT01935518). As a previously approved drug this makes it an ideal candidate 
to fast-track through clinical trial and approval for use in ciliopathies. 
ROCK2-specific inhibitors are also currently being developed for conditions 
involving fibrosis and have undergone successful pre-clinical testing. Fibrosis is 
a complication of diabetic neuropathy, idiopathic pulmonary fibrosis, Crohn’s 
disease and non-alcoholic steatohepatitis and thus these diseases are a major 
target for the commercial development of new ROCK2-specific inhibitors. RedX 
Pharmaceuticals have recently developed two new ROCK2 inhibitors, 
REDX10178 and REDX10325. Both inhibitors have been shown to be highly 
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selective for ROCK2 with minimal off-target effects across 468 kinases tested. 
They have IC50s of 1.4nM and 0.65nM respectively (when measuring 
phosphorylation of MYPT1), whereas the IC50 of KD025 is 70nM (441). 
Therefore, these clinical development compounds could also be taken forward 
for potential repurposing and clinical testing in ciliopathy patients. However, 
since these compounds are yet to be approved for any clinical use, they are 
unlikely to be an attractive choice for initial repurposing. However, if current 
clinical trials of KD025, REDX10178 and REDX10325 are successful and these 
drugs are approved for their original indications, these are better candidates to 
take forward for repurposing as data in this thesis shows that ROCK2-specific 
inhibition can rescue ciliogenesis. Other less specific drugs may have significant 
side-effects through off-target inhibition of other kinases. For example, fasudil 
dihydrochloride at 10uM inhibits ROCK2 to only 12% remaining kinase activity. 
However, it also significantly inhibits many off targets such as RSK1, ERK8, 
PRK2 and MSK1 to ≤20% kinase activity. Kinase profiling studies are important 
in defining the specificity of the potential drugs taken forward for ROCK2 
inhibition to identify off-target effects and can be downloaded from the Medical 
research council (MRC) protein phosphorylation and ubiquitination unit (PPU) 
international centre for kinase profiling, Kinase Profiling Inhibitor database 
(http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors). 
KD025 and other ROCK inhibitors could be tested in additional human cell 
models and ciliopathy model organisms such as iPSC organoids or mice, to 
build on work in this thesis and examine potential therapeutic benefit at an 
organism level. Work should also include other ROCK inhibitors and include 
testing a specific ROCK1 inhibitor such as GSK 429286 (442) in cell models to 
further confirm that ROCK2 is the main therapeutic target. However, a full 
clinical trial into ROCK inhibitors such as KD025 would be the obvious future 
project stemming from the work in Chapter 3 after pre-clinical testing confirmed 
its value. 
6.7.2 Current clinical trials of potential therapeutics for ciliopathies 
At the time of writing, current therapeutic clinical trials for primary ciliopathies 
are limited to targeting obesity or visual acuity in Bardet Biedl Syndrome and 
Alström syndrome, or are using drugs to specifically target polycystic kidney 
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disease. BBS and Alström syndrome patients with moderate or severe obesity 
are currently in a phase 3 randomised double-blind clinical trial since December 
2018 (ClinicalTrials.gov Identifier: NCT03746522). The trial is testing the effects 
of Setmelanotide on weight loss in the participants. Setmelanotide is a 
Melanocortin-4 Receptor (MC4R) Agonist, a receptor previously shown to 
regulate metabolism and body weight regulation in mice (443), and certain 
alleles have also been found in genome-wide association studies (GWAS) to be 
associated with high BMI (444). Patients with hyperphagia are included in the 
trial targeting MC4R to limit their food cravings and aid in weight loss. 
Setmelanotide is also being tested in a separate trial including a wider range of 
genetic disorders of obesity (ClinicalTrials.gov Identifier: NCT03013543). These 
trials are good examples of drugs being used to manage symptoms rather than 
target the underlying ciliary dysfunction.  
There are several clinical trials aiming to improve visual acuity in ciliopathy 
patients but with limited success. The trials also only target BBS and LCA 
patients. A phase 2 trial using Metformin to improve visual acuity in BBS 
patients has been withdrawn in April 2019 due to “unrealizable wishes of 
national authorities” (ClinicalTrials.gov Identifier: NCT03490019) and no further 
information has been provided as to why the clinical trial was withdrawn.  
Two other current drug trials are specifically targeting LCA patients with either a 
specific CEP290 p.Cys998X mutation (ClinicalTrials.gov Identifier: 
NCT03140969), or with mutations in GUCY2D (retinal guanylate cyclase) 
(ClinicalTrials.gov Identifier: NCT03920007). Both of these trials are early 
phase, but initial results from former have shown promising results 
(445).Therefore, there is potential of great impact in the clinical management 
and for patient outcomes in a drug that could be used across a broader range of 
ciliopathies, in particular a drug that targets the underlying ciliary dysfunction 
directly such as a specific ROCK2 inhibitor.  
KD025 is an experimental drug currently in Phase 2 clinical trials for systemic 
sclerosis (ClinicalTrials.gov Identifier: NCT03919799), idiopathic pulmonary 
fibrosis (ClinicalTrials.gov Identifier: NCT02688647) and chronic graft-versus-
host disease (ClinicalTrials.gov Identifier: NCT03640481) (446). Initial testing 
has reported promising safety results in patients from preclinical studies and 
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earlier Phase 1 clinical trials. It remains possible that this more specific ROCK2 
inhibitor could be repurposed and re-trialed for ciliopathy patients. The impact of 
a treatment that specifically targets the underlying molecular pathology of 
disease rather than treats symptoms would have an and presents an exciting 
opportunity to make an immeasurable difference to ciliopathy patients and their 
families. 
6.7.3 Developing a large scale combinatorial screen 
Since the work presented in this thesis was carried out, CRISPR/Cas9 and 
genome editing technology has greatly improved in both efficiency and 
specificity as discussed in 1.6.7. It would be valuable to up-scale the 
combinatorial screen with more gene-edited cell lines following these advances. 
During the development of the screen presented in Chapter 5, the most time-
consuming phase was the validation of the gene-edited cell lines. With 
improved editing efficiency, fewer cell lines would need to be screened to find 
deleterious mutations. 
At the present time, the best evidence for genetic interactions in ciliopathies 
was identified in genes that cause of Bardet-Biedl syndrome. It would therefore 
also be beneficial to develop a panel of positive controls for genetic interactions 
using this data. These control interactions would be in addition to the usual 
screening controls for transfection and image analysis, and would represent 
positive controls for synergistic, additive and antagonistic interactions. Inclusion 
of these controls would greatly increase the reliability and precision of this 
screening methodology. 
Alongside a larger panel of cell lines, a broader panel of siRNAs would also 
increase the scope of this validated and reliable methodology. This could 
include internal repeats and reciprocal testing for each of the potential 
interacting pairs and should include ARL13B siRNAs to ascertain whether 
previously published interactions can be confirmed by using this technique (as 
discussed in Chapter 5). As many of the siRNAs in the combinatorial screen 
panel were transition zone targets, it would be interesting to broaden the targets 
of the siRNA panel to include all ciliary compartments. This should include 
additional IFT and motor proteins, as these were some of the strongest 
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synthetic genetic interactions identified in the combinatorial screen, and are 
supported by evidence from previously published data (72).  
The current 87 defined transition zone proteins would be too many to screen in 
a single sitting. Therefore a panel of CRISPR/Cas9 edited cell lines of the most 
commonly mutated genes in ciliopathies, or genes that specifically cause a 
spectrum of disorders, such as CEP290, would make up an ideal screening 
panel for the large scale combinatorial screen. The over 1000 proteins in the 
ciliome could then easily be made into a custom siRNA screening panel. This 
larger scale combinatorial screen could be used to identify cilia incidence and 
length as tested but also the high-throughput format can easily be adapted for 
screening signalling responses. Cell lines which stably express Gli reporter 
assay systems could be edited using CRISRP/Cas9 and then transfected with 
the ciliome siRNA panel. It’s important to note that RPE-1 cells are not an ideal 
model to assess Gli response because they have cilia in deep pockets that 
have been do not respond strongly to Shh signalling. A possible ciliopathy cell 
model for signalling assays would be ARPE-19 cells. By using genes that are 
already known to cause a spectrum of disorders and by including signalling 
response assays, the combinatorial screen would have the potential to identify 
any, if not all, genetic interactions of ciliary genes that influence the spectrum of 
phenotypes in ciliopathies. 
Of high importance in the follow up work would be an examination of patient 
genome data to see if it correlates with any of the synergistic interactions 
identified. It may be that patients with more severe ciliopathy phenotypes have 
a second mutation or SNP in one of the suggested interacting pairs, with the 
primary disease causing mutation. 
6.8 Final Remarks 
6.8.1 Impact and Significance 
Although the role of actin remodelling in ciliogenesis is well-described, this is 
the first report of the specific negative regulation of this remodelling by ROCK2. 
Furthermore, this regulation by ROCK2 is not compensated for by its isozyme 
ROCK1. This work also highlights the important role of inhibition of acto-myosin 
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contraction in inducing ciliogenesis, a ROCK2-regulated pathway that has 
otherwise received little previous attention in this context. 
The work also demonstrates the value of re-tasking primary whole genome 
siRNA screens. Often, there is more to be learnt from these large data sets, 
even when looking at phenotypes for which the screens were not originally 
designed. 
6.8.1.1 ROCK2 and actin remodelling as a therapeutic target in 
ciliopathies 
Work in this thesis has shown that specific inhibition of ROCK2 is enough to 
provide a rescue of cilia incidence in some cell models of cilia loss such as 
IFT88 knock-downs (Figure 3.23). In contrast, ROCK2 inhibition was unable to 
rescue cilia loss in RPGRIP1L knock-downs. There are no known patients with 
IFT88 mutations, whereas there is a clinical need for a drug to restore cilia in 
patients with RPGRIP1L mutations. Therefore the applicability of KD025 or 
ROCK2 as potential drug targets with other inhibitors would need to be tested in 
additional disease models. It is unclear if the inhibition of off-target kinases, 
such as observed with other non-specific ROCK inhibitors that include Y27632, 
may further benefit cilia rescue. The current evidence and data presented in this 
thesis suggest that specific ROCK2 inhibition has the potential for high clinical 
impact. 
The value of small molecule inhibitors in rescuing ciliogenesis has been shown 
previously in CEP290 knock-out RPE-1 cells. These cells were unable to 
produce visible cilia, but a natural and synthetic compound screen identified that 
plant flavonoids were able to restore ciliogenesis in these cells through 
interaction with NPHP5. They specifically identified eupatilin, which has 
previously been approved for clinical use to treat gastritis and peptic ulcers 
(447). However, these gene knock-outs have also been shown to be rescued by 
targeting actin stability with cytochalasin D and lantrunculin B. In parallel, these 
drugs were also able to partially rescue cilia in IFT88 knock-downs (448). Thus, 
targeting specific protein interactions, or non-specifically targeting the actin 
cytoskeleton, could both be of value to patients with Senior-Loken syndrome, 
Joubert syndrome, or Leber Congenital amaurosis, all caused by mutations in 
CEP290 or NPHP5.  
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Other work on glomerulocystic kidney disease in mice caused by mutations in 
Arhgap35 showed that the ROCK1 inhibitor GSK 429286A or cytochalasin D 
were able to partially recuse loss of cilia incidence and length in these mice 
models (286). This is consistent with the data presented in Figure 3.14, showing 
that mIMCD3 wild-type cilia were elongated following ROCK1 knock-down. 
Independently, results from a small molecule inhibitor screen looking to rescue 
cilia in IFT88 and RPGRIP1L knock-down conditions, showed that a non-
specific ROCK inhibitor was amongst the top hits (personal communications 
with Dr. Claire E.L. Smith, University of Leeds). These findings suggest that 
ROCK pathways are a potential therapeutic target for ciliopathy patients.  
With such promising independent results and the case for drug repurposing, 
further pre-clinical work will not be extensive before a proposal could be 
presented to industry partners to start clinical trials using ROCK inhibitors. 
Providing a huge opportunity to increase the quality of life for ciliopathy patients. 
6.8.1.2 A new technique for investigating genetic interactions influencing 
ciliary phenotypes 
Genetic interactions and modifier alleles are thought to contribute to variations 
in Bardet-Biedl syndrome and thus have been the focus of several studies 
looking at human ciliopathy phenotypes (359, 371, 449). Genetic interactions 
and modifiers have also been suggested to contribute to retinal phenotype 
variation in ciliopathies (450). However, there have been very few studies 
looking at the impact of genetic interactions in general mammalian ciliary 
biology, which could in turn relate to our molecular understanding of 
ciliogenesis. This is the first work that looks at potential genetic interactions that 
perturb cilia incidence and size in a high-throughput format with a focus on the 
cellular and molecular level of ciliary biology. 
The combinatorial screen identified several potentially biologically important 
interactions for follow-up work which could significantly contribute to the growing 
evidence of the role of genetic interactions in ciliopathy phenotypes. Thus 
providing proof of concept that a large scale screen could be developed from 
this techniques with some further optimisation and development of cell lines.  
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As this work was completed in cell lines that were assumed to lack relevant 
clinical phenotypes, it is possible that complete knock-outs do not have the 
same genetic interactions as seen for the heterozygote cells lines and that the 
molecular mechanisms would therefore differ in ciliopathy patients. This does 
not minimise the value of this data as this work still gives novel insight into the 
molecular understanding of ciliary biology and has provided further evidence of 
genetic interactions between IFT and the transition zone. The main advantage 
of this technique to identify genetic interactions over big data in silico genetic 
interaction studies and genome-wide association studies (451, 452), is that this 
technique, although more laborious, provides biological data and presents the 
exact phenotype of the genetic interactions tested.  
A large scale screen would not only aid our understanding of ciliogenesis and 
ciliopathy disease pathology but allow the improvement of genetic counselling 
services for patients. With an understanding of the influence of different alleles 
and their interactions with primary disease causing mutations the severity of 
phenotypes could be predicted. Helping patients not only better understand 
their disease compared to the ciliopathy community but also allow parents of 
these patients to be more informed for future family planning.  
6.8.2 Summary of findings 
Through the chapters of this thesis, work has been presented to show novel 
regulators and synthetic genetic interactions that influence ciliogenesis. In 
Chapter 3 it was shown that ROCK2 is a specific regulator of the actin 
remodelling required in ciliogenesis and that the isozyme ROCK1 cannot 
compensate for the loss of ROCK2 in actin regulation of ciliogenesis. The role 
of acto-myosin contractions in ciliogenesis was presented, highlighting a 
previously under-appreciated means of actin remodelling in the negative 
regulation of ciliogenesis, and providing further evidence to support an essential 
role in dynamic actin remodelling during ciliogenesis. Rudimentary testing of the 
ROCK2-specific inhibitor KD025 also suggested ROCK2 as a potential 
therapeutic target for ciliary disease. The previously highlighted role of actin 
remodelling in the pathogenesis of several ciliopathies further shows the 
potential clinical impact of taking a ROCK2 inhibitor forward for pre-clinical 
testing.  
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In Chapter 4 the link between centrosome maturation and supernumerary cilia 
was investigated. The mechanism highlighted in that chapter supports previous 
reports that centrosome over duplication, or retention of centrioles, is the main 
molecular mechanism that causes supernumerary cilia. However, this is the first 
work showing that RACGAP1-mediated cytokinesis is not a prerequisite for 
centriole maturation and the formation of supernumerary cilia. 
In Chapter 5, novel synthetic genetic interactions were identified across a range 
of structural ciliary compartments that influence cilia incidence and cilia length. 
A triad of synergistic reciprocal interactions were identified between IFT88, 
TMEM67 and RPGRIP1L, alongside data showing biochemical associations 
between these proteins. Another novel synergistic genetic interaction was also 
identified between RPGRIP1L and TMEM107 which affected ciliary structure, 
and implicated TMEM107 in ciliary gate function or membrane tethering. 
However, further investigation into potential biochemical interactions are 
required. 
6.8.3 Conclusion 
In summary, reverse genetics techniques and whole genome siRNA screen 
data sets have been shown to be highly valuable in a hypothesis-neutral 
strategy for identifying novel regulatory pathways in ciliogenesis throughout this 
thesis. 
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Appendix A 
siRNA and primer sequences 
A.1  siRNAs 
A.1.1  mIMCD3 Secondary screen controls 
These siRNAs were purchased from Dharmacon as 5nmol stocks, in tube 
format. All siRNAs targeted the mouse orthologue of the genes listed, except 
MLNR which was used as a negative control as it targeted the human 
orthologue, and the scrambled negative control which is non-targeting 
sequence across all species. These control siRNAs were used in Chapters 3 
and 4. 
Table A.1 mIMCD3 Secondary Screen siRNA Controls 
Gene Symbol Gene 
Accession 























A.1.2.  Increase cilia incidence secondary screen 
These siRNAs were purchased from Dharmacon as an RNAi Cherry-pick 
Library, 0.1nmol stocks, in 96 well plate format for screening. All siRNAs 
targeted the mouse orthologue of the genes listed. These siRNAs were used in 
Chapter 3. 
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Table A.2 Increase Cilia Incidence Secondary Screen siRNAs 
Gene Symbol Gene 
Accession 
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A.1.3  Increase incidence of cells with two or more cilia 
(supernumerary cilia) secondary screen 
These siRNAs were purchased from Dharmacon as an RNAi Cherry-pick 
Library, 0.1nmol stocks, in 96 well plate format for screening. All siRNAs 
targeted the mouse orthologue of the genes listed and were used in Chapter 4. 
Table A.3 Increase incidence of cells with two or more cilia 
(supernumerary cilia) secondary screen siRNAs 
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A.1.4  Combinatorial screen 
Table A.4 Combinatorial Screen siRNAs 
These siRNAs were purchased from Dharmacon as 5nmol stocks, in 
tube format. All siRNAs targeted the human orthologue of the genes listed, 
except the scrambled negative control which is non-targeting sequence 
across all species. The siRNAs were diluted before and used in both the 









































A.1.5  Other siRNAS 
Table A.5 Other Human siRNAs used 
These siRNAs were purchased from Dharmacon as 5nmol stocks, in 
tube format. All siRNAs targeted the human orthologue of the genes listed. 
The siRNAs were diluted and used in downstream tertiary validation work 
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Table A.6 Other Mouse siRNAs used 
These siRNAs were purchased from Dharmacon as 5nmol stocks, in 
tube format. All siRNAs targeted the mouse orthologue of the genes listed. 
The siRNAs were diluted and used in downstream tertiary validation work 

















Table A.7 Other control siRNAs used 
These siRNAs were purchased from Dharmacon as 5nmol stocks, in 
tube format. PLK1 was used as a positive control for transfection as knock-
down causes significant cell loss. The siRNAs were diluted and used as 
controls in downstream tertiary validation work of the secondary screens in 





ON-TARGETplus siRNA SMARTpool Target 
Sequences 
PLK1 (Human) NM_005030 
GCACAUACCGCCUGAGUCU, CCACCAAGGUUUUCGAUUG, 
GCUCUUCAAUGACUCAACA, UCUCAAGGCCUCCUAAUAG 
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A.2  Primers 
A.2.2  PCR, Sequencing and T7 Primers 
These primers were designed and optimised specifically for use within this 
project. Other universal sequencing primers were used for cloning validation 
throughout the project.  
Table A.8 PCR Primer Sequences 
Primers designed for PCR, sequencing and T7 assay of CRISPR/Cas9 
edited genes for use in Chapter 5. Primers were designed using Primer3 
(http://bioinfo.ut.ee/primer3/) to amplify exons and adjacent intronic 





Forward Sequence Reverse Sequence 
ARL13B 1 CAGGACTCTCCAGCCACTCA GACACCCTGGGAATGAAAGC 
CEP290 2 GATCAAGGCTATTTTGCCCA TTTCCCCTACACACCCTTTT 
CEP290 2 ATGATTGTCGGCCTTCCA AGAACACTTCCAGATTGTGACA 
CEP290 2 TACAGAGGTGGAGCACAGTG TCCCCTACACACCCTTTTAGA 
IFT88 7 TGAAATAGCTTATGCGAGGTTTT TATGTGAGCTGGTGTGGTGG 
RPGRIP1L 2 AAGCAGCACATGTGGACAAT CCAGGCAATTCAGTTTGGAG 
TMEM67 1 TTGAAAATATCGCTGGGCTC TGAAACTCCATTTACGGGGA 
TMEM67 1 GATGGGTTTATTGCGGGGAG TGCCTTGGCTTCCTCTACAA 
TMEM67 1 TATGCTCAAACCTGGCAGGA TGCCTTGGCTTCCTCTACAA 
TMEM216 2 GACTGGAAGCAGGACCTCTG AGGAAAGGCAATCCCATAGC 
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A.2.2  RT -PCR Primers 
Table A.9 RT-PCR Primer Sequences 
These primers were designed to target an intron-exon boundary across all 
known and predicted transcripts of each gene to produce a product less 
than 250bp in size. These primers were used within this project to validate 
siRNA knock-downs and CRISPR/Cas9 edited cell-lines. Primers 
conditions were optimised individually and work is presented in Chapters 4 
and 5. 
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Appendix B 
FIJI Macro Script for Cilia Recognition and Quantification 
B.1  Fiji Macro Script 
This script was adapted from a script kindly shared by Thomas Stevenson, 
University of Bristol. Before the macro was run, the DAPI channel was adjusted 
to optimal brightness and maximum contrast.  
run("Z Project...", "projection=[Max Intensity]"); 
//run("Channels Tool..."); 
title Get Title(); 
run("Split Channels"); 
selectWindow("C1-" + title); 
run("8-bit"); 
run("Auto Threshold", "method=Huang)"); 




run("Analyze Particles...", "size=30-infinity 
circularity=0.30-1.00 show=Nothing display exclude clear 
summarize"); 
selectImage("C2-" + title); 
run("Subtract Background...", "rolling=5"); // removes 
background. If this is too harsh increase the "rolling" 
value. 
run("Median...", "radius=3");  
//run("Gamma...", "value=0.70"); //optional line may help 
to include for some noisy images. 
setAutoThreshold("Yen dark"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); // Generate binary image. 
run("Dilate"); 
run("Dilate"); // makes each thresholded cilia one pixel 
wider, to join any gaps. Possible to omit if results show 
cilia are too long. 
run("Skeletonize"); 
run("Set Measurements...", "area perimeter redirect=None 
decimal=3"); 
run("Analyze Particles...", "size=0.05-100 show=[Overlay 
Masks] display exclude clear include summarize add 
in_situ"); 
        for(n=0; n<nResults;n++) { 
         setResult("Cilia Length", n, 
((getResult("Perim.", n))/2));        } // this for loop 
takes the results of each cilia perimeter, divides by 2 to 
give the length and adds it to the results table. 
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Appendix C 
gRNA Sequences 
C.1  CRISPR Guide RNAs 
The guide RNA sequences used were cloned into pX458 plasmid and 
expressed as a full sgRNA under a U6 promoter.  
Table C.1 CRISPR Guide Sequences 
Guides were designed using crispr.mit.edu (no longer available) and were 
designed to the first coding exon. To ensure good expression from the U6 
promoter a G was added to the start of every guide sequence. These were 
used to make the CRISPR heterozygote cell lines used in Chapter 5. 
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Appendix D 
Screen Plate Maps 
D.1  Secondary screen plates 
 
Figure D.1 Secondary Screen Plate Map 
Dharmacon Library plates were purchased with columns 1 and 12 blank 
for manual addition of control siRNAs. Library plates were sub plated into 
working assay plates (PerkinElmer View Plates) for experimental use 
using a Agilent Bravo liquid handling platform. Any central wells without an 
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D.2  Combinatorial screen plates 
 
 
Figure D.2 Combinatorial screen plate maps 
A) This layout was used to screen ARL13B, IFT88, RPGRIP1L and 
TMEM216 CRISPR/Cas9 edited cell-lines. B) This layout was used to 
screen CEP90 and TMEM67 CRISRP/Cas9 edited cell lines. All plates 
were done in duplicate to ensure two technical replicates per run. All 
siRNAs and cell lines were plated manually using and 8-channel multi-
pipette. 
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Appendix E 
Automated Columbus Recognition Protocols 
E.1  Increase cilia incidence screen recognition protocol 
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E.2  Increase incidence of cells with two or more cilia 
(supernumerary cilia) screen recognition protocol 
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E.3  Combinatorial screens recognition protocol 
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Appendix F 
Inconsistent results from phosphorylated myosin light chain 
antibodies 
F.1  p-MLC (Ser19) 
 
Figure F.1 Immunoblotting results for p-MLC 
Example images of the different staining patterns received with CST 
Phospho-Myosin Light Chain 2 (Ser19) Antibody #3671. Expected single 
band size was 18kDa. 
F.2  pp-MLC (Ser19/Thr18) 
 
Figure F.2 Immunoblotting results for pp-MLC 
Example images of the different staining patterns received with CST 
Phospho-Myosin Light Chain 2 (Thr18/Ser19) Antibody #3674. Expected 
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Appendix G 
KD025 treatment of cell-lines 
G.1  RPE-1 Cells: p-MLC structure 
G.1.1  48hr KD025 treatment raw image data 
 
Figure G.1 Raw image data p-MLC structure in RPE-1 cells with 48hr 
KD025 treatment 
A qualitative difference can be seen in the presence of fibre like structures 
in both p-MLC and pp-MLC immunostaining. There is also a change in cell 
shape and cell number per field of view after 48hrs KD025treatment at 
5µM concentration.  
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G.2  mIMCD3 cells: p-MLC structure 
G.2.1  2hr and 48hr KD025 Treatment 
 
Figure G.2 p-MLC structures in mIMCD3 cells treated with KD025  
2hr KD025 treatment of IMCD3s showed a qualitative loss of p-MLC and 
pp-MLC structures. 48hr KD025 treatment showed a both a qualitative and 
a significant loss in p-MLC and pp-MLC structures. However, there was 
also a loss of structure in MLC, suggesting general dispersal of MLC 

































































- 312 - 
G.3  mIMCD3 cells: cilia incidence and length 
G.3.1  2hr KD025 treatment 
 
Figure G.3 mIMCD3 cilia incidence and length after 2hrs KD025  
mIMCD3 cells treated for 2hrs with KD025 had no significant increase in 
cilia incidence. There was a significant decrease in cilia length (n=3 and at 
least 100 cilia measured per replicate), however this was assumed to be 
an artefact from the FIJI analysis macro as it best measured cilia lying flat, 
whereas mIMCD3 cilia extend through the Z-stacks of images taken. 
Qualitatively there was a large increase in cilia length. Significance 
calculated with one-way ANOVA with Dunnett’s test for multiple 
corrections (cilia incidence) and Kruskal-Wallis test with Dunn’s multiple 
comparisons test (cilia length). **=p<0.01, ****=p<0.0001. # Is the control 
all data sets were compared to in statistical tests. 
G.3.2  48hr KD025 treatment 
 
Figure G.4 mIMCD3 Cilia incidence and length after 48hrs KD025 
treatment 
There was a significant increase in both cilia incidence and length in 
mIMCD3 cells treated for 48hrs with KD025. Samples were prepared to 
ensure cilia lay flat for accurate length measurements (n=3 and at least 
100 cilia measured per replicate). Significance calculated with one-way 
ANOVA with Dunnett’s test for multiple corrections (cilia incidence) and 
Kruskal-Wallis test with Dunn’s multiple comparisons test (cilia length). 
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Appendix H 
Sanger sequencing of CRISPR/Cas9 edited cell lines 
H.1  Sanger sequencing results 
 
Figure H.1 Electropherogram results from CRISPR/Cas9 edited cell lines 
Sequencing data from CRISPR/Cas9 edited cell lines used in Chapter 5. 
Green highlights = PAM sequence, Red highlights = gRNA target 
sequence, Blue arrows = Predicted cut site. 
